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A window into my mind. 
As it is custom to write an acknowledgment when writing a PhD thesis, so shall I 
write one. I have to admit that this was one of the hardest parts to write not because 
I don’t know who to thank, but more because I don’t know who to thank first. 
At the beginning of this PhD adventure I had no idea whether I would ever end up 
writing a PhD thesis, as I could not image gathering enough data to write one. 
During my PhD I learned that mens biggest friend and foe is its mind. It creates 
and destroys. Luckily for me, and don’t mind me being a bit narcissistic, my mind 
is quite positive (perhaps brilliant?). It creates more than it can destroy, so in the 
end I was able to write this marvelous PhD thesis, if I say so myself.  
But still I wonder, after these four years of science, can I call myself a scientist? 
Marie Skłodowska Curie once described a scientist as someone that not only knows 
his way around a laboratory, but as a child placed before a natural phenomenon 
which impresses him or her like a fairy tale. And that’s exactly how I see science, 
as a world of magic and wonder. A place where much is known but even more is to 
be known, where the roads to discovery are adventures that are undertaken with 
much pleasure and enjoyment. Where the tales of others are inspirations for new 
discoveries or even new fields. In short it is amazing to be part of, it is like your own 
little Middle Earth or Westeros. 
One of the first people I would like to thank are my supervisors, Mario and Rob. 
Without your continuing guidance I don’t know whether I would have been able to 
finish this PhD, or whether I would have loved phages as much as I love them now. 
I would like to send my gratitude for your never-ending patients in my sometimes 
grand endeavors. Foremost I thank you for giving me the opportunity and 




and seminars, where I was able to meet and talk to people who shared a common 
interest, phages. Where I could be the phage nerd that I am, where people shared 
my enthusiasm, and where I was able to meet some of those brilliant phage minds. 
Some of which I was able to turn into long time phage friends. Phage friends that 
have helped me stay critical about my research but also about phage research in 
general, who showed me the many possibilities of phages. The fact that I was able 
to attend these conferences especially these last two, undoubtedly shaped my future 
(phage?) research career. For this I thank you! 
Maya, besides the fact that you might have been a time-traveler as you appear on 
photo’s next to d’Herelle and Eliava, during these four PhD years you were always 
close by. Your inexhaustible phage knowledge has inspirited me from the start and 
it has been a true honor to learn many of the phage techniques directly from you. It 
brings me true happiness that you were willing to share your knowledge and that I 
can call you my friend. To you I say, never stop baking! Your cakes, pies and 
chocolates are stunning! 
Furthermore it is impossible to write this section without thanking my many 
colleagues of the Laboratory of Microbial Research (LBR). Leen, you are the genuine 
godmother of the lab. No problem was too big or you had a solution. When we were 
unable to find a product, you were always the one who found it, even when you were 
the one who hid it in the first place! If I were any kind of  brilliant scientist I would 
develop a shrinking ray, so I could shrink you to the size of a glass and take you 
with me wherever I would go. Unfortunately I’m not that brilliant. Leen to you I 
say, if I ever come across an Akkermansia I will send you the strain! But also thank 
you Tessa, Hans, Masha, Abel and Antonio, you guys make the LBR what the LBR 
is, a fun place to be. Did you notice that I said “be” and not “work”? That’s how fun 
you guys were. It never felt like working at all! I will cherish the relationshit (this 
one was for you Tessa) that we build during these years. To you I bestow the 
knowledge that through hard work and collaboration no task is too big to finish. I 




My gratitude also goes to the two thesis students (Cara and Liesl) I had over these 
past four years, it was an honor to share with you my phage enthusiasm. I hope I 
was able to get you excited about science, if it is only a fraction of the excitement 
that I have then I know I did a good job. 
But don’t let me forget the people formerly known as Block A but now going under 
the name MRB2, or in short my lovely colleagues: Caroline, Lena and Sylvie, Katia 
and Sophie, Karin, Els, Imke, Juliette, Laura, Marieke, Mathias, Sigrid, Steven, 
Sylvie, Jet and Eelke. But don’t forget the awesome people of the ARL: Kenny, Els, 
Laura, Leen, Marlies, Delfien, Virginie and Chris. You made Block A, or MRB2 
since we moved, into what it is, one big family. 
This PhD thesis certainly would not have been possible without the help of CEVAC, 
more specifically Frédéric Clement. You gave us the initial idea of how to tackle the 
immune problem during my master dissertation. You gave us the opportunity to use 
your facilities, without which this dissertation was certainly doomed to fail. Well 
that might be a bit of an exaggeration, but still it gave us a nice advantage. Thanks 
also goes to Peter, Leen and Sabrina, together with their many colleagues of CEVAC 
who were always ready to help or give advice. I know that most of the time I was 
probably just keeping you from your work, but still you don’t know how much I 
appreciated your help. Even when it seemed like it was no help at all. 
Now it is probably time for the most personal section of this acknowledgement, the 
section where I thank my friends and family. I could start with thanking myself for 
constantly believing in myself, but that would be way to egocentric and a lie as well. 
If it weren’t for the constant support of my parents and brothers (Marnix and 
Steven), I wouldn’t know what I would have done. Mom, Dad, thank you for the 
uncountable opportunities you gave me. For always believing in me and for 
supporting all my wildest dreams. Thank you Marnix, Marijke, Nand, Ella and 





Steven, from the moment you started your own academic carrier, I was intoxicated 
by the curiosities you were able to share. You might not have noticed, or you did 
notice but never let me notice that you noticed, that it was thanks to you that I 
studied what I studied. It took me five years before I was able to tell you something 
science related that you didn’t know, that was when I was doing my second master 
and you were starting to finish your PhD. It took me an additional four years to call 
myself an equal, not only to you but also to Marnix. The brothers Van Belleghem, 
PhD. BAM! This is probably the only time I will use that title. Unless I’m on a plane 
and somebody asks for a doctor… 
Thank you Joe Yee for your constant support, you entered my life when the hardest 
part of my PhD had yet to start, the writing. You stuck with me during this harsh 
period and you have no idea how much that means. You are the wind beneath my 
wings. In the meanwhile we underwent a few adventures on our own, and hopefully 
you’ll join me for our next big quest (whatever it may be). 
Thank you Leen. Yes, yet another Leen. It seems as if the world only consists of 
Leens? Thanks for moving in when Steven left the apartment for his Puerto Rican 
adventures, leaving me with a way to expensive “kot”. The late night talks that we 
had, or just the talks during dinner or TV always seemed to relax me to some extent. 
You often gave me the input that I needed in order to not see myself as some crazy 
scientist. 
Finally thanks to the many friends from Ghent (Jan, Sam, Patrick and Dries), from 
Sint-Niklaas (Wout, Filip, Bastiaan and Viola), and the phage field I met along the 
way. Thanks for the much needed distraction. Jan, Sam, Patrick and Dries during 
our studies and PhD’s (how crazy is it that all four of us were able to follow the same 
path in different fields?) we were able to have some crazy adventures, Hannover, 
beer brewing, crazy nights out. I can only hope that there are still many to follow 
(and don’t forget to invite me for your defenses)! Wout, Filip, Bastiaan and Viola, 




talking about you! During those years you undoubtedly must have thought, what 
the frack is he talking about. To be honest, more than half of the time I myself had 
no clue what I was trying to say (but I’ll still deny this in conversations). Still we 
had some pretty good times, hopefully you’ll join me for some more! 
In the end there are not enough words to express my gratitude to everyone who had 
a part in this thesis. I will never forget the many adventures I had these four years, 
and I know that this will probably be the only part that will be read by everyone 
holding this book (perhaps I should include some of my results in here?).  
 
Let me end with the legendary words of Homer J Simpson: 
“The war has ended and the future won, the past never had any chance man!” 
The Simpsons - American History X-cellent (S21E17) 
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ABC ATP-binding cassette 
Abi Abortive infection 
AID Activation-induced cytidine deaminase 
AIRE Autoimmune regulator 
AMP Adenosine monophosphate 
APC Antigen presenting cell 
APE Apurinic/apyrimidinic endonuclease 
ASC  Apoptosis-associated speck-like protein containing a CARD 
ATP Adenosine triphosphate 
 
BAM Bacteriophage adherence to mucus 
BCR B-cell receptor 
BER Base excision repair 
BFGF Basic fibroblast growth factor 
BIR Baculovirus inhibitor of apoptosis repeat  
bp Base pair 
 
C Constant gene element 
cAMP Cyclic AMP 
CAMP Cationic antimicrobial peptide 
CARD Caspase activation and recruitment domain 
Cas CRISPR-associated 
cDC Conventional dendritic cell 
CF Cystic fibrosis 
CH Immunoglobulin heavy chain constant 
CIS Cytokine-induced SRC-homology-2 protein 
CLIP Class II-associated Ii peptide 
CMC Critical micellar concentration 
CNTF Ciliary neurotrophic factor 
CR1 Complement receptor 1 




CR3 Complement receptor 3 
CRISPR Clustered regulatory interspaced short palindromic repeat 
CRP C-reactive protein 
crRNA CRISPR RNA 
CSR Class switch recombination 
CT1 Cardiotrophin-1 
CTL Cytosolic T lymphocyte 
 
D Diverse gene element 
DCs Dendritic cells 
DD Death domain 
DEG Differentially expressed gene 
DNA Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
dsDNA Double stranded deoxyribonucleic acid 
dsRNA Double stranded ribonucleic acid 
dU Deoxyuracil 
 
EF-2 Elongation factor-2 
EGF Epidermal growth factor 
EPO Erythropoietin 
Erm Erythromycin methylase 
ER Endoplasmatic reticulum 
ESBL Extended-spectrum β-lactamase 
ETA Exfoliative toxin A 
ETB Exfoliative toxin B 
EU Endotoxin units 
EU European Union 
GAP GTPase-activating protein 
G-CSF Granulocyte colony-stimulating factor 
GEO Gene expression omnibus 




GM-CSF Granulocyte-macrophage colony-stimulating factor 




HAP Hospital-acquired pneumonia 
HCAP Healthcare-associated pneumonia 
HCMV Human cytomegalovirus 
Hep L-glycero-D-manno-heptose (Hep) 
HGT Horizontal gene transfer 
HMG1 High-motility-group 1 
HMG2 High-motility-group 2 
Hoc Highly antigenic outer capsid protein 
HSV1 Herpes simplex virus 1 
 
iE-DAP γ-D-glutamyl-meso-diaminopimelic acid  
IFN Interferon 
Ig Immunoglobulin 
IGF1 Insulin-like growth factor-1 
Ii Nonpolymorphic invariant chain 
IKK IκB kinase 
IL Interleukin 
IL1R Interleuking 1 receptor  
IL1RN IL1 receptor antagonist 
IRAK-4 IL1 receptor associated kinase-4 
ISGs  Interferon-stimulated genes 
ITAM Immunoreceptor tyrosine-based activation motif 
 
J Joining gene element 
JAK Janus kinase 
 






LBP LPS-binding protein 
LIF Leukemia inhibitory factor 
LPS Lipopolysaccharide 
LRR Leucine-rich-repeat  
LAT Linker of activated T cells 
LTA Lipoteichoic acid 
 
MAC Membrane attack complex 
MAL TIRAP/MyD88-adaptor like 
MAPK Mitogen-activated protein kinase 
MASP 1 MBL-associated serine protease 1 
MASP 2 MBL-associated serine protease 2 
MASP 3 MBL-associated serine protease 3 
MBL Mannose-binding lectin 
M-CSF Macrophage colony-stimulating factor 
MDP Muramyl dipeptide  
MFS Major facilitator subfamily 
MHC Major-histocompatibility-complex  
MIIC MHC class II compartment 
MIP-1α Macrophage inflammatory protein 1α 
MMR Mismatch repair 
MMTV Mouse mammary tumor virus 
MPS Mononuclear phagocyte system 
MSCRAMMs Microbial surface components recognizing adhesive matrix 
molecules 
Myd88 Myeloid differentiation primary response gene 88 
 
NHEJ Nonhomologous end-joining 
NLR NOD-like receptor 
NOD Nucleotide binding oligomerization domain 
 
OM Outer membrane 
OSM Oncostatin M 
 




PBP Penicillin binding protein 
PBP2a Penicillin-binding protein 2a 
PCNA Processivity factor proliferating cell nuclear antigen 
pDC Plasmacytoid dendritic cell 
PDGF Platelet-derived growth factor 
PG Peptidoglycan 
PLCγ1 Phospholipase Cγ1  
PMN Polymorphonuclear lymphocytes 
Pol β DNA polymerase β 
PRL Prolactin 
PRR Pattern recognition receptors  
PTSAg Pyrogenic toxin superantigen 
 
QRDR Quinolone resistance-determining region 
 
RAG1 Recombination-activating gene 1 
RAG2 Recombination-activating gene 2 
RD Repressor domain 
rFC Recombinant factor C 
RHIM Rip homotypic interaction motif 
RIP1 Receptor-interacting protein 1 
RLR RIG-I-like receptor 
R-M Restriction-modification 
RNA Ribonucleic acid 
RND Resistance/nodulation/cell division family 
RORγt Retinoic acid receptor related orphan receptor γt  
ROS Reactive oxygen species 
RSS Recombination signal sequence 
RSV Respiratory syncytial virus 
 
SARM Sterile α and HEAT-Armadillo motifs-containing protein µ 
SEA Staphylococcal enterotoxin A 
SEB Staphylococcal enterotoxin B 
SEC Staphylococcal enterotoxin C 




SEE Staphylococcal enterotoxin E 
SEG Staphylococcal enterotoxin G 
SEH Staphylococcal enterotoxin H 
SEI Staphylococcal enterotoxin I 
SH2P SH2-domain-containing protein tyrosine phosphatase 2 
SHM Somatic hyper mutations 
sMAP Small MBL-associated protein 
SMR Small multidrug regulator family 
SOAP Short oligonucleotide analysis package 
SOAP2 SOAP aligner 
SOCS Suppressor of cytokine signaling 
SSB Single stranded DNA break 
ssDNA Single stranded deoxyribonucleic acid 
ssRNA Single stranded ribonucleic acid 
STAT Signal transducer and activator of transcription 
 
T2SS Type 2 secretion system 
T3SS Type 3 secretion system 
TAK1 Transforming growth factor-β-activated kinase 
TANK TRAF family member-associated NF-κB activator 
TAP Transporter associated with antigen presentation 
TBK1 TANK binding kinase 1 
TCR T-cell receptor 
TdT Terminal deoxynucleotidyl transferase 
TGFβ Transforming growth factor-β 
TICAM1 TRIF/TIR-domain-containing molecule 1 
TIR domain Toll/IL1R homology domain 
TIRAP TIR-associated protein 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TPO Thrombopoietin 
TRAF6 TNF receptor-associated factor 6 
TRAM TRIG-related adaptor molecule 





TSLP Thymic stromal lymphopoietin 
TSST-1 Toxic shock syndrome toxin-1 
 




UEV1A Ubiquitin-conjugating enzyme E2 variant 1 isoform A 
 
V Variable gene element 
VAP Ventilator-associated pneumonia 
VISA Vancomycin intermediate-resistance Staphylococcus aureus 
 











Bacteria that inhabit the intestine and skin are generally regarded as stable 
residents that may confer metabolic and/or immune benefits to their hosts 
(Turnbaugh et al., 2009). The host immune system has evolved mechanisms to 
tolerate these commensal organisms while at the same time providing protection of 
the host from pathogens (Moon and Stappenbeck, 2012). Similarly, metagenomic 
studies of microbiota at various tissue sites have revealed that a vast variety of 
bacteriophages (phages) are associated with healthy human tissues (Minot et al., 
2011; Pride et al., 2012; Reyes et al., 2010). In the case of phages, a persistent 
nonpathogenic association seems possible as viral replication occurs in bacterial 
hosts, which can themselves be stable members of the microbiota (Duerkop and 
Hooper, 2013). 
It is known that the oral administration of phages leads to the translocation of the 
phages from the gut to the blood (Duerr et al., 2004; Hamzeh-Mivehroud et al., 2008; 
Weber-Dąbrowska et al., 1987). This suggests that mammals have evolved 
mechanisms for the uptake and delivery of phages that may allow intestinal phages 
to elicit innate and adaptive immune responses. Knowing that phages are present 
everywhere and that we are in constant contact with phages, the question can be 
asked to what extent phages interact with our immune system. More specifically, 
do they have anti-inflammatory properties? Otherwise, how can they work 
systemically without inducing an immune response? 
In order to find an answer to these questions it is not only important to have a 
broader understanding of the human immune response but also to understand the 
need of phage therapy when antibiotic resistant bacteria are becoming an 
increasing problem, and why it is important to investigate the interaction of phages 
with the human immune system.  gives a detailed account of the 
human immune response, which can be divided into two branches: the innate and 
the acquired immune response (Akira et al., 2006). The main function of the innate 
immune response is to provide a direct defense against invading pathogens. These 
defenses are mainly provided by recognizing pathogens by means of pathogen-
associated molecular patterns (PAMPs) (Janeway, 1989). This innate immunity is 
responsible for most of the inflammatory responses and are triggered in first 
instance by macrophages, polymorphonuclear leukocytes and mast cells (Janeway 
and Medzhitov, 2002). The recognition of PAMPs is mediated through pathogen 
recognition receptors (PRRs), such as Toll-like receptors (TLR), which activate 
signal-transduction pathways that induce the expression of a variety of immune-
response genes (Kawai and Akira, 2010; Kumar et al., 2009a; Ozinsky et al., 2000; 
Takeuchi and Akira, 2010). 
The adaptive immunity is activated upon the recognition of a pathogen by antigen 
presenting cells (APCs) (Pulendran et al., 2001). These dendritic cells phagocytose 
the pathogen and subsequently undergo cell maturation. This includes the 
induction of costimulatory activity, antigen processing, increased major 
histocompatibility complex (MHC) molecule expansion, and migration into the 
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lymph nodes (Orsini et al., 2003). The adaptive immune system manifests an 
exquisite specificity for its target antigens, unlike the innate immunity. The so-
called T and B cells play major key roles in the adaptive immune response, through 
the expression of specific receptors (Bonilla and Oettgen, 2010; Chaplin, 2010; 
Schroeder and Cavacini, 2010). 
Regarding the reduction of human morbidity and mortality, the introduction of 
antibiotics was one of the most important medical interventions. Unfortunately, the 
intense (mis)use of antibiotics has led to an increased frequency of antibiotic 
resistant bacteria (Guay, 2008; Lew et al., 2008; Woodford and Livermore, 2009). 
 discusses the mechanisms by which antibiotic resistance might 
occur. By understanding these antibiotic resistance mechanisms, it becomes clear 
why alternative strategies for combating multidrug resistant bacteria such as phage 
therapy are promising new therapies. 
 gives a complete description about the function and biological 
characteristics of lipopolysaccharides. Endotoxins (lipopolysaccharides, LPS) 
produced by Gram-negative bacteria are widely recognized for their immunological 
properties, as they cause septic shock, multiple organ dysfunction and failure 
(Epstein and Parrillo, 1993; Petsch and Anspach, 2000). Therefore, it is important 
to understand their chemical structure and biochemical properties, not only to 
understand the mechanisms by which they are made or interact with the human 
immune system, but also to develop strategies to circumvent their pro-
inflammatory properties or develop protocols for their removal from biological 
samples. The removal of endotoxins from phage preparations becomes important 
when using phages that have Gram-negative bacteria as their host.  
 provides an in-depth description of these bacterial viruses, 
also called phages. The emergence of pathogenic bacteria resistant to most, if not 
all, currently available antibiotics has become a critical problem in modern 
medicine. Prior to the discovery and widespread use of antibiotics (around World 
War II), it had been suggested (around World War I) that bacterial infections could 
be prevented and/or treated by the administration of bacteriophages. 
Bacteriophages are the most abundant entities on Earth with an estimated number 
of 1030 particles (Suttle, 2005). Every bacterial cell can harbor many phages. These 
viruses use bacteria as a mean to replicate, invariably destroying their prokaryotic 
host in the process. Current knowledge states that phages ignore every cell except 
the strain of bacteria they have evolved to infect. This makes them ideal candidates 
to treat bacterial infections, while being harmless to mammalian cells and even non-
target bacteria (Thiel, 2004).  
Additionally, it has been demonstrated that oral uptake of phages by animals 
results in the translocation of phages to systemic tissues (Duerr et al., 2004; 




for the uptake and delivery of phages. The resulting contact between systemic 
tissues and phages may allow phages to elicit innate and adaptive immune 
responses. One possible uptake route involves dendritic cells, which are known to 
sample intestinal luminal contents and can actively phagocytize phage particles in 
culture (Barfoot et al., 1989; Rescigno et al., 2001). It is also interesting to consider 
whether phages might elicit antiviral innate immune responses. Mammalian cells 
are endowed with the ability to detect eukaryotic viral nucleic acids through several 
pattern-recognition receptors that are positioned to detect viral entry into cells 
(Duerkop and Hooper, 2013). For a global overview of phage-human host 
interactions see  
Finally, in order to answer the question stated above: “do bacteriophages have 
immunological properties”, this dissertation can be subdivided into two main parts: 
The presence of endotoxins in samples, whether they are proteins, pharmaceuticals 
or phages play an important role in the outcome of their observed effects. Therefore, 
it was important to use highly purified, endotoxin-free, phage preparations to 
deduce whether phages are able to induce an immune response. Seven different 
endotoxin removal strategies were evaluated and validated for their endotoxin 
removal efficacy. The results obtained regarding these seven endotoxin removal 
strategies are discussed in  and have been 
published (Van Belleghem et al., 2017a). 
Once highly purified phage preparations were obtained, their potential to induce an 
immune response was evaluated. This was done by stimulating peripheral blood 
mononuclear cells (PBMCs) with these highly purified phage preparations, after 
which the gene expression of twelve immunity-related genes was evaluated. The 
results concerning these immune responses are described in 
, , and 
. 
The combined results of these first two chapters are summarized and published in 












Living organisms are constantly threatened by the invasion of microorganisms and 
vertebrates have evolved elaborate systems of immune defense to prevent infection 
and eliminate infective pathogens in the body. The mammalian immune system can 
be divided in two branches: innate immunity, and acquired or adaptive immunity 
(Table 2. 1) (Akira et al., 2006). The innate immune response is the first line of host 
defense against pathogens and is mediated by phagocytes including macrophages 
and dendritic cells (DCs) (Kumar et al., 2011). Acquired or adaptive immunity is 
involved in the elimination of pathogens in the late phase of infection as well as the 
generation of immunological memory. The main cells involved in the acquired or 
adaptive immune response are T and B lymphocytes (Mackay et al., 2000).  
Table 2. 1: Innate and adaptive immunity. Adapted from Janeway and Medzhitov (2002). 
Property Innate immune system Adaptive immune system 
Receptors 
 
Fixed in genome 
Rearrangement is not necessary 
Encoded in gene segments 
Rearrangement is necessary 
Distribution Non-clonal 
All cells of a class identical 
Clonal 
All cells of a class distinct 
Recognition Conserved molecular patterns Detailed molecular structures 
Self-Nonself 
discrimination 
Perfect: selected over 
evolutionary time 
Imperfect: selected in 
individual somatic cells 
Action time Immediate activation of effectors Delayed activation of effectors 
Response Co-stimulatory molecules 
Cytokines 
Chemokines 
Clonal expansion or anergy 
Cytokines 
 
The innate immunity is an evolutionary ancient part of the host defense 
mechanisms, the same molecular modules are found in plants and animals, 
meaning it arose before the split into these two kingdoms (Hoffmann et al., 1999). 
It is believed that the innate immune system predates the adaptive immune 
response on several grounds. First, innate host defenses are found in all 
multicellular organisms, whereas adaptive immunity is found only in vertebrates. 
Second, innate immune recognition distinguishes self from non-self perfectly. Third, 
the innate immune system uses receptors that are ancient in their lineage, whereas 
adaptive immunity appears to use the same effector mechanisms guided by clonally 
specific antibodies and T-cell receptors (TCR) encoded in rearranging genes of the 
Ig gene superfamily (Medzhitov and Janeway, 1997). The virtues of having an 
innate immune system of pathogen recognition lies not only in the delaying tactics 
of inflammation upon infection, but also in the activation of the adaptive immune 




Innate immunity covers many areas of the host defense against pathogenic 
microbes and viruses, including the recognition of pathogen-associated molecular 
patterns (PAMPs) (Janeway, 1989). In vertebrates, which are the only phylum that 
can mount an adaptive immune response, there are also mechanisms to inhibit the 
activation of innate immunity (Janeway and Medzhitov, 2002). Innate immunity 
lies behind most inflammatory responses, and are triggered in first instance by 
macrophages, polymorphonuclear leukocytes and mast cells through their innate 
immune receptors (Janeway and Medzhitov, 2002).  
Invasion of a host by a pathogenic infectious agent triggers a battery of immune 
responses through interactions between a diverse array of pathogen-borne virulence 
factors and the immune surveillance mechanisms of the host. Host-pathogen 
interactions are generally initiated via host recognition of conserved molecular 
structures known as pathogen-associated molecular patterns (PAMPs) that are 
essential for the life cycle of the pathogen (Janeway and Medzhitov, 2002; Kumar 
et al., 2011). However, these PAMPs are either absent or compartmentalized inside 
the host cell, and are sensed by the host’s germline encoded pattern recognition 
receptors (PRRs), which are expressed on innate immune cells such as dentritic 
cells, macrophages and neutrophils (Blasius and Beutler, 2010; Kawai and Akira, 
2010; Medzhitov, 2007; Takeuchi and Akira, 2010). One advantage of these germ-
line-encoded receptors is that they evolved by natural selection to have defined 
specificities for infectious microorganisms (Mackay et al., 2000). The strategy of the 
innate immune response may not be to recognize every possible antigen, but rather 
to focus on a few, highly conserved structures present in large groups of 
microorganisms (Janeway, 1989). Effective sensing of PAMPs rapidly induces host 
immune responses via the activation of complex signaling pathways that culminate 
in the induction of inflammatory responses mediated by various cytokines and 
chemokines, which subsequently facilitate the eradication of the pathogen (Kumar 
et al., 2009a). 
The innate immune system uses a variety of pattern recognition receptors that can 
be expressed on the cell surface, in intracellular compartments, or secreted into the 
bloodstream and tissue fluids (Medzhitov and Janeway, 1997). The principle 
functions of PRRs include opsonization, activation of complement and of coagulation 
cascades, phagocytosis, activation of pro-inflammatory signaling pathways, and 
induction of apoptosis of the infected cells. Functionally, PRRs can be divided into 
three classes: secreted, endocytic and signaling. 
Secreted PRR molecules function as opsonins by binding to microbial components 
and flagging them for recognition to the complement system and phagocytoses 
(Hawlisch and Köhl, 2006; Laarman et al., 2010; Morgan et al., 2005). The best 




of the calcium-dependent lectin family that binds to microbial carbohydrates to 
initiate the lectin pathway of complement activation (Fraser et al., 1998). 
Endocytic pattern-recognition receptors occur on the surface of phagocytes. Upon 
recognition of a PAMP on a microbial cell, these receptors mediate the uptake and 
delivery of the pathogen into lysosomes. Pathogen-derived proteins can then be 
processed, and the resulting peptides can be presented by the major-
histocompatibility-complex (MHC) molecules on the surface of the macrophages 
(Mackay et al., 2000). The macrophage mannose receptor, which is also a member 
of the calcium-dependent lectin family, is an endocytic PRR. It specifically 
recognizes carbohydrates with large numbers of mannoses, which are typical for 
bacteria (Suzuki et al., 1997; Thomas et al., 2000). 
Signaling receptors recognize PAMPs and activate signaling-transduction 
pathways that induce the expression of a variety of immune-response genes, 
including inflammatory cytokines (Kawai and Akira, 2010; Kumar et al., 2009b; 
Ozinsky et al., 2000; Takeuchi and Akira, 2010). Toll-like receptors (TLRs) are the 
most widely studied PRRs and are considered to be the primary sensors of 
pathogens (Kumar et al., 2011). 
Toll-like receptors (TLRs) are evolutionarily conserved from the worm 
Caenorhabditis elegans to mammals (Akira and Takeda, 2004; Beutler, 2004; 
Hoffmann, 2003; Janeway and Medzhitov, 2002). Toll, the founding member of the 
TLR family, was initially identified as a gene product essential for the development 
of embryonic dorsoventral polarity in Drosophila (Belvin and Anderson, 1996; 
Hashimoto et al., 1988). It was later shown to play a critical role in the antifungal 
response of flies (Lemaitre et al., 1996). In humans, ten TLR family members have 
been identified. TLR1 to 9 are conserved in both humans and mice. TLR10 is 
expressed in humans but not in mice, whereas TLR11 is expressed in mice but not 
in humans (Kawai and Akira, 2010). TLRs are type I integral membrane 
glycoproteins characterized by the extracellular domains containing varying 
numbers of leucine-rich-repeat (LRR) motifs and a cytoplasmic signaling domain 
homologous to that of the interleukin-1 receptor (IL1R), termed the Toll/IL1R 
homology (TIR) domain (Bowie and O’Neill, 2000). Based on their primary sequence, 
TLRs can be further divided into several subfamilies, each of which recognizes 
related PAMPs: the subfamilies of TLR1, TLR2 and TLR6 recognize lipids, whereas 





Table 2. 2: TLR recognition of bacterial or viral components. Adapted from Akira et 
al. (2006). 
TLR  PAMPs Species Reference 
Bacteria    
TLR4  LPS Gram-negative 
bacteria 
Poltorak et al. (1998) and 
Shimazu et al. (1999) 
TLR6/TLR2  Diacyl lipopeptides Mycoplasma Thoma-Uszynski et al. (2001) 
TLR1/TLR2  Triacyl lipopeptides Bacteria and 
mycobacteria 
Thoma-Uszynski et al. (2001) 
TLR2  Lipoteichoic acid (LTA) Group B 
Streptococcus 
Alexopoulou et al. (2002); 
Ozinsky et al. (2000); Takeuchi 
et al. (2001, 2000) 
TLR2  Peptidoglycan (PG) Gram-positive 
bacteria 
Alexopoulou et al. (2002); 
Ozinsky et al. (2000); Takeuchi 
et al. (2001, 2000) 
TLR2  Porins Neisseria  
TLR2  Lipoarabinomannan Mycobacteria Gilleron et al. (2003) 
TLR5  Flagellin Flagellated bacteria Hayashi et al. (2001) 
TLR9  CpG-DNA Bacteria and 
mycobacteria 
Hemmi et al. (2002) 
Viruses    
TLR9  DNA Viruses Hochrein et al. (2004); Krug et al. 
(2004a, 2004b); Lund et al. (2003); 
Tabeta et al. (2004) 
TLR3  dsRNA Viruses Alexopoulou et al. (2002) 
TLR7 and TLR8  ssRNA RNA viruses Diebold et al. (2004); Heil et al. 
(2004); Hemmi et al. (2002) 
TLR4  Envelope proteins RSV, MMTV Kurt-Jones et al. (2000) 
TLR2  Hemagglutinin protein Measles virus Bieback et al. (2002); Compton 
et al. (2003) 
TLR2  ND HCMV, HSV1 Kurt-Jones et al. (2004) 
Legend: RSV: respiratory syncytial virus; MMTV: mouse mammary tumor virus; HCMV: 





The first indication that mammalian TLRs may function as PRRs came with the 
description of a human homologue of Drosophilla Toll, now known as TLR4 
(Medzhitov R et al., 1997). TLR4 recognizes LPS (Hoshino et al., 1999; Poltorak et 
al., 1998; Qureshi et al., 1999), but is not the sole receptor involved in the LPS 
recognition. Capture and transport of LPS molecules in the serum is mediated by 
LPS-binding protein (LBP)(Ulevitch and Tobias, 1995). At the plasma membrane, 
LBP is thought to transfer LPS monomers to CD14; a glycophosphatidylinositol 
(GPI) linked cell surface protein. It is not clear how CD14 facilitates recognition of 
LPS by TLR4, but its crucial role has been underscored by the LPS-hyporesponsive 
phenotype of CD14-deficient mice (Haziot et al., 1996; Moore et al., 2000). In order 
to complete the LPS recognition complex, MD-2 also plays an important role (da 
Silva Correia et al., 2001; Lien et al., 2000; Poltorak et al., 2000). This protein lacks 
a transmembrane anchor but is associated with the extracellular region of TLR4 
(Shimazu et al., 1999).  
TLR2 recognizes the largest number of ligands among the mammalian TLRs and 
perhaps of all PRRs (Janeway and Medzhitov, 2002). These include peptidoglycans 
(PG)(Schwandner et al., 1999; Takeuchi et al., 1999), bacterial lipoproteins 
(Aliprantis, 1999; Brightbill, 1999; Takeuchi et al., 2000b), a phenol soluble factor 
of Staphylococcus epidermidis (Hajjar et al., 2001), LPS from Porphyromonas 
gingivalis (Hirschfeld et al., 2001) and Leptospira interrogans (which differs in 
structure from the LPS of Gram-negative bacteria)(Werts et al., 2001), 
glycosylphosphatidylinositol lipid from Trypanosoma cruzi (Campos et al., 2001) 
and zymosan, a component of yeast cell walls (Underhill et al., 1999). TLR2 does 
not recognize these PAMPs independently, but functions by forming heterodimers 
with either TLR1 or TLR6 (Ozinsky et al., 2000; Takeuchi et al., 2001). This 
cooperation leads to the increased repertoire of ligand specificities. 
TLR5 recognizes flagellin, the protein subunit that makes up bacterial flagella 
(Hayashi et al., 2001). Flagellin is a protein and does not contain any obvious 
features to flag it as nonself or pathogen-associated, unlike most other PAMPs (e.g. 
LPS or PG) it is very conserved at the N- and C-terminal ends that form its 
hydrophobic core, and therefore it is likely that this conserved region is recognized 
by TLR5 (Janeway and Medzhitov, 2002).  
Unmethylated CpG DNA was long known for its immunostimulatory effects 
(Hartmann and Krieg, 1999; Heeg and Zimmermann, 2000; Lund et al., 2003; 
Tabeta et al., 2004). The logic of this recognition is that most of the mammalian 
genome is methylated at CpG sites, while bacteria lack CpG methylation enzymes 
(Krieg, 2000). Unlike most TLRs, which are expressed on the cell surface, TLR9 
localizes intracellularly (Häcker et al., 1998; Krieg et al., 1995). 
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The engagement of TLRs by microbial components triggers the activation of 
signaling cascades, leading to the induction of genes involved in antimicrobial host 
defense, including inflammatory cytokines and chemokines, antimicrobial peptides, 
costimulatory molecules, MHC molecules, and other effectors necessary against the 
invading pathogen (Janeway and Medzhitov, 2002). After ligand binding, TLRs 
dimerize and undergo conformational changes required for the recruitment of TIR-
domain-containing adapter molecules to the TIR domain of the TLR (Figure 2. 1). 
There are four adaptor molecules, namely MyD88, TIR-associated protein 
(TIRAP)/MyD88-adaptor like (MAL), TIR-domain-containing adaptor protein-
inducing IFN-β (TRIF)/TIR-domain-containing molecule 1 (TICAM1)(Oshiumi et 
al., 2003; Yamamoto et al., 2002), and TRIF-related adaptor molecule 
(TRAM)(Akira et al., 2006). The recruitment of these adaptor molecules activates 
various transcription factors such as NF-κB, IRF3/7, and MAP kinases to induce 
the production of pro-inflammatory cytokines and type I interferons (Kumar et al., 
2011). The signaling pathways activated by TLR are similar to the ones activated 
by the IL1R and identical molecules comprise the two signaling cascades (Kopp and 
Medzhitov, 1999). All TLRs, except TLR3, recruit MyD88 and initiate MyD88-
dependent signaling to activate NF-κB and MAP kinases to induce pro-
inflammatory cytokines in macrophages and conventional DCs (cDCs). In addition 
to MyD88, TLR1, TLR2, TLR4 and TLR6 recruit TIRAP which serves as a linker 
adaptor between the TIR domains of the TLR and MyD88 (Kumar et al., 2009b, 
2011). 
Upon ligation of TLR4, the adaptor MyD88 is recruited to the receptor complex 
(Medzhitov et al., 1998; Muzio et al., 1998). MyD88 has a C-terminal TIR domain 
that mediates its homophilic interaction with the receptor and an N-terminal death 
domain that engages the death domain of its downstream target IRAK (Wesche et 
al., 1997). Upon association with MyD88, IRAK, a serine threonine kinase, 
undergoes autophosphorylation. The RING-finger containing adaptor TRAF6 is also 
part of this activated signaling complex (Cao et al., 1996). It has been suggested 
that TRAF6 functions as an E3 ligase to ubiquitinate an as-yet-unidentified target 
that is necessary for TLR- and IL1R-mediated IκB kinase β (IKK-β) (Deng et al., 
2000). Activated IKK phosphorylates and targets the NF-κB inhibitor IκB for 
degradation, thereby freeing NF-κB to translocate to the nucleus and turn on 
transcription of target genes (Ghosh et al., 1998). 
The RIG-I-like receptor (RLR) family consist of three members, namely RIG-I, 
MDA5 and LGP2. These sensors recognize the RNA from RNA viruses in the 
cytoplasm of infected cells and induce inflammatory cytokines and type I interferons 
(Figure 2. 1). This leads to the recruitment of macrophages and dendritic cells 





Activation of RLR leads to the induction of type I interferons, which consist of 
several structurally related IFN-α proteins and a single IFN-β protein, which can 
bind directly to infected cells in an autocrine or paracrine manner through a 
common receptor and initiate the transcription of several interferon-stimulated 
genes (ISGs). Type I interferons, together with ISGs, induce an antiviral state in all 
infected and healthy cells by altering various cellular processes. This inhibits viral 
replication, induces apoptosis in infected cells, increases the lytic capacity of natural 
killer cells, up-regulates the expression of MHC class I molecules and activates 
various components of the adaptive immune response (Kumar et al., 2011). 
 
 
Figure 2. 1: Pattern recognition receptor (PRR) mediated signaling. Toll-like 
receptor (TLR) signaling| Recognition of PAMPs by plasma membrane-localized TLRs 
such as TLR2 (forms a heterodimer with TLR1 or TLR6 to from a functional receptor 
complex), TLR4, and TLR5 and endosomal-localized TLRs, such as TLR3, TLR7 and TLR9, 
activates TLR signaling pathways. All TLRs, except TLR3, recruit MyD88 and activate 
MyD88-dependent signaling. TLR1, 2, 4 and 6 recruit the additional adaptor molecule, 
TIRAP, for the recruitment of MyD88. TLR3 recruits TRIF and activates TRIF-dependent 
signaling. TLR4 also activates TRIF-dependent signaling through an additional adaptor 
molecule, TRAM. In cDCs, MyD88-dependent signaling is initiated through the recruitment 
and activation of various signaling molecules, such as IRAK family proteins, TRAF6 and 
TAK1 that activate the IKK complex. The IKK complex activates NF-κB subunits (i.e. P50 
and P65) to initiate the transcription of inflammatory cytokine genes. In pDCs, the TLR7 
and TLR9-mediated signaling pathways activate NF-κB via a MyD88-dependent signaling 
pathway in the same manner as for cDCs. cDCs stimulated with TLR3 PAMPs activate the 
TRIF-dependent signaling pathway through recruitment of TRIF to induce transcription of 
inflammatory cytokines and type I interferons through IKK complex and TBK1/IKKi, 
respectively, via the activation of NF-κB and IRF3/IRF7. RIG-I-like receptor (RLR) 
signaling| Recognition of PAMPs by cytosolic sensors, such as RIG-I and Mda5, activates 
signaling through the mitochondria-localized adaptor protein IPS-1 leading to the activation 
of NF-κB and IRF3/IRF7 through the IKK complex and TBK1/IKKi, respectively, which 
results in the production of inflammatory cytokines and type I interferon. LGP2, also a 
member of the RLR family, potentiates the RIG-I- and MDA5-mediated signaling pathway. 
NOD-like receptor (NLR) signaling| Recognition of PAMPs by NOD1 and NOD2 initiates 
the recruitment of RICK, which activates NF-κB via the IKK complex. Another member of 
the NLR family constitutes the inflammasome. The inflammasome is a multi-protein 
complex required for the maturation or activation of pro-IL1 family cytokines to its bioactive 
IL1 family cytokine. Figure adapted from Kumar et al. (2011, 2009a and 2009b) and Takeuchi 







NOD-like receptors (NLRs) are a family of PRRs that sense a wide range of ligands 
within the cytoplasm of cells and comprises 23 members in humans (Franchi et al., 
2009; Kumar et al., 2009a; Shaw et al., 2008; Takeuchi and Akira, 2010). Proteins 
in this family possesses LRRs that mediate ligand sensing, a nucleotide binding 
oligomerization domain (NOD) and a domain for the initiation of signaling (e.g. 
CARDs, PYRIN, or baculovirus inhibitor of apoptosis repeat (BIR) domains 
(Inohara et al., 2005; Martinon and Tschopp, 2005). The most well studied NLRs 
are NOD1 and NOD2, which comprise of C-terminal LRRs, a central 
oligomerization domain and an N-terminal domain containing either one (NOD1) 
or two (NOD2) CARDs. These proteins are mainly expressed in the cytosol of various 
cells (Barnich et al., 2005; Kufer et al., 2008). NOD1 and NOD2 detect γ-D-
glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), found 
in bacterial PG (Chamaillard et al., 2003; Richardella et al., 2010). Ligand binding 
to NOD1 and NOD2 causes their oligomerization and results in NF-κB activation 
through the recruitment of RIP2/RICK, a serine/threonine kinase, to the NODs via 
their respective CARD domains by hydrophobic interactions (Figure 2. 1)(Akira et 
al., 2006). 
Complement is a major component of the innate immune system, and is involved in 
defending the host against pathogens through complement fragments that 
participate in opsonization, chemotaxis and activation of leukocytes (Rus et al., 
2005). The complement proteins also play an important role in modulating adaptive 
immunity (Carroll, 2000). The complement system is a general term attributed to 
more than 30 soluble plasma and body fluid proteins and to a number of cell 
receptors and control proteins found in blood and tissues. The activation of the 
complement system provides a cascade-like defense barrier against bacteria, 
viruses, virus-infected cells, parasites, and tumor cells (Tegla et al., 2011). The 
complement system can be divided in three pathways, i.e. the classical, the 
alternative, and the lectin pathway (Figure 2. 2). All three pathways converge at 
the point of C3 cleavage and then generate the membrane attack complex C5b-9, 
leading to bacterial cytolysis (Rus et al., 2005). 
Complement plays an important role in humoral immunity by enhancing both co-
receptor signaling on B cells and antigen retention in follicular dendritic cells 
(Fearon, 2000). Particularly C3 plays multiple roles in regulating the B cell response 
to antigen (Morgan et al., 2005). Its activated form (C3b) binds covalently to the 
target (e.g. antigen), thus tagging it for recognition by the host. Bound C3b is 
proteolytically processed to smaller fragments, C3dg and C3d, which serve as 
ligands for CD21 on B cells and follicular dendritic cells (Cherukuri et al., 2004; Rus 
et al., 2005). Moreover, complement retention on the follicular DCs enhances the 
generation of antibody responses and the maintenance of immunologic memory 
(Youd et al., 2002). 
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 is initiated by C1q binding, primarily to antigen-antibody 
complexes (IgG and IgM) but also to viral envelopes, Gram-negative bacterial walls 
and C-reactive protein (CRP). Activation of C1r and C1s, with generation of C1s 
esterase, is followed by cleavage of C4 and C2. This cleavage releases small 
anaphylactic peptides (C4a and C2b) and allows the assembly of the C3 convertase, 
C4bC2a. The C3 convertase then cleaves C3, generating C3b and C3a, and C3b 
binding to C4b generates the C5 convertase, C4b2a3b. C3b and its further cleavage 
products, iC3b and C3dg, can interact with complement receptors type 1 (CR1), 2 
(CR2) and 3 (CR3) (Ahearn and Fearon, 1989; Krych-Goldberg and Atkinson, 2001). 
, C3 is spontaneously activated at low levels, and the 
resulting C3B covalently attaches to both host cells and pathogens. Host cells 
produce a series of proteins, such as factors H and I, that cause C3b cleavage and 
Bb decay (Xu et al., 2001), as such preventing the complement reaction from 
proceeding on their cell surface. Because pathogens lack these proteins, they are 
singled out for destruction (Alberts et al., 2002). The activation of a serine protease, 
factor D, cleaves factor B into Ba and Bb, when factor B is complexed with 
spontaneously hydrolyzed C3b. Bb is a serine protease that generates the C3 
convertase (C3bBb) of the alternative pathway, whose role is to cleave C5 and of 
which the activity is increased by properdin.  
 is initiated by binding of mannose-binding lectin (MBL) and 
ficolins to carbohydrate groups on the surface of bacterial cells (Fujita et al., 2004). 
Mannose-binding lectin is a serum protein that forms clusters of six carbohydrate-
binding heads around a central collagen-like stalk. This assembly binds specifically 
to mannose and fucose residues in bacterial cell walls that have the correct spacing 
and orientation to match up perfectly with the six carbohydrate-binding sites 
(Alberts et al., 2002). 
Mannose-binding lectin and ficolins are the pattern-recognition molecules typical of 
the lectin pathway and serve to attach the MBL-associated serine proteases (MASP) 
1, 2 and 3, thus activating MASP esterase activity. Upon activation, MASPs cleave 
and activate C4 and C2, thus generating the C3 convertase, C4bC2a (Dahl et al., 
2001; Petersen et al., 2000). Activation of the classical or lectin pathways also 






Figure 2. 2: Activation pathways of the complement system. The classical pathway 
is initiated by the binding of the C1 complex to antibody already bound to antigen, leading 
to the formation of C4b2a enzyme complex (the C3 convertase). The C1 complex consists of 
C1q and two molecules, each of C1r and C1s. The binding of the recognition subcomponent 
C1q to the Fc portion of immunoglonulins results in the autoactivation of the serine protease 
C1r. C1r then cleaves and activates C1s, which translates the activation of the C1 complex 
into complement activation through the cleavage of C4 and C2 to form a C4bC2a enzyme 
complex. C4bC2a acts as a C3 convertase and cleaves C3. The lectin pathway is activated 
by binding of either mannose binding lectine (MBL) or Ficolin and MAPS1, 2, and 3 to an 
array of carbohydrate groups (mannose) groups on the surface of the bacterial cells. MASP2, 
similar to C1s, is responsible for the activation of C4 and C2, which leads to the generation 
of the same C3 convertase (C4bC2a) as in the classical pathway. MASP1 is able to cleave C3 
directly. The alternative pathway is initiated by the low-grade activation of hydrolyzed C3 
(C3H
2
O) and activated factor B (Bb). The activated C3b binds factor B (B), which is then 
cleaved into Bb by factor D (D) to form the alternative pathway C3 convertase, C3bBb. Once 
C3b is attached to the cell surface, the amplification loop consisting of the alternative-
pathway components is activated, and the C3-convertase enzymes cleaves many molecules 
of C3 to C3b, which bind covalently around the site of complement activation. Generation of 
C3 convertase allows the formation of the C5 convertase, which initiates the formation of the 
C5b9 terminal complement complex, i.e. the membrane attack complex (MAC). Figure 
adapted from Fujita (2002), Rus et al. (2005) and Tegla et al. (2011). 
17 
 
Membrane-immobilized C3b molecules, produced by any of the three pathways, 
trigger a further cascade of reactions that leads to the assembly of the late 
components of the complement reaction to form membrane attack complexes. The 
activation of C5 through C9 and the assembly of C5b-9 begins when the C5 
convertase (i.e. C4b2a3b and C3bBb) cleaves C5 to generate C5a and C5b. C5b then 
undergoes a conformational change, exposing a metastable binding site for C6. The 
C5b6 complex can then bind reversibly to the cell membrane. Subsequently, the 
interaction of C7, C8 and C9 with C5b6 complexes leads to the assembly of a 
supramolecular C5b-9 complex, which is able to form transmembrane pores 
(Müller-Eberhard, 1988). This C5b-9 complex, which is effective in inducing cell 
lysis, is also called the membrane attack complex (MAC) (Tegla et al., 2011). 
Adaptive immunity is a relative newcomer on the evolutionary landscape. Because 
the mechanism of generating receptors in the adaptive immune system involves 
great variability and rearrangement of receptor gene segments, the adaptive 
immune system can provide specific recognition of foreign antigens, immunological 
memory of infection, and pathogen-specific adaptor proteins. However, the adaptive 
immune response is also responsible for allergy, autoimmunity and the rejection of 
tissue grafts (Janeway and Medzhitov, 2002). The adaptive immunity adds specific 
recognition of proteins, carbohydrates, lipids, nucleic acids and pathogens to the 
underlying innate immune system. The two systems, i.e. innate and adaptive 
immune system, are linked through the use of the same effector cells (dendritic cells 
or macrophages) (Janeway, 1989). 
Activation of the adaptive immune system occurs upon pathogen recognition by 
antigen presenting cells (APCs), that play a pivotal role at the interface of innate 
and adaptive immunity (Pulendran et al., 2001). Immature dendritic cells reside in 
the peripheral tissues, where they actively sample their environment by endocytosis 
and micropinocytosis. Upon encountering a pathogen, they undergo a 
developmental program called dendritic cell maturation, which includes induction 
of costimulatory activity, antigen processing, increased MHC molecule expression, 
and migration to the lymph nodes, where they can prime naïve antigen-specific T 
cells (Orsini et al., 2003).  
Unlike the innate mechanisms of host defense, the adaptive immune system 
manifests exquisite specificity for its target antigens. Adaptive responses are based 
primarily on the antigen-specific receptors expressed on the surface of T and B 
lymphocytes. The antigen-specific receptors of the adaptive response are encoded 
by genes that are assembled by somatic rearrangement of germline gene elements 
to form intact T-cell receptor (TCR) and immunoglobulin (B-cell antigen receptor) 
genes. This is in contrast to the germline-encoded recognition molecules of the 
innate immune response. The assembly of antigen receptors from a collection of a 




different antigen receptors, each with potentially unique specificity for a different 
antigen (Bonilla and Oettgen, 2010; Chaplin, 2010; Schroeder and Cavacini, 2010). 
The adaptive immunity is mediated by immunoglobulins and T cell receptors 
(TCRs), which are generated through the recombination of variable (V), diversity 
(D) and joining (J) gene segments (Tonegawa, 1983). The V(D)J recombination 
process depends on the recognition of recombination signal sequences (RSSs), which 
flank the segmental elements and this creates extensive variation in the receptor 
structure at junctional (joining) interfaces. The V(D)J rearrangement form of 
somatic recombination occurs in the progenitors of B and T cells and is mediated by 
recombination-activating genes 1 (RAG1) and 2 (RAG2), which function in a 
lymphocyte- and site-specific recombinase complex and are supported by ubiquitous 
DNA repair factors (Gellert, 2002).  
A major challenge faced by the immune system is to identify host cells that have 
been infected by microbes that subsequently use the cell to multiply within the host. 
A major role of the T-cell arm of the immune response is to identify and destroy 
infected cells. T cells can also recognize peptide fragments of antigens that have 
been taken up by antigen presenting cells (APCs) through the process of 
phagocytosis or pinocytosis. The immune system permits T cells to recognize 
infected host cells by the recognition of both a self-component and a microbial 
structure. This is mediated through the use of major histocompatibility (MHC) 
molecules. MHC molecules (also called HLA antigens) are cell-surface glycoproteins 
that bind peptide fragments of proteins that either have been synthesized within 
the cell (class I MHC molecules) or that have been ingested by the cell and 
proteolytically processed (class II MHC molecules) (Chaplin, 2010; Davis and 
Bjorkman, 1988; Menéndez-Benito and Neefjes, 2007; Watts, 2004). 
There are three major MHC class I molecules, i.e. HLA-A, HLA-B and HLA-C. The 
class I HLA molecules are cell-surface heterodimers consisting of a polymorphic 
transmembrane α chain associated with the nonpolymorphic β2-microglobulin 
protein (Bjorkman, 1997). It is the α chain that determines whether the class I 
molecule is an HLA-A, HLA-B or HLA-C molecule. The α-chain gene encodes three 
extracellular domains (α1, α2 and α3), a transmembrane domain that anchors the 
protein in the cell membrane and a short intracellular domain. The α1 and α2 
domains associate with each other, forming a groove in which the antigenic peptide 
can bind (Cresswell et al., 1999; Monaco, 1992; Rammensee et al., 1993). 
The antigenic peptides that are found bound in the peptide-binding groove of the 
MHC class I molecules are derived from proteins synthesized within the cell (Figure 
2. 3)(Huston, 1997).  
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The peptide fragments are generated from cellular proteins through the action of 
the proteasome (Niedermann, 2002). After exiting the proteasome, peptide 
fragments are transported into the endoplasmatic reticulum (ER) by the action of a 
specific multi-subunit transmembrane transporter, the transporter associated with 
antigen presentation (TAP). Once in the ER, the peptides are loaded into the class 
I protein-binding groove under the direction of the ER protein tapasin with the help 
of the calcium-binding chaperone protein calreticulin and the oxidoreductase Erp57 
(Garbi et al., 2006; Momburg and Tan, 2002). Before its interactions with β2-
microglobulin, the class I protein is maintained in a conformation that favors the 
interaction with peptide fragments by association with chaperone protein calnexin. 
Interaction with β2-microglobulin stabilizes the complex, causing dissociation of 
calnexin and permitting transport of the peptide-loaded class I molecule through 
the Golgi complex into exocytic vesicles that release the intact complexes onto the 
cell surface. This pathway is well adapted to delivering viral peptides produced in 
a virus-infected cell to the cell surface bound class I HLA molecules in a form that 
can be recognized by cytotoxic CD8+ T cells (Melief, 2003; Sigal et al., 1999). 
The complex forming the class I MHC molecule and antigenic peptide produces a 
composite structure that is the molecular target of the TCR. The TCR contacts both 
the antigenic peptide and the flanking α-helices of the peptide-binding groove. The 
TCR has no measurable affinity for the antigenic peptide alone and very low affinity 
for MHC molecules (Zinkernagel and Doherty, 1997). A key biological consequence 
of requiring the T cell to recognize antigenic peptides only when they are bound into 
the groove of an MHC molecule is that this permits the T cell to ignore free 
extracellular antigen and to focus rather on cells that contain the antigen. In the 
case of cells that are infected by a pathogenic microbe, this permits the T cells to 
focus their response on the infected cells. The α3 domain of the class I heavy chain 
interacts with the CD8 molecule on cytolytic T cells. The binding of CD8 expressed 
by the T cell to the α3 domain of the class I molecule expressed by the APC 
strengthens the interaction of the T cell with the APC and helps ensure that full 
activation of the T cell occurs (Joshi and Kaech, 2008). 
Like the class I molecules, the class II MHC molecules consist of two polypeptide 
chains, but in this case both are MHC-encoded transmembrane proteins and are 
designated α and β. There are three major class II proteins, i.e. HLA-DR, HLA-DQ 
and HLA-DP. Each chain of the class contains a short cytoplasmatic anchor, a 
transmembrane domain, and two extracellular domains designated for the α chain, 
α1 and α2, and for the β chain,β1 and β2 (Bjorkman, 1997). When the α and β chains 
pair, the α1 and β1 domains combine to form a peptide-binding groove very similar 
in structure to that formed by the association of the α1 and α2 domains of the MHC 
class I proteins. The α2 and β2 domains of the proteins provide support for this 
peptide-binding domain. The β2 domain also interacts with CD4 expressed on the 




expressing APCs in a fashion similar to the way that CD8 is bound to the MHC 
class I molecule and enhances the cytotoxic T-cell activation (König et al., 1996).  
 
 
Figure 2. 3: The basic MHC class I antigen presentation pathway. The presentation 
of intracellular antigenic peptides by MHC class I molecules is the result of a series of 
reactions. First, antigens are degraded by the proteasome. Then, the resulting peptides are 
translocated via transporter associated with antigen presentation (TAP) into the 
endoplasmic reticulum (ER) lumen and loaded onto the MHC class I molecules. Peptides-
MHC class I complexes are released from the ER and transported via the Golgi to the plasma 
membrane for antigen presentation to CD8+ T cells. β2m, β2-microglobulin; TCR, T cell 
receptor. Figure adapted from Chaplin (2010) and Neefjes et al. (2011). 
 
The class II proteins are expressed constitutively on the B-cells, dendritic cells, 
monocytes and macrophages. All these cells present antigens to CD4+ T cells. 
Expression of MHC class II proteins can also be induced on many additional cell 
types, including epithelial and endothelial cells after stimulation with IFN-γ, 
permitting these cells to present antigens to CD4+ T cells at sites of inflammation 
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(Dengjel et al., 2005; Dongre et al., 2001; Menéndez-Benito and Neefjes, 2007). 
Antigens that are presented by class II proteins are loaded into the class II peptide-
binding groove through the “exogenous” pathway that starts by endocytosis or 
phagocytosis of extracellular proteins (Huston, 1997). The exogenous antigens 
include antigenic proteins of extracellular pathogens, such as most bacteria, 
parasites and virus particles that have been released from infected cells and taken 
up by phagocytosis (Figure 2. 4).  
The ingested antigens are processed to linear peptide fragments by means of 
proteolysis after fusion of lysosomes with the phagocytic vacuoles or endosomes to 
form an acidic compartment (Turley, 2000). The peptide fragments then accumulate 
in the MHC II loading compartment, where they encounter nascent class II 
proteins. The α and β chains of the class II molecules are synthesized in the ER. To 
protect the class II molecule’s peptide-binding groove so that it can later 
accommodate an antigenic peptide, the α and β chains associate with the 
nonpolymorphic invariant chain (Ii), assisted by the chaperone protein calnexin. A 
portion of the Ii chain designated class II-associated invariant chain peptide lies in 
the peptide-binding groove of the class II heterodimer, preventing binding of 
antigenic peptides. Once the class II-Ii complex has formed, it dissociates from 
calnexin and is transported to the class II loading compartment (Van Kaer, 2001). 
In the class II loading compartment, the bulk of the Ii is degraded by acid proteases, 
such as cathepsins, and exchange of the class II-associated invariant-chain peptide 
for an antigenic peptide is catalyzed by the action of the HLA-DM molecule, 
resulting in the formation of a mature class II protein (Sadegh-Nasseri et al., 2008; 
Van Lith et al., 2010). The class II proteins loaded with antigenic peptide are then 
delivered to the cell surface by means of fusion of the class II+ endosome to the 
plasma membrane (Chaplin, 2010). 
V(D)J recombination, i.e. the recombination of variable (V), diversity (D) and joining 
(J) gene segments, is the specialized DNA rearrangement used by cells of the 
immune system to assemble T-cell receptor and immunoglobulin genes from 
preexisting gene segments (Figure 2. 5). Because there is a large choice of segments 
to join, this process accounts for much of the diversity of the immune response. 
V(D)J recombination is initiated by breakage at precisely defined locations in the 
DNA, but is then completed by a repair process related to the repair of DNA breaks 
caused by ionizing radiation or other genotoxic agents (Fugmann et al., 2000; 






Figure 2. 4: The basic MHC class II antigen presentation pathway. MHC class II α- 
and β-chains assemble in the endoplasmic reticulum (ER) and form a complex with the 
invariant chain (Ii). The Ii-MHC class II heterotrimer is transported through the Golgi to the 
MHC class II compartment (MIIC), either directly and/or via the plasma membrane. 
Endocytosed proteins (or pathogens) and Ii are degraded by resident proteases in the MIIC. 
The class II associated Ii peptide (CLIP) fragment of Ii remains in the peptide groove of the 
MHC class II dimer and is exchanged for an antigenic peptide with the help of the dedicated 
chaperone HLA-DM. MHC class II molecules are then transported to the plasma membrane 
to present antigenic peptides to CD4+ T cells. APC, antigen-presenting cells; TCR, T cell 
receptor. Figure adapted from Chaplin (2010) and Neefjes et al. (2011). 
 
Two types of nucleotide insertions are found in coding joints, nontemplated and 
templated. Nontemplated tracts up to 15 nucleotides in length (so-called N regions) 
are added by the enzyme called terminal deoxynucleotidyl transferase (TdT). 
Expression of TdT is normally limited to early lymphoid cells where V(D)J 
recombination is active and therefore these insertions are relatively specific to this 
type of recombination. TdT adds deoxynucleotides without a template to the ends of 
DNA chains, but with a preference for G residues that results in N regions being 
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generally GC-rich (Gilfillan et al., 1993; Komori et al., 1993). A templated type of 
nucleotide addition is also found in coding joints. These additions are more 
significant for the basic recombination mechanism. These palindromic nucleotide 
insertions add a few nucleotides complementary to the last bases of the coding end 
next to the RSS. They result from off-center nicking of the hairpin DNA 
intermediates that are formed at coding ends by the action of the RAG proteins 
(Lafaille et al., 1989; Lewis, 1994b). 
The V(D)J recombination has two distinct stages. In the first stage, the RAG1 and 
RAG2 proteins cooperate to recognize the RSSs and to ensure their correct 12/23 
pairing, and to break the DNA between each heptamer and the neighboring coding 
sequence. In the later stage, factors, that are also used in other types of 
nonhomologous end joining, process and link the ends into coding joints and signal 
joints (Gellert, 2002). 
The later steps of V(D)J recombination have many aspects in common with general 
DNA double-strand break repair, and the two processes share a number of factors 
(e.g. DNA-dependent protein kinase (DNA-PK) Ku protein, DNA ligase IV, Xrcc4, 
Artemis, histone H2AX and the Mre11/Rad50/Nbs1 complex) (Jeggo, 1998; Steen et 
al., 1996). V(D)J recombination is regulated in at least two ways, first by the 
expression pattern of RAG1 and RAG2, and secondly by the limited access of the 
recombination machinery to particular DNA sites. RAG1 and RAG2 are normally 
expressed together, and only in early lymphoid cells (Nagaoka et al., 2000). 
Antibody class, or isotype, is determined by the heavy chain constant (CH) region, 
which is important for determining the antibody’s effector function. The CH region 
is bound by cell-surface receptors, e.g., Fc receptors on many cell types, poly Ig 
receptors on mucosal epithelial cells, and by complement. Different CH regions have 
different affinities for these proteins, thus greatly influence antibody function 
(Horikawa et al., 2007; Martin and Goodnow, 2002; Waisman et al., 2007). 
Isotype switching occurs by an intrachromosomal deletional recombination event 
(Figure 2. 5). Class switch recombination (CSR) occurs between switch (S) regions 
located upstream of each of the CH regions except Cδ and results in a change from 
IgM and IgD expression by naïve B cells to expression of one of the downstream 
isotypes. IgD expression occurs by alternative transcription termination/splicing of 
the Cμ – Cδ genes. S regions consist of tandem repeats of short G-rich sequences 
(20 – 80 bp), which differ for each isotype, with an overall length varying from ~1 
kb to 12 kb, and CSR can occur anywhere within or near the S regions (Dunnick et 
al., 1993; Min et al., 2005). Class switch recombination occurs by end-joining type 








Figure 2. 5: Antigen receptor diversification. A| Schematic of the B-cell receptor (BCR) 
heavy locus. Antigen receptor repertoire diversity is primarily established during 
lymphocyte development, during which V (green), D (brown), and J (blue) gene segments are 
rearranged through the process of V(D)J recombination. (Murphy et al., 2008). During the 
recombination process, nucleotides may be added or deleted at segment junctions (not 
shown), contributing to additional sequence diversity. In class-switch recombination, gene 
segments encoding constant regions (dark green) are rearranged resulting in the production 
of antibodies with different isotypes and corresponding effector functions. BCRs and TCRs 
are similarly organized. The TCRβ locus undergoes similar V(D)J recombination as the BCR, 
with the exception of somatic hypermutation and class-switch recombination. B| BCRs are 
composed of two distinct subunit chains: light chain and heavy chain. The antigen binding 
surface is formed by the variable region of each chain, which is encoded by recombined V, J, 
and D heavy gene segments. Abbreviations: BCR, B cell receptor; TCR, T cell receptor; V, J, 




B cells undergo antibody, or Ig, class switching in vivo after B-cell maturation which 
is driven by immunization or infection, or upon appropriate activation in culture. 
Engagement of the CD40 receptor on B cells by CD40L (CD154) provides crucial 
signaling for CSR (Stavnezer et al., 2008). The process of class-switching is partly 
under cytokine control, e.g. IL4 and IL13 promote switching to IgE and IFN-γ can 
antagonize this effect (Oettgen, 2000). IL10 and TGFβ promote switching to IgA 
(Johansen and Brandtzaeg, 2004). Class switch recombination requires a minimum 
of two complete rounds of cell division for IgG and IgA CSR and perhaps additional 
rounds for IgE CSR (Deenick et al., 1999; Hasbold et al., 1998; Hodgkin et al., 1996; 
Rush et al., 2005). This requirement seems to be at least partially due to the 
requirements for induction of activation-induced cytidine deaminase (AID) 
expression (Rush et al., 2005). Naïve B cells have the potential to switch to any 
isotype, and cytokines secreted by T cells and other cells direct the isotype switching 
(Stavnezer, 1996a, 1996b).  
Class switch recombination and somatic hyper mutation (SHM) are initiated by 
AID, which converts cytosines in S regions and Ig variable regions to uracils (dU) 
by deamination (Chaudhuri et al., 2003; Dickerson et al., 2003; Muramatsu et al., 
2000; Petersen-Mahrt et al., 2002; Pham et al., 2003; Revy et al., 2000). Subsequent 
repair of the dU residues leads to single-stranded DNA breaks (SSBs) within the 
donor Sµ region and within an acceptor Sx region, to initiate the process of 
intrachromosomal DNA recombination. Removal of the dU residues by enzymes 
within the base excision repair (BER) pathway is required to introduce the DNA 
breaks necessary for CSR (Petersen-Mahrt et al., 2002; Rada et al., 2002; Schrader 
et al., 2005). BER consists of highly active ubiquitous DNA repair pathways for 
repairing oxidized and deaminated bases, which are generated more than 104 times 
per cell per day by oxidation, especially during inflammation, and by spontaneous 
hydrolysis (Christmann et al., 2003). There are four mammalian uracil DNA 
glycosylases in the BER pathway, UNG, SMUG1, MBD4 and TDG. It is UNG that 
excises the dU residue created by AID activity (Bardwell et al., 2003; Rada et al., 
2002). 
The BER enzyme that repairs the abasic sites left by UNG activity is 
apurinic/apyrimidinic endonuclease (APE), which incises the phosphate backbone 
of DNA at abasic sites, producing SSBs (Christmann et al., 2003). In the canonical 
BER pathway, the single-nucleotide gap generated by the action of UNG and APE 
is filled in by the DNA polymerase β (Pol β) (Barnes and Lindahl, 2004; Beard and 
Wilson, 2006). A second repair pathway, mismatch repair (MMR), contributes to 
CSR but is not essential. The major role of MMR in all cells is to correct 
misincorporated nucleotides during DNA synthesis (Kunkel and Erie, 2005). The 
most attractive model for the role of MMR during CSR is to convert SSBs that are 
not near each other on the opposite DNA strands to DSBs (Stavnezer and Schrader, 
2006). If the SSBs that are introduced by AID-UNG-APE are near each other on 




not destabilize the duplex and are simply repaired. As S regions are large and the 
breaks appear to occur anywhere within S regions (Dunnick et al., 1993; Min et al., 
2005; Schrader et al., 2005), it seems unlikely that the SSBs would be sufficiently 
proximal to form a DSB most of the time. Mismatch repair could convert these distal 
SSBs to DSBs that are required for CSR. After DSB formation, 5’ or 3’ single-
stranded overhangs remain. These tails must be excised or filled in to create blunt, 
or nearly blunt, DSBs appropriate for an end-joining recombination with the other 
S regions (Schrader et al., 2004). MMR normally recruits the processivity factor 
proliferating cell nuclear antigen (PCNA) and replicative DNA polymerase for fill-
in synthesis of 5’ overhangs (Kunkel and Erie, 2005). However, replicative Pol 
cannot replicate past an abasic site, resulting in the recruitment of error-prone 
translation Pols. After formation of the DSBs in the donor and acceptor S regions, 
the S regions are recombined using ubiquitous proteins that perform 
nonhomologous end-joining (NHEJ) in all cell types (Stavnezer et al., 2008).  
The major class of T cells are defined by its surface expression of the αβ T cell 
receptor (TCR). This receptor has evolved primarily to recognize peptide antigens 
presented in complex with class I or class II MHC proteins. αβ T cells differentiate 
into several different subsets, CD8+ T cells act primarily to kill cells infected with 
intracellular microbes, whereas CD4+ T cells regulate the cellular and humoral 
immune response (Bonilla and Oettgen, 2010; Chaplin, 2010).  
Each individual T cell bears antigen receptors of a single specificity. A repertoire of 
T cells that can protect against the vast universe of microbial pathogens must 
therefore include a very large number of cells encoding a huge array of discrete 
TCRs. These receptors are somatically assembled using VDJ recombination 
(Nguyen et al., 2007). 
Selection of cells carrying functional TCR genes occurs in the thymus (Hedrick, 
2008; Huston, 1997; Jenkinson et al., 2006; Miller, 2002; Takahama, 2006). The 
thymus contains three compartments, i.e. the subcapsular zone, the thymic cortex 
and the thymic medulla. The subcapsular zone is where bone marrow-derived 
prothymocytes begin to differentiate, proliferate, and rearrange their TCR β chains. 
The cells then move to the thymic cortex, where the α chain gene elements 
rearrange, potentially forming a functional, mature αβ TCR. In the cortex, the TCR 
are tested for a sufficient affinity for MHC molecules to permit them to ultimately 
recognize antigen-MHC complexes. This involves the interactions between the 
developing lymphocyte and the specialized cortical epithelium (Nitta et al., 2008). 
If the lymphocyte fails this positive selection, it undergoes apoptosis and is cleared 
by the thymic cortical macrophages. In the thymic medulla the thymocytes are 
screened for potential autoreactivity. This screening includes testing for reactivity 
for an extensive array of tissue-specific proteins that are expressed by a population 
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of thymic medullary epithelial cells under the control of a gene called autoimmune 
regulator (AIRE) (Mathis and Benoist, 2009). Cells that recognize self-peptides 
expressed by these epithelial cells are removed by means of apoptosis, and cells that 
have survived this negative selection are exported to the circulation.  
During their progress through the thymus, αβ T cells differentiate into discrete 
subpopulations, each with defined repertoires of effector functions. The major 
subsets are defined by their selective surface expression of CD4 and CD8. In the 
thymus, most developing T cells follow a developmental program in which they first 
express neither CD4 nor CD8 (double negative) and then express both CD4 and CD8 
(double positive), in the cortex (von Boehmer et al., 1989). Double-positive cells are 
tested by means of positive selection in the thymic cortex, and those that are 
selected on class I MHC molecules become CD4-CD8+ and those selected on class II 
MHC molecules become CD4+CD8-. CD4+ T cells are generally designated helper 
cells and activate both humoral immune responses (B-cell help) and cellular 
responses (delayed-type hypersensitivity responses). CD8+ cells show a major 
cytotoxic activity against cells infected with intracellular microbes and against 
tumor cells but also contain regulatory cells that down-regulates immune responses 
(suppressor cells) (Chaplin, 2010).  
Less than 5 % of the developing T cells survive positive and negative selection. 
Approximately 90 to 95 % of the circulating T cells use the αβ TCR, the other 5 to 
10 % use an alternate heterodimeric TCR composed of γ and δ chains. The γ and δ 
chains also assemble by means of RAG1/RAG2-mediated rearrangement of V, D (for 
the δ chain only) and J elements. A portion of the γδ T cells are generated in the 
thymus, but a major fraction appears to be generated in an extra thymic 
compartment, resulting in cells that largely populate the gastrointestinal tract 
(Ishikawa et al., 2007). 
The antigen-specific α and β chains of the TCR associate with invariant accessory 
chains that serve to transduce signals when the TCR binds to antigen-MHC 
complexes (Salmond et al., 2009). These accessory chains make up the CD3 complex, 
consisting of the transmembrane CD3γ, CD3δ and CD3ε chains plus a largely 
intracytoplasmic homodimer of two CD3ξ chains. Interaction of the TCR/CD3 
complex with antigenic peptide presented in an HLA molecule provides only a 
partial signal for cell activation.  
Although the basic principles of thymic development and the mechanisms of 
activation are shared by all T cells, there is a remarkable diversity of effector 
functions that are elicited in response to activation. T cells can play direct roles in 
elimination of pathogens by killing infected target cells. Moreover, they can also 
function as helper cells, providing cognate (involving direct cellular contact) or 
cytokine signals to enhance both B- and T-cell responses, as well as causing 
activation of mononuclear phagocytes. Finally, T-cells regulate the immune 




inflammatory immune responses (Bonilla and Oettgen, 2010). Both CD4+ and CD8+ 
T cells differentiate into functionally distinct subsets after exposure to antigen.  
Mature T-cells are activated on interaction of their TCRs with antigenic peptides 
complexed with MHC molecules. CD8+ T cells can interact with peptides on almost 
any cell expressing MHC class I (Melief, 2003; Sigal et al., 1999), whereas the TCRs 
of CD4+ T cells engage peptides bearing MHC class II (König et al., 1996). The T-
cell activation is initiated when the TCR and associated proteins recognize a 
peptide/MHC complex on an APC, leading to rapid clustering of TCR-associated 
molecules at the physical interface between T cells and APCs and the formation of 
a so-called immunologic synapse (Dustin, 2009). The T-cell side of the synapse is 
focused around a central cluster of CD3 (γ, δ, ε and ξ) and TCR (α and β), which bind 
specifically to the peptide/MHC complex, as well as CD4/CD8 molecules, which 
stabilize this interaction by binding to nonpolymorphic regions of MHC class I or 
MHC class II, respectively. Adhesion molecules known as integrins stabilize the 
synapse. The aggregation of these molecules in the synapse facilitates the early 
events in TCR signaling (Bonilla and Oettgen, 2010; Nurieva et al., 2009).  
Simultaneous binding to MHC/peptide on the APCs by TCRs and CD4/CD8 in the 
synapse brings the cytosolic domains of these molecules into proximity. As a result, 
the CD4- and CD8-associated Src family protein tyrosine kinase Lck is able to 
phosphorylate tyrosine residues contained in cytoplasmic immunoreceptor tyrosine-
based activation motifs of the TCR-associated CD3 chains. This results in the 
recruitment of the critical adaptor molecule, ξ-associated protein, 70 kd (ZAP-70), 
which binds to immunoreceptor tyrosine-based activation motif phosphotyrosines 
and phosphorylates a number of cytosolic proteins. This subsequently triggers the 
assembly of an intracellular complex of scaffolding and activated signaling proteins, 
including linker of activated T cells (LAT) and SH2-containing leukocyte protein, 
76 kd (Bonilla and Oettgen, 2010; Dustin, 2009). 
B-cells constitute around 15 % of peripheral blood leukocytes and are defined by 
their production of immunoglobulin (Chaplin, 2010). An important function of B 
cells during an immune response is to produce high affinity antigen-specific (Ag-
specific) immunoglobulins (Ig) which facilitate the eradication by phagocytosis of 
infectious pathogens through efficient opsonisation. Following antigenic 
stimulation, IgM+ IgD+ naïve B cells can undergo isotype switching to produce IgG, 
IgA or IgE antibodies while retaining their antigen specificity (Snapper et al., 1997). 
B cells obtain help from T cells by acting as antigen-specific APCs. Antigen 
recognition is sequential rather than simultaneous: first, the B-cell binds antigen 
with its antigen receptor membrane Ig and internalizes and degrades the antigen. 
Subsequently it presents peptides from the antigen on the cell surface bound class 
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II MHC molecules. Finally the T cell recognizes the processed antigen on the B cell 
surface and mutual activation results (Parker, 1993). Each Ig has two identical 
antigen-binding sites. The carboxyl terminal portions of the heavy and light chains 
are constant in each subclass of antibody. The heavy chain constant regions pair to 
form the Fc domain of the molecule that is responsible for most of the effector 
functions of the Ig molecule, including the binding of Fc receptors on macrophages 
and the activation of the complement system (Hoebe et al., 2004). 
Mature B cells recirculate through secondary lymphoid organs, including lymph 
nodes, the spleen and mucosal-associated lymphoid tissues. In the lymph nodes, B 
cells are concentrated in the cortex in primary follicles in contact with follicular 
dendritic cells. T cells are in the paracortical areas. Low-molecular-weight antigens 
might diffuse directly into B-cell areas in secondary lymphoid tissues (Batista and 
Harwood, 2009). Antigens complexed to varying degrees with IgM, IgG, and 
complement might be carried on the surfaces of specialized macrophages, follicular 
dendritic cells, or even B-cells themselves, all of which have receptors for IgG Fc 
and complement fragments. Antigen presented on these surfaces can stimulate B 
cells through Ig receptor cross-linking, expression of other interacting surface 
molecules, and cytokine secretion. B cells require two principle types of signals to 
become activated.  
B-cells are activated as APCs and express peptides along with MHC class II on their 
surface (Pulendran et al., 2001). These peptides can arise from processed antigen 
that was internalized after binging on to the B-cell surface immunoglobulin 
receptor. When the B-cell contacts a CD4+ T cell specific for the combination of such 
a peptide with self-MHC class II and that has been previously activated by an APC, 
the CD4+ T cell is able to provide cognate help and activate the B cell for further 
differentiation into memory cells or plasma cells (König et al., 1996). The activated 
B cells enters one of two pathways, i.e. they either immediately become short-lived 
plasma cells secreting low-affinity antibodies without somatic mutation, or they 
enter a follicle to establish a germinal center (Allen et al., 2007). In the germinal 
center, B cells undergo class-switching (Stavnezer et al., 2008). 
At the same time that class-switching is occurring, a mechanism of nucleotide 
substitution is activated, leading to the accumulation of point mutations in the 
immunoglobulin heavy and light chains of the variable regions, in a process known 
as SHM (Peled et al., 2008; Steele, 2009). Also here, the enzymes AID and UNG are 
important for the DNA cutting and splicing event of class-switching, as well as for 
the nucleotide substitutions leading to SHM (Peled et al., 2008). 
The immune response to the first exposure to an antigen is called the primary 
response. It is relatively slow, taking a few weeks to develop fully, and leads to 




such as IgG, IgA or IgE, appear relatively late (often more than two weeks) and 
show higher affinity (affinity maturation). During the primary response, memory T 
cells and B cells are generated. In a subsequent exposure to the same antigens, 
these cells are activated more quickly in comparison with a primary response, so 
that production of high-affinity IgG (or IgA or IgE) is established within one week. 
This is called a secondary response (Bonilla and Oettgen, 2010; Murphy et al., 2008).  
Cells of the immune system require communication networks that can, as required, 
act locally or at a distance, specifically or globally, and transiently or in a sustained 
manner. This immune cell communication is conducted mainly by cytokines and 
chemokines. The term cytokine defines a large group of non-enzymatic proteins 
whose actions are both diverse and overlapping and which affect diverse and 
overlapping target cell populations (Kelso, 1998; Opals and DePalo, 2000). 
Chemokines on the other hand are essential for the trafficking of immune effector 
cells to sites of infection. Moreover, their function is necessary to translate an innate 
immune response into an adaptive response. Innate immune stimuli, through 
activation of TLR, set in motion a genetic program that induces the expression of a 
subset of chemokines from resident tissue macrophages and dendritic cells, and 
modulates the expression of chemokine receptors on dendritic cells (Luster, 2002; 
Nomiyama et al., 2010). 
Chemokines are small heparine-binding proteins that form a family of chemotactic 
cytokines that regulate migration and tissue localization of various kinds of cells in 
the body (Charo and Ransohoff, 2006; Moser et al., 2004; Zlotnik and Yoshie, 2000). 
In particular, they participate in inflammatory leukocyte recruitment, in 
lymphocyte recirculation and homing, and even in cancer metastasis (Ben-Baruch, 
2008; Gerard and Rollins, 2001). Chemokines have a well conserved region of four 
cysteines and are grouped into five subfamilies, CXC, CC, XC, CX3C and CX, based 
on the arrangement of the two N-terminal cysteine residues (Table 2. 3) (Nomiyama 
et al., 2010). A single chemokine can bind to several chemokine receptors, whereas 
a single chemokine receptor can have multiple chemokine ligands (Zlotnik and 
Yoshie, 2012). The recognition of chemokine-encoded messages is mediated by 
specific cell-surface G-protein-coupled receptors (GPCRs) with seven 
transmembrane domains (Murphy, 2002). 
Infectious microorganisms can directly stimulate chemokine production by tissue 
dendritic cells (DCs) and macrophages as well as by many parenchymal and stromal 
cells. Conserved microbial PAMPs induce chemokines through pattern recognition 
receptors, such as TLRs, or NOD1 and NOD2 (Girardin et al., 2003; Janeway and 
Medzhitov, 2002). Classically the major inflammatory and immunomodulatory 
cytokines such as IL1, TNFα, IFNγ, IL4, IL5, IL6, IL13, and IL17, induced in injury 
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or infection, stimulate through their respective receptors the production of many 
different chemokines (Baggiolini et al., 1997; Luster, 1998; Rollins, 1997). 
Cytokines are local mediators produced by cells of the lymphoid and macrophage 
lineage as well as by epithelial and mesenchymal cells. Cytokines are involved in a 
variety of biological processes, including cell activation, growth, and differentiation, 
and they are central to the development of inflammation and immunity (Elson, 
1996; Sartor, 1994). Cells of the innate immune system, such as macrophages and 
monocytes, are able to mount a rapid response to a danger signal, e.g. an infectious 
agent, by secreting several pro-inflammatory cytokines such as interleukin (IL)1, 
IL6, IL12, and tumor necrosis factor (TNF)-α. The cytokine milieu subsequently 
directs the development of adaptive immunity mediated by T and B lymphocytes 
(Papadakis and Targan, 2000). The typical cytokine is a glycosylated monomeric 
peptide of about 150 amino acids (Kelso, 1998). The cytokines are not, however, 
members of a single gene superfamily. Remarkably few similarities have been noted 
in their primary nucleotide or amino acid sequences and their genes are, for the 
most part, scattered throughout the genome (Dinarello, 2000). Currently, there are 
18 cytokines with the name interleukin (IL) (Cannon, 2000). Some cytokines clearly 
promote inflammation and are called pro-inflammatory cytokines, whereas other 
cytokines suppress the activity of pro-inflammatory cytokines and are called anti-
inflammatory cytokines (Dinarello, 2000).  
The concept that some cytokines function primarily to induce inflammation while 
others suppress inflammation is fundamental to cytokine biology and also to clinical 
medicine (Dinarello, 2000; Opals and DePalo, 2000). A dynamic and ever-shifting 
balance exists between pro-inflammatory cytokines and anti-inflammatory 
components of the human immune system. The regulation of inflammation by these 
cytokines and cytokine inhibitors is complicated by the fact that the immune system 
has redundant pathways with multiple elements having similar physiologic effects 
(Kasai et al., 1997; Munoz et al., 1991). The net effect of any cytokine is dependent 
on the timing of cytokine release, the local milieu in which it acts, the presence of 
competing or synergistic elements, cytokine receptor density, and tissue 
responsiveness to each cytokine (Cannon, 2000; Dinarello, 1998). Different 
immunogens induce the synthesis of different cytokines, which in turn activate 
different immune effector mechanisms. Although every nucleated cell type can 
produce cytokines, most lineages express only a subset of cytokine genes (Cannon, 
2000; Kelso, 1998). 
Within a given lineage, there are several critical levels of control of cytokine 
synthesis. One is the inducing signal. Cytokines are generally not produced 
constitutively but the nature of the stimuli that can trigger synthesis varies with 
the cell type and its differentiation or activation state, and determines which 




recognizing either specifically or non-specifically as non self: antigen or antigen-
MHC complexes acting via clonotypic receptors on B or T cells; antigen-antibody 
complexes acting via FC and complement receptors on various lymphoid and 
inflammatory cell types; superantigens (such as bacterial endotoxins) acting via 
non-polymorphic regions of certain TCR Vβ chains; and other constituents of micro-
organisms (Kelso, 1998; Thomson and Lotze, 2003). Once cytokine genes become 
amenable to transcriptional activation, there are two major levels at which 
synthesis of cytokines is regulated: transcription rate and mRNA turnover. This has 
the practical consequence that cytokine mRNA levels are a valid guide to protein 
production levels in many situations (Akira and Kishimoto, 1997; Jain et al., 1995; 
Rao et al., 1997; Smale, 2014). Most cytokines are synthesized with a conventional 
signal sequence that results in their translocation into the Golgi apparatus and 
rapid secretion from the cell. There are, however, several translational and post-
translational levels at which production and release of some cytokines are 
regulated. 
Cytokines deliver signals to target cells via membrane-spanning receptors 
(Dinarello, 1994; Nicola and Metcalf, 1988). Most cytokine receptors comprise two 
or more ligand-binding polypeptide chains and, in many cases, one or more of these 
chains is shared with the receptor for another cytokine. A consequence of this 
multimeric structure is that most cytokine receptors can exist in two or more 
affinity states, depending on the availability of individual receptor chains to join the 
complex (Karnitz and Abraham, 1996; Sugamura et al., 1996). Ligand-induced 
cross-linking of cytokine receptor chains causes interaction of their associated 
Janus kinases (JAKs). It is thought that the Jaks first phosphorylate each other 
and thereafter phosphorylate sites in the cytoplasmic receptor domains (Yamaoka 
et al., 2004). The latter events enable Signal Transducer and Activator of 
Transcription (STAT) binding and phosphorylation, as well as triggering the 
Ras/MAP kinase and phosphatidylinositol cascades (Karnitz and Abraham, 1996). 
Activation of the bound STAT molecules causes homo- or heterodimerization to 
another STAT molecule. These STAT dimers then translocate to the nucleus where 
they bind to the regulatory regions of the relevant cytokine-responsive genes to 
initiate transcription (Kelso, 1998). In general, specificity in cytokine receptor 
signaling appears to be achieved through the association between the receptor itself 
and a particular STAT, rather than via the JAKs (Kaplan et al., 1996a, 1996b; Kopf 
et al., 1993; Kuhn et al., 1991).  
Here we will discuss some, i.e., IL1, IL2, IL6, IL10 and TGFβ, but not all 
interleukins. The IL1 cytokine family comprises four main members IL1α, ILβ, IL1 
receptor antagonist (IL1ra/IL1RN) and IL18 (Girn et al., 2007). The IL1 family is 
primarily considered to be pro-inflammatory, as it can up-regulate host defenses 
and act as an immunoadjuvant (Dinarello, 1997a). IL1β plays a significant role in 
inflammation, as it has been implicated in enhancing expression of cell adhesion 
molecules on the endothelial surface and has consequently been deemed to be pro-
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atherogenic (Dinarello, 1999). The only member of this family with paradoxical 
properties is IL1RN, a naturally occurring cytokine antagonist, which plays an anti-
inflammatory role in regulating IL1 function (Dinarello and Thompson, 1991; 
Perrier et al., 2006). IL1RN blocks the action of IL1α and IL1β functional ligands 
by competitive inhibition at the IL1 receptor level (Dinarello, 1997b; Sims et al., 
1993). After attachment of IL1 to its receptor, intracellular signaling occurs after a 
heterodimeric complex is formed between the IL1 receptor and an essential second 
protein known as IL1 receptor-accessory protein (Greenfeder et al., 1995). IL1RN 
will bind with high affinity to the IL1 receptor but fails to engage the IL1 receptor 
accessory protein. This occupies the membrane-bound IL1 receptor binding site and 
prevents cellular activation by IL1α or IL1β by steric inhibition (Schreuder et al., 
1997). The anti-inflammatory cytokines IL4, IL6, IL10 and IL13 inhibit the 
synthesis of IL1β and stimulate the synthesis of IL1RN (Dinarello, 1997b).  
The IL2 family comprises four representative members: IL2, IL4, IL5 and 
granulocyte-monocyte colony stimulating factor (GM-CSF). The most noteworthy 
action of IL2 relates to its mitogenic effects on T lymphocytes in response to 
antigenic stimulation, including the generation of both cytotoxic and suppressor T 
cells (Girn et al., 2007). IL4 is a highly pleiotropic cytokine that is able to influence 
TH cell differentiation. Early secretion of IL4 leads to polarization of TH cell 
differentiation towards TH2-like cells (Mosmann et al., 1986), which secrete their 
own IL4, and subsequently autocrine production of IL4 supports cell proliferation. 
The TH2 cell secretion of IL4 and IL10 leads to the suppression of TH1 responses by 
down-regulating the production of macrophage-derived IL12 and inhibiting the 
differentiation of TH1-type cells (Brown and Hural, 1997; Kelso, 1995; Mosmann et 
al., 1986). IL4 drives TH2 responses, mediates the recruitment and activation of 
mast cells, and stimulates the production of IgE antibodies via the differentiation 
of B cells into IgE-secreting cells (Brown and Hural, 1997; Wang et al., 1995). IL4 
has marked inhibitory effects on the expression and release of the pro-inflammatory 
cytokines. It is able to block or suppress the monocyte-derived cytokines including 
IL1, TNFα, IL6, IL8 and macrophage inflammatory protein (MIP)-1α (Brown and 
Hural, 1997; Paul, 1991; te Velde et al., 1990; Wang et al., 1995). It has also been 
shown to suppress macrophage cytotoxic activity, parasite killing and macrophage-
derived nitric oxide production (Vannier et al., 1992). In addition to its inhibitory 
effects on the production of pro-inflammatory cytokines, it stimulates the synthesis 
of the cytokine inhibitor IL1RN (Dinarello, 1997b; Hart et al., 1989). 
IL6 has long been regarded as a pro-inflammatory cytokine induced by LPS along 
with TNFα and IL1. It is often used as a marker for systemic activation of pro-
inflammatory cytokines (Barton and Medzhitov, 2002). Like many other cytokines, 
IL6 has both pro- and anti-inflammatory properties. Although IL6 is a potent 
inducer of the acute-phase protein response, it has anti-inflammatory properties as 
well (Barton et al., 1996). After binding to its specific α receptor, IL6 complexes with 




receptor ligands that includes IL11, leukemia inhibitory factor, ciliary neurotrophic 
factor, oncostatin M, and cardiotrophin-1. IL6 down-regulates the synthesis of IL1 
and TNFα (Libert et al., 1994; McGeough et al., 2012). IL6 attenuates the synthesis 
of the pro-inflammatory cytokines while having little effect on the synthesis of anti-
inflammatory cytokines such as IL10 and transforming growth factor β (TGFβ). IL6 
induces the synthesis of glucocorticoids and promotes the synthesis of IL1RN and 
soluble TNF receptor release in human volunteers (Ruzek et al., 1997; Tilg et al., 
1994). At the same time, IL6 inhibits the production of pro-inflammatory cytokines 
such as GM-CSF, IFNγ and MIP-2 (Barton, 1997). 
IL10 is the most important anti-inflammatory cytokine produced by a variety of 
cells, including T and B lymphocytes, thymocytes, macrophages, mast cells, 
keratinocytes and intestinal epithelial cells (Opals and DePalo, 2000). It is a potent 
inhibitor of TH1 cytokines, including both IL2 and IFNγ, but also of IL1, IL6 and 
TNFα (Hagenbaugh et al., 1997; Howard and O’Garra, 1992; Lalani et al., 1997; 
Opal et al., 1998). IL10 is also a potent deactivator of monocyte/macrophage pro-
inflammatory cytokine synthesis (Brandtzaeg et al., 1996; Clarke et al., 1998). It 
also inhibits cell surface expression of MHC class II molecules and the LPS 
recognition and signaling molecule CD14 (Opal et al., 1998).  
TGFβ is synthesized as an inactive precursor and requires activation before 
exerting its effects (Nørgaard et al., 1995). It is an important regulator of cell 
proliferation, differentiation, and formulation of the extracellular matrix (Letterio 
and Roberts, 1997). Like many cytokines (e.g. IL6), TGFβ has both pro- and anti-
inflammatory effects. It functions as a biological switch, antagonizing or modifying 
the action of other cytokines and growth factors. The presence of other cytokines 
may modulate the cellular responses of TGFβ, and the effect may differ depending 
on the activation state of the cell (Kingsley, 1994). TGFβ is capable of converting an 
active site of inflammation into one dominated by resolution and repair (Letterio 
and Roberts, 1997).  
The cytokine induced immune responses can be further regulated by suppressors of 
cytokine signaling (SOCS) and the cytokine-inducible SH2 protein (CIS) family of 
intracellular proteins (Alexander, 2002; Greenhalgh et al., 2002; Yasukawa et al., 
2000). In total there are eight SOCS proteins (i.e. SOCS1, SOCS2, SOCS3, SOCS4, 
SOCS5, SOCS6, SOCS7 and CIS), each of which has a central SH2 domain, an 
amino-terminal domain of variable length and divergent sequence, and a carboxy-
terminal 40-amino-acid module that is known as the SOCS box (Illson et al., 1998). 
The function of the SOCS box is the recruitment of the ubiquitin-transferase 
system. The SOCS box interacts with elongins B and C, cullins, Rbx-1 and E2 
(Kamura et al., 1998; Zhang et al., 1999b). Thus, CIS and SOCS family proteins, as 
well as other SOCS box-containing molecules, probably function as an E3 ubiquitin 
ligase and mediate the degradation of proteins associated through their N-terminal 
regions. However, the SOCS box is also important for the stabilization and/or 
degradation of the SOCS1 and SOCS3 proteins themselves (Kamura et al., 1998). 
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Interaction of the SOCS box with elongin C stabilizes SOCS3 protein expression, 
whereas phosphorylation of SOCS box tyrosine residues disrupts the complex and 
enhances proteasome-mediated degradation of SOCS3 (Haan et al., 2003). 
The best characterized SOCS-family members, SOCS1, SOCS2, SOCS3 and CIS 
(Table 2. 4), seem to act in a classical negative-feedback loop to inhibit cytokine 
signal transduction (Alexander, 2002). CIS and SOCS2 bind to phosphorylated 
tyrosine residues on activated (phosphorylated) cytokine receptors. They also 
compete with STATs or can sterically hinder the STAT binding sites of receptors, 
inhibiting STAT activation, as in the case of STAT5 (Ram and Waxman, 1999; 
Yoshimura et al., 2007). CIS is induced by cytokines that activate STAT5, such as 
erythropoietin, IL2, IL3, prolactin and growth hormone (Yoshimura et al., 1995).  
SOCS1 has an important regulatory function in macrophages and dendritic cells. 
The inhibitory activity of SOCS2 is not as strong as that of CIS, and SOCS2 seems 
to be a relatively specific negative regulator of the growth hormone-STAT5 pathway 
(Metcalf et al., 2000). Both SOCS1 and SOCS3 can inhibit JAK tyrosine kinase 
activity. They have a kinase inhibitory region in their N-terminal domain, which 
probably functions as a pseudosubstrate (Yasukawa et al., 1999). SOCS1 uses its 
SH2 domain to directly bind the activation loop of JAKs and binds the catalytic 
pocket of JAKs through its kinase inhibitory region (Giordanetto and Kroemer, 
2003).  
The mechanism of SOCS3-mediated inhibition of signaling involves both the 
cytokine receptors and JAKs (Hansen et al., 1999; Nicholson et al., 2000; Sasaki et 
al., 2000). SOCS3 binds activated receptors but does not seem to interfere with 
STAT recruitment (Bjørbaek et al., 1998; Cohney et al., 1999; Hansen et al., 1999; 
Nicholson et al., 2000; Sasaki et al., 2000). Rather, SOCS3 inhibits JAKs catalytic 
activity in a manner that is analogous to SOCS1, but SOCS3 relies on receptor 
binding, rather than a direct interaction with JAKs, to gain access to the JAK 
activation loop. Moreover, SOCS3 binds the GP130 receptor at a specific 
phosphorylated receptor tyrosine that is the same as that used by the signaling 
molecule SH2-domain-containing protein tyrosine phosphatase 2 (SHP2) for 
receptor interaction (Nicholson et al., 2000; Schmitz et al., 2000). As SH2P can 
promote GP130 signaling through the activation of mitogen-activated protein 
kinases, it is possible that SOCS3 will suppress aspects of GP130 signaling also by 
competing with SHP2 for receptor binding. Thus SOCS3 selectively blocks IL6 
signaling, interfering with the ability of the latter to inhibit LPS signaling (Kubo et 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The introduction of antibiotics is one of the most important medical interventions 
with regard to reducing human morbidity and mortality. However, the intensive 
use of antibiotics has dramatically increased the frequency of resistance among 
human pathogens and threatens a loss of therapeutic options and a post-antibiotic 
era in which the medical advances are no longer effective (Guay, 2008; Lew et al., 
2008; Woodford and Livermore, 2009). The clinical use of antibiotics, and therefore 
the effective treatment of bacterial infections, is under considerable threat due to 
the emergence of bacteria that are resistant to many classes of commonly used 
antibiotics. In the traditional sense, antibiotic resistance is often considered to be a 
trait acquired by previously susceptible bacteria, the basis of which can be 
attributed to the horizontal acquisition of new genes, or the occurrence of 
spontaneous mutations within chromosomally located genes that are subsequently 
transmitted vertically as the bacteria replicate (Davies, 2007; Martinez and 
Baquero, 2000). In addition to the ability of bacteria to ‘acquire’ resistance, different 
bacterial species are also intrinsically resistant to different classes of antibiotics 
(Cox and Wright, 2013). 
The accumulation of antibiotic resistance in bacteria provides the most drastic 
demonstration of Darwinian selection available to us, and one with serious practical 
consequences (Livermore, 2007). Antibiotics select for those bacteria that are 
inherently resistant or that have acquired resistance via mutation or DNA transfer. 
Upon the introduction of antibiotics, it was assumed that the development of 
antibiotic resistance was unlikely, although addressed by Alexander Flemming in 
his nobel prize acceptance speech (Fleming, 1945). This was based on the 
assumption that the frequency of mutations generating resistant bacteria was 
neglectable (Davies, 1994). Bacterial mutation rates in the laboratory are usually < 
10-7 and are often ≤ 10-9, whilst plasmid transfer rates are generally < 10-5 per donor 
cell, but these apparently low rates must be multiplied by the huge numbers of 
bacteria exposed. The human gut is estimated to contain 1013 – 1014 bacteria, tenfold 
more than the total amount of human cells in the body, and these are exposed to 
selection pressure whenever antibiotics are used (Guarner and Malagelada, 2003). 
Moreover, antibiotics are not only used in human medicine but have also been 
applied for treatment, mass prophylaxis and growth promotion in animals, with 
resistant bacteria passed to humans via the food chain (Livermore, 2007). 
To understand how antibiotics work, and subsequently how antibiotic resistance 
can develop, insights regarding the targets of the main classes of these antibacterial 
drugs is required: bacterial cell-wall biosynthesis, bacterial protein synthesis and 
bacterial DNA replication and repair (Table 3. 1) (Walsh, 2000).  
Bacterial resistance to antibiotics can be intrinsic or innate, which is characteristic 
for a particular bacterium and depends on the biology of the microorganism, or can 
be acquired (Alanis, 2005; Giedraitienė et al., 2011). Resistance of Mollicutes (best 
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known genus is Mycoplasma) to β-lactam antibiotics is an example of intrinsic 
resistance, explained by the lack of a cell wall in this class of bacteria (Bébéar and 
Pereyre, 2005). Acquired resistance occurs from acquisition of exogenous genes by 
uptake of free DNA (transformation) plasmids (conjugation), transposons 
(conjugation), integrons and bacteriophages (transduction), mutation or a 
combination of these mechanisms (Hawkey, 1998). The main types of biochemical 
mechanisms that bacteria use for defense against antibiotics are enzymatic 
inactivation or modification, decreased uptake or efflux, and alteration or 
overproduction of the target (Chen et al., 2011; Wright, 2005). 
Pseudomonas aeruginosa is an important bacterial pathogen, particularly as cause 
of infections in hospitalized patients and immunocompromised hosts such as burn 
wound patients and patients witsh cystic fibrosis. P. aeruginosa is a Gram-negative 
aerobic opportunistic bacterium that normally inhabits the soil and surfaces in 
aqueous environments (Gellatly and Hancock, 2013). It is an important cause of 
both community- and hospital-acquired infections. Community-acquired infections 
include, but are not limited to, ulcerative keratitis (usually associated with contact 
lens use), otitis externa (typically in immunocompromised hosts such as those with 
diabetes mellitus), and skin and soft tissue infections (including diabetic foot 
infections and infections of burn wounds) (Driscoll et al., 2007). Hospitalized 
patients may be colonized with P. aeruginosa or may acquire it during their hospital 
stay. P. aeruginosa can be isolated from nearly any conceivable source within 
hospitals (Bonten et al., 1999; Pirnay et al., 2003). Nosocomial infections caused by 
P. aeruginosa include pneumonias, urinary tract infections, bloodstream infections, 
surgical site infections and skin infections in the setting of burn injuries. Infections 
with P. aeruginosa are not only common, they also have been associated with high 
morbidity and mortality when compared with other bacterial pathogens (Harbarth 
et al., 2002; Kollef et al., 2005; Osmon et al., 2004; Rello et al., 2002). 
P. aeruginosa has been identified as the second most common cause of hospital-
acquired pneumonia (HAP), healthcare-associated pneumonia (HCAP) and 
ventilator-associated pneumonia (VAP), exceeded in frequency only by 
Staphylococcus aureus (Gaynes et al., 2005; Kollef et al., 2005). P. aeruginosa is 
often identified as the most frequent infectious isolate in burn units, and accounts 
for a large percentage of documented wound infections, bacteremia and VAP in 
these units (Lari and Alaghehbandan, 2000; Sewunet et al., 2013; Song et al., 2001). 
P. aeruginosa also plays an important role in patients with cystic fibrosis (CF), in 





P. aeruginosa possesses a single flagellum that enables motility and that may 
mediate initial surface interactions (O’Toole and Kolter, 1998). P. aeruginosa also 
has multiple cell surface pili (type IV) that are responsible for adherence to cell 
membranes and other surfaces (Kipnis et al., 2006; Lau et al., 2005). During an 
infection, the bacterium can adhere to host epithelial cells through the binding of 
its flagellum to the asialyated glycolipid asialoGM1 and can elicit a strong NF-κB-
mediated inflammatory response via signaling through TLR5 and a caspase-1-
mediated response through the NLR Ipaf (Miao et al., 2007). Type IV pili are the 
most important adhesion molecules of P. aeruginosa and are also involved in 
twitching motility and the formation of biofilms (Kipnis et al., 2006). Pili can also 
lead to aggregation, causing the bacteria to form microcolonies on target tissues, 
effectively concentrating the bacteria in one location and potentially offering 
protection from the host immune system and from antibiotics (Craig et al., 2004; 
Sriramulu et al., 2005). Some isolates of P. aeruginosa overproduce the extracellular 
polysaccharide alginate (a condition called mucoidy), with associated mucoid 
morphology apparent on culture (Lau et al., 2005). Alginate has been noted to have 
a number of effects that may impede bacterial clearance by the infected host, 
including scavenging of free radicals released by macrophages, providing a physical 
barrier that impairs phagocytosis, and inhibiting neutrophil chemotaxis and 
complement activation (Ramsey and Wozniak, 2005). 
Many pathogenic Gram-negative bacteria, such as Yersinia, Salmonella, Shigella 
and Pseudomonas species share a type three secretion system (T3SS) as a means of 
injecting toxins directly into host cells (Kipnis et al., 2006). As such, the P. 
aeruginosa T3SS is a major determinant of virulence, and its expression is 
frequently associated with acute invasive infections and has been linked to 
increased mortality in infected patients (Hauser, 2009; Sadikot et al., 2005). The 
needle-like appendage of the T3SS, evolutionarily related to flagella, permits the 
translocation of effector proteins from the bacterium into the host cell through a 
pore formed in the host cell membrane (Hauser, 2009). There are four known toxins, 
variably expressed in different strains and isolates, injected into host cells by P. 
aeruginosa through the T3SS: ExoS, ExoT, ExoY and ExoU (Gellatly and Hancock, 
2013; Kipnis et al., 2006). 
ExoS is a bifunctional cytotoxin with two active domains, a C-terminal ADP-
ribosyltransferase domain and an N-terminal Rho GTPase-activating protein (GAP) 
domain (Fu et al., 1993). The pathogenic role of ExoS is mainly attributable to the 
ADP-ribosyltransferase activity leading to disruption of normal cytoskeletal 
organization (Maresso et al., 2004; Shaver and Hauser, 2004). The C-terminal 
domain binds to TLR2 and the N-terminal domain binds to TLR4, showing that 
ExoS may also modulate the host immune and inflammatory response (Epelman et 
al., 2004). ExoT is similar to ExoS, with dual ADP-ribosyltransferase and GAP 
activities, although the ExoT ADP-ribosyltransferase targets different pathways 
(Aktories and Barbieri, 2005; Henriksson et al., 2002). ExoY is an adenylate cyclase 
injected directly into the host cytosol by the T3SS and increases cytosolic cyclic AMP 
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(cAMP), enhanced by a eukaryotic cofactor (Yahr et al., 1998). This increased 
cytosolic cAMP leads to increased pulmonary microvascular intercellular gap 
formation and increased lung permeability (Sayner et al., 2004). ExoU was recently 
found to have a phospholipase/lysophospholipase activity disrupting eukaryotic cell 
membranes after translocation into the cell by the T3SS and activation by a yet 
unknown eukaryotic cofactor (Pankhaniya et al., 2004; Sato et al., 2003; Tamura et 
al., 2004). 
Besides these four toxins, P. aeruginosa is able to secrete additional virulence 
factors, such as pyocyanin and pyoverdine, proteases, phospholipase C and exotoxin 
A (ExoA). Pyocyanin is a blue pigment metabolite of P. aeruginosa that has been 
shown to have numerous pathogenic effects such as an increase in IL8, depression 
of host-response, and induction of apoptosis in neutrophils (Allen et al., 2005; 
Denning et al., 1998; Leidal et al., 2001). Pyoverdine is a siderophore, a small 
molecule chelating iron from the environment for use in P. aeruginosa metabolism 
(Meyer et al., 1996; Takase et al., 2000). Phospholipase C, more specifically 
hemolytic phospholipase C, is a phospholipase secreted by P. aeruginosa into the 
extracellular space through a type two secretion system (T2SS). It targets 
eukaryotic membrane phospholipids (König et al., 1997; Wiener-Kronish et al., 
1993). ExoA, secreted into the extracellular space through a T2SS, is an ADP-
ribosyltransferase inhibiting elongation factor-2 (EF-2), thereby inhibiting protein 
synthesis and leading to cell death (Pavlovskis et al., 1978; Wick et al., 1990). 
Another major virulence factor of P. aeruginosa are its lipopolysaccharides. 
Lipopolysaccharide is a complex glycolipid that forms the outer leaflet of the outer 
membrane of Gram-negative bacteria and has roles in antigenicity, the 
inflammatory response, exclusion of external molecules, and in mediating 
interactions with antibiotics (King et al., 2009). P. aeruginosa produces a three-
domain lipopolysaccharide consisting of a membrane-anchored lipid A, a 
polysaccharide core region, and a highly variable O-specific polysaccharide (Gellatly 
and Hancock, 2013). The production, function and virulence of lipopolysaccharides 
are discussed more thoroughly in . 
Surveillance of P. aeruginosa isolated from hospitalized patients has revealed 
alarming antimicrobial resistance increase (Driscoll et al., 2007; Solomon et al., 
2002). Infections by P. aeruginosa are notoriously difficult to treat due to its 
intrinsic ability to acquire resistance. All known mechanisms of antibiotic 
resistance can be displayed by this bacterium (Moore and Flaws, 2011). In the case 
of P. aeruginosa, intrinsic resistance is due to the low permeability of its outer 
membrane, the constitutive expression of membrane efflux pumps, and the natural 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































The outer membrane of Gram-negative bacteria acts as a selective barrier for 
uptake of antibiotics (Nicas and Hancock, 1983). P. aeruginosa has a large exclusion 
limit owing to the limited number of large channels of its major porin OprF, and the 
small size of the channels of other porins that mediate the passage of other 
molecules of the size of antibiotics, including OprD and OprB (Breidenstein et al., 
2011). Members of the RND family of efflux pumps appear to be the most significant 
contributors to antimicrobial resistance of P. aeruginosa (Poole, 2007).  
P. aeruginosa also has an intrinsic resistance against β-lactams through the 
expression of AmpC and PoxB (Girlich et al., 2004; Kong et al., 2005; Lodge et al., 
1990). While the original β-lactamases were plasmid-encoded restricted-spectrum 
class A enzymes that only hydrolyzed penicillins and older, narrow-spectrum 
cephalosporins, more recently described acquired β-lactamases in P. aeruginosa 
include the extended-spectrum β-lactamase (ESBL) enzymes able to hydrolyze a 
wider range of β-lactams, including the carbapenems (Zhao and Hu, 2010). 
Multidrug resistant strains of P. aeruginosa typically exhibit several resistance 
mechanisms simultaneously, whereby resistance to specific antibacterials may be 
mediated by different combinations of these mechanisms (Deplano et al., 2005; 
Dubois et al., 2001). 
Staphylococcus aureus is both a commensal organism and a pathogen. The anterior 
nares are the main ecological niche for S. aureus. Approximately 20 % of individuals 
have nares persistently colonized with S. aureus, and 30 % are intermittently 
colonized. However, numerous other sites may be colonized, including the axillae, 
groin, and gastrointestinal tract (Gordon and Lowy, 2008). Colonization increases 
the risk for subsequent infection (Kluytmans et al., 1997; Wertheim et al., 2005). 
Those with S. aureus infections are generally infected with their colonizing strain 
(Williams et al., 1959). Colonization also allows S. aureus to be transmitted among 
individuals in both health care and community settings. The primary mode of 
transmission of S. aureus is by direct contact, usually skin-to-skin contact with a 
colonized or infected individual, although contact with contaminated objects and 
surfaces might also have a role (Kazakova et al., 2005; L and K, 2006; Miller and 
Diep, 2008; Muto et al., 2003).  
S. aureus produces a wide variety of exoproteins that contribute to its ability to 
colonize and to cause disease in mammalian hosts. Nearly all strains secrete a group 
of enzymes and cytotoxins, which includes four hemolysins (alpha, beta, gamma, 
and delta), nucleases, proteases, lipases, hyaluronidase, and collagenase. The main 
function of these proteins may be to convert local host tissues into nutrients 
required for bacterial growth. Some strains produce one or more additional 
exoproteins, which include toxic shock syndrome toxin-1 (TSST-1), the 




exfoliative toxins (ETA and ETB), and leucocidin (Dinges et al., 2000). Toxic shock 
syndrome toxin-1 and the staphylococcal enterotoxins are also known as pyrogenic 
toxin superantigens (PTSAgs) and are secreted by either S. aureus or Streptococcus 
pyogenes (Bohach et al., 1990). Each of these exotoxins exhibits at least three 
biological properties: pyrogenicity, superantigenicity, and the capacity to enhance 
the lethality of endotoxin in rabbits up to 100,000 fold (Bohach et al., 1990; Marrack 
and Kappler, 1990). TSST-1 is unique in its ability to cross mucosal surfaces and is 
the only PTSAg known to reactivate bacterial cell wall-induced arthritis (Hamad et 
al., 1997; Schwab et al., 1993). The best characterized property of the PTSAgs is 
superantigenicity, which refers to the ability of these exotoxins to stimulate 
proliferation of T lymphocytes without regard for the antigen specificity of these 
cells by linking the TCR and the MHC class II molecule (Fleischer and 
Schrezenmeier, 1988; Marrack and Kappler, 1990; Rödström et al., 2014; White et 
al., 1989).  
In addition to their functional similarities, the staphylococcal PTSAgs share a 
number of genetic and biochemical characteristics. Like most proteins secreted by 
S. aureus, they are produced primarily in the postexponential phase of growth 
(Dinges et al., 2000). Comparison of the three-dimensional structure of TSST-1 to 
those of SEA, SEB and SEC, it was demonstrated that each of these proteins is 
folded into a highly prototypical structure. This high level of structural homology is 
not surprising in view of their functional relatedness. Of considerable interest are 
the molecular structures of PTSAgs in complex with MHC class II molecules or the 
β-chain of the TCR (Hoffmann et al., 1994; Papageorgiou et al., 1999; Prasad et al., 
1997; Schad et al., 1995; Swaminathan et al., 1992). 
In establishing an infection, S. aureus has numerous surface proteins, called 
microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) that mediate adherence to host tissues. MSCRAMMs bind molecules 
such as collagen, fibronectin, and fibrinogen, and different MSCRAMMs may 
adhere to the same host-tissue component (Foster and Höök, 1998; Menzies, 2003; 
Patti et al., 1994; Tung et al., 2000). Once S. aureus adheres to the host tissue or 
prosthetic materials, it is able to grow and persist in various ways. S. aureus can 
form biofilms on host and prosthetic surfaces, enabling it to persist by evading host 
defenses and antimicrobials (Donlan and Costerton, 2002). In vitro, S. aureus can 
also invade and survive inside epithelial cells, including endothelial cells, which 
theoretically may also allow it to escape host defenses, particularly in endocarditis 
(Gordon and Lowy, 2008; Hamill et al., 1986; Moreillon et al., 2002; Ogawa et al., 
1985). S. aureus may also secrete chemotaxis inhibitory protein of staphylococci or 
the extracellular adherence protein, which interfere with neutrophil extravasation 
and chemotaxis to the site of infection (Foster, 2005). The mortality of S. aureus 
bacteremia remains approximately 10 – 30 % despite the availability of effective 
antimicrobials (van Hal et al., 2012). S. aureus is now the leading overall cause of 
nosocomial infections and, as more patients are treated outside the hospital setting, 
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is an increasing concern in the community (Diekema et al., 2001; Solomon et al., 
2002). 
S. aureus is naturally susceptible to virtually every antibiotic that has ever been 
developed. Resistance to antibiotics is often acquired by the horizontal transfer of 
genes from outside sources, although chromosomal mutation is also important 
(Chambers and Deleo, 2009). As rapidly as new antibiotics have been introduced, 
staphylococci have developed efficient mechanisms to neutralize them (Table 3. 2). 
Staphylococcal resistance to penicillin is mediated by blaZ, the gene that encodes β-
lactamase. This predominantly extracellular enzyme, synthesized when 
staphylococci are exposed to β-lactam antibiotics, hydrolyzes the β-lactam ring, 
rendering the β-lactam inactive (Wilke et al., 2005). Methicillin resistance requires 
the presence of the chromosomally localized mecA gene (Chambers, 1997; Wilke et 
al., 2005). The mecA gene is responsible for synthesis of penicillin-binding protein 
2a (PBP2a), an alternative transpeptidase with reduced affinity for β-lactam 
antibiotics (Ghuysen, 1994; Hartman and Tomasz, 1984). Thus, resistance to 
methicillin confers resistance to all β-lactam agents. PBP2a also differs from other 
PBPs in that its active site blocks binding of all β-lactams but allows the 
transpeptidation reaction to proceed (Lim and Strynadka, 2002). Additional series 
of genes, the fem genes (factor essential for resistance to methicillin resistance) play 
a role in cross-linking peptidoglycan strands and also contribute to the 
heterogeneity of expression of methicillin resistance (Berger-Bächi, 1994). 
Staphylococcal resistance to vancomycin in clinical isolates was first reported in a 
strain of S. haemolyticus (Schwalbe et al., 1987). Currently two forms of S. aureus 
resistance to vancomycin have been identified (Walsh and Howe, 2002). The reduced 
susceptibility to vancomycin appears to result from changes in peptidoglycan 
biosynthesis. The vancomycin intermediate-resistant S. aureus (VISA) strains are 
notable for the additional quantities of synthesized peptidoglycan that can result in 
irregularly shaped, thickened cell walls. There is also decreased cross-linking of 
peptidoglycan strands, which leads to the exposure of more D-Ala-D-Ala residues 
(Hanaki et al., 1998a, 1998b). The altered cross-linking results from reduced 
amounts of L-glutamine that are available for amidation of D-glutamate in the 
pentapeptide bridge (Walsh and Howe, 2002). The second form of vancomycin 
resistance has resulted from the probable conjugal transfer of the vanA operon from 
a vancomycin-resistant Enterococcus faecalis (Showsh et al., 2001). Resistance in 
these strains is caused by alteration of the terminal amino acids D-Ala-D-Ala to D-
Ala-D-Lac. Synthesis of D-Ala-D-Lac occurs only with exposure to low 
concentrations of vancomycin. 
Fluoroquinolones were initially introduced for the treatment of Gram-negative 
bacterial infections in the 1980s. Because of their Gram-positive bacterial spectrum, 
they have also been used to treat bacterial infections caused by pneumococci and 




prominently among the methicillin-resistant strains. As a result, the ability to use 
fluoroquinolones as antistaphylococcal agents was dramatically reduced. 
Fluoroquinolone resistance develops as a result of spontaneous stepwise 
chromosomal mutations in the target of the antibiotic, topoisomerase IV or DNA 
gyrase, or by the induction of a multidrug efflux pump (Hooper, 2002). 
The confluence of high bacterial density, the likely preexistence of resistant 
subpopulations, and the sometimes limited quinolone concentrations achieved at 
sites of staphylococcal infections creates conditions that fosters selection of resistant 
mutants (Hooper, 2002). Amino acid changes in critical regions of the enzyme-DNA 
complex (quinolone resistance-determining region (QRDR)) reduce quinolone 
affinity for both of its targets. The ParC subunit (GrlA in S. aureus) of 
topoisomerase IV is the most common site of resistance mutations. Topoisomerase 
IV mutations are the most critical, since they are the primary drug targets in 
staphylococci (Ng et al., 1996). An additional mechanism of resistance in S. aureus 
is induction of the NorA multidrug resistance efflux pump. Increased expression of 







































































































































































































































































































































































































































































































































































































































































Both Gram-positive and Gram-negative bacteria possess a cytoplasmic membrane 
surrounding the cytosol, a double phospholipid layer which constitutes a physical 
semi-permeable barrier that regulates the flux of endogenous and exogenous 
substances in and out of the cell. Gram-negative bacteria possess an additional 
asymmetric outer membrane (OM) which surrounds a thin layer of peptidoglycan. 
The outer membrane is composed of an asymmetric phospholipid bilayer, whose 
inner leaflet is made of glycerophospholipids while the external leaflet is formed by 
lipopolysaccharides (LPS) (Silipo and Molinaro, 2010).  
Lipopolysaccharides constitute a physical barrier protecting the bacterium from 
host defenses, mediate direct interactions with host cell receptors and antibiotics, 
and are potent signaling molecules which initiate some of the events leading to host 
tissue damage and much of the pathology associated with bacteremia (King et al., 
2009; Moskowitz and Ernst, 2010; Raetz, 1990). They are heat-stable complex 
amphiphilic macromolecules indispensable for the bacterial growth, viability and 
for the correct assembly of the outer membrane (Alexander and Rietschel, 2001; 
Raetz and Whitfield, 2002; Raetz et al., 2007). Lipopolysaccharides typically consist 
of a hydrophobic domain known as lipid A (or endotoxin), a non-repeating core 
oligosaccharide, and a distal polysaccharide (or O-antigen) (Raetz and Whitfield, 
2002). The biosynthetic pathway and export mechanism of LPS has been well 
characterized in E. coli and is shared by most Gram-negative bacteria, but the exact 
structures of LPS differ in different bacteria (Wang and Quinn, 2010). 
Lipopolysaccharides can bind to the PRR TLR4 (Akira et al., 2006; Poltorak et al., 
1998).  
Lipopolysaccharides can cause symptoms such as septic shock, multiple organ 
dysfunction and failure. Understanding the biochemistry of LPS modifications and 
their impact on pathogenesis could lead to novel treatment options for these 
diseases as well as lead to strategies for the removal of LPS from different sample 
types (Epstein and Parrillo, 1993; Petsch and Anspach, 2000). 
The biosynthesis of LPS is initiated from a small molecule, UDP-N-
acetylglucosamine (UDP-GlcNAc), which is also one of the two major building blocks 
of the peptidoglycan layer. Multiple enzymes sequentially function to convert UDP-
GlcNAc into core-lipid A, and to synthesize LPS. Among the three parts of LPS, the 
structure of lipid A is more widely conserved in different bacteria than that of core 
sugars or O-antigen and so are the enzymes involved in the biosynthesis of lipid A. 
The first stage of LPS biosynthesis is to synthesize Kdo2-lipid A (Figure 4. 1; 
Doerrler, 2006; Raetz and Whitfield, 2002).  
The core oligosaccharides are sequentially assembled on lipid A at the cytoplasmic 
surface of the inner membrane in a process that involves a number of membrane-
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associated glycosyltransferases, using nucleotide sugars as donors. The 
biosynthesis of core oligosaccharides is rapid and efficient, suggesting that the 
glycosyltransferases function as a coordinated complex. Core oligosaccharides can 
be divided into two structurally distinct regions: the inner core, which connects to 
lipid A, and the outer core that connects to the O-antigen. The inner core 
oligosaccharides typically contain residues of Kdo and L-glycero-D-manno-heptose 
(Hep). The Kdo residue is the most conserved component found in the core region of 
LPS. The outer core oligosaccharides show more structural diversity than those of 
the inner core. The sugars found in the outer core oligosaccharides are Kdo, Hep, D-
glucose and D-galactose (Wang and Quinn, 2010). 
Similar to the core oligosaccharides, O-antigen is synthesized at the cytoplasmic 
surface of the inner membrane. Using the sugar nucleotides as donors, the units of 
O-antigen are assembled by glycosyltransferase enzymes on the membrane-bound 
carrier, undecaprenyl phosphate which is also used for synthesis of peptidoglycan 
and capsular polysaccharides (Raetz and Whitfield, 2002). The O-antigens of LPS 
exhibit considerable diversity. The connection of units in O-antigen may be linear 
or branched. The O-antigen repeats can be homopolymers or heteropolymers (Wang 
and Quinn, 2010). 
Nascent LPS molecules are synthesized in the periplasm and shuttled to the inner 
surface of the outer membrane by proteins LptA, LptB, LptC, LptF and LptG. The 
ABC transporter LptBFG, functioning with LptC and LptA, translocates LPS to the 
inner leaflet of the outer membrane (Sperandeo et al., 2007, 2008). Thereafter, the 
protein complex LptD/LptE assembles LPS into the outer surface of the outer 
membrane (Ruiz et al., 2008; Sperandeo et al., 2007, 2008).  
After synthetization, the LPS structure can be modified. The most conserved part 
of lipid A is its backbone, the disaccharide of glucosamine, but the groups connecting 
to this backbone can be modified (Table 4. 2). The modification of LPS cannot only 
occur in the hydrophobic acyl chain (lipid A) but also in the hydrophilic 
polysaccharide (O-antigen). Modifications of LPS usually occur at the periplasmic 
face of the inner membrane or in the outer membrane. These structural 
modifications of LPS might help bacteria to resist the cationic antimicrobial 
peptides (CAMPS) released by the host immune system, or evade recognition by the 







Figure 4. 1: Structure and biosynthetic pathway of Kdo2-lipid A in Escherichia coli. 
This involves nine enzymes (Table 4. 1), takes place in the cytoplasm at first and ends up on 
the cytoplasmic surface of the inner membrane. The first three reactions of the Kdo2-lipid A 
biosynthesis are catalyzed by soluble enzymes LpxA, LpxC and LpxD, resulting in the 
addition of two 3-OH fatty chains to the 2- and 3- positions of the UDP-GLCNAc to form 
UDP-diacyl-GlcN. Both LpxA and LpxD are acyltransferases and their active forms are 
homotrimers. LpxC is a Zn2+-dependent deacetylase which has no sequence homology with 
other deacetylases (Barb et al., 2007). UDP-diacyl-GlcN is subsequently hydrolyzed by LpxH 
to form lipid X, which is further condensed with its precursor UDP-diacyl-GlcN by LpxB to 
form disaccharide-1-P (Babinski et al., 2002a, 2002b, Crowell et al., 1986, 1987; Metzger IV 
and Raetz, 2009). In the final steps, LpxK phosphorylates the 4’-position of the disaccharide-
1-P to form lipid IV A (Garrett et al., 1998). KdtA incorporates two 3-deoxy-D-manno-
octulosonic acid (Kdo, depicted as an R-group) residues at the 6’-position of the lipid IV A, 
using a sugar nucleotide CMP-Kdo as the donor (not depicted in the figure). The resulting 
Kdo2-lipid IV A undergoes further reactions catalyzed by LpxL and LpxM to form Kdo2-lipid 
A. LpxL adds a secondary lauroyl residue and LpxM a myristoyl residue to the distal 
glucosamine unit. Figure adapted from Wang and Quinn (2010). 
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Table 4. 1: Information on nine enzymes required for the biosynthesis of Kdo2-lipid 
A in Escherichia coli. Adapted from Wang and Quinn (2010). 
Enzyme Function Substrate Donor Reference 






LpxC Deacetylase UDP-3-O-(acyl) 
GlcNac 
















GlcN; Lipid X 
None Crowell et 
al. (1987; 
1986) 
LpxK 4’-kinase Disaccharide  
1-phosphate 
None Garrett et al. 
(1998; 1997) 
KdtA Kdo transferase Lipid IVA CMP-Kdo Brozek et al. 
(1989) 
LpxL Acyltransferase Kdo2-lipid IVA Lauroyl ACP Brozek and 
Raetz (1990) 
LpxM Acyltransferase Kdo2-penta-lipid A Myristoyl ACP Brozek and 
Raetz (1990) 
 
Membrane proteins PgaP, PagL, LpxR and LpxO have been reported to modify the 
fatty acyl chain region of LPS. PagP is a palmitoyl transferase which locates in the 
outer membrane and transfers a palmitate from glycerophospholipids to the β2-
position of lipid A resulting in a hepta-acylated structure (Ahn et al., 2004). PagL is 
a lipase that removes the 3-O-linked acyl chain of lipid A but plays no role in 
antimicrobial peptide resistance (Kawasaki et al., 2004). The negative charge of 
Lipid A allows the binding of positively charged cAMPs produced by the immune 
system. To evade the attack by the immune system some bacterial pathogens have 
evolved less negatively charged variations of lipid A by removing or decorating the 
phosphate groups at the 1- and 4’-positions. The decoration includes the addition of 
amine-containing residues such as α-L-Ara4N and phosphoethanolamine. The 
modifications result in resistance to cAMPs and are controlled by the PmrA-PmrB 
two-components system (Wang and Quinn, 2010; Wang et al., 2004). Another 
strategy that bacteria employ to decrease the surface negative charge is the addition 
of amino groups at 1- and 4’-phosphate of lipid A. EptA is necessary for addition of 






Table 4. 2: Enzymes involved in the structural modification of LPS in Gram-
negative bacteria. Adapted from Wang and Quinn (2010). 
Enzyme Function Reference 
LpxE Remove the phosphate group from the 1-
position of lipid A 
Wang et al. (2004) 
LpxF Remove the phosphate group from the 4’-
position of lipid A 
Wang et al. (2006) 
LpxO Add an OH group to the αβ3’-position of lipid 
A 
Gibbons et al. (2008; 
2000) 
Arnt Transfer the L-Ara4N unit to lipid A Trent et al. (2001) 
LpxR Remove the 3’-acyloxyacyl moiety of lipid A Reynolds et al. (2006) 
PagL Remove the 3-O-linked acyl chain of lipid A Rutten et al. (2006) 
PagP Transfer a palmitate to the β2-position of 
lipid A 
Bishop (2008); Hwang 
et al. (2004) 
LpxXL Add a very long fatty acid chain to the β2’-
position of lipid A 
Haag et al. (2009) 
LpxT Transfer a phosphate group to the 1-
phosphate of lipid A 
Touzé et al. (2008) 
LpxQ Oxidize the proximal glucosamine of lipid A 
to form an aminogluconate unit 
Que-Gewirth et al. 
(2003) 
LmtA Catalyze the methylation of 1-phosphate of 
lipid A 
Boon Hinckley et al. 
(2005) 
RgtA Add a GalA moiety to the distal unit of Kdo Kanjilal-Kolar et al. 
(2006) 
RgtB Add a GalA moiety to the distal unit of Kdo Kanjilal-Kolar et al. 
(2006) 
RgtC Add a GalA moiety to the mannose residue of 
the core oligosaccharide of LPS 
Kanjilal-Kolar et al. 
(2006)  
EptA Add a phosphoethanolamine to 1-position of 
lipid A 
Lee et al. (2004) 
EptB Add a pEtN moiety to the distal unit of Kdo  Reynolds et al. (2005) 
Lipopolysaccharides have been shown to be among the most powerful classes of 
immunostimulators known to physiologically function as specific indicators for 
infection by Gram-negative bacteria of diverse eukaryotes ranging from man to 
insect. In general, the lipid A region represents the primary immunoreactive center 
of LPS due to the specific and often highly sensitive recognition of this bacterial 
lipid structure by numerous cellular and humoral components of innate immunity 
(Hoffmann et al., 1999; Janeway and Medzhitov, 2002; Mackay et al., 2000). 
Lipopolysaccharides commonly induce a broad spectrum of biological effects in 
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various eukaryotic organisms. The primary target cells of LPS in mammalian 
species are the professional phagocytes of innate or natural immunity, i.e. 
peripheral monocytes, tissue macrophages and neutrophils, which constitutively 
express the membrane-bound form of the CD14 antigen as well as TLR4 (Haziot et 
al., 1988; Kitchens, 2000; Muzio et al., 1998, 2000; Zhang et al., 1999a). 
Lipopolysaccharide stimulation of mammalian cells occurs through a series of 
interactions with several proteins including the LPS binding protein (LBP), CD14, 
MD-2 and TLR4 (Figure 4. 1)(Gioannini and Weiss, 2007; Miyake, 2007). LBP is a 
soluble shuttle protein which directly binds to LPS and facilitates the association 
between LPS and CD14 (Tobias et al., 1986; Wright et al., 1989). CD14 is a 
glycosylphosphatidylinositol-anchored protein, which also exists in a soluble form. 
CD14 facilitates the transfer of LPS to the TLR4/MD-2 receptor complex and 
modulates LPS recognition (Wright et al., 1990). MD-2 is a soluble protein that non-
covalently associates with TLR4 but that can directly form a complex with LPS in 
the absence of TLR4 (Gioannini and Weiss, 2007; Nagai et al., 2002; Shimazu et al., 
1999). 
Upon LPS recognition, TLR4 undergoes oligomerization and recruits its 
downstream adaptors through interactions with the TIR domains. TIR domains 
contain three highly conserved regions, which mediate protein-protein interactions 
between the TLRs and signal transduction adaptor proteins. The TIR domain of 
TLR4 is critical for signal transduction, because a single point mutation in the TIR 
domain can abolish the response to LPS (Poltorak et al., 1998). In total, there are 
five TIR domain-containing adaptor proteins: MyD88, TIRAP, TRIF, TRAM and 
SARM (O’Neill and Bowie, 2007). TLR4 signaling has been divided into MyD88-
dependent and MyD88-independent (TRIF-dependent) pathways (Figure 4. 2A and 
B). The MyD88-dependent pathway was shown to be responsible for pro-
inflammatory cytokine expression, while the MyD88-independent pathway 
mediates the induction of type I interferons and interferon-inducible genes (Lu et 
al., 2008).  
In addition to the TIR domain, MyD88 also contains a death domain (DD), which 
can recruit other DD-containing molecules through homotypic interactions. Upon 
LPS stimulation, MyD88 recruits and activates a DD-containing kinase, IL1 
receptor associated kinase-4 (IRAK-4) (Suzuki et al., 2002). IRAK-4 also plays a role 
in the mRNA stability of certain cytokines and chemokines, such as TNFα (Kim et 
al., 2007). 
Another adaptor protein TRAF6 (TNF receptor-associated factor 6), is critical for 
the MyD88-dependent pathway downstream of IRAK4 and IRAK1 (Figure 4. 2A). 
TRAF6 forms a complex with UBC13 (ubiquitin-conjugating enzyme 13) and 
UEV1A (ubiquitin-conjugating enzyme E2 variant 1 isoform A), and activates TAK1 
(transforming growth factor-β-activated kinase) (Gohda et al., 2004; Lomaga et al., 
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1999). TAK1 then activates downstream IKK (IκB kinase) and MAPK (mitogen-
activated protein kinase) pathways (Sato et al., 2005). IKKα, IKKβ and IKKγ form 
a complex and phosphorylate IκB proteins. This phosphorylation leads to the 
degradation of IκB proteins and the subsequent translocation of NF-κB, which 
controls the expression of pro-inflammatory cytokines, in addition to other immune 
related genes (Lu et al., 2008).  
Figure 4. 2: Overview of LPS/TLR4 signaling. LPS recognition is facilitated by LBP and 
CD14, and is mediated by TLR4/MD-2 receptor complex. LPS/TLR4 signaling can be 
separated into (A) MyD88-dependent and (B) MyD88-independent pathways. A| MyD88-
dependent pathway. MyD88 activates IRAKs/TRAF6 as well as the transcription factors 
NF-κB and AP-1. These transcription factors induce expression of pro-inflammatory 
cytokines. B| MyD88-independent pathway. TRIF signals the induction of Type I 
interferons by recruiting TRAF3 and RIP1 to activate transcription factor IRF3, as well as 
NF-κB and AP-1. Figure adapted from Lu et al. (2008). 
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TRIF is an important TIR-containing adaptor protein that mediated MyD88-
independent signaling (Figure 4. 2B). The C-terminal region of TRIF, which 
contains a Rip homotypic interaction motif (RHIM), mediates the interaction with 
RIP1 (receptor-interacting protein 1). As a serine/threonine kinase, RIP1 was 
initially identified as an important component of TNFα-mediated NF-κB activation 
(Meylan et al., 2004). TRIF recruits TRAF3 to activate IRF3. TRAF3 can associate 
with TANK (TRAF family member-associated NF-κB activator), TBK1 (TANK 
binding kinase 1) and IKKi to mediate downstream signaling (Guo and Cheng, 
2007; Oganesyan et al., 2006). TBK1 and IKKi are important for the dimerization 
and translocation of IRF3 (Fitzgerald et al., 2003; Hemmi et al., 2004). IRF3, 
together with NF-κB, activates the transcription of target genes, such as type I 
interferons (Honda and Taniguchi, 2006; Moynagh, 2005). The induction of type I 
interferons and interferon-inducible genes are important for anti-viral and anti-
bacterial responses (Bowie and Haga, 2005; Perry et al., 2005). 
Endotoxins liberated by Gram-negative bacteria are frequent contaminants of 
protein solutions derived from bioprocesses. Due to their toxicity in vivo and in vitro, 
their removal is essential for safe parenteral administration (Petsch and Anspach, 
2000). The threshold level of endotoxins for intravenous applications is set to five 
endotoxin units (EU) per kg body weight per hour by all pharmacopoeias (Council 
of Europe., 1997). The term EU describes the biological activity of an endotoxin. As 
a rule of thumb, one EU corresponds to 100 pg of endotoxins; the amount present in 
105 bacteria. Meeting this threshold level, knowing that a single E. coli contains 
about two million LPS molecules per cell, has always been a challenge in biological 
research and pharmaceutical industry (Berthold and Walter, 1994; de Oliveira 
Magalhães et al., 2007). 
Common purification strategies that include several chromatographic steps, such 
as ion exchange, hydrophobic interaction chromatography and gel filtration, may 
provide sufficient endotoxin clearance. Generally, high endotoxin concentrations 
can be reduced to about 100 EU/ml without special treatment (Petsch and Anspach, 
2000). The most secure way to avoid any microbial contamination and with it the 
release of endotoxins is absolute sterility during the production and downstream 
processes. Yet, if a decontamination method is used, it must ensure a high recovery 
of the target product. At present, three endotoxin removal strategies are available 
for the removal of LPS from protein samples, i.e., ultrafiltration, two-phase 
extraction, and adsorption (such as anion-exchange chromatography and affinity 
adsorption) (Petsch and Anspach, 2000). 
. Gel filtration chromatography reveals that more than 80 % of the 
endotoxin activity of a protein-free solution elutes as aggregates with the void 
volume (Morrison and Leive, 1975). Ultrafiltration can also be used to remove 
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endotoxins from product solutions if the products are low of molecular weight 
(Petsch and Anspach, 2000). 
. Through addition of detergents, an improvement of 
chromatographic protocols is possible (Karplus et al., 1987). Above the critical 
micellar concentration (CMC) of detergents, endotoxins are accommodated in the 
micellar structure by non-polar interactions of the alkyl chains of lipid A and the 
detergent and are consequently separated from the water phase (Brandenburg and 
Wiese, 2004; Israelachvili, 2011). Detergents of the Triton series show a miscibility 
gap in aqueous solutions. Above a critical temperature, the so-called cloud point, 
micelles aggregate to droplets with very low water content, as such forming a new 
phase. Endotoxins remain in the detergent-rich phase. Through centrifugation or 
further increase in temperature the two phases separate with the detergent-rich 
phase being the bottom phase (Aida and Pabst, 1990; Bordier, 1981). If necessary, 
this process is repeated until the remaining endotoxin concentration is below the 
threshold limit. The cloud point of Triton X-114 is at 22 °C, which is advantageous 
when purifying proteins. It requires mixing of the endotoxin-containing protein 
solution in the cold (usually at 4 °C) and allows separation of the two phases at T > 
22 °C. In contrast, the cloud point for Triton X-100 is at 75°C, which is not 
acceptable for most proteins (Petsch and Anspach, 2000). 
Most frequently, adsorption techniques are employed for the 
removal of endotoxins from protein solutions. In principle, non-selective adsorption 
on activated carbon or other adsorber materials is possible (Nagaki et al., 1991). 
Since endotoxins are negatively charged, anion exchangers are employed for their 
adsorption from protein-free solutions, such as DEAE chromatographic matrices or 
DEAE membranes or matrices functionalized with quaternary amino groups (Gerba 
and Hou, 1985; Hou and Zaniewski, 1990a, 1990b; Neidhardt et al., 1992). 
Clearance factors of more than five orders of magnitude can be obtained. According 
to the concept of affinity interactions, clearance by an endotoxin-selective affinity 
sorbent should be possible and should guarantee a protein recovery of almost 100% 
(Petsch and Anspach, 2000). 
Most types of lipid A molecules are detected at picomolar levels by an ancient 
receptor of the innate immune system present on macrophages and endothelial cells 
of animals (Raetz and Whitfield, 2002). Indeed, cells which are highly sensitive to 
LPS or lipid A have been detected in the hemolymph system of the American 
horseshoe crab Limulus polyphemus, and its Asian variant Tvoluit tridendatus, 
which have existed more than 400 million years.  
The horseshoe crab hemolymph contains mainly one type of blood cells called 
amoebocytes, which are extremely sensitive to LPS. During a Gram-negative 
infection, the amoebocytes release granular components into the plasma to 
participate in self-defense via blood coagulation, which incapacitates the invading 
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microbe (Iwanaga and Lee, 2005). Lipopolysaccharides from Gram-negative 
bacteria induces the amoebocytes to degranulate, thus initiating the blood 
coagulation cascade (Armstrong and Rickles, 1982). This cascade is based on three 
serine proteases zymogens, Factor C, Factor B, proclotting enzyme and one clottable 
protein, coagulogen (Figure 4. 3) (Muta and Iwanaga, 1996). Factor C, at the first 
step of the coagulation pathway, is sensitive to LPS and is a unique LPS-binding 
protein found only in the horseshoe crab. In the presence of LPS, the Factor C serine 
protease zymogen is automatically activated to an active form, which activates the 
proenzyme Factor B. This in turn activates proclotting to active clotting enzyme. 
Clotting enzyme then converts coagulogen into a coagulin clot, which traps the 
invading bacteria (Ding and Ho, 2010). 
This evolutionary ancient system, originally described by Levin and Bang in 1964 
(Levin and Bang, 1964), provided the basis for the development of the limulus 
amoebocyte lysate (LAL) assay, which today is a standard procedure for the 
detection of LPS or free lipid A in diverse settings (Hurley, 1995; Levin, 1988; Levin 
and Bang, 1964). 
After two to three decades of conventional pyrogen testing using the blood extract 
of the horseshoe crab, and the problems associated with LAL, Factor C was 
recombinantly expressed (Rotundicauda, 1998). This yielded an enzymatically 
active recombinant Factor C (rFC) that is activated by trace levels of LPS, with a 
remarkable sensitivity of 0.001 EU/ml. Furthermore, being capable of binding both 
free and bound LPS/lipid A with high affinity, the rFC has other potential 
applications, such as the removal of LPS from contaminated samples (Ding and Ho, 
1999). rFC is a proenzyme until it encounters trace levels of endotoxin where it 
unequivocally exhibits full enzymatic activity, hence, acting as a very sensitive and 
specific biosensor for endotoxin. The resulting activated rFC acts as a catalyst to 
hydrolyse a synthetic substrate to form a quantifiable, fluorimetric, product, which 
measures the level of endotoxins. A comparison of rFC with commercial LAL, under 
the same assay conditions, showed that rFC has a lower background reading and a 




Figure 4. 3: The coagulation cascade in the horseshoe crab amoebocyte lysate. In 
the presence of the endotoxin LPS, the Factor C serine protease zymogen is autocatalytically 
activated to an active form, Factor C’, which activates the proenzyme Factor B into Factor 
B’. This in turn activates the proclotting to the active clotting enzyme. The clotting enzyme 
then converts coagulogen into a coagulin gel clot, which traps the invading bacteria. Figure 
adapted from Ding and Ho (2010). 
 
The disadvantage of the LAL assay, even when rFC is used, is that the a part of the 
sample is used as a whole. This means that certain rFC-inhibiting or rFC-activating 
components may be present, which could lead to either a false negative or false 
positive result. For this reason an alternative method has been developed, called 
EndoLISA. This method uses phage-derived receptor proteins, exhibiting high 
affinity and specificity for the conserved core region of LPS, that are immobilized 
on a microplate. This enables, after binding of the sample LPS to the microplate, to 
wash the original sample matrix off, thereby eliminating potentially interfering 












Viruses are a group of biological entities with a genome consisting of either DNA or 
RNA and encapsulated in a protein coat (capsid), and sometimes even with a lipid 
membrane. The species concept has been applied to viruses and a viral species is 
defined as a polythetic class of viruses that constitutes a replicating lineage and 
occupies a particular ecological niche (van Regenmortel, 1992).  
Bacterial viruses were discovered twice, by Twort in 1915 and by d’Herelle in 1917 
(Summers, 2011, 2016). There are constant debates on whether the discovery of 
bacterial viruses should be attributed to Félix d’Herelle or to Frederick William 
Twort (Duckworth, 1976). d’Herelle coined the name ‘bacteriophages’ for these 
infectious agents lysing bacteria, which literally means ‘eaters of bacteria’. As it 
often happens in science, it is not enough to discover something new. It is equally 
important to see the possible applications of a new discovery. Félix d’Herelle clearly 
recognized the viral nature of his agent and devoted the rest of his scientific carreer 
to it. He also pioneered several principle lines of bacteriophage research by 
introducing phage treatment of bacterial infections, and by hinting that 
bacteriophages are suitable for research on the nature of the gene (Summers, 2016). 
It is therefore that he can be seen as the true ‘phage father’. Research on 
(bacterio)phages played a central role in deciphering molecular principles of life 
such as the finding that DNA is the hereditary molecule and led to the development 
of an entirely new science, molecular biology (Duckworth, 1987). Right after their 
discovery, phages were also used in an early form of biotechnology to fight bacterial 
pathogens (Levin and Bull, 1996). In Western Europe and the United states, phage 
therapy was abandoned due to ambiguous results and the discovery of antibiotics 
(Sulakvelidze, 2001). 
Bacteriophages occur everywhere in the biosphere and have colonised even such 
forbidding habitats as volcanic hotsprings. Their main habitats are the oceans and 
topsoils (Ackermann, 2011). Phages have double-stranded (ds) or single-stranded 
(ss)DNA or RNA. Besides tailed phages, also cubic, spindle, lemon-shaped, 
filamentous, pleomorphic and even ‘hairy’ phages have been described (Ackermann 
and DuBow, 1987; Børsheim, 1993; Bradley, 1967; Buttimer et al., 2017; Demuth et 
al., 1993; Frank and Moebus, 1987; Proctor, 1997). 
Tailed phages constitute the order Caudovirales with three families, characterized 
by contractile (Myoviridae), long and noncontractile (Siphoviridae), or short tails 
(Podoviridae). Caudovirales represent over 96 % of known phages (Ackermann, 
2011). A typical Caudovirales phage has a head and a tail, hold together by a 
connector. 
Several steps during the life cycle of a prokaryotic virus can be distinguished that 
are common to all viruses: adsorption, separation of nucleic acids from protein coat, 
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expression and replication of the nucleic acids, virion assembly, release, and 
transmission (Weinbauer, 2004). Phage adsorption occurs in two steps. The first 
step of adsorption to a defined cell surface structure is reversible. During the second 
step, an irreversible binding between a phage structure (e.g. tail fibers) and the 
receptor on the host bacterium is accomplished. After adsorption, the cell wall is 
made penetrable, using tail associated lysins, and the nucleic acid is transported 
into the cell, whereas the capsid remains outside the cell. Following injection, the 
genetic material is either integrated into the host genome or stays in the cytoplasm. 
Phages can show several life cycles, i.e. lytic, lysogenic, chronic infection or 
pseudolysogenic (Figure 5. 1)(Ackermann and DuBow, 1987). 
. In the lytic life cycle, the phage genome exists within the host but 
outside the host genome. Lytic or virulent phages repeat a cycle in which self-
proliferation is synchronous with the destruction of bacteria (i.e. the lytic cycle or 
the virulent infection; Matsuzaki et al., 2005). In this stage, gene expression, 
genome replication and morphogenesis occurs, i.e. the formation of the genomes and 
the capsids (and tails) and the packing of the genomes in the capsids (Ackermann, 
1998).  
. In the lysogenic cycle, the genome of the (temperate or 
lysogenic) phage is integrated in the chromosome of the host (prophage) and 
replicates along with the host (now called a lysogen), until the lytic cycle is induced 
(Ackermann, 1998; Weinbauer, 2004).  
. Chronically infecting phages produce progeny that are constantly 
released from the host cell by budding or extrusion without lysis of the host cell 
(Weinbauer, 2004).
. Pseudolysogeny and carrier-state are widely used as 
synonyms. Pseudolysogeny can be defined as the stage of stalled development of a 
bacteriophage in a host cell without either multiplication of the phage genome (as 
in lytic development) or its replication synchronized with the cell cycle and stable 
maintenance in the cell line (as in lysogenization), which proceeds with no viral 
genome degradation, thus allowing the subsequent restart of virus development 
(Łoś and Węgrzyn, 2012). This phenomenon is usually caused by unfavorable 
growth conditions for the host cell (such as starvation) and is terminated with 
initiation of either true lysogenization or the lytic cycle when growth conditions 
improve (Paul and Jiang, 2001). Pseudolysogeny has been known for tens of years; 
however, its role has often been underestimated. Currently, it is being considered 
more often as an important aspect of phage-host interactions. Pseudolysogeny 
seems to play an important role in phage survival, as bacteria in a natural 
environment are often starved or their growth is very slow. This phenomenon can 
be an important aspect of phage-dependent bacterial mortality and may influence 




Figure 5. 1: Types of phage life cycles. Due to spontaneous mutations bacteria can 
become resistant to the phage infection, which the phage can overcome by slight adaptations 
in its tail fibers. After phage adsorption, phage DNA is injected into the bacterium 
(represented as a coiled molecule). This can become integrated into the host chromosome as 
a prophage in lysogeny. By the process of induction, the prophage is excised, and can go into 
the lytic phage replication. In pseudolysogeny, the host cell can mutate to an adhesion-
impaired or deficient state, whereby collisions result in a low success rate of infection. 
Another type of pseudolysogeny, termed carrier state, can occur when the prophage does not 
integrate but is maintained as a plasmid. Both types of pseudolysogeny result in a high 
abundance of both phages and host cells simultaneously. When phages continuously produce 
progeny phages through budding or extrusion without lysis of the host cell, is a process called 
chronic infection. Adapted from Weinbauer (2004). 
However, the carrier state is more strictly used for bacteria with a plasmid-like 
prophage. Mechanisms for establishing the carrier state include a reduced success 
rate of infection conferred by limited available receptors or by enzymatic loss of 
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receptors or superinfection immunity of a temperate phage (Barksdale and Arden, 
1974).  
Bacterial cells and their viral predators (phages) are locked in a constant battle. In 
order to proliferate in phage-rich environments, bacteria have evolved an 
impressive arsenal of defense mechanisms, and in response, phages have evolved 
counter-strategies to evade these antiviral systems (Samson et al., 2013). Bacterial 
antiphage systems include the inhibition of phage attachment to cell surface 
receptors, cleavage of the invading phage genome and even the induction of an 
altruistic cell suicide to abort phage infection. However, despite this arsenal, a large 
proportion of bacteria succumb to phage infection. Owing to their genomic plasticity 
and rapid multiplication rates, phages have evolved equally diversified strategies 
to thrive in apparently well-protected bacterial cells (Labrie et al., 2010).  
Adsorption of phages to host receptors is the initial step of infection and, perhaps, 
one of the most intricate events, as phages must recognize a particular host-specific 
cell component. 
. To efficiently attach to the surface of its bacterial host, a 
phage targets cell surface receptors. Given that adsorption is often intricately 
coupled to the injection of phage DNA, and that both of these interdependent steps 
must be achieved to enable intracellular phage replication, the specific interaction 
between the phage receptor-binding protein and its bacterial cell surface receptor is 
one of the primary parameters defining phage infection kinetics (Bertin et al., 2011; 
Moldovan et al., 2007). To limit phage propagation, bacteria can adapt the structure 
of their cell surface receptors or their three-dimensional conformation. S. aureus, 
for example, produces a cell-wall-anchored virulence factor, immunoglobulin G-
binding protein A, which binds to the Fc fragment of immunoglobulin G (Foster, 
2005). It has been shown that phage adsorption improves when bacteria produce 
less protein A, indicating that this protein masks the phage receptor (Nordström 
and Forsgren, 1974). On the other hand, tailed phages can evolve to modify their 
receptor-binding proteins to acquire novel receptor tropism (Samson et al., 2013). 
Furthermore, some lysogenic phages, e.g. P. aeruginosa phage D3, is able to alter 
the LPS structure of the P. aeruginosa infected bacteria. This protects the lysogen 
from being infected and lysed by the same phage (Kropinski, 2000). 
. The production of structured extracellular 
polymers can promote bacterial survival in various ecological niches by protecting 
the bacteria against harsh environmental conditions and, in some cases, providing 
a physical barrier between phages and their receptors. Some phages have also 
evolved to specifically recognize these extracellular polymers and even to degrade 
them (Stummeyer et al., 2006; Sutherland, 1995, 1999; Sutherland et al., 2004). 
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Polysaccharide-degrading enzymes can be classified into two groups: the lyases and 
the hydrolases. The lyases cleave the linkage between the monosaccharides and the 
C4 of uronic acid and introduce a double bond between the C4 and C5 of uronic acid 
(Sutherland, 1999). The hydrolases break the glycosyl-oxygen bond in the glycoside 
linkage (Sutherland, 1995). These viral enzymes are found either bound to the 
phage structure (connected to the receptor-binding complex) or as free soluble 
enzymes from lysed bacterial cells (Sutherland, 1995). 
. Molecules that are naturally present in the 
bacterial environment can bind specifically to the phage receptors, rendering these 
receptors unavailable for phages (Labrie et al., 2010). For example, E. coli FhuA is 
an iron transporter, but also a port of entry for phage T1 and T5. The anti-microbial 
molecule microcin J25, produced under conditions of nutrient depletions and plays 
a role in the growth inhibition of phylogenetically related strains, also uses FhuA 
as a receptor and can outcompete phage T5 for binding to FhuA (Destoumieux-
Garzón et al., 2005). 
Superinfection exclusion (Sie) systems are proteins that block the entry of phage 
DNA into the host cells, thereby conferring immunity against specific phages. These 
proteins are predicted to be membrane anchored or associated with membrane 
components. The genes encoding these proteins are often found in prophages, 
suggesting that in many cases Sie systems are important for phage-phage 
competition rather than phage-host interactions.  
Coliphage T4, a well-characterized virulent phage, has two Sie systems encoded by 
imm and sp. These systems cause rapid inhibition of DNA injection into cells, 
preventing subsequent infection by other T-even-like phages. Imm prevents the 
transfer of phage DNA into the bacterial cytoplasm by changing the conformation 
of the injection site. Imm has two non-conventional transmembrane domains and is 
predicted to be localized to the membrane, but Imm alone does not confer complete 
phage immunity and must be associated with another membrane protein to exert 
its function and achieve complete exclusion (Lu et al., 1993). The membrane protein 
Sp inhibits the activity of the T4 lysozyme, thereby preventing the degradation of 
peptidoglycan and the subsequent entry of phage DNA. The T4 lysozyme is found 
at the extremity of the tail and creates holes in the cell wall, facilitating the injection 
of phage DNA into the cell (Lu and Henning, 1994; Moak and Molineux, 2000). 
Many bacterial genera possess restriction-
modification (R-M) systems. Their activities are due to several heterogeneous 
proteins that have been classified into at least four groups (type I – type IV). The 
principal function of the R-M system is thought to be protecting the cell against 
invading DNA, including viruses (Pingoud et al., 2005; Robinson et al., 2001). 
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When unmethylated phage DNA enters a cell harboring a R-M system, it will be 
either recognized by the restriction enzyme and rapidly degraded or, to a lesser 
extent, methylated by a bacterial methylase to avoid restriction, therefore leading 
to the initiation of the phage’s lytic cycle (Krüger and Bickle, 1983). 
. The clustered regulatory interspaced short palindromic 
repeats (CRISPRs) and the CRISPR-associated (cas) genes provide bacteria and 
archaea with adaptive immunity against phages and plasmids. The mechanisms of 
action of CRISPR-Cas systems can be divided in three stages: acquisition, 
expression and maturation, and interference (Amitai and Sorek, 2016). The 
acquisition stage contains the recruitment of new spacers. In this stage the Cas 
proteins identify the target (phage) DNA and acquire a new spacer from their 
targets. This spacer sequence is integrated into the CRISPR array and forms the 
immunological memory, which reflects the chronology of past infections (van der 
Oost et al., 2014). The expression stage contains the transcription of the CRISPR 
array and subsequent processing of the precursor transcript into smaller CRISPR 
RNAs (crRNAs). The crRNA-directed cleavage of invading DNA by Cas nucleases 
forms the interference stage (Amitai and Sorek, 2016; van der Oost et al., 2014; 
Sampson et al., 2013). 
Bacteria carry a wide range of heterologous proteins that provide resistance 
through the abortion of phage infection. These abortive infection (Abi) systems also 
lead to the death of the infected cell, which is not the case for the antiphage systems 
described above. Typically, these Abi systems target a crucial step of phage 
multiplication such as replication, transcription or translation (Labrie et al., 2010). 
Abortive infection results in the destruction of the cell before phages can replicate. 
This suicidal sacrifice protects the cells of the same population from infection by 
phages (Forde and Fitzgerald, 1999; Weinbauer, 2004) 
With the rising prevalence of antibiotic-resistant bacteria and the serious concerns 
raised by the World Health Organization (WHO), new approaches to deal with 
bacterial infections have become an urgent need (Levy and Marshall, 2004). Phage 
therapy is the application of bacteria-specific viruses to combat bacterial infections 
(Summers, 2001).  
The advantages of phage therapy over the use of chemical antibiotics can be framed 
in terms of the phage properties: i.e. the lytic activity of the phages, auto-dosing, 
low inherent toxicity, minimal disruption of normal microflora, narrower potential 
for inducing resistance (and if resistance against a specific phage is observed, new 
phages can be easily isolated), lack of cross-resistance with antibiotics, rapid 
discovery, formulation and application versatility and possibly biofilm clearance 
(Loc-Carrillo and Abedon, 2011). Auto–dosing phages are capable of increasing their 
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number during the bacterial-killing process and disappear after the target is 
cleared. The term auto dosing refers to the fact that phages themselves contribute 
to establishing the phage dose (Carlton, 1999; Chan and Abedon, 2012; Skurnik and 
Strauch, 2006). Finally, phages, like antibiotics, can be versatile in terms of 
formulation development, such as being combined with certain antibiotics (Alisky 
et al., 1998; Kutter et al., 2010). They are also versatile in application form, as 
liquids, creams, impregnated into solids, in addition to being suitable for most 
routes of administration (Carlton, 1999; Kutateladze and Adamia, 2010; Kutter et 
al., 2010). Different phages can be mixed as cocktails to broaden their properties, 
typically resulting in a collectively greater antibacterial spectrum of activity and 
possibly limiting the risk of resistance development(Goodridge, 2010; Merabishvili 
et al., 2009). 
Phages as pharmaceuticals are protein-based, infectious biological agents that can 
potentially interact with the body’s immune system, can actively replicate, and can 
even evolve during manufacture or use, but are far from unique in these regards. 
Many protein-based pharmaceuticals can stimulate the immune system, e.g., 
antibiotics that lyse bacteria will release bacterial toxins in situ (Loc-Carrillo and 
Abedon, 2011). The use of phages as drugs may differ dramatically from 
pharmaceuticals/antibiotics due to differences in the phage pharmacokinetics 
(Payne and Jansen, 2003). Phage therapy is often complicated by additional factors 
and as such possess unique pharmacokinetics and pharmacodynamics that remain 
poorly understood (Cooper et al., 2016). The pharmacokinetics of phages are 
complicated due to the self-replicating nature of phages. The in vitro growth data 
for a phage cannot be directly applied to the in vivo situation, and the in vivo data 
for one phage cannot be transferred to another phage (Skurnik and Strauch, 2006). 
Critical parameters that affect phage therapy are the phage adsorption rate, burst 
size, latent period and initial phage dose, and also density-dependent thresholds 
and associated critical times should be considered (Payne and Jansen, 2001). 
Another parameter is the clearance rate of the phage particles from the body fluids 
by the mononuclear phagocyte system.  
Lytic bacteriophages targeting individual bacterial pathogens have therapeutic 
potential as an alternative or adjunct to antibiotics. Phage therapy has been used 
for decades, but clinical trials in this field are rare, leaving many questions 
unanswered as to its effectiveness for many infectious diseases (Reindel and Fiore, 
2017). As a consequence, phage therapy is not used or accepted in most parts of the 
world (Parracho et al., 2012). The therapeutic use of phages started in Paris in 1919 
when d’Herelle used oral phage preparations to treat bacterial dysentery (Kutter 
and Sulakvelidze, 2004). Patients treated with a single dose of phage preparation 
started to recover within 24 h of treatment (Abedon et al., 2011; Sulakvelidze, 2001). 
Not long after this, Bruynoghe published, together with his student Maisin, on the 
first use of phages in a phage therapeutic context (Lavigne and Robben, 2012). 
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In order to achieve clinical use, rigorous trials to validate safety and efficacy need 
to be established. The regulatory foundation for clinical studies and clinical trials 
in humans is to ethically establish the potential toxicity, efficacy and side effects of 
new drugs and to prioritize the health of the participants over the generation of 
results. It is equally important that sufficient data support the claim of potential 
benefits and that these benefits outweigh anticipated risk. Clinical studies and 
trials should be carried out in a scientifically correct and transparent manner, be 
designed to result in trustworthy data and assess the pharmacological properties of 
the new drug in a stepwise process adapted to available information (Cooper et al., 
2016). Since bacteriophages replicate only in the presence of their host bacteria, 
first-in-human data with phages in healthy participants may not address safety 
concerns that are unique to phage-bacteria interaction in the setting of active 
infection, such as tolerability of therapy, immune response to therapy and endotoxin 
release. Assessment of phage pharmacokinetics and pharmacodynamics in 
otherwise healthy patients who are colonized by target strain(s) may provide some 
insights, such as the impact on the microbiome, but may still not predict what 
happens in the setting of higher bacterial burden associated with infection (Reindel 
and Fiore, 2017). The interpretation of pharmacokinetic data may also be affected 
by immune clearance of the bacteriophage (Dąbrowska et al., 2005; Merril et al., 
1996).  
Animal studies have generally supported the utility and safety of bacteriophage 
therapy against bacterial pathogens, such as P. aeruginosa (McVay et al., 2007; 
Soothill, 1994), S. aureus (Wills et al., 2005), vancomycin-resistant Enterococcus 
faecium (Biswas et al., 2002) and Clostridium difficile (Ramesh et al., 1999). Such 
research has culminated in preclinical and veterinary trials, such as the application 
of a phage cocktail to treat P. aeruginosa otitis in dogs (Hawkins et al., 2010).  
The available phage therapy trials have primarily addressed safety issues. No 
adverse events have been reported so far. Intralytix has performed a clinical trial 
in Texas on 42 patients with chronic venous leg ulcers. These patients were treated 
for twelve weeks with either a saline control or a bacteriophage cocktail against P. 
aeruginosa, S. aureus and E. coli. Although this study was not designed as an 
efficacy trial, no significant differences were determined between the test and 
control groups for frequency of healing, but no adverse events were attributed to the 
study product (Rhoads et al., 2009). 
The use of phages against P. aeruginosa has been examined in other clinical trials 
as well. Wright et al. (2009) reported the efficacy and safety of a therapeutic phage 
preparation (Biophage-PA). The study contained twelve patients with antibiotic-
resistant P. aeruginosa chronic otitis who were treated with a single dose of phage 
preparation and followed up at 7, 21 and 42 days after treatment. The treated 
patients showed significant clinical improvements compared to the placebo group, 
although both groups still had P. aeruginosa at day 42 (Wright et al., 2009). 
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Another clinical trial was conducted in a Belgian Military Hospital on burn wound 
patients. Nine patients with burn wounds infected with multidrug-resistant P. 
aeruginosa or S. aureus were treated with a sterile-filtered cocktail of well-
characterized phages, purified of endotoxin and lacking cytotoxicity (Merabishvili 
et al., 2009). Although only one treatment was carried out and the bacterial load 
remained unchanged in the patients, the authors were able to overcome important 
psychological hurdles to the use of phage therapy. The authors encountered 
numerous pitfalls, such as that the natural phage isolates were required to go 
through safety checks for genetically modified organisms, insurance companies put 
the patients in a higher risk class, and reviewers asked for conventional 
pharmaceutical tests of the phage cocktail, which would have cost millions of euros 
(Rose et al., 2014). The lack of adverse events observed in this pilot trial led to the 
establishment of a dedicated phage therapy center by the Belgian Army. 
Nevertheless, these small scale clinical trials have opened the debate discussing the 
regulatory frame that could fit the re-introduction of bacteriophage therapy without 
losing safety, quality and efficacy aspects (Debarbieux et al., 2016; Verbeken and 
Pirnay, 2015; Verbeken et al., 2014a, 2014b, 2016). 
Although several safety studies have been conducted, not all of them take into 
account or report the removal of endotoxins as a crucial step in the preparation of 
the therapeutic phages. Endotoxin removal strategies used during these trials 
range from the use of specific endotoxin removal kits [e.g. Detoxi-endotoxin removal 
gel (Pierce) and Endotrap Blue (Hyglos)] (McVay et al., 2007; Merabishvili et al., 
2009), CsCl ultracentrifugation (Biswas et al., 2002) or the use of custom made 0.07 
µm filters (Soothill, 1994). 
A large scale clinical trial using burn wound patients was setup to further evaluate 
the efficacy of phage therapy, Phagoburn. Phagoburn is a European Union (EU) 
funded project to explore the use of phage therapy to treat burn wounds infected 
with bacteria. Phagoburn involves institutions and hospitals in Belgium, France 
and Switzerland (Matsuzaki et al., 2014). Pherecydes Pharma is leading this clinical 
trial and developed two topical phage treatments for the trial, aimed at E. coli and 
P. aeruginosa infections. Initially they planned to enroll 220 patients from eleven 
participating hospitals. Half of these would receive phages, and the other half silver 
sulfadiazine, an antibacterial cream routinely used on burn infections. However, in 
the six months after recruitment began in July 2015, Phagoburn found just 15 
eligible patients with P. aeruginosa infections and one with E. coli. Due to the 
difficulties in patient recruitment, the team decided to drop the E. coli study 
altogether, leaving just the intended 110-person P. aeruginosa study (Servick, 
2016). The difficulties that the Phagoburn trial currently is having, shows the long 
way phage therapy trials have to accomplish in order to become a fully implemented 
treatment.  
In order to achieve a therapeutic application and regulatory approval, a deep 
understanding of the phage-host interaction, phage diversity, phage dynamics and 
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genome function is crucial (Pires et al., 2015). Moreover, the interaction of phages 
with the mammalian immune system is understudied, although it might play an 
important role in the outcome of phage therapy. 
The human body is colonized by commensal microorganisms that encompass diverse 
phyla from the three domains of life: Eukarya, Archaea and Bacteria. Most of these 
microorganisms reside at body surfaces that are in direct contact with the 
environment, including the intestine, skin and upper respiratory tract. Research 
efforts over the past two decades have focused primarily on the bacterial component 
of the human microbiota and its associated genes (Duerkop and Hooper, 2013). 
These efforts have yielded a wealth of insight about the composition of human-
associated bacterial communities, how these resident bacteria interact with the 
immune system and how bacteria-immune system interactions are altered in 
disease (Hooper et al., 2012; Lozupone et al., 2012). Recently, it has become 
apparent that the microbiota of healthy humans also include important numbers of 
viruses, termed the virobiota (White et al., 2012). Metagenomic studies have 
revealed that the human microbiome includes many viral genes (the virome) 
(Handley et al., 2012; Minot et al., 2011; Reyes et al., 2010). About 90 % of the gut 
virome consist of phages (Scarpellini et al., 2015). 
Bacteria that inhabit the intestine and skin are generally regarded as stable 
residents that confer metabolic and/or immune benefits to their hosts (Turnbaugh 
et al., 2009). Therefore, it is reasonable to ask whether viruses can also be stably 
associated with healthy human tissues and whether they are able to influence the 
immune response. Phage populations in the intestine diversify as new members of 
the bacterial community are introduced, which suggests that phage diversity and 
bacterial diversity are linked (Breitbart et al., 2008). Although there is minimal 
variation of intestinal phage populations within individuals over time, there is 
substantial variation between individuals, even when those individuals have 
similar bacterial community structures (Minot et al., 2011; Reyes et al., 2010; 
Turnbaugh et al., 2009). It is thus interesting to consider whether phage infection 
of intestinal bacteria could alter community composition in ways that impact 
function of the immune system and influence the spread of pathogenic viruses 
(Duerkop and Hooper, 2013; Ivanov et al., 2008; Mazmanian et al., 2005). Part of 
how the microbial community influences host immunity is by limiting pathogen 
colonization through niche occupation and resource use. These indirect protective 
effects may extend to the viral members of the microbiota, of which there are an 
estimated 109 viruses per gram of faeces. Some of these viruses target mammalian 
cells but phages, which exclusively infect bacteria, make up the majority of this viral 
community (Cadwell, 2015).  
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Although humans are routinely exposed to phages on a daily basis, concerns persists 
over their immunogenicity and overall safety, presenting an additional stumbling 
block for the adoption of phage therapy (Cooper et al., 2016). 
A critical immunological barrier protecting all animals against invading bacterial 
pathogens but also supporting large communities of commensal microorganisms are 
the mucosal surfaces (e.g. human gut and respiratory tract)(Johansson et al., 2008; 
Linden et al., 2008). The mucus is predominantly composed of mucin glycoproteins, 
of which the amino acid backbone incorporates tandem repeats of exposed 
hydrophobic regions alternating with blocks bearing extensive O-linked 
glycosylation (Cone, 2009). By offering both structure and nutrients, mucus layers 
commonly support higher bacterial concentrations than the surrounding 
environments (Martens et al., 2008; Poulsen et al., 1994). Secretions produced by 
the underlying epithelium influence the composition of this microbiota (Hooper et 
al., 1999; Schluter and Foster, 2012; Sonnenburg, 2005). When invaded by 
pathogens, the epithelium may respond by increasing the production of 
antimicrobial agents, hypersecretion of mucin, or alteration of mucin glycosylation 
patterns to subvert microbial attachment (Gill et al., 2013; Jentoft, 1990; Schulz et 
al., 2007). Besides bacteria, phages are also present in these mucus layers. 
Moreover, phage concentrations are elevated in mucus relative to the surrounding 
environment (Barr et al., 2013).  
Phages in the human gut encode a population of hypervariable proteins (Minot et 
al., 2012). Approximately half of these phage proteins possess the C-type lectin fold 
previously found in the major tropism determinant protein at the tip of the 
Bordetella phage BPP-1 tail fibers (Medhekar and Miller, 2007). These Ig-like 
proteins, similar to antibodies and T-cell receptors, can accommodate large 
sequence variation (Halaby and Mornon, 1998). Ig-like domains are also displayed 
in the structural proteins of many phages (Fraser et al., 2006, 2007). That most of 
these displayed Ig-like domains are dispensable for phage growth in the laboratory 
led to the hypothesis that they aid adsorption to their bacterial host under 
environmental conditions (Fraser et al., 2007; McMahon et al., 2005). For phage T4, 
it has been shown that the increased concentration of phage on mucosal surfaces is 
mediated by weak binding interactions between the variable Ig-like domains on the 
T4 phage capsid and mucin-displayed glycans (Figure 5. 2). These Ig-like domains 
are present in approximately one quarter of the sequenced genomes of the 
Caudovirales, and are only found in the virion structural proteins and are typically 
displayed on the virion surface (Fraser et al., 2006). It was thus postulated that they 
play an important role in the binding to bacterial surface carbohydrates during 
infection (Fraser et al., 2006, 2007). The predominant macromolecular constituent 
of mucus, the mucin glycoproteins, display hundreds of variable glycan chains to 
the environment that offer potential sites for binding by phage Ig-like proteins. 
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Furthermore, Barr et al. (2013) speculated that phages use the variability of the Ig-
like protein scaffold to adapt to the host’s ever-changing patterns of mucin 
glycosylation. 
The presence of an Ig-like protein (highly antigenic outer capsid protein, Hoc) 
displayed on the capsid of T4 phage significantly slowed the diffusion of the phage 
on mucin solutions. Although phage particles, being inanimate and small, act as 
colloidal particles, they use subdiffusive motions instead of a Brownian motion. This 
was shown in experiments using phage T4, where the subdiffusive motions of phage 
T4 in mucus increases the frequency of host encounters. Thus, phage Ig-like 
domains that bind effectively to the mucus layer would be under a positive selection. 
These findings lead to the development of the bacteriophage adherence to mucus 
(BAM) model (Figure 5. 2), which provides a non-host-derived antibacterial defense 
(Barr et al., 2013; 2015). 
Figure 5. 2: The bacteriophage adherence to mucus (BAM model). (1) Mucus is 
produced and secreted by the underlying epithelium. (2) Phage bind variable glycan residues 
displayed on mucin glycoproteins via variable capsid proteins (e.g., Ig-like domains). (3) 
Phage adherence creates an antimicrobial layer that reduces bacterial attachment to and 
colonization of the mucus, which in turn lessens epithelial cell death. (4) Mucus-adherent 
phage are more likely to encounter bacterial hosts, thus are under positive selection for 
capsid proteins that enable them to remain in the mucus layer. (5) Continual sloughing of 




Phages interact with non-target tissues to some extent, and at least some phages 
are taken up from the gastrointestinal tract into the blood. Therefore there is reason 
to think that such uptake can be a consequence of specific phage-to-epithelium 
interactions, as also appears to be the case given phage interaction with the 
mononuclear phagocyte system (Duerr et al., 2004; Górski et al., 2006a; Merril, 
2008).  
The passage of indigenous bacteria colonizing the intestine through the mucosa to 
local lymph nodes and internal organs is termed bacterial translocation. It is a 
recurrent event that happens throughout the gut and is not always a critical step 
in the pathology of various disorders (Guarner and Malagelada, 2003; Wiest and 
Garcia-Tsao, 2005). While bacterial translocation is a well-described phenomenon, 
little is known about the translocation of viruses. Studies have shown that the oral 
administration of phages to animals results in the translocation of phages to 
systemic tissues (Duerr et al., 2004; Hamzeh-Mivehroud et al., 2008; Keller and 
Engley, 1958). As such, the oral administration of phages is very effective in the 
treatment of alimentary tract infections in calves, lambs and piglets (Dąbrowska et 
al., 2005). Both the feeding and gastric lavage of animals with phages resulted in 
irregular but consistent recovery of phages from the blood (Keller and Engley, 1958).  
Recent work from the Barr Lab demonstrated that phages can enter the body via 
epithelial transcytosis (Nguyen et al., 2017). This transcytosis preferentially occurs 
in an apical-to-basal direction and is mediated by different cell types (e.g. gut, lung, 
liver, kidney and brain cells). The transcytosis of phages across epithelial cells 
provides a mechanistic explanation for the occurrence of phages within the human 
body in the absence of disease. This work showed that the transcytosis of 
bacteriophages across polarized epithelial cells and into the body is a natural 
occurring and ubiquitous process that adds credence to the use and application of 
phages in a biomedical setting. 
The penetration of phages in higher organisms leads to the direct contact of phages 
with eukaryotic cells. Therefore it is important to know whether these phages are 
able to interact or infect eukaryotic cells. Infection seems unlikely, because 
elements of the phage capsids only binds to specific molecules on the surfaces of 
their target bacteria. Furthermore, it is generally recognized that phages cannot 
infect the cells of organisms more complex than bacteria, because of major 
differences in key intracellular machinery that is essential for replication (Kutter 
and Sulakvelidze, 2004). This was illustrated by Di Giovine et al. (2001) who re-
engineered the filamentous phage M13 to infect mammalian cells. A gene for the 
adenovirus penton base protein was inserted into the phage genome. This protein 
is originally involved in the attachment of adenoviruses to integrin receptors, 
internalization of viral particles, and release of the capsid from the endosome 
(Wickham et al., 1993; 1994). Although subsequently binding and internalization of 
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the re-engineered phage were observed, no multiplication of the phage was detected 
(Di Giovine et al., 2001). 
In 1940, Bloch observed an accumulation of phages in cancer tissue and inhibition 
of tumor growth (Bloch, 1940). Later it was demonstrated that phages bind cancer 
cells in vitro and in vivo and attach to the plasma membrane of lymphocytes 
(Kantoch and Mordarski, 1958; Northrop, 1958; Wenger et al., 1978). Another study 
showed that phage T4 and its substrain HAP1 bind to melanoma cells and 
significantly inhibited the metastasis of murine B16 melanoma cells (Dąbrowska et 
al., 2004). The authors suggested that this interaction occurs through the binding 
of β3 integrins on the target cells with the phage capsid protein gp24 (containing a 
KGD-amino acid motif). Eriksson et al. (2009) reported that genetic modification of 
phage M13 (designated WDC-2) led to the production of a tumor-specific phage that 
was able to bind 93 % of tested tumor cells (Eriksson et al., 2009). Moreover, 
administration of this tumor-specific phage initiated the infiltration of neutrophilic 
granulocytes with subsequent regression of established B16 tumors in mice 
(Eriksson et al., 2007, 2009). The authors observed that the mechanisms of this 
phage-induced tumor regression is TLR-dependent as no signs of tumor destruction 
or neutrophil infiltration were observed in tumors of MyD88-/- mice, whereby TLR 
signaling was abolished. Although the effects observed by these phages are not 
induced by a natural phage, they do indicate the possibility of phages used in 
different therapeutic settings or as a platform for the development of new 
therapeutics. 
The molecular basis of these interactions is based on a Lys-Gly-Asp (KGD) 
tripeptide motif that forms a ligand for the β3 integrins on cells. This mechanism 
was first coined by Gorski in 2003 (Gorski et al., 2003). The tripeptide motif can be 
found in the phage T4 structural protein gp24, which is not directly involved in the 
infection process of the phage. The authors suggested ways in how this hypothesis 
might be tested, e.g. using purified phages and immobilizing the phage on a plastic 
plate and evaluate the cell adhesion by ELISA, or confirming the bind though means 
of electron microscopy, or confirming the binding through the use of agents that 
block the β integrin function. Unfortunately the authors have not tried any of these 
suggestions, leaving this hypothesis still untested. Interestingly, the adenovirus, 
used in the experiments of Di Giovine, binds to this integrin (Ling et al., 2002). 
While the effects of bacteria and viruses on reactive oxygen species (ROS) activity 
have been described, much is not known about the effects of bacteriophages on the 
ROS production. A preliminary study performed by Przerwa et al. (2006) suggested 
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that phage T4 influences the phagocyte system. In vitro experimental models have 
shown that phages can diminish phagocytosis. This phenomenon may be of little 
significance on clinical situations, since the process of eliminating bacteria in phage-
treated patients is predominantly accomplished by both phages and phagocytes 
(Przerwa et al., 2006). Furthermore, phage T4 inhibits the ROS production in 
response to pathogenic bacteria (i.e. Escherichia coli), and this phenomenon appears 
to depend on specific phage-bacterium interactions, as P. aeruginosa phage F-8 did 
not affect the ROS production induced by E. coli on the phagocytic cells. Although 
the authors conclude that the reduction of ROS production is due to the direct effect 
of the phage, the host-specific effect could indicate that the ROS reduction is caused 
by a reduction of bacteria, due to infection and lysis by the phage. This might also 
explain why phage T4 had an effect and not phage F-8 on the reduction of ROS 
induced by E. coli. 
A more comprehensive follow-up study was conducted where polymorphonuclear 
leukocytes (PMN) were stimulated with one of three different R-type E. coli strains 
(i.e. E. coli B and E. coli J5, both susceptible for T4, and E. coli R4, resistant to T4) 
or with LPS derived from these three strains (Miedzybrodzki et al., 2008). The 
authors used these R-type strains as only the R-type LPS was able to activate ROS 
production by the peripheral blood PMNs, as was previously observed by Kapp et 
al. (1987). Through this setup, the authors could observe a reduction in ROS 
production when PMNs were stimulated with either the live bacteria or their LPS 
in the presence of phage T4. Moreover, this reduction was seen not only when T4 
was able to infect the E. coli strains but also for the T4 resistant E. coli strain, 
although the T4 resistant E. coli strain induced a less strong ROS production 
compared to the T4 susceptible strains. Moreover, when only phages were added to 
the phagocytic cells, only a minimal ROS release was observed, indicating that 
phages do not directly have a pro-inflammatory response on phagocytic cells. The 
results provided by the authors indicate that phages can indirectly lower the pro-
inflammatory responses induced by the bacteria by captering the released LPS and 
making it less available to PMNs (Miedzybrodzki et al., 2008).  
Furthermore, when phages were administered together with the host bacteria, one 
recent study showed that, phages were able to stimulate bacterial phagocytosis, and 
this is attributed to opsonization of bacterial cells by phages. In addition, phages 
can remain active and infective when adsorbed onto the bacteria during intake by 
granulocytes (Kaur et al., 2014). Therefore, some authors have suggested that 
during phagocytosis, phages continue lysing the phagocytosed bacteria, helping the 




The innate immune system, particularly by the components of the mononuclear 
phagocyte system (MPS), could be a mechanism for removing phages that are 
circulating in the human body (Górski et al., 2012; Navarro and Muniesa, 2017). 
The MPS was credited for the rapid removal of administered wild-type phage λ from 
the circulatory system in humans (Merril et al., 1973). Moreover Merril et al. (1996) 
were able to identify certain phage λ mutants that were capable of circumventing 
the MPS immune response, whereby these mutants prevailed for longer periods in 
the blood stream than the wild-type phage. These phage λ mutants contained a 
single amino acid change in the λ capsid protein E, whereby a Glu was replaced by 
a Lys leading to a conversion of a negative charge to a positive charge (Merril et al., 
1996). 
Among the mechanisms responsible for the recognition of microbial and viral 
structures are the TLR (Kawai and Akira, 2011). Viral nucleic acids act as PAMPs 
and are recognized by multiple TLRs. It could thus be postulated that phage DNA 
might be recognized by TLR9, which is responsible for the recognition of viral DNA 
(Janeway and Medzhitov, 2002), after phagocytosis of the phage.  
Clear evidence concerning the cooperation of phages with the innate immune 
system was first provided by Tiwari et al. (2011), showing the necessity of a 
neutrophil-phage synergy in the resolution of P. aeruginosa infections. The authors 
showed that neutrophils or phages alone were not sufficient to remove a bacterial 
infection. The cooperation of the innate immune system and phages is necessary as 
the presence of neutrophils removed the phage resistant bacteria, which emerge 
during the phage therapeutic treatment when only a single phage is used. This was 
later repeated by Pincus et al. (2015) and Roach et al. (2017). 
Immunological studies, in vitro as well as in vivo, on the cellular immune response 
induced against phages have been conducted in recent years. For example, analysis 
of the cytokine production of mice treated intraperitoneal for 5.5 h with four phage 
T4 capsid proteins (i.e. gp23*, gp24*, Hoc and Soc) showed that no cytokines were 
induced (Miernikiewicz et al., 2013). The lack of cytokine production can be 
explained by the early time point by which the mice were tested for the presence of 
cytokines or through the rapid removal of the phages from circulation. Another 
immunological study evaluated the cytokine production in mice induced by phage 
T7, after the mice were fed for 10 days with phage T7. A single dose was fed every 
24 h, although an exact concentration was not provided by the authors (Park et al., 
2014). Although this study had its limitations, the authors were able to demonstrate 
that phage T7 induced a minor increase of inflammatory cytokine production in 
mice, but no histological changes were observed in the tissues of the gastrointestinal 
organs. As no caution was taken to the presence of endotoxins, the immune 
responses that were observed could be, partially, due to endotoxin contamination of 
the used phage stock. 
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The effect of phages on the production of TNFα and IL6 in serum has also been 
studied, as well as the ability of blood cells to produce these cytokines in culture. 
The authors of this study used blood derived from 51 patients with long-term 
suppurative infections of various tissues and organs caused by drug-resistant 
strains of bacteria (Weber- Dąbrowska et al., 2000). These patients were treated 
with phages and blood samples were collected and tested for the presence of TNFα 
and IL6. The authors were able to observe a reduction in the production of these 
cytokines after long-term treatment (i.e. 21 days). Unfortunately, the authors were 
not able to show whether the observed immune response was due to the presence of 
the phage or due to the reduction of the bacterial count through their lysis by the 
phage. 
Recent data indicates that Cronobacter sakazakii phage ES2 enhances the 
maturation of dendritic cells and induces the expression of IL12p40 via NF-κB 
signaling (An et al., 2014). This maturation presumably happens after the 
phagocytosis of the phage by the dendritic cells. The maturation of these dendritic 
cells play an important role in generating a cell-mediated immune response and 
subsequently in the production of phage specific antibodies. 
It should be noted that many experiments performed concerning the immune 
response induced by phages have been carried out using phage lysates. This means 
that these preparations could contain remnants of bacteria lysed by the phages (e.g. 
LPS, cytosolic proteins, or membrane particles) or perhaps fragments of the host 
bacterial cell wall adhered to the phage tails. This makes it extremely difficult to 
determine the components truly responsible for the modulation of the immune 
response. Although, more and more studies are undertaken using highly purified 
phages with less than 10 EU/ml. Furthermore, only a limited amount of data is 
useful to assess the immunological effects induced by phages, as most studies do 
not differentiate between an effect induced by the phage and an effect induced by a 
reduction of the bacteria due to lysis by the phage. 
Since phages consist of tightly packed DNA or RNA and a protein coat, and since 
the coat consists of a relatively large number of proteins, it appears obvious that 
neutralizing antibodies should be produced in individuals subjected to phage 
therapy or exposed to naturally occurring phages. In fact, naturally occurring 
bacteriophages are able to induce a humoral immunity. Phage-neutralizing 
antibodies, that were not stimulated by phage treatment, were detected in the sera 
of different species (e.g. human) (Dąbrowska et al., 2005).  
Phage immunogenicity has been employed in medicine as a test for immune 
competence of immunodeficient patients, e.g. HIV patients (Fogelman et al., 2000). 
In fact, immunization with bacteriophage φX174 has been used extensively to 
diagnose and monitor primary and secondary immunodeficiencies since the 1970s, 
without reported adverse events, even in patients in whom prolonged circulation of 
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the phage in the bloodstream was observed. This suggests an intrinsically low 
toxicity of phage φX174, even in patients with a compromised immune system (Ochs 
et al., 1971; Rubinstein et al., 2000; Shearer et al., 2001). 
One of the major effects of using phages as therapeutics is a humoral response to 
the phage (Górski et al., 2012; Kamme, 2009; Smith et al., 1987). Soon after the 
discovery of phages, it was observed that antibodies against phages were produced 
in humans or animals (Jerne, 1952, 1956). It is indeed very easy to generate phage 
antisera by immunization of humans or animals with phages (Bacon et al., 1986; 
Górski et al., 2012; Puig et al., 2001). The humoral response does not follow a simple 
scheme of induction. It depends on the route of administration and on individual 
features of the phage. Moreover, it depends on the dose and application schedule 
(Dąbrowska et al., 2014a; Górski et al., 2006a, 2012; Łusiak-Szelachowska et al., 
2014). The humoral response induced against phages can be devastating on the 
phage activity (Huff et al., 2010), but it has also been reported that the anti-phage 
activity of serum does not exclude a favorable result of phage therapy in humans 
(Łusiak-Szelachowska et al., 2014). 
Initial safety studies of phage T4 performed by Bruttin and Brüssow in 2005 on 
humans revealed no antibody induction in phage-treated volunteers at all (Bruttin 
and Brüssow, 2005). Another study performed by Dąbrowska et al. (2014) evaluated 
the anti-phage antibody production against phage T4 in 50 healthy volunteers who 
had never been subjected to phage therapy or were involved in phage work. Of the 
investigated sera, 82% significantly decreased phage activity. In these positive sera, 
natural IgG antibodies specific to the phage proteins gp23*, gp24*, Hoc and Soc 
were identified. Their results clearly showed that anti-T4 phage antibodies are 
frequent in the human population, but it is not the highly antigenic outer capsid 
(Hoc) protein that induced most of the humoral response, but the antibodies specific 
to the major capsid protein gp23* (Dąbrowska et al., 2014a).  
Recently a study concerning the production of IgG, IgA and IgM in human patients 
undergoing phage therapy was carried out (Zaczek et al., 2016). In this study, 20 
patients were treated, for an undisclosed time, with the MS-1 phage cocktail 
(containing three lytic S. aureus phages, 676/Z, A5/80 and P4/6409) either orally 
and/or locally. For the majority of patients, no antibodies could be detected. For the 
few patients that produced elevated levels of IgG or IgM, the presence of anti-phage 
antibodies did not translate into an unsatisfactory clinical result of the phage 
therapy. The low antibody production against the phage cocktail could be due to the 
small time-scale by which the patients were treated. On the other hand, the 
elevated antibody production in a few patients could be due to a previous encounter 
of one of the phages used in the cocktail and the presence of an immunological 
memory. Unfortunately, the authors did not mention whether the antibodies were 
tested against individual phages or against the phage cocktail as a whole. 
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Currently it is difficult to make assumptions on the anti-phage antibody production 
in humans, as such studies often have contradictory results. Majewska et al. (2015) 
performed an extensive study on the antibody production against a single phage 
(i.e. E. coli phage T4) in mice over a period of 240 days. Phage T4 was orally given 
to mice for 100 days, followed by 112 days without phage treatment. The treatment 
was then repeated with the same phage up to day 240. It was demonstrated that 
the long term oral treatment of mice with phage T4 led to a humoral response, in 
contrast to previous human trials where no such responses were detected (Bruttin 
and Brüssow, 2005). The authors observed that this response emerged from the 
secretion of IgA in the gut lumen but also as an IgG production in the blood 
(Majewska et al., 2015). The intensity of this response and the time necessary for 
its induction depended on the exposure to phage antigens, which is related to the 
phage dose. The factor limiting phage activity in the gut was the production of 
specific IgA. As long as the secretory levels of IgA were low, phages remained 
present in the feces. When the IgA level, around day 80, increased, there were no 
active phages present in the feces. On the other hand, when secretory IgA decreased 
with time (on day 213, it became similar to its initial levels); phages could be 
detected again, until phage-specific IgA levels increased again. 
According to the same authors, the induction of serum IgG suggested that phages 
could translocate from the gut lumen to the circulation. This observation is further 
strengthened by recent data of transcytosing phages. Furthermore, it was possible 
to isolate phages from murine blood after application of high phage doses (4 x 109 
pfu/ml of drinking water). When lower phage doses were used, it was not possible 
to detect translocation of phages to the circulation, although long-lasting secondary 
immune response could be induced. 
Besides the phage as a whole, it is interesting to evaluate the immune responses 
induced to individual phage proteins. Majewska et al. (2015) demonstrated that 
phage T4 Hoc protein and gp12 strongly stimulated the IgG and IgA antibody 
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Bacterial endotoxins have high immunogenicity. Phage biology studies as well as 
therapeutic phage applications necessitate highly purified phage particles. In this 
study, we compared combinations of seven different endotoxin removal strategies 
and validated their endotoxin removal efficacy for five different phages (i.e. four 
Pseudomonas aeruginosa phages and one Staphylococcus aureus phage). These 
purification strategies included Endotrap HD column purification and/or CsCl 
density centrifugation in combination with Endotrap purification, followed by 
organic solvent (1-octanol), detergent (Triton X-100), enzymatic inactivation of the 
endotoxin using alkaline phosphatase and CIM monolithic anion exchange 
chromatography. We show that CsCl density purification of the P. aeruginosa 
phages, at an initial concentration of 1012 - 1013 pfu/ml, led to the strongest reduction 
of endotoxins, with an endotoxin removal efficacy of up to 99 %, whereas additional 
purification methods did not result in a complete removal of endotoxins from the 
phage preparations and only yielded an additional endotoxin removal efficacy of 23 
to 99 %, sometimes accompanied with strong losses in phage titer. 
The purification of bacteriophage particles is important for two reasons: either to 
investigate the phage particle on its own (i.e. phage biology studies) or for 
therapeutic application of phages, which is currently undergoing a resurgence 
(Adhya et al., 2014; Dąbrowska et al., 2014b; Ly-Chatain, 2014; Międzybrodzki et 
al., 2012; Thiel, 2004; Vandenheuvel et al., 2015). When phages are propagated on 
Gram-negative bacterial hosts, endotoxins or lipopolysaccharides (LPS) have to be 
removed from these preparations. Endotoxins are part of the Gram-negative 
bacterial outer membranes and play an important role in the organization and 
stability of the bacterial cell (Ki et al., 1994). Bacterial endotoxins are well known 
for their immunogenic, pro-inflammatory and pyrogenic effects (Aderem and 
Ulevitch, 2000). In conditions where the body is exposed to endotoxins excessively 
or systemically, a systemic inflammatory reaction can occur, leading to multiple 
pathophysiological effects such as endotoxin shock, tissue injury and death 
(Anspach, 2001; Erridge et al., 2002; Ogikubo et al., 2004). Therefore, when phages 
are prepared for therapeutic purposes, it is crucial that different bacterial 
contaminants are removed which affect the efficacy and safety of the administration 
during phage therapy. The maximal level of endotoxins for intravenous applications 
of pharmaceutical and biological products is set at 5 endotoxin units (EU), i.e. 500 
pg of endotoxins, per kg of body weight per hour (Daneshian et al., 2006). 
Additionally, bacterial endotoxins may also interfere with phage biology studies, 
especially when trying to establish the interaction of phages with the immune 
system. 
Several strategies have been described for the removal of endotoxins from phage 
preparations. Here we compared different endotoxin removal strategies for the 
removal of endotoxins from five phages, i.e. four Gram-negative Pseudomonas 
aeruginosa phages and one Gram-positive Staphylococcus aureus phage (Table 6. 
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1). The S. aureus phage forms a negative control for the endotoxin determination 
assay, as this phage is grown on a Gram-positive host that produces no endotoxins. 
Strategies were compared, taking into account the efficacy in removing endotoxins 












































































































































































































































































































































































































































































































































































































































































































































In this study, we evaluated the endotoxin removal efficacy of seven purification 
strategies (Figure 6. 1). To determine which strategy has the best endotoxin removal 
capacity, in combination with the minimal amount of phage loss, we calculated the 
‘endotoxin removal efficacy’, defined as the ratio of the endotoxin units (EU) per 
plaque forming unit (pfu) multiplied by the phage recovery of the purified sample 
and the original sample subtracted from one (Table 6. 2). The endotoxin 
quantification by Endozyme was validated by endotoxin quantification by means of 
Endosafe-PTS, for a selected number of samples. Both detection methods gave 
similar results within the same order of magnitude. 
 
The endotoxin removal strategies include either (1) Endotrap HD column 
purification alone (Merabishvili et al., 2009) (φET), or (2) CsCl density gradient 
ultracentrifugation alone (Lavigne et al., 2009) (φC) or (3) followed with Endotrap 
HD purification (φCET), and φET or φCET followed by either (4) organic solvent (1-
octanol; Szermer-Olearnik and Boratyński, 2015) treatment (OS), (5) detergent 
(Triton X-100; Marcus and Prusky, 1987; Petsch and Anspach, 2000) treatment 
(TX), (6) enzymatic inactivation of the endotoxin using alkaline phosphatase 
(Bentala et al., 2002) (AP) or (7) anion-exchange chromatography (CIM DEAE disk 
column (CIM); Adriaenssens et al., 2012). We opted for these combined strategies, 
to compare the efficacy of purifying raw phage lysates (φET) versus CsCl-purified 
phages (φCET). As expected, phage ISP preparations from a Gram-positive host did 
not show any detectable endotoxin levels before or after any of the purification 
strategies. The four P. aeruginosa phages contained between 31,020 and 7,465,000 
EU/ml. This concentration was measured after purification of phage lysates with 
Endotrap HD and therefore may initially be higher.  
  
Figure 6. 1: Schematic representation of the different endotoxin strategies used, starting 
from different phage preparations. Phage lysates were obtained by the overlay-agar method. 
Part of this phage lysate was used either for (A) endotoxin removal using Endotrap HD (φET) 
or (B) further purified through CsCl density centrifugation followed by Endotrap HD (φCET). 
These preparations were further treated for the removal of endotoxins through different 
strategies: (OS) Organic solvent: 1-octanol; (TX) detergent treatment: Triton X-100; (AP) 
Enzymatic inactivation of endotoxins: alkaline phosphatase; or (CIM) anion-exchange 
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However, it is possible that these values correspond largely to the initial order of 
magnitude of the endotoxins present in the crude phage preparations, because the 
removal efficacy of the Endotrap HD purification, starting from the CsCl purified 
phages, was only between 63.09 – 94.56 % (Table 6. 2). Cooper et al. (2014) showed 
that crude P. aeruginosa phage preparations contained more than 105 EU/ml, which 
was in correspondence with our quantification of preparations that were purified 
only once with Endotrap HD. Dufour et al. (2016) recently described that three to 
five consecutive rounds of Endotrap HD-based endotoxin removal, starting from 
CsCl purified phages, led to a further reduction of the endotoxin concentration to 
below 0.5 EU/ml, but this is a time-consuming strategy with a variable and phage-
dependent outcome. 
The organic solvent extraction was described by Szermer-Olearnik and Boratyński 
(2015) and is based on the principle that endotoxins partition favorably in the 
organic phase, while the molecules of interest (in our case phages) are retained in 
the aqueous phase. Our results show that the organic solvent strategy has an 
endotoxin removal efficacy between 63.83 and 99.98 % for φET and between 23.40 
and 63.36 % for the φCET samples. The only exception is P. aeruginosa phage 
LUZ19 where there was an enrichment of endotoxins after the 1-octanol treatment, 
i.e. an endotoxin removal efficacy of -16.55 %. This enrichment could be explained 
by a potential release of endotoxins bound to the phage particle, which when bound 
are not detectable in the endotoxin detection assay.  
The organic solvent strategy led to the strongest reduction of endotoxins in the P. 
aeruginosa phage PNM φET and phage LUZ19 φET preparations, with an 
endotoxin removal efficacy of 99.98 and 99.68 % respectively. This was only 
accompanied with a reduction of the P. aeruginosa phage PNM with two orders of 
magnitude. For both phages, a strong reduction in phage titer of up to five orders of 
magnitude difference was observed.  
The endotoxin removal strategy using detergents such as Triton X-100 has been 
well-established. According to Petsch and Anspach (2000), endotoxins can be 
removed using a two-phase extraction, employing detergents such as those of the 
Triton series. An endotoxin removal efficacy of up to 93.21 % and 99.96 % could be 
observed for the φET and φCET phage samples, respectively (Table 6. 2). The use 
of activated charcoal for the removal of Triton X-100 led to a reduction in the 
endotoxin concentration after three consecutive rounds. Around 6.29 – 7.14 % 
endotoxins remained for the φET preparations and between 0.31 – 43.6 % 
endotoxins remained for the φCET preparations. However, the activated carbon was 
not able to remove all of the Triton X-100. This became apparent when the samples 
became viscous when stored at 4 °C for prolonged time. The phage recovery for the 
φET was between 0.07 – 17.20 % and for the φCET it was between 1.80 – 52.22 % 
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(Table 6. 3), indicating that the Triton X-100 strategy has an effect on the phage 
activity. 
An alternative method for the removal of endotoxins is enzymatic inactivation of 
endotoxins by the removal of the phosphate group of the lipid A fraction by means 
of alkaline phosphatase (Bentala et al., 2002). Consequently, the treated endotoxin 
becomes immunologically inactive and should not be detected in a classical Limulus 
Amebocyte Lysate (LAL) assay or by recombinant factor C (rFC) assays as used in 
this study. However, the treatment of the φET and φCET phage preparations with 
alkaline phosphatase had very low endotoxin removal efficacies (i.e. lower than 
20 %; Table 6. 2) and did not lead to a reduction in the endotoxin concentration. In 
addition, this method had a negative impact on the number of infectious phage, 
dropping 2 – 4 orders of magnitude (Table 6. 3). 
Although this strategy has been described for the inactivation of purified 
endotoxins, when it was applied on phage samples, there was no reduction in the 
endotoxin concentration. This might indicate that either the phages inhibit the 
enzymatic activity of the alkaline phosphatase or that the phages, through the 
binding of the endotoxins, hide the phosphate groups on the lipid A part. 
Consequently, this can result in the endotoxins not being completely inactivated by 
the enzyme while still being detectable in the endotoxin detection assay. 
The final strategy that was evaluated was the anion-exchange purification using 
CIM DEAE columns. This technique was previously described for its application in 
the purification and concentration of phages (Adriaenssens et al., 2012), but the 
authors did not evaluate the endotoxin removal potential. In this strategy, the 
phages are retained on the column through ionic interactions. This purification 
protocol was only performed for the φET preparations of P. aeruginosa phages PNM 
and LUZ19. Although the two phages that were purified by this method (i.e. P. 
aeruginosa phage PNM and LUZ19) have a high sequence similarity, the endotoxin 
removal efficacy varied between these two phages (i.e. 98.15 and 40.39 %, 
respectively; Table 6. 2). A strong reduction in phage titers from 1013 to 1011 pfu/ml 
for both the P. aeruginosa phages PNM and LUZ19 was observed (Table 6. 3). The 
limited reduction in endotoxin concentration after the anion-exchange purification 
could be explained by the fact that endotoxins also have the ability to interact with 
anion-exchange columns. According to Hou and Zaniewski (1990), the capacity of 
endotoxin removal by anion-exchange matrices through charge interaction depends 
on the number of available positively charged groups existing in the matrices. They 
observed a maximum adsorption of endotoxins at pH 6.8 when DEAE columns were 
used, and at pH 8.0 when QA columns were used. They also found that the 
endotoxin adsorption was found to be unaffected at up to 0.2 M salt concentration 
(Hou and Zaniewski, 1990a). We found that both phages were retained at the 
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column at a pH of 7.5 and eluted at a NaCl concentration above 0.6 M. Therefore, 
the removal of endotoxins without loosening the phages from the column is 
cumbersome. Hence, the endotoxins co-elute with the phages minimizing the ability 
to obtain endotoxin free phage preparations. The reduction in phage titers results 
from the phage binding capacity of the columns, which is phage-dependent. 
Starting from between 2.5 x 1012 and 8 x 1013 pfu/ml of four different P. aeruginosa 
phages (Table 6. 3), contaminated by 31,020 and 7,465,000 EU/ml, we found that 
CsCl density gradient ultracentrifugation established an endotoxin removal efficacy 
between 18.42 and 99.68 % (Table 6. 2) while reducing the number of phages with 
maximum of two orders of magnitude (Table 6. 3). Further endotoxin removal of 
these CsCl preparations with Endotrap, OS, TX, AP or CIM did reduce endotoxins 
further with a maximum endotoxin removal efficacy of 99.9 %, whereas several of 
these additional treatments were detrimental for the phage titer, which was even 
reduced to 0.0004 % for the P. aeruginosa phage PNM φCET OS treated sample. 
From our comparative study, it becomes clear that it is hard to achieve complete 
removal (i.e. ≥ 99.99 %) of endotoxins from a phage sample. For therapeutic 
purposes, only 5 EU/ml/kg/h can be present in the samples for intravenous 
applications (Daneshian et al., 2006). We clearly find that the removal of large 
volumes of endotoxins is easier than the removal of small residual endotoxins, as 
the endotoxin removal efficacy of the different procedures starting from the phage 
lysate (φET) preparation is much higher than those form the CsCl purified (φCET) 
preparations (Table 6. 2). Unfortunately, we were not able to obtain a universal 
strategy that could be used for the removal of endotoxins from any given phage 
preparation. Therefore, each phage needs to be evaluated individually for the 
optimal strategy for the removal of endotoxins, taking into account the potential 
drop in phage titers. The CsCl purification (φC) seems to have the highest efficacy 
in removing endotoxins. Although this technique might not be suitable for all 
applications such as phage therapy where high throughput and up scaling is a must, 
this strategy might be important for phage biology studies in which endotoxin 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































Since the phage titers used for phage therapy are usually around 108 pfu/ml 
(Merabishvili et al., 2009), the phage preparations can be further diluted leading to 
a further drop of the endotoxin concentration (ranging from 0.0002 to 316 EU/ml for 
108 pfu/ml phage preparations; Figure 6. 2) and subsequent safe use. Therefore, 
labor-intensive endotoxin removal strategies should not be necessary for 
therapeutic phage preparations, knowing that the dilution of high titer phage 
preparations would be sufficient. Unfortunately, dilution of the phage preparations 
is not always possible when performing phage biology studies such as evaluating 
the immunological properties of phages on the mammalian immune system, where 
high phage titers might be advised (Biswas et al., 2002; Miernikiewicz et al., 2013). 
Although this study has as a limitation that no technical replicates were obtained 
for the different endotoxin removal strategies, our results do indicate that the 
endotoxin removal is phage dependent, and thus needs to be evaluated individually 
for each phage. To obtain a complete removal of endotoxins, a combination of 
strategies could be used, such as treating the phage lysate with Triton X-100 
followed by a purification and concentration of the phages through means of anion-
exchange (i.e. DEAE disks) or by using consecutive rounds of Endotrap HD 





Figure 6. 2: Final endotoxin concentration (EU/ml) present after different 
purification strategies for four different Pseudomonas aeruginosa phages, 
normalized against a phage therapeutic titer (i.e. 108 pfu/ml). φET: lysates after 
Endotrap HD, φC: CsCl purification, φCET: φC after Endotrap, OS: Organic Solvent, TX: 




























Bacteriophage stocks (Table 6. 1) were prepared using the double-agar overlay 
method as described in Merabishvili et al. (2009). Briefly, one ml of the phage 
preparation containing 106 plaque forming units (pfu) of bacteriophages was mixed 
with 3 ml of molten (45 °C) Lysogeny Broth (LB) (Becton Dickinson, Erembodegem, 
Belgium) top Bacto agar (0.6 %) (Becton Dickinson) and 100 µl of the host strain 
suspension (end concentration of 107 cfu/ml) in a sterile 14 ml tube (Falcon, Becton 
Dickinson). This mixture was plated onto freshly made 90 mm diameter Petri dishes 
(Plastiques Gosselin, Menen, Belgium), filled with a bottom layer (20 ml) of 1.5 % 
LB agar, and incubated aerobically at 32 °C for 16 h. Subsequently, 200 µl of 
chloroform was added to the lids of the Petri dishes and the inverted plates were 
further incubated at 4 °C for 1 h. The top layer of the double-agar layer was scraped 
off using a sterile Drigalski spatulum and transferred to a sterile 14 ml tube. 
The harvested phages were centrifuged for 20 min at 6,000 x g at 4 °C. The 
supernatant was aspirated using a sterile 10 ml syringe (BD Plastipak, Becton 
Dickinson) with a 30 G sterile needle (BD Microlance 3, Becton Dickinson) and 
passed through a 0.22 µm membrane filter (Sartorius Stedim, Zellik, Belgium). The 
filtrate was subsequently centrifuged at 35,000 x g for one hour. The phage pellet 
was resuspended in 5 ml saline and stored at 4 °C overnight before determining the 
phage titer. Preferably, the titer of the phage lysate should be checked at least one 
day later according to the above described procedures. This will allow phage 
particles that may have clumped together during centrifugation steps to disengage 
(Kutter and Sulakvelidze, 2004). 
The bacteriophage titer was determined by assaying decinormal serial dilutions 
(log(0) to log(-12)) of the bacteriophage suspension with the overlay method 
(Merabishvili et al., 2009). One ml of each dilution was mixed with 3 ml of molten 
(45 °C) LB 0.6 % top Bacto agar and the host strain (end concentration of 107 cfu/ml) 
in a sterile 14 ml tube. This mixture was plated in triplicate onto 90 mm diameter 
Petri dishes, filled with a bottom layer of 1.5 % LB agar, and incubated for 16 h at 
37 °C. To determine the original bacteriophage concentration, plates with one to 
100 distinguishable homogenous plaques were counted. The mean was then 
calculated for the triplicate plates. 
All manipulations were carried out using endotoxin-free reagents. Figure 6. 1 gives 
a schematic representation of the different purification strategies used. 
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Phage lysates particles were further purified and concentrated by means of 
ultracentrifugation (104,000 x g, 4 °C) for 3.5 h in a CsCl (PanReac AppliChem, 
Darmstadt, Germany) gradient with densities of 1.33 to 1.70 g/cm3 in a swigging 
bucket centrifuge as described by Lavigne et al. (2009). The resulting high-titer 
phage suspension (ca. 3 – 4 ml) was dialyzed with a Slide-A-lyzer Mini Dialysis 
device (10,000 MWCO, Thermo Scientific, Hudson, NH) three times for 30 min at 
4 °C against 1 l of saline to remove residual CsCl. The CsCl-purified phage samples 
(φC) were stored at 4 °C and the phage titer was determined on the following day. 
Phage φET and φCET preparations were 
treated with an organic solvent (1-octanol; Sigma-Aldrich, Munich, Germany), as 
described by Szermer-Olearnik and Boratyński (2015). Briefly, 500 µl of the phage 
preparation (either phage lysate (φET) or CsCl purified phages (φCET)) was 
transferred to a 1.7 ml Eppendorf tube. Subsequently, MgCl2 (Sigma-Aldrich) was 
added to a final concentration of 0.02 M. This mixture was incubated for 1 h at 4 °C. 
After incubation, 1-octanol (40 % v/v) was added and mixed overnight by inverting 
in a vertical rotator at room temperature. The mixture was incubated for 1 h at 4 °C 
prior to centrifugation at 4,000 x g for 10 min. The upper 1-octanol phase was 
removed and the lower aqueous phase was transferred to Slide-A-lyzer Mini 
Dialysis device (10,000 MWCO). Dialysis was performed against ethanol (25 %) for 
five subsequent rounds (one overnight incubation and four 2 h incubations). 
Subsequently, the samples were dialyzed against endotoxin-free saline for four 
rounds (one overnight and three incubations of two hours). The purified phage 
solution was stored overnight at 4 °C and the phage titer was determined on the 
following day. 
The Triton X-100 removal of endotoxins is based 
on general protocols for the removal of endotoxins from protein preparations, as 
described by Petsch and Anspach (2000). Above the critical micelle concentration of 
some detergents, endotoxins are trapped in a micellar structure by non-polar 
interactions of the alkyl chains of lipid A and the detergent and are consequently 
separated from the water phase. Detergents of the Triton series show a miscibility 
gap in aqueous solution. Above a critical temperature, the so-called cloud point, 
micelles aggregate to droplets with very low water content, thus forming a new 
phase. Endotoxins remain in the detergent-rich phase. The cloud point of Triton X-
114 is at 22 °C, which is advantageous when purifying proteins. It requires mixing 
of the endotoxin-containing protein solution in the cold (usually at 4 °C) and allows 
separation of the two phages at temperatures of 22 °C or above. In contrast, the 
cloud point for Triton X-100 is at 75 °C, which is not acceptable for most proteins or 
phages, because high temperatures might lead to inactivation. In the classical 
protocols, Triton is removed by centrifugation. This has as downside that it is 
impossible to remove all the Triton present in the sample. Alternatively, Triton can 
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be removed by using activated charcoal (Marcus and Prusky, 1987), which has as 
an additional advantage that it is not necessary to use a two-phase system, which 
makes it possible to use Triton X-100 (which has, due to its higher cloud point, the 
advantage of being used at room temperature). A total volume of 200 µl of the phage 
solution (i.e. φET or φCET) was transferred to a 1.7 ml Eppendorf tube. To this 
solution, 3 % (v/v) Triton X-100 (Sigma-Aldrich) was added and incubated for 30 
min at room temperature while shaking at 750 rpm. After incubation, 12 % 
activated carbon (Sigma-Aldrich) was added to remove the Triton X-100 (Marcus 
and Prusky, 1987). An additional 30 min of incubation was performed at room 
temperature while shaking at 750 rpm. The solution was centrifuged at maximum 
speed for 1 min, after which it was passed through a 0.45 µm membrane to remove 
residual activated carbon. All steps were repeated for an additional two rounds, i.e. 
a total of three Triton X-100 treatments. The purified phage solution was stored 
overnight at 4 °C and the phage titer was determined on the following day. 
The inactivation of endotoxins through enzymatic degradation by means of alkaline 
phosphatase was described by Bentala et al. (2002). Briefly, alkaline phosphatase 
(rSAP (1,000 U/ml;7.5 U/reaction of 300 µl), New England Biolabs, New England, 
MA) together with the CutSmart buffer (New England Biolabs; as described by the 
manufacturer) was added to the phage sample and incubated for 60 min at 37 °C. 
Subsequently the enzyme was inactivated by heating the solution for 5 min at 65 °C. 
Following endotoxin inactivation, the titer of the phage solution was determined. 
Endotrap HD is an affinity chromatography based strategy using 
bacteriophage-phage derived proteins that are fixed on the column matrix and bind 
endotoxins with a high affinity and specificity. According to the manufacturer, 
Endotrap HD is able to remove endotoxins from protein, peptides, antibodies, 
RNA/DNA, antigens and plant extract samples with an endotoxin removal 
efficiency of 99.99 %. It also is claimed to have a wide pH range (4 – 10) of activity 
and that high salt concentrations do not affect the endotoxin removal capacity. The 
phage lysates (φET) or CsCl purified phage lysates (φCET) were further purified 
from endotoxins using the commercially available kit Endotrap HD (Hyglos, 
Bernried am Starnberger Seen, Germany), according to the instructions of the 
manufacturer. Briefly, 3 ml of the phage preparations were transferred to a sterile 
15 ml Falcon tube (Becton Dickinson) and CaCl2 (Sigma-Aldrich) was added to a 
final concentration of 0.001 M. Prior to the addition of the phages to the columns, 
the columns were activated by the addition of 3 ml regeneration buffer. The columns 
were drained out completely before repeating the addition of the regeneration 
buffer. Subsequently, 3 ml of the equilibration buffer was added and the columns 
were drained out completely before a second wash with the equilibration buffer was 
performed. Finally, the phage samples were added to the column and the eluate was 
collected in a sterile 15 ml Falcon tube (Becton Dickinson). The columns were then 
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regenerated by washing them twice with 3 ml regeneration buffer. The columns 
could then be used for a second purification round or be stored by adding 1 ml of the 
storage buffer supplemented with 0.02 % sodium monoazide (Sigma-Aldrich). 
Following endotoxin removal, the titer of the phage solution was determined. 
Phage 
purification using monolithic anion-exchange chromatography with CIM DEAE 
disk columns (BIA Separations, Ljubljana, Slovenia) was carried out, basically as 
described by Adriaenssens et al. (2012). Briefly, prior to phage purification, the 
complete chromatography set up (Äkta FPLC system (GE Healthcare, Little 
Chalfont, UK with a P900 pump system) was flushed with 1 M NaOH. The loading 
column was washed three times with endotoxin-free water. Next, approximately 10 
ml of one of the high titer phage preparations was loaded onto the chromatography 
set up. Pump A contained Tris-HCl (20 mM, pH 7.5) buffer whereas pump B 
contained Tris-HCl (20 mM, pH 7.5) with NaCl (2 M) buffer. Prior to the elution of 
the phages from the CIM DEAE disk column, the column (containing the phages) 
was washed with the Tris-HCl (20 mM, pH 7.5) buffer. Elution of the phages from 
the CIM DEAE disk columns was achieved by washing with an increasing 
percentage of the Tris-HCl (20 mM, pH 7.5) with NaCl (2 M) buffer relative to the 
Tris-HCl (20 mM, pH 7.5) buffer.  
Quantification of the endotoxin concentrations in the differently treated phage 
preparations was performed using two different commercially available methods. 
Prior to the endotoxin determination, all phage samples were diluted using 
Endotoxin-Free Dulbecco’s PBS (Millipore, Darmstadt, Germany). 
The endotoxin removal efficacy of each purification approach was calculated by first 
determining the amount of endotoxins per plaque forming unit (pfu) by dividing the 
endotoxin concentration by the phage titer for each preparation (1). 
Normalized endotoxin content =
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙
     (1) 
Subsequently the normalized endotoxin content of each sample was determined by 
multiplying the endotoxins per pfu with the phage recovery (2), i.e. the phage titer 
of the purified preparation divided by original preparation.  
Phage recovery =  
(𝑝𝑓𝑢/𝑚𝑙)𝑝𝑢𝑟𝑖𝑓𝑖𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
(𝑝𝑓𝑢/𝑚𝑙)𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
     (2) 
The endotoxin removal efficacy (3) was then calculated by dividing the normalized 
endotoxin concentration of the purified sample by the normalized endotoxin 




Endotoxin removal efficacy = 1 − 
[(
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙⁄ )×phage recovery]𝑝𝑢𝑟𝑖𝑓𝑖𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
[(
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙⁄ )×phage recovery]𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
  (3) 
According to the manufacturer, EndoZyme (Hyglos, Bernried am Starnberger See, 
Germany) is an endpoint fluorescent microplate assay intended for in vitro 
quantitative determination of endotoxin (lipopolysaccharides, LPS) in 
pharmaceuticals and biological substances as well as for medical device testing 
using recombinant factor C (rFC). The enzymatically active rFC is activated by 
trace amounts of endotoxins. It is capable of binding both free and bound LPS/lipid 
A (the biologically potent moiety of LPS) with high affinity. Being at the initial step 
of the coagulation cascade, Factor C functions as a very sensitive and specific 
biosensor of endotoxins, capable of detecting pictogram to nanogram levels of 
endotoxins (Ding and Ho, 2010). Endozyme is able to reliably detect endotoxins 
within the range of 0.005 to 50 EU/ml. The phage samples were diluted until their 
endotoxin concentration fell within this range. The assay was performed as 
described by the manufacturer. 
According to the manufacturer, the Endosafe-PTS (Charles River, CA) is a rapid, 
point-of-use test system that provides quantitative LAL results within 15 minutes. 
It is a miniaturized version of the LAL assay using rFC. It is able to detect 
endotoxins within the range of 0.005 to 10 EU/ml. The endotoxin determination was 
performed by the VIB Protein Service Facility (Ghent University) as described by 
the manufacturer. 
Pseudomonas aeruginosa phage GE-vB_Pae-Kakheti25 was kindly provided by Dr. 
Marina Goderdzishvili (Head of Laboratory of General Microbiology at the Eliava 
Institute of Bacteriophage, Tbilisi, Georgia). The authors are supported by the FWO 
Vlaanderen “PhageBiotics” research community. Jonas D Van Belleghem holds a 
predoctoral fellowship of the Institute for innovation through science and 
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Bacteriophages, the most abundant biological entities on Earth, are well known for 
their therapeutic applicability, but their effect on the human immune system is less 
known. Here we describe an RNA transcriptome analysis of peripheral blood 
mononuclear cells stimulated either with P. aeruginosa phage PNM or its bacterial 
host P. aeruginosa strain 573. P. aeruginosa phage PNM was able to increase the 
production of IL10, IL6, SOCS1, SOCS3, CXCL2, CXCL3, CXCL6 and decrease the 
production of lysozyme, HLA-DMA, HLA-DMB, HLA-DRB1 and HLA-DRB4, 
CCL17, CCR1, CCR2 and CCR5. P. aeruginosa strain 573 on the other hand was 
able to down-regulate the production of CD14, TLR4 and lysozyme. The results 
shown here indicate that bacteriophages might play a bigger role in the immune 
response triggered during phage therapy than previously described and might have 
a broader effect than the clearing of bacterial infections alone, such as the 
suppression of the immune response. 
The use of phage therapy has persisted without interruption in Eastern Europe, 
particularly in centers such as the Eliava Institute of Bacteriophage, Microbiology 
and Virology in Tbilisi, Georgia and the institute of Immunology and Experimental 
Therapy in Wroclaw, Poland (Housby and Mann, 2009; Kutter and Sulakvelidze, 
2004). Phage interactions with animals in general and human beings in particular 
have been comprehensively reviewed (Kutter and Sulakvelidze, 2004), and there 
have been no reports of significant adverse reactions despite their long history of 
administration to humans.  
Viruses and their components are potent activators of signal pathways leading to 
increased cytokine and chemokine production in human and in animals. The effects 
exerted on the immune system are usually mediated by viral proteins, which 
stimulate cytokine and/or reactive oxygen species (ROS) production in immune cells 
(Thannickal and Fanburg, 2000). Efficacy of phage therapy has been confirmed in 
various bacterial infections caused by, e.g. methicillin-resistant Staphylococcus 
aureus (MRSA) (Capparelli et al., 2007; Mann, 2008; Matsuzaki et al., 2003), 
Pseudomonas aeruginosa (Debarbieux et al., 2010; Watanabe et al., 2007) and 
Escherichia coli, in a number of research centers (Bruttin and Brüssow, 2005; 
Międzybrodzki et al., 2012). Complementary to the progress in phage therapy 
practice, advancement of knowledge about the influence of bacteriophages on the 
mammalian immune system is necessary. Previous studies of bacteriophage 
interaction with the immune system indicated that at least some phages may exert 
immunomodulating effects in mammals, such as an important role in 
transplantation tolerance, the reduction of ROS production, or in the controlling of 
invading pathogens by adhering of phages on mucosal surfaces (Barr et al., 2013; 




Although some preliminary data on phage-mediated immunobiological activities 
are available, the exact mechanisms of those interactions remain obscure and 
require further studies. For example, a study by Ochs et al. described the use of 
phage to study immunodeficiency’s in normal and patient populations where high 
concentrations of phages were administered intravenously without any toxic effects, 
despite the potent antigenic properties of this particular phage φX174 (Ochs et al., 
1971). Humoral antibody responses can be mounted to phages that have been used 
to immunize animals at high titers (Inchley and Howard, 1969). It has also been 
shown that phages can inhibit the activation and proliferation of human T cells in 
vitro through an unknown mechanism (Górski et al., 2006b). Since antibodies can 
decrease phage viability dramatically resulting in the loss of antibacterial effects 
(Międzybrodzki et al., 2012; Smith et al., 1987), immunogenicity of phages is one of 
the most important issues that may contribute to the success or failure of 
therapeutic use of bacterial viruses (Górski et al., 2012; Sulakvelidze et al., 2001). 
Thus, several studies have shown that phages can trigger a host immune response 
or can modulate host immunity. 
Here we show a transcriptome analysis of human peripheral blood mononuclear 
cells (PBMCs), derived from one individual, which were stimulated with either P. 
aeruginosa or a P. aeruginosa phage PNM lysate, thus containing bacterial proteins 
but no life active bacteria besides the infectious phage particles. The P. aeruginosa 
phage PNM lysate condition most closely reflects the immunological condition 
obtained during phage therapy, when the phage titer is the highest and only 
bacterial fragments remain. These data suggest that certain immunological 
pathways are activated during/after phage therapy. In addition, it could give a 
better insight in the efficacy of phages during phage therapy. 
An average of 47 million reads was obtained for the unstimulated and stimulated 
PBMCs after cleaning and quality checks were carried out. Out of the total number 
of reads, approximately 85 % (Table 7. 1) could be mapped to the human genome 
(UCSC version hg19) using the short oligonucleotide analysis package (SOAP) 
aligner (SOAP2)(Li et al., 2009). The transcriptome analysis from the unstimulated 
PBMCs versus P. aeruginosa strain 573 revealed a total of 996 up-regulated genes 
and 1377 down-regulated genes compared to the 704 up-regulated and 392 down-
regulated genes when the PBMCs were stimulated with P. aeruginosa phage PNM.  
Comparing both data sets, 359 differentially expressed genes could be identified 
which were exclusively present in the phage PNM stimulated dataset that did not 
appear in the P. aeruginosa strain 573 dataset. Of these 359 differentially expressed 




Table A 2). These genes could be seen as uniquely induced by the phage, although 
further research is needed. 
The functional classification based on the biological process revealed that a 
significant percentage of genes were assigned to immune system response (19.8 %), 
defense response (13.2 %), response to stress (23.2 %) and regulation of cytokine 
production (5.3 %). Molecular functions were assigned to, for a high percentage, 
receptor binding (12.3 %), protein binding (38.2 %), cytokine activity (2.1 %) and 
cytokine receptor binding (3.2 %). For the functional class of cellular components, 
many genes were assigned to membrane (56.2 %). 
Among the biological process terms, a significant percentage of the genes were 
assigned to the immune system processes (16.6 %), response to stimulus (34.9 %), 
defense response (10.5 %) and regulation of cytokine production (4.9 %). Molecular 
functions were assigned to, for a high percentage, protein binding (36.5) and 
receptor binding (10.7 %). For the functional class of cellular components, many 
genes were assigned to membrane (55.9 %), membrane part (47.3 %) and intrinsic 
to membrane (41.2 %). This might indicate that many genes that are differentially 
expressed after stimulation with P. aeruginosa play some role in signal 
transduction. 
Antigens presented on Major Histocompability Complex (MHC) class II are 
typically exogenous proteins that are endocytosed by the antigen-presenting cell 
(APC) or endogenous proteins that reside in the secretory system (Schmid et al., 
2007, ). Analysis of peptides eluted from MHC class II 
molecules revealed that a substantial proportion of natural MHC class II ligands 
(up to 20%) are derived from cytosolic and nuclear proteins (Chicz et al., 1993; 
Dengjel et al., 2005; Dongre et al., 2001). 
The major MHC class II genes HLA-DMA, HLA-DMB, HLA-DRB1 and HLA-DRB4 
were significantly down-regulated after P. aeruginosa phage PNM stimulation. 
Human HLA-DM plays an important role in the induction and/or stabilization of 
MHC class II conformation from which weakly bound peptides are able to dissociate. 
In the absence of HLA-DM, the peptide-editing process fails. This leads to the 
appearance of weakly bound peptides and peptide-MHC class II conformations that 
are structurally immature (Watts, 2004). 
In case of PBMCs stimulated with P. aeruginosa strain 573, our results show that 
most of the genes involved in the antigen presentation by MHC I and MHC II are 
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not differentially expressed, with exception of HLA-DRB4 (Log2 fold change of -
1.00) and HLA-L (Log2 fold change of 1.02). Gao et al. (2010), using an array 
approach for porcine PBMCs, reported MHC class II reduction after LPS 
stimulation.  
The CD1c molecule is also significantly down-regulated (P-value = 8.21E-06) in the 
P. aeruginosa phage PNM dataset, the CD1 molecules are MHC-like proteins that 
bind β2 microglobulin but, in contrast to MHC class I, their principal domain of 
action is in the endocytic pathway (Watts, 2004). Two classes of CD1 proteins can 
be distinguished: those that are recognized by conventional αβ T cells (CD1a–CD1c 
and CD1e) and that present lipid antigens such as mycolic acid and lipopeptides 
from mycobacteria, and CD1d, which is the restricting element for the specific 
subset of cells, usually called NKT cells, that express an invariant Vα14 (mouse) or 
Vα24 (human) T cell receptor and are selected on double-positive thymocytes rather 
than thymic epithelial cells (Bendelac et al., 1995; Brigl and Brenner, 2004; Joyce 
and Van Kaer, 2003). By binding to lipid-based molecules, CD1 proteins diversify 
the range of determinants in foreign pathogens that the immune system can 
recognize. 
These and probably other interactions result in continual cycling of CD1 molecules 
through the endocytic system but with steady-state distributions that broadly place 
CD1a and CD1c in early endosomes, and CD1b and CD1d in late endosome and/or 
lysosomes. Lipid ligand selection is probably controlled by a combination of 
differential CD1 trafficking and by intrinsic binding-site differences among 
different CD1 molecules (Gadola et al., 2002; Zajonc et al., 2003). 
Lipopolysaccharide perception through TLR4 plays an important role in the 
immune response against Gram-negative bacteria, such as the bacterial host of 
phage PNM. We observed a down-regulation of TLR4. Normally TLR4 activation 
induces the secretion of pro-inflammatory molecules such as chemokines and 
cytokines which amplify the response to infection (Feezor et al., 2003; Takeuchi et 
al., 1999). 
Both P. aeruginosa strain 573 and P. aeruginosa phage PNM have the ability to 
down-regulate TLR4, i.e. -3.89 Log2 fold reduction and -1.26 Log2 fold reduction, 
respectively. In addition P. aeruginosa strain 573 was able to down-regulate CD14 
(Log2 fold change of -7.96) and lymphocyte antigen 96, encoded by the LY96 gene 
(Log2 fold change of -2.04), also known as MD2. Both genes play an important role 





































































































































































































































































































































































































































































































































































































































































































































































Furthermore, it is interesting to note that lysozyme is strongly down-regulated 
(Log2 fold change of -7.83) after P. aeruginosa strain 573 stimulation. These data 
suggest that P. aeruginosa has evolved a mechanism to circumvent its LPS 
detection. The precise mechanisms by which the bacteria does this are currently 
unknown to us. 
Besides the differential expression in the MHC class II, many cytokines were up- 
and down-regulated. Of the differentially expressed cytokines, the IL10 family 
cytokines (i.e. IL10, IL19, IL20, IL22, IL24, IL26, IL28A and IL28B) are of 
particular interest for their anti-inflammatory properties and tissue protection. On 
the one hand, these cytokines prevent excessive tissue damage caused by bacterial 
and viral infections as well as pro-inflammatory responses. On the other hand, 
uncontrolled tissue repair processes, such as the wound-healing responses triggered 
by IL20 subfamily cytokines, can result in diseases, such as psoriasis (Ouyang et 
al., 2011). 
IL10, known for its interaction with leukocytes and its anti-inflammatory 
properties, had an up-regulation after P. aeruginosa phage PNM stimulation (Log2 
ratio of 4.32), and after P. aeruginosa strain 573 stimulation (Log2 ratio of 4.28). 
IL10, a TH2 cytokine that inhibits innate and adaptive immune activities, blocks 
the expression of pro-inflammatory cytokines, including TNF, IFN-γ, IL1, IL12, and 
CXC and CC chemokines. The suppression of these cytokines is clearly visible in 
our data. It also suppresses MHC class II and co-stimulatory molecules CD80 and 
CD86 on macrophages, and it inhibits the generation of reactive oxygen and 
nitrogen intermediates from macrophages and neutrophils. Our data indicate a 
slight up-regulation of CD80 (Log2 ratio of 1.66 for P. aeruginosa phage PNM and 
Log2 ratio of 1.64 for P. aeruginosa strain 573) and a down-regulation of CD86 (Log2 
ratio of -1.46 for P. aeruginosa phage PNM and Log2 ratio of -1.75 for P. aeruginosa 
strain 573). 
The IL20 subfamily cytokines, composed of IL19, IL20, IL24 and IL26, primarily 
acts on various epithelial cells and protects these cells from invasion by 
extracellular pathogens such as bacteria and yeast. From this group only IL19 (Log2 
ratio of 3.1 for P. aeruginosa phage PNM and Log2 ratio of 2.77 for P. aeruginosa 
strain 573), IL20 (Log2 ratio of 7.10 for P. aeruginosa phage PNM and Log2 ratio of 
5.65 for P. aeruginosa strain 573) and IL24 (Log2 ratio of 3.22 for P. aeruginosa 
phage PNM and Log2 ratio of 1.1 for P. aeruginosa) were differently expressed. In 
addition, IL20 subfamily cytokines enhance tissue remodeling and wound-healing 
activities, which help to maintain tissue integrity and restore homeostasis of 




IL28A and IL28B, belonging to the type III IFN group were not differentially 
expressed. 
Interleukin-6 (IL6; Log2 ratio of 6.55 for P. aeruginosa phage PNM and a Log2 ratio 
of 6.37 for P. aeruginosa strain 573), originally considered to be a pro-inflammatory 
cytokine, has anti-inflammatory properties (Spooren et al., 2011). For instance, IL6 
inhibits neutrophil accumulation after LPS injection and antagonizes the actions of 
interleukin-1β (IL1β) and tumor necrosis factor-α (TNFα) via induction of the 
soluble IL1 receptor antagonist and the soluble TNFα receptor (Ulich et al., 1991). 
Under certain conditions IL6 obtains anti-inflammatory characteristics in 
macrophages (Yasukawa et al., 2003). Finally, IL6 is crucially involved in the 
induction and regulation of a novel type of T cells, the so-called TH17 cells (named 
after the cytokine IL17 which they produce), which are important players in 
autoimmune reactions. TH17 cells are believed to be important in autoimmune 
responses, whereas Treg cells (from T regulatory cells) are suppressors of 
autoimmune responses and protect against tissue injury. IL6 is crucial for the 
induction of TH17 cells (Bettelli et al., 2006; Veldhoen et al., 2006). The inhibitory 
effect of IL6 and TGFβ was suggested to be due to induction of the anti-
inflammatory cytokine IL10 and the failure to up-regulate pro-inflammatory 
chemokines (Spooren et al., 2011). 
Of particular interest was the up-regulation of pro-inflammatory cytokines such as 
tumor necrosis factor alpha (TNFα; Log2 ratio of 1.17 and Log2 ratio of 2.77 for P. 
aeruginosa phage PNM and P. aeruginosa strain 573 respectively), interleukin 1β 
(IL1β; Log2 ratio of 4.44 for P. aeruginosa phage PNM and Log2 fold change of 2.01 
for P. aeruginosa strain 573), and IL6, characteristic for the classically activated 
macrophages (M1 phenotype), as well as the up-regulation of anti-inflammatory 
mediators, such as IL1 decoy receptor (IL1RN) – also known as the IL1 receptor 
antagonist (IL1ra; Log2 ratio of 3.78 for P. aeruginosa phage PNM and Log2 ratio 
of 2.50 for P. aeruginosa strain 573) and IL10, associated with alternative 
macrophage activation (M2 phenotype) (Goldmann et al., 2004; Gordon, 2003; 
Mosser, 2003). 
The migration of dendritic cells to tissues and from tissues to lymph nodes is central 
for immune surveillance, priming and tolerance. Monocytes and “immature” 
dendritic cells exit blood in tissues and scavenge for pathogens. These cells express 
the “inflammatory” chemokine receptors CCR1 (Log2 ratio of -1.41 for P. aeruginosa 
phage PNM and Log2 ratio of -6.25 P. aeruginosa strain 573), CCR2 (Log2 ratio of -
3.51 for P. aeruginosa phage PNM and Log2 ratio of -3.31 for P. aeruginosa strain 
573), CCR5 (Log2 ratio of -1.21 for P. aeruginosa phage PNM and Log2 ratio of -2.42 
for P. aeruginosa strain 573), CXCR2 and CCR6 as well as receptors for classical 
chemo-attractants, formyl peptides and C5a/GPR77 (Log2 ratio of -3.85 for P. 
aeruginosa phage PNM and Log2 ratio of -10.24 for P. aeruginosa strain 573) (Cook 
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et al., 2000; Dieu et al., 1998; Mackay, 2001; Sallusto et al., 1998; Sozzani et al., 
1998). One of the ligands of CCR4, CCL17 (thymus- and activation-regulated 
chemokine, or TARC), is expressed in inflamed skin but not mucosal tissues and is 
down-regulated by P. aeruginosa phage PNM and by P. aeruginosa strain 573 (Log2 
ratio of -3.26 and -3.06, respectively) (Mackay, 2001). 
Chemokines are typically induced in either monocytes/macrophages or in epithelial, 
endothelial or fibroblastic cells by pro-inflammatory cytokines (e.g. IL1 or TNFα) or 
stimuli (LPS) (Rossi and Zlotnik, 2000). This is in fact the most common perceived 
role for chemokines, a pro-inflammatory function, frequently associated with a TH1 
cytokine expression profile (IFN-c, IL2, IL12) and thus with a TH1 cell infiltrate at 
the inflammation site. However, not all chemokines fit this pattern. For example, 
other chemokines (e.g. C10, DC-CK1/AMAC-1/PARC) are specifically induced by 
TH2 cytokines (IL 4, IL10, IL13) in monocytes or other cells (Kodelja et al., 1998; 
Orlofsky et al., 1994; Rossi and Zlotnik, 2000). Several chemokine receptors are 
associated with the TH1 phenotype (including CXCR3 and CCR5), while others are 
associated with the TH2 phenotype (CCR3, CCR4, and CCR8) (O’Garra et al., 1998). 
Adaptive immunity begins in lymphoid organs, where mature dendritic cells or 
macrophages present immunogenic peptides to naive or memory T cells. This 
encounter is governed with remarkable precision by two chemokines, CCL19 (Log2 
ratio of 4.33 for P. aeruginosa phage PNM and Log 2 ratio of 6.61 for P. aeruginosa 
strain 573) and CCL21, and their receptor, CCR7 (Charo and Ransohoff, 2006; 
Cyster, 1999, 2003; Sozzani et al., 2000). Once immature dendritic cells ingest 
antigens and become able to present antigens to T cells, they increase their display 
of CCR7 (Mantovani, 1999). These CCR7+ dendritic cells enter lymph nodes through 
the afferent lymph or the bloodstream, using vessel-bound CCL19 and CCL21 to 
sense their destination. The absence of the up-regulation of CCR7 indicates that P. 
aeruginosa phage PNM is not ingested by the dendritic cell and thus no phage 
antigens are presented to T-cells, further experiments need to be performed to 
validate this observation. 
Macrophage inflammatory protein 1α (MIP-1α )/CCL3 chemo-attracts a variety of 
cells, including lymphocytes, monocytes, basophils, and eosinophils (Koch, 2005; 
Szekanecz et al., 2003). MIP-1α /CCL3, produced by CD44 T cells, is augmented by 
IL15 (Log2 ratio of 1.08 for P. aeruginosa phage PNM and Log2 ratio of 1.16 for P. 
aeruginosa strain 573) stimulation (Wang and Liu, 2003). MIP-3α /CCL20 is a CC 
chemokine that chemo-attracts T cells, B cells, monocytes, and immature dendritic 
cells. 
P. aeruginosa phage PNM but also its bacterial host is able to reduce the production 
of CCR1 (Log2 ratio of -1.41 and -6.25, respectively) and CCR2 (Log2 ratio of -3.51 
and -3.31, respectively). The up-regulation of CCR1 and CCR2 are clinical 
indications of rheumatoid arthritis (Charo and Ransohoff, 2006; Katschke et al., 




receptor has produced varied outcomes. Antibody-mediated blockade of CCR2 
during initiation of collagen-induced arthritis (CIA) in mice resulted in markedly 
improved clinical signs of arthritis, while blockade during disease progression 
(therapeutic administration) worsened the clinical and histologic signs of arthritis 
(Brühl et al., 2004). Elevated levels of CC chemokines, particularly CCL2 (Log2 
ratio of -6.57 for P. aeruginosa strain 573) and CCL3 (Log2 ratio of 4.52 for P. 
aeruginosa phage PNM and Log2 ratio of 4.01 for P. aeruginosa strain 573) in the 
joints of patients with rheumatoid arthritis coincide with the recruitment of 
monocytes and T cells into synovial tissues. It appears that targeting CCR1/CCR5 
may be useful in experimental arthritis. This indicates that P. aeruginosa phage 
PNM might reduce symptoms associated with rheumatoid arthritis.  
It is interesting to note that P. aeruginosa phage PNM seems to have the ability to 
up-regulate the production of superoxide dismutase 2 (SOD2; Log2 ratio of 2.21), 
which can play an important role in the reduction of ROS, which could lead to a 
possible explanation of the observation of Miedzybrodzki et al. (2008). 
Suppressors of cytokine signaling (SOCS) proteins are a family of intracellular 
proteins that control cytokine signaling by suppressing cytokine signal transduction 
process. In total there are eight members known, SOCS1 to 7 and cytokine-inducible 
SH2-containing protein (CIS). Studies have shown that SOCS1 and 3 specifically 
participate in regulation of TH1 and TH2 cytokine signaling (Diehl and Rincón, 2002; 
Dong et al., 2009). SOCS1 (Log2 ratio of 1.87 for P. aeruginosa phage PNM and Log2 
ratio of 1.40 for P. aeruginosa strain 573) is a key modulator of interferon-γ (IFN-γ) 
signaling. Mice lacking SOCS1 exhibit deregulated responses to IFN-γ resulting in 
excessive T-cell activation and are hyper-responsive to viral infections (Alexander 
et al., 1999; Marine et al., 1999). SOCS3 (Log2 ratio of 2.02 for P. aeruginosa phage 
PNM, no differential expression for P. aeruginosa strain 573) functions to control 
IL6 induced TH2 associated response via its receptor gp130 (Lang et al., 2003). In 
macrophages, SOCS3 mediates IL10 inhibition of TNFα and nitric oxide production 
(Qasimi et al., 2006). Induction of SOCS3 is regulated via IL6 receptor trans-
signaling. The observation of increased IL10 in SOCS3 over-expressed trophoblast 
after IL6 challenge is in line with the concept of the pro-inflammatory role of IL6 in 
trophoblasts and SOCS3 signaling in regulation with cytokine production 
(Egwuagu et al., 2002). 
Both SOCS1 and 3 can inhibit JAK tryrosine kinase activity and can thus interfere 
with cytokine signaling (Kubo et al., 2003). It has been suggested that SOCS3 
negatively regulates IL6, which regulates macrophage activation, B cell 
development, the production of hepatic acute-phase proteins and the initiation of 
organ repair (Bernad et al., 1994; Croker et al., 2003; Ramsay et al., 1994). 
Expression of SOCS3 is induced by numerous factors including Toll-like receptors 
(TLR) agonists (e.g. LPS or CpG-DNA), IL10, IL6 and other gp130/IL6ST signaling 
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cytokines, leptin and IFN-γ (Cassatella et al., 1999; Lang et al., 2003). The Socs3 
gene has also been shown to be a direct target of STAT3 (Auernhammer et al., 1999). 
These properties suggest that SOCS3 may broadly regulate cytokine signaling and 
might be a chief factor in reducing inflammation, particularly in activated 
macrophages (Lang et al., 2003). 
The IL10-mediated induction of SOCS3 in macrophages has led to the notion that 
SOCS3 is an essential component of the anti-inflammatory effects mediated by IL10 
(Berlato et al., 2002). Recent studies have established strong potential for SOCS 
proteins to regulate M1 and M2 macrophage polarization (Arnold et al., 2014; Qin 
et al., 2012; Whyte et al., 2011; Wilson, 2014). Overall it is proposed that a high 
SOCS1 to SOCS3 ratio could be a potential marker for M2 macrophages while high 
SOCS3 expression is associated with M1 cells (Wilson, 2014). It is clear that SOCS3 
is higher expressed than SOCS1, indicating that the immune response induced by 
P. aeruginosa phage PNM is most likely associated with M1 macrophages. 
However, it is not only macrophages that are affected by SOCS proteins. Other cell 
types up-regulate and react to SOCS proteins to shape cellular functions. Targeting 
SOCS specifically on macrophages is therefore important as an efficient means of 
changing the inflammatory response (Wilson, 2014). 
Our results clearly show that P. aeruginosa phage PNM induces an immune 
response (e.g. the expression of TGFBI, IL1 and IL6 after 20 h stimulation of 
PBMCs), which we further evaluate in using highly purified phages. We 
show that this phage in a phage therapy setting (i.e. in the presence of bacterial 
proteins and membrane fragments) is able to interact with human immune cells 
and induce an immune response (such as the induction of IL6, IL10, SOD2, SOCS1 
and SOCS3).  
The group of Gorski and Dąbrowska have recently shown that the T4 phage head 
surface proteins gp23*, gp24*, Hoc and Soc, both as elements of the phage capsid 
and as isolated agents, do not induce an IL10 response (Dąbrowska et al., 2014a; 
Miernikiewicz et al., 2013). Nor did they detect the presence of pro-inflammatory 
cytokines such as TNFα, IL1 and IL6 in mice, murine dendritic cell cultures or 
human blood. In contrary to what we show, they postulated (based on their findings) 
that bacteriophages do not induce an immune response. This difference in results 
might be explained in two ways, first by the use of different incubation times (where 
we used 20 h as a stimulation time), and second by the use of different detection 
platforms (i.e. gene expression compared to physiological secretion of cytokines). 
Although the up-regulation of certain genes does not necessarily mean the secretion 
of an active protein or the induction of a biological effect, it does indicate the 




On the other hand, they did observe the presence of specific T4-antibodies, 
indicating prior exposure to this phage. This exposure could occur due to the fact 
that phages are present in food, water and as a natural part of the animal and 
human gut microbiome (Letarov and Kulikov, 2009). 
Recently Liu et al. (2014) showed that phage λ has a physical adaptation to the 
environment of E. coli in a human host. The phage λ genome undergoes a solid-to-
fluid-like disordering transition as function of temperature, resulting locally in less 
densely packed DNA, reducing DNA-DNA repulsions. Once phage λ is inside the 
host, the increased temperature induces the necessary mobility of the viral genome, 
facilitating its infection of bacterial cells. This demonstrates an evolutionary 
physical adaptation of viruses to their host environment (Liu et al., 2014). It can 
thus be speculated that phages that infect bacteria present in a mammalian host 
might have numerous adaptations, which leads to their survival and multiplications 
in a mammalian host. 
Although bacteriophages, viruses of bacteria, are mainly known for their 
relationship with bacteria, they are clearly able to interact with a broader range of 
eukaryotic cells. It is clear that although phages are known for almost one hundred 
years, not all is known of these bacterial viruses and further research into this field 
is warranted. 
Pseudomonas aeruginosa strain 573 (received from the Eliava IBMV, Tbilisi, 
Georgia) was grown on a Lysogeny Broth (LB) agar plate (Becton Dickinson, 
Erembodegem, Belgium) and incubated overnight at 37 °C. One colony was 
subsequently used to inoculate a 15 ml tube containing a 4 ml LB agar slant, and 
incubated overnight at 37 °C. Five ml saline was added to yield a suspension with 
a final concentration of 107 cfu/ml, as confirmed by culture of serial hundredfold 
dilutions.  
 Bacteriophage stocks were prepared using the double-agar 
overlay method as described in Merabishvili et al. (2009). Briefly, one ml of phage 
preparation containing 106 plaque forming units (pfu) of bacteriophages was mixed 
with 3 ml of molten (45 °C) LB top Bacto agar (0.6 %) (Becton Dickinson) and 100 
µl of the host strain suspension (end concentration of 107 cfu/ml) in a sterile 14 ml 
tube (Falcon, Becton Dickinson). This mixture was plated onto freshly made 90 mm 
diameter Petri dishes (Plastiques Gosselin, Menen, Belgium), filled with a bottom 
layer (20 ml) of 1.5 % LB agar, and incubated aerobically at 32 °C for 16 h. 
Subsequently, 200 µl of chloroform was added to the lids of the Petri dishes and the 
inverted plates were further incubated at 4 °C for 1 h. The top layer of the double-
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agar layer was scraped off using a sterile Drigalski spatulum and transferred to a 
sterile 50 ml tube. 
The harvested phages were centrifuged for 20 min at 6,000 x g at 4 °C. The 
supernatant was aspirated using a sterile 10 ml syringe (BD Plastipak, Becton 
Dickinson) with a 30 G sterile needle (BD Microlance 3, Becton Dickinson) and 
passed through a 0.22 µm membrane filter (Sartorius Stedim, Zellik, Belgium). The 
filtrate was subsequently centrifuged at 35,000 x g for one hour. The phage pellet 
was resuspended in 5 ml saline and stored at 4 °C overnight before determining the 
phage titer. Preferably, the titer of the phage lysate should be checked at least one 
day later according to the above described procedures. This will allow phage 
particles that may have clumped together during centrifugation steps to disengage 
(Kutter and Sulakvelidze, 2004). 
 The bacteriophage titer was determined by assaying 
decinormal serial dilutions (log(0) to log(-12)) of the bacteriophage suspension with 
the overlay method (Merabishvili et al., 2009). One ml of each dilution was mixed 
with 3 ml of molten (45 °C) LB 0.6 % top Bacto agar and the host strain (end 
concentration of 107 cfu/ml) in a sterile 14 ml tube. This mixture was plated in 
triplicate onto 90 mm diameter Petri dishes, filled with a bottom layer of 1.5 % LB 
agar, and incubated for 16 h at 37 °C. To determine the original bacteriophage 
concentration, plates with one to 100 distinguishable plaques were counted. The 
mean was then calculated for the triplicate plates. 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from a buffycoat after 
informed consent (Blood Transfusion Centre, Ghent), using a Lymphoprep (Axis-
Shield, Dundee, Scotland) gradient. Fifty ml of the buffycoat was added to 250 ml 
Hank’s Balanced Salt Solution, without Ca2+ and Mg2+ (HBSS) (Invitrogen). Of this 
dilution, eight aliquots of 35 ml were each added to 15 ml Lymphoprep in a 50 ml 
Falcon tube. These mixtures were subsequently centrifuged at 500 x g for 20 min at 
room temperature. The inner whitish ring of PBMCs, present between the 
lymphoprep and the plasma phase, was transferred to 25 ml HBSS and centrifuged 
at 450 x g for 10 min at room temperature. The supernatants was removed and the 
cell pellet was resuspended in 10 ml HBSS. All resuspended cells were pooled into 
a 50 ml Falcon tube and HBSS was added to a total volume of 50 ml. A small fraction 
of this cell solution was used to count the number of cells present, before it was 
centrifuged again at 350 x g for 10 min at room temperature.  
The total number of cells was counted using a Sysmex KX-21 (Sysmex, Norderstedt, 
Germany). The cell pellet was resuspended in heat-inactivated fetal calf serum with 
10 % dimethyl sulfoxide (DMSO) to a concentration of 2 x 107 cells/ml and divided 




Stimulations were performed in 100 µl volumes containing 106 PBMCs. One vial of 
stored PBMCs, containing 2 x 107 cells/ml, was thawed at 37 °C prior to adding 9 
ml HBSS (without Ca2+ and Mg2+). This suspension was subsequently centrifuged 
at 350 x g for 10 min. The obtained cell pellet was resuspended in 5 ml HBSS 
(without Ca2+ and Mg2+) and 80 µl was used for cell counting on a Sysmex KX-21. 
This cell suspension was centrifuged at 350 x g for 10 min. The resulting cell pellet 
was resuspended in RPMI 1640 (supplemented with 2 mM L-glutamic acid, 1X 
MEM non-essential amino acids, 1 mM sodium pyruvate, 60 U of penicillin/ml, 10 
mg/ml streptomycin, 2 mM L-glutamine and 10 % heat inactivated fetal calf serum) 
to a final concentration of 107 cells/ml (Moore et al., 1967). 
The PBMCs (i.e. 106 PBMCs/100 µl) were subsequently stimulated with 10 µl of the 
bacterial host (i.e. P. aeruginosa at a concentration of 107 cfu/ml or 10-1 cfu/PBMC), 
10 µl of the phage suspensions at concentrations between 1011 pfu/ml, i.e., 103 
pfu/PBMC. As a negative control, 10 µl saline was added to the cells. The PBMCs 
were incubated for 20 h at 37 °C in 5 % CO2. All stimulation experiments and 
controls were carried out on PBMCs derived from one anonymous donor in 
triplicate. We confirm that all methods were carried out in accordance to relevant 
guidelines and regulations and that all experimental protocols were approved by 
the ethical committee of Ghent University (EC/2017/0558). 
 After 20 h of PBMC stimulation, the total cell volume 
was transferred to 1 ml Qiazol (Qiagen, Valencia, CA) and stored at -80 °C for at 
least 16 h before extracting the RNA. The total RNA fraction was isolated using a 
semi-automated procedure of NucliSens EasyMag (Biomérieux, Marcy l’Étoile, 
France). Briefly, 900 µl EasyMag lysis buffer was added to the 1.1 ml Qiazol 
solution. This mixture was subsequently transferred to an NucliSens EasyMag 
cartridge. Finally, 100 µl magnetized silica was added and the cartridge was loaded 
on the machine (according to the manufacturer). In a final step, the nucleic acids 
were eluted with 35 µl NucliSens EasyMag elution buffer. 
 DNase digest was performed immediately after nucleic acid extraction 
to remove DNA from the sample. Five µl of the nucleic extract was added to one µl 
of DNase (1 U/µl), one µl 10X DNase reaction buffer (Promega, Mannheim, 
Germany) and three µl of RNase free H2O to make up a total volume of 10 µl. This 
mixture was incubated for 30 min at 37 °C. The DNase digestion was terminated by 
adding 1 µl of DNase Stop Solution and incubating the mixture at 65 °C for 10 min. 
DNase digested RNA samples were stored at -80 °C.  
 cDNA preparation and Illumina HiSeqTM 
sequencing was performed at the Beijing Genome Institute (BGI) as described by 
Ren et al. (2012). The cDNA libraries were prepared according to the manufacturer’s 
instructions (Illumina, San Diego, CA). Beads coated with oligo(dT) were used to 
isolate eukaryotic poly(A) mRNA from the total RNA. Purified mRNA was then 
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fragmented in RNA fragmentation buffer (Ambion, Austin, TX). Using these short 
fragments as templates, random hexamer-primers (Illumina) were used to 
synthesize the first-strand cDNA. The second-strand cDNA was synthesized using 
buffer, dNTPs, RNase H and DNA polymerase I. Short double-stranded cDNA 
fragments were purified with a QIAquick PCR extraction kit (Qiagen) and eluted 
with elution buffer for end repair and the addition of a terminal ‘A’ nucleotide. Next, 
Illumina sequencing adaptors were ligated to the DNA fragments. DNA fragments 
of a selected size were gel-purified and amplified by PCR. The amplified library was 
sequenced on an Illumina HiSeqTM 2000 sequencing machine at BGI, using single-
end sequencing with an expected library size of 160 bp and a read length of 90 nt. 
 The images generated by the sequencer 
were converted into nucleotide sequences by a base-calling pipeline. The raw reads 
were saved in fastq format, and the dirty raw reads were removed prior to analyzing 
the data. Dirty raw reads were removed according to the following criteria: reads 
with sequence adaptors, reads with more than 10 % ‘N’ bases; low quality reads (i.e. 
the percentage of low quality bases is over 50 % in a read, BGI defined the low 
quality base to be the base whose sequencing quality is no more than 10). All 
subsequent analyses were based on clean reads. 
The reference sequences used were human genome and transcriptome sequences 
downloaded from the UCSC website (version hg19). Clean reads were respectively 
aligned to the reference genome and transcriptome using SOAP2 (Li et al., 2009). 
No more than three mismatches were allowed in the alignment for each read. Reads 
that could be uniquely mapped to a gene were used to calculate the expression level. 
The gene expression level was measured by the number of uniquely mapped reads 
per kilobase of exon region per million mappable reads (RPKM) (Mortazavi et al., 
2008).  
 Using ‘The significance of digital gene 
expression profiles’ (Audic and Claverie, 1997), differentially expressed genes 
between P. aeruginosa-stimulated PBMCs and non-stimulated PBMCs were 
identified, based on the following criteria: False Discovery Rate (FDR) ≤ 0.001 and 
an absolute fold change ≥ 2. The data discussed have been deposited in NCBI's Gene 
Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series 
accession number GSE95573 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= 
GSE95573).  
 Based on the assumption that genes that have 
a similar expression pattern usually have a functional correlation, cluster analysis 
of gene expression patterns was performed using the cluster (Langmead et al., 2009) 
and javaTreeview (Saldanha, 2004) software.  
 The gene ontology analysis of DEGs was performed 




enriched in a list of DEGs by comparing to a genome background and subsequent 
filtering the DEGs that correspond to specific biological functions. In this method 
all DEGs are first mapped to GO terms in the GO database 
(http://www.geneontology.org ), calculating gene numbers for every term, then 
using hypergeometic tests to find significantly enriched GO terms in the input list 
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The ability of bacteriophages to kill bacteria is well known, as is their potential use as 
alternatives to antibiotics. As such, bacteriophages reach high doses locally through infection 
of their bacterial host in the human body. In this study we assessed the gene expression profile 
of peripheral blood monocytes from six donors for twelve immunity-related genes (i.e. CD14, 
CXCL1, CXCL5, IL1A, IL1B, IL1RN, IL6, IL10, LYZ, SOCS3, TGFBI and TNFA) induced by 
Staphylococcus aureus phage ISP and four Pseudomonas aeruginosa phages (i.e. PNM, LUZ19, 
14-1 and GE-vB_Pae-Kakheti25). The phages were able to induce clear and reproducible 
immune responses. Moreover, the overall immune response was very comparable for all five 
phages: down-regulation of LYZ and TGFBI, and up-regulation of CXCL1, CXCL5, IL1A, IL1B, 
IL1RN, IL6, SOCS3 and TNFA. The observed immune response was shown to be endotoxin-
independent and predominantly anti-inflammatory. Addition of endotoxins to the highly 
purified phages did not cause an immune response comparable to the one induced by the 
(endotoxin containing) phage lysate. In addition, the use of an intermediate level of endotoxins 
tipped the immune response to a more anti-inflammatory response, i.e. up-regulation of IL1RN 
and a strongly reduced expression of CXCL1 and CXCL5. 
We show that bacteriophages are able to induce an (innate) immune response, in 
contrast to some other recent reports. Additionally, we have strong indications that 
the phage-induced response is overall anti-inflammatory, which may contribute to 
the beneficial therapeutic effects of phages during phage therapy. 
Bacteriophages are the most abundant entities on Earth, impacting ecological 
niches ranging from the ocean to the gut microbiome (Focà et al., 2015; Hofer, 2013; 
Mills et al., 2013; Suttle, 2005; Weinbauer, 2004). Furthermore, it is known that 
phages are immensely specific towards a specific bacterial host without infecting 
other bacterial strains. Moreover, there is currently no data available on phages 
infecting eukaryotic cells. This makes them ideal candidates to treat bacterial 
infections, while being harmless to mammalian cells and even non-target bacteria 
(Thiel, 2004).  
Bacteria that inhabit the intestine and skin are generally regarded as stable 
residents that may confer metabolic and/or immune benefits to their hosts 
(Turnbaugh et al., 2009). The host immune system has evolved mechanisms to 
tolerate these commensal organisms while at the same time providing protection 
for the host from pathogens (Moon and Stappenbeck, 2012). Similarly, metagenomic 
studies have revealed that a vast variety of bacteriophages are associated with 
healthy human tissues (Minot et al., 2011; Pride et al., 2012; Reyes et al., 2010). In 
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case of phages, a persistent nonpathogenic association seems possible as viral 
replication occurs only in bacterial hosts, which can themselves be stable members 
of the microbiome (Duerkop and Hooper, 2013).  
It has been demonstrated that oral uptake of phages by animals results in the 
translocation of phages to systemic tissues (Duerr et al., 2004; Hamzeh-Mivehroud 
et al., 2008). This suggests that mammals have mechanisms for the uptake and 
delivery of phages from the gut to the blood. The contact between systemic tissues 
and phages may allow intestinal phages to elicit innate and adaptive immune 
responses. One possible uptake route involves dendritic cells, which are known to 
sample intestinal luminal contents and can actively phagocytize phage particles in 
culture (Barfoot et al., 1989; Rescigno et al., 2001). It is also interesting to consider 
whether phages might elicit antiviral innate immune responses. Mammalian cells 
are endowed with the ability to detect viral nucleic acids through several pattern-
recognition receptors that are positioned to detect viral entry into cells (Duerkop 
and Hooper, 2013). 
A study performed by Weber-Dąbrowska et al. (2000) demonstrated that phage 
therapy can normalize TNFα serum levels and the production of TNFα and IL6 by 
blood cell cultures. Miernikiewicz et al. (2013) performed an extensive study of the 
immunological effects of phage T4 and its head surface proteins. They found that 
phage T4 and its surface proteins gp23*, gp24*, Hoc and Soc did not affect 
production of the inflammatory cytokine and ROS production. Recently Majewska 
et al. (2015) followed the antibody production (i.e. IgM, IgG and secretory IgA) after 
oral application of phage T4 to mice. However, the orally applied phage T4 induced 
anti-phage antibodies only after a combination of long exposure times (i.e. IgG day 
36 and IgA day 79) and high doses.  
The use of phage therapy has persisted without interruption in Eastern Europe, 
particularly in centers such as the Eliava Institute of Bacteriophage, Microbiology 
and Virology in Tbilisi, Georgia and the Institute of Immunology and Experimental 
Therapy in Wroclaw, Poland (Housby and Mann, 2009; Kutter and Sulakvelidze, 
2004). Phage interactions with animals in general and human beings in particular 
have been comprehensively reviewed (Kutter and Sulakvelidze, 2004), and there 
have been no reports of significant adverse reactions despite their long history of 
administration to humans.  
Here, we report on the immune response induced by individual (highly purified) 
phages. It has previously been described that CsCl gradient ultra-centrifuged 
phages are free from residual DNA, RNA and bacterial proteins released during the 
lysis of the bacterial cell (Reddy et al., 1988). Hence, the immune responses observed 
in our study are induced by the phages. We previously conducted a whole 
transcriptome analysis of human peripheral blood mononuclear cells (PBMCs) 
stimulated with either P. aeruginosa or a P. aeruginosa phage PNM lysate (
). The P. aeruginosa phage PNM lysate condition most closely reflects the 
immunological condition obtained during phage therapy, when the phage titer is 
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the highest and predominantly bacterial fragments, from the lysed bacterial cells, 
remain. These data suggest that certain immunological pathways are activated 
during and/or after phage therapy and may contribute to the efficacy of phages 
during phage therapy. Next, to understand to what extent the phage particles 
interact with the human immune system, the immune response induced by two 
different phage purification strategies (i.e. either a phage lysate or a highly purified 
phage) was compared. Using twelve immunity-related genes, the immune response 
induced by five different phages were compared, four infecting P. aeruginosa and 
one S. aureus phage. These five phages represent the three major phage 
morphologies (Table 8. 1). This might give us an idea whether the immune response 
might be phage host specific or phage morphology dependent.  
Stimulation of PBMCs, derived from six donors (each stimulated in triplicate), with 
either an S. aureus phage ISP lysate, the highly purified phage ISP (undiluted and 
100-fold diluted), or the S. aureus host strain showed that the immune response 
within each condition was highly reproducible (Figure 8. 1). Diluting the highly 
purified phage ISP led to an almost complete reduction of the observed immune 
response, with the exception of TNFA and CXCL5 which have the same induction 
as the undiluted phage and IL1B and CXCL1 which are both up-regulated but are 
significantly different from the undiluted phage condition, i.e. up-regulated but 
significantly less strong than the undiluted phage. These clear titration effects 
indicate that sufficiently high phage titers (i.e. ≥ 103 pfu/PBMC) are necessary in 
order to induce an immune response. 
Interestingly, the highly purified phage ISP induced an almost identical response 
as its bacterial host strain (except for CXCL5, IL1RN, IL6 and IL10), whereas the 
phage lysate, still containing bacterial contamination, induced a much weaker 
overall response (except for CXCL1, CXCL5, IL1B, IL1RN and TNFA). The highly 
purified phage ISP significantly (p-value < 0.05) up-regulates the CXCL1, IL1A, 
IL1B, IL1RN, IL6 and TNFA genes and down-regulates CD14, LYZ and TGFBI 
compared to the phage lysate. 
The immune response induced by the phage and its bacterial host (i.e. S. aureus 
strain 6538) also shows a strong down-regulation of the LYZ gene expression, in 
agreement with the transcriptome results (Figure 8. 1). The values between the 




















































































































































































































































































































































































































































































































































































































































To determine whether the observed immune response was induced by the 
bacteriophage rather than by possible endotoxin contamination present in the 
phage lysate or purified phage (Table 8. 1), PBMCs were stimulated with either S. 
aureus phage ISP alone, i.e. completely endotoxin free (Table 8. 1), at concentrations 
of 103 pfu/PBMC, or in combination with different concentrations of a commercial 
endotoxin preparation (i.e. 10-1, 10-3 or 10-7 EU/ PBMC). 
The addition of up to 10-1 EU/PBMC to 103 pfu/PBMC of S. aureus phage ISP did 
not lead to a significant difference in the immune response as induced by the phage 
alone (Figure 8. 2 A - C). However, the immune response induced by phage ISP at 
103 pfu/PBMC (with or without endotoxins) differed significantly (p-value < 0.05) 
from the immune response induced by the endotoxins alone, for CXCL5, LYZ, 
TGFBI and TNFA. The combination of phage with endotoxins led to a stronger up-
regulation of TNFA or stronger down-regulation of LYZ and TGFBI in comparison 
with endotoxins alone, whereas the expression of CXCL5 was reduced compared to 
endotoxin alone when a combination of phage ISP with endotoxins was used. 
Lowering the endotoxin concentration added to phage ISP from 10-1 EU/PBMC to 
10-3 EU/PBMC, resulted in a significant difference (p-value <0.05) in the gene 
expression of CXCL1, CXCL5, IL1RN, LYZ, TNFA and TGFBI, between the phage 
ISP with endotoxins (i.e. 103 pfu and 10-3 EU/PBMC) and endotoxins alone (i.e. 10-3 
EU/PBMC). Of particular interest was the down-regulation of CXCL1 and CXCL5 
when stimulation was carried out with both endotoxin and phage compared to 103 
pfu of phage ISP/PBMC alone or 10-3 of EU/PBMC alone (Figure 8. 2B). Further 
reduction of the endotoxin concentration to 10-7 EU/PBMC did not significantly 
differ from the immune response induced by the phage alone, with the exception of 
CXCL1 and IL1A (Figure 8. 2C), which were less expressed when the PBMCs were 
challenged with 10-7 EU/PMBC added to the phage instead of when stimulated by 
the phage alone. 
Lowering the phage concentration from 103 pfu/PBMC to 10 pfu/PBMC, in 
combination with 10-1, 10-3 or 10-7 EU/PBMC led to an immune response more 
similar to the one induced by the endotoxin alone than the one induced by the phage 
alone (Figure 8. 2D – F). 
Comparable to the observations for S. aureus phage ISP, the immune response 
induced by the P. aeruginosa phage PNM lysate (at 105 pfu/PBMC) differs 
significantly (p-value < 0.05) from the one induced by the highly purified phage (at 
105 pfu/PBMC). However, it was the P. aeruginosa phage PNM lysate-induced 
response that was most consistent with the response to its bacterial host strain (10-
1 cfu/PBMC), except for CD14, CXCL5, LYZ and TNFA. A significant difference in 
the induced immune response between the phage lysate and the purified phage 
could be observed for CXCL1, IL1A, IL1B, IL6, TNFA and TGFBI (Figure 8. 3 ). 
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Because this difference could be due to endotoxin contamination, we compared the 
stimulation of the PBMCs with a highly purified phage PNM preparation with the 
addition of endotoxins (i.e. 10-1 EU/PBMC), in order to equalize the endotoxin 
concentration with that of the phage lysate (3 x 10-1 EU/PBMC, Table 8. 1). 
Nonetheless, this did not bring the observed immune response closer to the one 
induced by the phage lysate and even had the opposite effect for e.g. IL1A, IL6 and 
IL10 (Figure 8. 3). This indicates that the difference in immune response induced 
by the highly purified phage compared to the phage lysate is not due to the presence 
of endotoxins in the phage lysate, but rather due to the presence of bacterial 
contaminants (e.g. bacterial DNA or proteins) in the phage lysate. 
All four P. aeruginosa phages [i.e. PNM (105 pfu/PBMC), LUZ19 (105 – 103 
pfu/PBMC), 14-1 (104 – 103 pfu/PBMC and Ge_vB_Pae-Kakheti25 (104 pfu/PBMC)] 
induced a comparable immune response (Figure 8. 4). For all four phages, there is 
a clear difference in the level of the gene expression induced in the PBMCs by the 
stimulation of the phage lysate or the highly purified phage. For all four phages, 
the phage lysate induces a stronger immune response compared to the highly 
purified phage. 
All four P. aeruginosa phages induce IL6 and the anti-inflammatory genes IL1RN, 
IL10 and SOCS3, as well as the pro-inflammatory genes CXCL1, CXCL5, IL1A and 
IL1B. Only the expression of TNFA is different between the four phages, with phage 
PNM and 14-1 inducing a significant slight up-regulation while phages LUZ19 and 
GE_vB_Pae-Kakheti25 induced a down-regulation (Figure 8. 4). Moreover, the 
phage lysates strongly resembled the immune response induced by their bacterial 
host, i.e. P. aeruginosa strain 573. 
Based on the transcriptome analysis described in 
 we were able to show that P. aeruginosa phage PNM does 
activate immunological pathways. Subsequent in depth analysis of twelve selected 
immunity-related genes (Table 8. 3) by means of RT-qPCR confirmed that five 
different bacteriophages, one with a Gram-positive host and four with a Gram-
negative host (Table 8. 1), were able to induce an immune response. Our study 
addressed only the cytokine gene expression level and not the cytokine protein level, 
for several reasons. First, stimulation times for cytokine protein levels are much 
longer (Kranzer et al., 2004; Zelante and Ricciardi-Castagnoli, 2012) and such 
longer stimulation times are not optimal for freshly isolated PBMCs. Furthermore, 
an early response and fluctuations in the response are more rapidly detected at the 






We found that for all five phages, the overall immune response (as determined by 
RT-qPCR) is very comparable (Figure 8. 5), but differs from the immune response 
induced by their bacterial host. The observed immune response is in large 
correspondence with the transcriptome analysis. Moreover, the immune response 
induced by a large number of phages (i.e. 103 pfu/PBMC) seems to be endotoxin 
independent, the addition of endotoxins to the highly purified S. aureus phage ISP 
did not subvert the immune response to the one induced by the S. aureus phage ISP 
lysate. Furthermore, the stimulation of PBMCs with either a P. aeruginosa phage 
PNM lysate or a highly purified P. aeruginosa phage PNM preparation 
supplemented with endotoxins in concentration of 10-1 EU/PBMC (Figure 8. 3) did 
not bring the observed immune response closer to the one induced by the phage 
PNM lysate, indicating that the immune response induced by the phage 
preparations is not due to the presence of endotoxins but more due to presence of 
other bacterial components in the phage lysate preparation. Additionally, it has 
recently been shown that Escherichia coli phage T4 gp12 can decrease the immune 
response induced by endotoxins, through the binding of endotoxins to gp12 
(Miernikiewicz et al., 2016). 
Whether phages induce a highly comparable overall immune response or whether 
only specific parts of the immune response are similar needs to be further evaluated, 
as we specifically looked at twelve immunity-related genes. However, the ability of 
these five phages to induce a, largely, similar immune response might be due to the 
modular nature of phage genomes (Bérard et al., 2016). Based on the modular 
nature of phages genomes, it can be hypothesized that phage capsid proteins might 
have similar folds and subsequently induce similar immune responses. For 
instance, it has been shown that gp23 and gp24 of E. coli phage T4 have a similar 
fold as that of the E. coli phage HK97 capsid protein (Fokine and Rossmann, 2014; 
Fokine et al., 2005). Yet a single point mutation can change the serotype of the 
phage. This might also be the case for P. aeruginosa phage PNM and LUZ19, which 
are homologous, yet slightly differ in the induced immune response. 
 
Figure 8. 2: Gene expression analysis of 12 immunity-related genes, assessed by means of 
RT-qPCR, after 20 h of stimulation of PBMCs with Staphylococcus aureus phage ISP in 
combination with endotoxins (i.e. 10-1, 10-3 or 10-7 EU/ml). (A, B, C) 103 pfu/PBMC in 
combination with (A) 10-1 EU/PBMC, (B) 10-3 EU/PBMC or (C) 10--7 EU/PBMC leads to an 
immune response more similar to the one induced by the phage alone. (D, E, F) Reducing the 
phage titer to 10 pfu/PBMC causes the immune response to tilt in the direction of the 














































































































































































































































































































































































































































































































































































































































































































At this point, it is difficult to establish whether the phages are predominantly pro- 
or anti-inflammatory, although the phages have the tendency to induce an anti-
inflammatory response, as assessed based on these twelve immunity-related genes 
and on the premise of a sufficiently high phage concentration (i.e. 103 pfu/PBMC). 
It is on the other hand very clear that they do activate several immunological 
pathways (Figure 8. 6).  
The influence of phages on the cytokine mRNA production, as observed in this 
study, may not be all that unexpected, since there are several indications for other 
interactions of phages with human cells. For example, they may play a significant 
role in transplantation as it was shown that in mice they reduce cellular infiltration 
of allogenic skin allografts (Górski et al., 2006b). Phages might do this by inhibiting 
the adhesion of platelets and, to some extent, of T- cells to fibrinogen, a protein 
which plays an important role in transplant rejection, angiogenesis and metastasis 
(Gorski et al., 2003; Kurzȩpa et al., 2009). A more recent study demonstrated that 
bacteriophages are also able to inhibit the production of reactive oxygen species 
(ROS) as part of the response of granulocytes to the presence of bacteria, which may 
be beneficial because overproduction of ROS leads to tissue damage (Miedzybrodzki 
et al., 2008; Przerwa et al., 2006). Another study proved that phages can aid in the 
killing of phagocytosed S. aureus (Kaur et al., 2014). The authors showed that phage 
particles absorbed to the bacterial surface have an impact on the killing of engulfed 
S. aureus inside phagocytic cells (e.g. macrophages) by 38.7 %. Furthermore, it has 
been indicated that phages are able to interact with human mucosal surfaces and 
from a non-host derived immune barrier (Barr et al., 2013, 2015). 
It was recently shown that the surface proteins gp23*, gp24*, Hoc and Soc of phage 
T4 do not induce an IL10 response, neither as elements of the integral phage capsid 
nor as isolated proteins. This is in accordance to our findings for S. aureus phage 
ISP, but not for the P. aeruginosa phages (Dąbrowska et al., 2014a; Miernikiewicz 
et al., 2013). Nor did these authors detect the presence of pro-inflammatory 
cytokines such as TNFA, IL1 and IL6 in mice, murine dendritic cell cultures or 
human blood. Contrary to what we show here, they postulate (based on their 
findings) that bacteriophages do not induce an immune response. This difference in 
results might be explained by the use of different incubation times, since we used 
20 h as a stimulation time (optimal time frame for the detection of IL10 mRNA) 
instead of 5 – 6 h. Another major difference is that they studied an Escherichia coli 
phage (T4), which might suggest a species/phage specific response. 
The up-regulation of IL1RN by all five phages, as shown in our study, is of 
particular interest. All five phages induce the pro-inflammatory cytokines IL1A and 
IL1B, but the simultaneous induction of the anti-inflammatory IL1 receptor 
antagonist (IL1RN) will interfere with the pro-inflammatory IL1 signal and thus 
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Figure 8. 3: Effect of endotoxins in the presence P. aeruginosa phage PNM. A| Gene 
expression analysis of 12 immunity-related genes by means of RT-qPCR after 20 h 
of stimulation of PBMCs. PBMCs were stimulated with P. aeruginosa phage PNM, either 
a phage lysate (105 pfu/PBMC; 0.1 EU/PBMC) or a highly purified phage preparation (105 
pfu/PBMC; 10-5 EU/PBMC) in combination with 0.1 EU/PBMC. The pro-inflammatory 
markers IL1A, IL1B, CXCL1 and CXCL5, and the anti-inflammatory markers SOCS3, IL10, 
IL1RN and IL6 are upregulated The addition of 0.1 EU/PBMC to the highly purified P. 
aeruginosa phage preparation does not revert the observed immune response to that of the 
phage lysate for IL10, IL1A, IL6, TNFA and CXCL1. B| Principal components analysis 
of P. aeruginosa phage PNM with or without the addition of endotoxins. The 
immune response induced by the highly purified phage PNM (▪) differs from the one induced 
by the phage PNM lysate (•), as these two groups are visibly separated. When endotoxins 
are added to a final concentration of 0.1 EU/PBMC to the highly purified phage (▪), the 
immune response is similar to the highly purified phage (▪) and not towards the phage lysate 
(•), indicating that the observed difference is not due to the presence of LPS but due to 
bacterial proteins present in the phage lysate 
 
In a previous study, , we showed the 
difficulty to remove endotoxins from phage preparations (Van Belleghem et al., 
2017a), making it impossible to completely remove all endotoxins from high titer P. 
aeruginosa phage preparations. To exclude that the observed immune response for 
the P. aeruginosa phages were, partially, due to incomplete endotoxin removal, we 
compared the response of S. aureus phage ISP, shown to be completely endotoxin-
free with that of ISP phage in combination with three concentrations of endotoxins 
(10-1, 10-3 or 10-7 EU/PBMC ). Our results strongly indicate that the addition of even 
the highest concentration of endotoxins to a high concentration of S. aureus phage 
ISP (103 pfu/PBMC) has no effect on the induced immune response (Figure 8. 2A). 
Intriguingly, when an intermediate level of endotoxins was added, the immune 
response tipped to a more anti-inflammatory response (i.e. an up-regulation of 
IL1RN and a strongly reduced expression of CXCL1 and CXCL5) and differed from 
that after stimulation with the highly purified phage or with only endotoxin. 
The up-regulation of IL1RN (Interleukin-1 Receptor Antagonist) and SOCS3 
(Suppressor of Cytokine Signaling 3) by all five phages, or the down-regulation of 
CXCL1 and CXCL5 by S. aureus phage ISP in addition of endotoxins, might indicate 
that these phages have evolved anti-inflammatory properties while some pro-















































































































































































































































































































































































































































Figure 8. 5: Principal component analysis (PCA). Comparison of the immune response 
of PBMCs induced by all five tested phages (Highly purified or phage lysate; magenta) and 
their bacterial host strain (blue). The PCA clearly shows that the bacteria (blue) and phages 
(magenta) for two separate groups, indicating that the immune response induced is different 
between these two types of stimuli. There is no clear distinction between the different phages, 
indicating that these five different phages induced similar responses. Moreover the gene 
expression of IL1RN, IL1B and SOCS3, IL6 and IL1A, TNFA and IL10, and LYZ and TGFBI 
are correlated 
 
It could thus be theoretically postulated that by reducing the immune response, 
phages first reduce the chance to be removed from the human body and be degraded. 
Secondly, these responses might promote the survival of their bacterial host which 
in turn provides the phage with a higher fitness and better opportunities to 
proliferate but also to remove the pathogenic bacteria, in case of bacterial infections. 
This could be further argued from the point of view that when the phage 
concentration reaches a certain threshold this could lead to lysis from without. 
When the phage subsequently reduces the immune response and the bacterial 
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concentration rises, the overall phage to bacterial concentration could drop below 
the lysis from without threshold enabling the phages to once again infect the 
bacteria and propagate. With regard to phage therapy, these anti-inflammatory 
effects of phages might increase the capacity of the phages to suppress bacterial 
numbers and thus infections, with the addition of dampening the negative site of 
the inflammatory response. 
Pseudomonas aeruginosa strain 573 (received from the Eliava IBMV, Tbilisi, 
Georgia) and Staphylococcus aureus strain ATCC 6538 were grown on a Lysogeny 
Broth (LB) agar plates (Becton Dickinson, Erembodegem, Belgium) and incubated 
overnight at 37 °C. One colony was subsequently used to inoculate a 15 ml tube 
containing a 4 ml LB agar slant, and incubated again overnight at 37 °C. Five ml 
saline was added to yield a suspension with a final concentration of 107 cfu/ml, as 
confirmed by culture of serial tenfold dilutions.  
 Bacteriophage stocks (Table 8. 1) were prepared using the double-
agar overlay method as described in Merabishvili et al. (2009). Briefly, one ml of 
phage preparation containing 106 plaque forming units (pfu) of bacteriophages was 
mixed with 3 ml of molten (45 °C) LB top Bacto agar (0.6 %) (Becton Dickinson) and 
100 µl of the host strain suspension (end concentration of 107 cfu/ml) in a sterile 14 
ml tube (Falcon, Becton Dickinson). This mixture was plated onto freshly made 90 
mm diameter Petri dishes (Plastiques Gosselin, Menen, Belgium), filled with a 
bottom layer (20 ml) of 1.5 % LB agar, and incubated aerobically at 32 °C for 16 h. 
Subsequently, 200 µl of chloroform was added to the lids of the Petri dishes and the 
inverted plates were further incubated at 4 °C for 1 h. The top layer of the double-
agar layer was scraped off using a sterile Drigalski spatulum and transferred to a 
sterile 50 ml tube. 
Figure 8. 6: Hypothetical representation of the interaction of bacteriophages with 
mammalian immune cells. Phages potentially interact with (currently unknown) immune 
receptors and induce corresponding immune responses. The immune responses induced by 
the bacteriophages can either be pro- of anti-inflammatory. For instance, the tested phages 
are able to induce the pro-inflammatory cytokines IL1α and IL1β. Through the induction of 
IL1RN by the phage, the phage is able to inhibit the pro-inflammatory responses that are 
otherwise induced by these cytokines. Pro-inflammatory cytokines are marked in red (i.e. 
TNFα, IFN-γ, IL1α, IL1β, IL6, IL17, CXCL1 and CXCL5), anti-inflammatory cytokines are 
depicted in green (i.e. TGFβ, IL4, IL10 and IL1RN). Dark orange depicts proteins that play a 







The harvested phages were centrifuged for 20 min at 6,000 x g at 4 °C. The 
supernatant was aspirated using a sterile 10 ml syringe (BD Plastipak, Becton 
Dickinson) with a 30 G sterile needle (BD Microlance 3, Becton Dickinson) and 
passed through a 0.22 µm membrane filter (Sartorius Stedim, Zellik, Belgium). The 
filtrate was subsequently centrifuged at 35,000 x g for one hour. The phage pellet 
was resuspended in 5 ml saline and stored at 4 °C overnight before determining the 
phage titer. Preferably, the titer of the phage lysate should be checked at least one 
day later according to the above described procedures. This will allow phage 
particles that may have clumped together during centrifugation steps to disengage 
(Kutter and Sulakvelidze, 2004). 
 The bacteriophage titer was determined by assaying 
decinormal serial dilutions (log(0) to log(-12)) of the bacteriophage suspension with 
the overlay method (Merabishvili et al., 2009). One ml of each dilution was mixed 
with 3 ml of molten (45 °C) LB 0.6 % top Bacto agar and the host strain (end 
concentration of 107 cfu/ml) in a sterile 14 ml tube. This mixture was plated in 
triplicate onto 90 mm diameter Petri dishes, filled with a bottom layer of 1.5 % LB 
agar, and incubated for 16 h at 37 °C. To determine the original bacteriophage 
concentration, plates with one to 100 distinguishable plaques were counted. The 
mean was then calculated for the triplicate plates. 
 Endotoxins were removed and quantified as described in Van 
Belleghem et al. (2017). Briefly, phage lysates were further purified using CsCl 
centrifugation. Subsequently, endotoxin concentrations were determined using the 
EndoZyme recombinant Factor C (rFC) Assay (Hyglos, Bernried am Starnberger 
See, Germany). For the P. aeruginosa phages, 10-5 – 10-10 EU/pfu remained after the 
CsCl purification. The S. aureus phage ISP contained no endotoxins (Table 8. 1). 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from a buffycoat after 
informed consent (Blood Transfusion Centre, Ghent), using a Lymphoprep (Axis-
Shield, Dundee, Scotland) gradient. Fifty ml of the buffycoat was added to 250 ml 
Hank’s Balanced Salt Solution, without Ca2+ and Mg2+ (HBSS) (Invitrogen). Of this 
dilution, eight aliquots of 35 ml were each added to 15 ml Lymphoprep in a 50 ml 
Falcon tube. These mixtures were subsequently centrifuged at 500 x g for 20 min at 
room temperature. The inner whitish ring of PBMCs, present between the 
lymphoprep and the plasma phase, was transferred to 25 ml HBSS and centrifuged 
at 450 x g for 10 min at room temperature. The supernatants was removed and the 
cell pellet was resuspended in 10 ml HBSS. All resuspended cells were pooled into 
a 50 ml Falcon tube and HBSS was added to a total volume of 50 ml. A small fraction 
of this cell solution was used to count the number of cells present, before it was 
centrifuged again at 350 x g for 10 min at room temperature.  
The total number of cells was counted using a Sysmex KX-21 (Sysmex, Norderstedt, 
Germany). The cell pellet was resuspended in heat-inactivated fetal calf serum with 
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10 % dimethyl sulfoxide (DMSO) to a concentration of 2 x 107 cells/ml and divided 
in 1 ml aliquots before cryostorage them in liquid nitrogen.  
Stimulations were performed in 100 µl volumes containing 106 PBMCs. One vial of 
stored PBMCs, containing 2 x 107 cells/ml, was thawed at 37 °C prior to adding 9 
ml HBSS (without Ca2+ and Mg2+). This suspension was subsequently centrifuged 
at 350 x g for 10 min. The obtained cell pellet was resuspended in 5 ml HBSS 
(without Ca2+ and Mg2+) and 80 µl was used for cell counting on a Sysmex KX-21. 
This cell suspension was centrifuged at 350 x g for 10 min. The resulting cell pellet 
was resuspended in RPMI 1640 (supplemented with 2 mM L-glutamic acid, 1X 
MEM non-essential amino acids, 1 mM sodium pyruvate, 60 U of penicillin/ml, 10 
mg/ml streptomycin, 2 mM L-glutamine and 10 % heat inactivated fetal calf serum) 
to a final concentration of 107 cells/ml (Moore et al., 1967). 
The PBMCs (i.e. 106 PBMCs/100 µl) were subsequently stimulated with 10 µl of the 
bacterial host (i.e. either P. aeruginosa or S. aureus, at a concentration of 107 cfu/ml, 
i.e., 105 cfu per 106 PBMC or 10-1 cfu/PBMC), 10 µl of the phage suspensions (i.e. 
either a phage lysate or a highly purified (CsCl) phage suspension (Table 8. 1)) at 
concentrations between 1013 and 109 pfu/ml, i.e., 105 or 10 pfu/PBMC, or phage 
suspension in combination with 10 µl endotoxins (commercial preparation derived 
from P. aeruginosa strain 10; Sigma Aldrich) at concentrations of 101, 105 or 107 
Endotoxin units/ml (EU/ml), i.e., 10-1, 10-3 or 10-7 EU/PBMC. As a negative control, 
10 µl saline was added to the cells. The PBMCs were incubated for 20 h at 37 °C in 
5 % CO2. All stimulation experiments and controls were carried out on six biological 
replicates (i.e. anonymous donors) in triplicate. We confirm that all methods were 
carried out in accordance to relevant guidelines and regulations and that all 
experimental protocols were approved by the ethical committee of Ghent University 
(EC/2017/0558). 
 After 20 h of PBMC stimulation, the total cell volume 
was transferred to 1 ml Qiazol (Qiagen, Valencia, CA) and stored at -80 °C for at 
least 16 h before extracting the RNA. The total RNA fraction was isolated using a 
semi-automated procedure of NucliSens EasyMag (Biomérieux, Marcy l’Étoile, 
France). Briefly, 900 µl EasyMag lysis buffer was added to the 1.1 ml Qiazol 
solution. This mixture was subsequently transferred to a NucliSens EasyMag 
cartridge. Finally, 100 µl magnetized silica was added and the cartridge was loaded 
on the machine (according to the manufacturer). In a final step, the nucleic acids 
was eluted with 35 µl NucliSens EasyMag elution buffer. 
 DNase digest was performed immediately after nucleic acid extraction 
to remove DNA from the sample. Five µl of the nucleic extract was added to one µl 
of DNase (1 U/µl), one µl 10X DNase reaction buffer (Promega, Mannheim, 
Germany) and three µl of RNase free H2O to make up a total volume of 10 µl. This 
mixture was incubated for 30 min at 37 °C. The DNase digestion was terminated by 
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adding 1 µl of DNase Stop Solution and incubating the mixture at 65 °C for 10 min. 
DNase digested RNA samples were stored at -80 °C.  
 The cDNA synthesis was preformed using the RevertAid RT kit 
(Thermo Scientific, Waltham, MA) in four times 40 µl volumes according to the 
manufacturer’s instructions. 
 Based on the RNA seq data, twelve target genes were selected for further 
evaluation by RT-qPCR. Combining the datasets of both the phage PNM lysate and 
P. aeruginosa stimulated PBMCs; we observed that a total of 2679 genes were 
uniquely expressed. As a cut-off for qPCR detection, a minimum of 7000 reads was 
selected either in the control condition or after stimulation, to ensure detection in 
the RT-qPCR. This led to a reduction to 418 genes. Furthermore, to detect a 
difference in gene expression in the qPCR, a Log2Fold change difference was needed 
after normalization of the target genes by the reference gene ACTB. This led to a 
further reduction to 176 potential target genes for qPCR-based analysis. From 
these, a total of twelve genes were selected on the basis of their possible importance 
in the immune response, i.e CD14, CXCL1, CXCL5, IL1A, IL1B, IL1RN, IL6, IL10, 
LYZ, SOCS3, TGFBI and TNFA (Table 8. 2). 
The RT-qPCR was performed in a total reaction volume of 10 µl using 0.5 µM of 
each primer (Table 8. 3), 2.5 µl cDNA and LightCycler 480 High resolution Melting 
master (Roche Applied Sciences, Indianapolis, Indiana). 
The selection of the most stable reference gene(s) was carried out as described by 
Vandesompele et al. (2002) using SybrGreen as means of detection. Using geNorm, 
we found that all six reference genes (i.e. ACTB, GADPH, HRPT1, PPIA, TBP and 
UBC; Table 8. 4) are sufficiently stable (internal control gene-stability measure M 
< 1.5). Therefore, the minimal optimal number of reference targets to be used in 
this experiment was 1 (V < 0.15). The mRNA levels are expressed in relative copy 
numbers normalized against the reference gene (ACTB), as described by Giulietti 
























TGFBI 34300 640 62 -5.68 -9.27 
CD14 134382 NA 594 NA -7.96 
LYZ 42484 3997 206 -3.34 -7.83 
CXCL5 249901 NA 8756 NA -4.97 
IL1B 30961 636519 137021 4.44 2.01 
IL1RN 3167 41322 19681 3.78 2.5 
TNF 2260 4823 16990 1.17 2.77 
IL1A 418 28048 8740 6.15 4.25 
IL10 363 6890 7771 4.32 4.28 
IL6 573 51002 52356 6.55 6.37 
SOCS3 20597 79658 NA 2.02 NA 
CXCL1 20185 152399 NA 2.99 NA 
Selection was based on number of reads in either control of stimulated condition (i.e. phage 
PNM lysate or P. aeruginosa strain PA573) which needs to exceed 6000 and the Log2ratio, 
which needs to be larger than |2|. NA indicated no differential expression for a specific 




Table 8. 3: List of primers used in the RT-qPCR for the validation of the RNA seq.  
Names Sequence (5' - 3') 
Tm 
(°C) 
IL10_F CATCGATTTCTTCCCTGTGAA 45.3 
IL10_R TCTTGGAGCTTATTAAAGGCATTC 47.2 
TNFa_F CCCAGGGACCTCTCTCTAATC 51.2 
TNFa_R ATGGGCTACAGGCTTGTCACT 49.2 
ACTB_F GGATGCAGAAGGAGATCACTG 49.2 
ACTB_R CGATCCACACGGAGTACTTG 62.0 
SOCS3_F GGCCACTCTTCAGCATCTC 60.0 
SOCS3_R ATCGTACTGGTCCAGGAACTC 49.2 
TGFBI_F GAAGGGAGACAATCGCTTTAGC 49.7 
TGFBI_R TGTAGACTCCTTCCCGGTTGAG 51.6 
CD14_F CGCTCCGAGATGCATGTG 58.0 
CD14_R TTGGCTGGCAGTCCTTTAGG 62.0 
LYZ_F AAAACCCCAGGAGCAGTTAAT 45.3 
LYZ_R CAACCCTCTTTGCACAAGCT 60.0 
CXCL5_F ATCTGCAAGTGTTCGCCATAG 47.3 
CXCL5_R ACAAATTTCCTTCCCGTTCTTC 46.0 
IL1B_F GGCCACATTTGGTTCTAAGAAA 46.0 
IL1B_R TAAATAGGGAAGCGGTTGCTC 47.3 
IL1RN_F GAAGATGTGCCTGTCCTGTGT 49.2 
IL1RN_R CGCTCAGGTCAGTGATGTTAA 47.3 
IL1A_F CGCCAATGACTCAGAGGAAGA 49.2 
IL1A_R AGGGCGTCATTCAGGATGAA 60.0 
IL6_F GGTACATCCTCGACGGCATC 64.0 
IL6_R GCCTCTTTGCTGCTTTCACAC 49.2 
CXCL1_F GGAAAGAGAGACACAGCTGCA 49.2 
CXCL1_R AGAAGACTTCTCCTAAGCGATGC 50.2 




Table 8. 4: Primers used to determine the most stable reference genes.  
mRNA target Name primer Sequence (5’- 3’) Tm (°C) 
ACTB  ACTB_F GGATGCAGAAGGAGATCACTG 49.2 
   ACTB_R CGATCCACACGGAGTACTTG 62.0 
HPRT1 HPRT1_F TCAGGCAGTATAATCCAAAGATGGT 49.3 
  HPRT1_R AGTCTGGCTTATATCCAACACTTCG  50.9 
UBC UBC_F TCGCAGCCGGGATTTG 52.0 
  UBC_R GCATTGTCAAGTGACGATCACA 47.9 
TBP TBP_F ATGTGAAGTTTCCTATAAGGTTAG 45.4 
  TBP_R AGGAAATAACTCTGGCTCATAAC 46.6 
GAPDH GAPDH_F TCACCACCATGGAGAAGGC  60.0 
  GAPDH_R GCTAAGCAGTTGGTGGTGCA  62.0 











Phages as pharmaceuticals are protein-based, biological agents that actively 
replicate, and even evolve during manufacture or use and that can potentially 
interact with the body’s immune system (Loc-Carrillo and Abedon, 2011). Phages 
may control bacterial infections in two ways. Under active treatment most of the 
bacteria are killed by secondary infections after extensive reproduction and 
transmission of the phage. If the phages do not increase in number, there can still 
be passive treatment in which the initial phage dosage is large enough to inundate 
the bacteria by primary infection alone or by lysis from without, whereby the 
bacterial cell loses its integrity due to membrane damage caused by massive phage 
adherence and penetration. Kinetically, passive treatment can be compared to 
antibiotic treatment, both lacking the advantage of amplification of the 
antibacterial agent, as is the case in active treatment, when secondary phage 
infections do occur (Payne and Jansen, 2000). 
When pharmaceutical agents are active replicating entities, a different set of 
pharmacokinetic principles is needed. Furthermore, these entities can interact, 
replicate and evolve, and demonstrate phenomena unknown in chemical kinetics of 
conventional drugs (Payne and Jansen, 2003). The specific pharmacokinetic 
phenomena expected to occur when actively replicating viruses are used to control 
bacterial infections have been described (Cairns et al., 2009; Kasman et al., 2002; 
Payne and Jansen, 2001, 2003, 2000). In these mathematical models, the rate at 
which a bacterial population declines due to phage infection, the rate at which the 
phage population increases and the levels at which they are maintained depends 
primarily on five parameters: the infectivity of the phage, the latency period, the 
burst size, the rate at which the phages are degraded or removed from the site of 
infection, and the bacterial growth rate. Besides these five parameters, two other 
variables need to be taken into account: the density of susceptible bacteria and the 
density of phage (Levin and Bull, 2004). In summary, these models describe phage 
pharmacodynamics as being analogous to the population dynamics of the phage-
bacterial interaction (Abedon and Thomas-Abedon, 2010), not taking into account 
potential interaction between bacteria and/or phages with the innate or adaptive 
immune response. 
Recently, these mathematical models have been further extended to include the 
mammalian host response towards the phage (Hodyra-Stefaniak et al., 2015). Based 
on experimental data, the authors developed a general scheme of the tripartite 
interactions between bacteriophages, bacteria and mammalian immunity. This 
scheme summarizes the main reciprocal dependencies, specifically the effect that 
limit the bacterial or phage survival, or the effects inducing the activation of the 
immune response (Figure 9. 1). There are three key assumptions on which their 
scheme is based. First, adaptive immunity specific to phages and adaptive 
immunity specific to bacteria have no important cross-talk; second, phages are not 
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able to boost an innate immune response (Miernikiewicz et al., 2013; Park et al., 
2014); and third, the boosted innate immune response acts against the bacteria, but 
at the same time also acts against the phage. These assumptions led to the 
development of a mathematical model based on those previously described by Levin 
and Bull (Levin and Bull, 1996, 2004), and Payne and Jansen (Payne and Jansen, 
2001, 2003). This led to the development of a model with a set of immunology-
representing variables; innate immunity (I), adaptive immunity specific to phages 
(A), and adaptive immunity specific to bacteria (B) (Addendum – Mathematical 
model). 
 
Figure 9. 1: Schematic representation of the immune response against phages and 
bacteria. P – Phage, S – susceptible bacteria, I – innate immunity, A – adaptive immune 
response to phage, B – adaptive immune response to bacteria. Green arrows represent a 
stimulatory effect; red arrows represent an inhibitory effect. Adapted from Hodyra-Stefaniak 
et al. (2015) with the addition of the anti-inflammatory property of the phage (dotted line). 
Abbreviations are further explained in addendum Table A 1. 
 
The Hodyra-Stefaniak in silico model predicts a successful intervention of phages 
in the removal of a bacterial infection when no interaction occurs between the innate 
immunity and the phages (Figure 9. 2A). Similar outcomes were predicted in an in 
silico model developed by Leung and Weitz (2017). This in silico model also does not 
include a direct interaction of phages with the innate immune response, but hints 
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to the importance of neutrophils in order to remove the remainders of the bacterial 
infection or the occurrence of phage resistant bacteria. The inclusion of the innate 
immunity-representing variable in the Hodyra-Stefaniak in silico model 
(Addendum – Mathematical model) demonstrates that the expected outcome of 
phage therapy could be abrogated by the innate immunity boosted by the bacteria 
(Figure 9. 2B). Moreover, the removal of the phage leads to a second increase in 
bacterial count. Subsequently, the phage therapeutic intervention fails, in contrast 
to phage therapy related data available ( ). According to this model, the 
undesirable effect could be counteracted by adjusting the phage dose or altering the 
timing, as long as the innate immunity is considered (Figure 9. 2D). These in silico 
models could eventually be further optimized, to more closely mimic the 
immunological outcome, by including the innate immune response induced by the 
phage. Whether the phage-induced immune response is dependent on the bacterial 
presence needs to be further evaluated, as such data are limited. 
The Hodyra-Stefaniak and Leung in silico models miss one key feature: the 
interaction of the phage with the innate immune response. This interaction can be 
anti-inflammatory, i.e. a suppression of the immune response, or pro-inflammatory, 
i.e. an increase of the immune response.  
Our results indicate that phages are able to induce innate immune responses and 
more specifically that they have anti-inflammatory properties ( ). Therefore, 
the in silico model of Hodyra-Stefaniak et al. (2015) could be further adapted to 
include an innate component effected by the phages. If the phage has anti-
inflammatory properties, the innate immune response should decrease. This should 
provide the phage with a higher survival rate. Therefore, we suggest to expand the 
equation of the innate immune response (Addendum – mathematical model - 
Equation 3), to include the effect of phages on the innate immune response (XP). We 
propose to divide the initial equation describing the innate immune response (I) into 
two parts (Addendum – Equation 4-9), one part describing the effect of bacteria on 
the innate immune response (XS; Addendum – Equation 4-6) and the other one 
describing the effect of phages on the innate immune response (XP; Addendum – 
Equation 7-9). Furthermore, additional constraints were given to the mathematical 
model. When the phage concentration (P) is larger than the critical phage 
concentration (PC), i.e. the phage concentration needed to induce an anti-
inflammatory response and to reduce the innate immune response, the phage decay 
rate (ϒdP) approaches one.  
Although only limited data are available about the interaction of phages with the 
innate immune response, the modified Hodyra-Stefaniak model more closely 
resembles a real-life outcome, but still forms a hypothetical model. Our adapted 
model thus describes the effect of innate and adaptive immunity on the success or 
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failure of phage antibacterial treatment, taking into account the anti-inflammatory 
nature of the phage (Figure 9. 2C, E, G and I). By including the anti-inflammatory 
property of phages to the innate immunity equation the prediction of the phage 
therapeutic outcome becomes successful again (Figure 9. 2C), in contrary to what 
the initial model predicts (Figure 9. 2B). The phage is able to subdue the innate 
immune response, subverting its rapid removal and hence clears the bacterial 
infection. When a bacterial infection is combated with an initial high phage dose, 
the effects of the innate immune response are negligible (Figure 9. 2D and E). Yet, 
if the phage has anti-inflammatory properties, the bacterial clearance occurs much 
faster. Nevertheless, if anti-phage antibodies are present prior to the phage 
therapeutic intervention, the intervention fails as the phages are rapidly removed 
(Figure 9. 2F and G).  
When no pre-immunization is present, and no anti-inflammatory phage properties 
are taken into account, the removal of the bacterial infection is attributed to the 
adaptive immune response against the bacteria (Figure 9. 2H). Initially the phages 
lead to a reduction of the bacterial count, but are themselves removed by a 
combination of the innate and adaptive immune response towards the phage. This 
leads to a second rise in the bacterial concentration. In a later stage the bacterial 
infection is removed by the adaptive immune response directed against the bacteria, 
hence the clearance of the bacterial infection is not due to the presence of the phage 
but due to the adaptive immune response against the bacteria. When assuming 
anti-inflammatory properties of the phages, the bacterial infection is cleared much 
faster and is attributed to the presence of the phage (Figure 9. 2I). 
The expanded hypothetical model clearly shows that, although the adaptive 
immunity is an important factor in the success or failure of phage antibacterial 
therapy, the anti-inflammatory properties of the phage could explain why the 
treatment of a bacterial infection is successful (Figure 9. 2C and I). Additionally, 
our model predicts that an anti-inflammatory effect of phage is necessary (Figure 
9. 2C and I), otherwise phage therapy could not be successful (Figure 9. 2B and H). 
We can conclude that phages have an effect on the human immune response, but 





Figure 9. 2: Effects of innate and adaptive immunity on the success or failure of 
phage antibacterial treatment, numerical simulations. Innate immune response. 
A| No relation between innate immunity and phage viability. The survival of the 
phage is independent of the presence of an innate immune response. B| Phage 
susceptibility to the innate immune response. The innate immunity has a negative 
effect on the phage survival and leads to its removal. Subsequently the bacteria are no longer 
infected by the phage, and a rise in bacteria is observed. C| Phage susceptibility to the 
innate immune response, taking into account the anti-inflammatory property of 
the phage. The anti-inflammatory characteristic of the phage leads to a decline in innate 
immune particles. This has as effect that the bacterial count diminish and the phage 
survives, similar to A. D| Phage susceptibility to innate immune response 
accommodated and counteracted by an increased phage dose. The higher phage dose 
leads to the removal of the pathogen and the survival of the phage. E| Phage susceptibility 
to innate immune response accommodated and counteracted by an increased 
phage dose, assuming the anti-inflammatory property of the phage. The effect is the 
same as in D, but the innate immune response is diminished. Innate and adaptive immune 
response. F| Phage susceptibility to the innate immune response and presence of 
pre-immunization towards the phage. Presence of pre-existing anti-phage antibodies 
leads to a rapid drop in phage concentration, hence the phages have no effect on the survival 
of the bacteria. Once an adaptive immune response against the bacteria is present, the 
bacterial count decreases. G| Phage susceptibility to the innate immune response and 
no pre-immunization to the phage exists, assuming the anti-inflammatory property 
of the phage. The anti-inflammatory response of the phage has no direct influence on the 
phage survival in the presence of an adaptive immune response against the phage. Overall, 
the response is similar as in F. H| Phage susceptibility to the innate immune response 
and no pre-immunization to the phage exists. The absence of a specific adaptive immune 
response against the phage leads to a decrease in the bacterial population. The combined 
effect of innate and adaptive immunity towards the phage leads to a drop in phage particle 
concentration. I| Phage susceptibility to the innate immune response and no pre-
immunization to the phage exists, assuming the anti-inflammatory property of the 
phage. Once the phage reaches a critical concentration (Pc, the concentration of phages 
needed to induce an anti-inflammatory response), the innate immune response decreases and 
the phage concentration grows until all bacteria are removed. Once an adaptive immune 
response is present against the phage, the phage concentration diminishes until completely 
removed. Variables and parameters used in these models are described in Addendum – 
Mathematical model – Table A1. The Y-axis represents the respective particle concentration 
















With the growing interest in phage therapy, due to the rising prevalence of 
antibiotic resistant bacteria, clinical trials are being set up to evaluate the efficacy 
and safety of this new type of therapeutic intervention (Levy and Marshall, 2004; 
Matsuzaki et al., 2014; Merabishvili et al., 2009; Rhoads et al., 2009; Wright et al., 
2009). Most of these available phage therapy trials primarily address safety issues 
of topically or orally applied phages.  
Phages, as pharmaceuticals, possess unique pharmacokinetics and 
pharmacodynamics that are generally poorly understood (Cooper et al., 2016). To 
further understand these pharmacokinetic and –dynamic properties it is important 
to perform in vivo and in vitro experiments. Furthermore, to perform such studies, 
it is of vital importance that the phage preparations are free of any contaminating 
molecules such as bacterial proteins or endotoxins, released during phage 
production. 
Unpublished data from the Barr lab indicates that phages possess the ability to 
transcytose from the apical-to-basal side of different cell types (i.e. cell lines 
originating from the gut, lung, liver, kidney and brain). This clearly demonstrates 
that phage are able to cross cell layers and provides further evidence into how 
phages are able to interact with the mammalian immune system. 
Endotoxin removal from phage preparations is one of the most important, but also 
highly cumbersome, steps in the use of phages in therapeutic settings. Furthermore, 
the removal of endotoxins is important when studying the effects of phages on 
eukaryotic cells, more specifically; peripheral blood mononuclear cells (PBMCs). 
Recently, several methods have become available for the purification of phage 
preparations, taking into account the removal of endotoxins, such as phage on tap 
(Bonilla et al., 2016). This protocol described a quick and efficient method for the 
preparation of homogenous phage stocks. Unfortunately, this method requires 
specific lab equipment, e.g. speed vacuum to remove residual organic solvent. Our 
results showed a low endotoxin removal efficacy when organic solvent (1-octanol) 
was used, this might be due to differences in the phages used (whereas we used P. 
aeruginosa phages, Bonilla used E. coli phages).  
We evaluated the efficiency of seven different endotoxin purification strategies, (i.e., 
Endotrap HD column purification and/or CsCl density centrifugation in 
combination with Endotrap purification, followed by organic solvent treatment, 
detergent treatment, enzymatic inactivation of the endotoxin using alkaline 
phosphatase, or CIM monolithic anion exchange chromatography) for five different 
phages ( ). Interestingly, large differences 
with regard to initial endotoxin concentrations were observed for the four different 
P. aeruginosa phages, ranging from approximately 104 to 106 EU/ml (Van Belleghem 
et al., 2017a). The removal of endotoxins by CsCl centrifugation leads to an 




endotoxins by additional strategies, such as the use of Endotrap HD, organic 
solvent, Triton-X100, alkaline phosphatase or anion-exchange chromatography 
enables a further reduction of the endotoxin content and a total endotoxin removal 
efficacy of 99.9 %.  
Although we were not able to include the endotoxin content of the original phage 
lysates, our results do show the difficulties related to obtaining endotoxin-free P. 
aeruginosa phage preparations. Even though phages infecting the same bacterial 
host seem similar, they clearly showed different endotoxin removal efficacies. This 
makes it hard to provide a universal strategy for the removal of endotoxins from 
phage preparations, although a combination of strategies might be advised for the 
complete removal of endotoxins. 
Comparing the endotoxin removal efficacy observed in our experiments with those 
described in the literature (which are often less than 102 EU/ml), the difference 
could be explained by the use of different phages. We mainly used P. aeruginosa 
phages whereas others have focused on E. coli phages (Bonilla et al., 2016; 
Boratynski et al., 2004; Szermer-Olearnik and Boratyński, 2015), or used repeated 
purification to obtain low endotoxin concentrations (Dufour et al., 2016). 
For therapeutic purposes, phage titers of 107 – 108 pfu/ml are used (Merabishvili et 
al., 2009). When starting from phage preparations of 1012 pfu/ml, the low endotoxin 
removal efficacy can be supplemented with further diluting the phage preparation. 
In our case this would lead to a further reduction in the endotoxin concentration 
ranging from 0.0002 to 31.6 EU/ml for 107 pfu/ml, which is within the 
therapeutically allowed range of 5 EU/ml/kg/h for therapeutic applications 
(Daneshian et al., 2006). For example, a patient weighing 75 kg can be treated with 
over a six hour period with a 107 pfu/ml phage preparation containing a maximum 
amount of 30 EU/ml. 
For other purposes, such as studying the immune responses induced by phages, 
lower endotoxin concentrations are advised without lowering the phage 
concentration. In case this is not possible, including control conditions with the 
same endotoxin concentration can be included, as was done in . Although 
this might complicate the analysis of the observed immune response, it enables one 
to establish to what extent the immune response is influenced by the residual 
endotoxins. 
It has been demonstrated that the oral uptake of phages by animals results in the 
translocation of phages to systemic tissues (Duerr et al., 2004; Hamzeh-Mivehroud 
et al., 2008; Majewska et al., 2015). This suggests that mammals have mechanisms 
for the uptake and delivery of phages. The resulting contact between systemic 
tissues and phages may allow intestinal phages to elicit innate and adaptive 




Therefor we evaluated the innate immune response induced by five different 
phages, i.e. four infecting P. aeruginosa and one infecting S. aureus. These five 
phages represent the three major phage morphologies: Myoviridae, Podoviridae and 
Siphoviridae. The initial immune responses were observed after 20 h of PBMC 
stimulation. To obtain a more in-dept view of the phage induced immune response, 
time course experiments could be conducted. 
Based on the fact that phages are present everywhere, and translocation of phages 
from the gut to the blood has been shown (Duerr et al., 2004; Hamzeh-Mivehroud 
et al., 2008; Majewska et al., 2015), it is not surprising that they elicit immune 
responses (Figure 8. 6). Moreover, the four P. aeruginosa phages tested have an 
overall comparable induced immune response, which largely corresponds to our 
previously performed transcriptome analysis of PBMCs stimulated with a P. 
aeruginosa phage PNM lysate (Van Belleghem et al., 2017b). Furthermore, the 
immune response induced by the Gram-negative P. aeruginosa phages is similar to 
the one induced by the Gram-positive S. aureus phage ISP. Although small 
differences in the expression of CD14, IL10, TGFBI and LYZ were observed (Figure 
8. 1 and 8. 4), this could be attributed to the difference in host bacteria instead of 
difference in the phage morphology, as the four P. aeruginosa phages belong to 
different phage morphologies.  
The removal of all endotoxins from the P. aeruginosa phages was not possible, 
leaving up to 106 EU/ml present in the phage preparations in the phage lysates. 
Therefore, we compared the immune response induced by the phage lysate and the 
highly purified phage, with the addition of endotoxins in the same concentration as 
present in the phage lysate. We observed that the immune response of the highly 
purified phage with addition of endotoxins did not bring it more closely to that of 
the phage lysate (Figure 8. 3). Furthermore, the addition of endotoxins to a highly 
purified S. aureus phage ISP preparation did not alter the observed immune 
response previously induced by the phage lysate or the highly purified phage 
preparation. 
This indicates that the observed immune response is endotoxin independent for the 
twelve immunity related genes evaluated during our studies. Our results indicate 
that phages can induce an anti-inflammatory response, as clearly shown by the up-
regulation of SOCS3 and IL1RN, which is a known inhibitor of the pro-
inflammatory IL1 response (Arend, 2001). 
Although our study of the phage induced immune response is based on direct gene 
expression and not protein production, our data clearly show that phages are able 
to induce an immune response. In order to further validate these observed response, 




The Hodyra-Stefaniak in silico model, not taking into account the possibility that 
phages might have anti-inflammatory properties, comes to the unexpected 
conclusion that phages would be inactivated by components of either the innate or 
adaptive immune response. This suggest that phages would not contribute to the 
clearing of the bacterial infection. This seems to contradict the well-established 
successes of many therapeutic applications of phages. 
Expanding the Hodyra-Stefaniak in silico model (Hodyra-Stefaniak et al., 2015), 
with the inclusion of the anti-inflammatory property of phages, predicted a 
successful phage therapeutic intervention. Based on the results obtained during 
this PhD thesis, and the mathematical predictions of this model, indicating that a 
reduction on the innate immune response is necessary for the phages to remove a 
bacterial infection, we conclude that phages can interact with the mammalian 
innate immune response and that these interactions have important effects on the 
outcome of a phage therapeutic intervention. These in silico models can be further 
extended to include the occurrence of phage resistant bacterial strains during the 
phage therapeutic intervention, which will significantly affect the predicted 
outcome (Leung and Weitz, 2017). 
Based on the in silico model ( ); our experiments can be further extended to 
include the bacterial host. If it can be further consolidated that phages are able to 
induce anti-inflammatory responses, as our data suggests, this should lead to a 
successful intervention and removal of the bacterial infection. Moreover, could the 
phage induced anti-inflammatory properties influence the survival of the bacteria, 
when phage resistant strains are used? Are phages able to influence the immune 
response in such a way that it affects the bacterial survival? To what extent might 
the anti-inflammatory effect of phages overcome the pro-inflammatory response 
induced by the bacteria? Is this anti-inflammatory response active during the whole 
phage infection or only at certain time points or phage concentration? Could the 
anti-inflammatory properties of the phages dampen the unwanted side effects of an 
overreacting immune response? And could they in this sense reduce tissue damage 
in chronic infections, such as in the case of cystic fibrosis lung infection? 
Answers to these questions should be able to give us a more in-depth view of what 
is occurring during phage therapy and might give us a better understanding why 
certain phage therapeutic interventions are more successful than others. 
Furthermore, separation of the immunological cells after stimulation with the 
phages could provide detailed information into which cells interact with the phages 
and induced the pro- and/or anti-inflammatory properties. 
Whether phages induce a highly comparable overall immune response or whether 
only specific parts of the immune response are similar could be further studied 




should be able to give us a more detailed view of the phage-induced immune 
response. Which time points are predominantly pro-inflammatory and which are 
predominantly anti-inflammatory. Moreover, which phage proteins are responsible 
for these anti-inflammatory responses? By comparing the immune response of a 
large set of phages, it will become possible, based on the phage genomes, to deduce 
the protein(s) responsible for these immune responses. Once these proteins are 
identified, their properties can be exploited to produce new anti-inflammatory drugs 
or to engineer new phages with elevated anti-inflammatory responses to increase 
the success rate of phage therapy. 
It is thus important to gather more data concerning the pharmacodynamics and -
kinetics of phages in an immunological context and further update these in silico 
models so they can be used to predict the outcome of a phage therapeutic 
intervention, such as determining the exact minimal concentration of phages 






Bacteriophages are the most abundant biological entities on Earth with an 
estimated number of up to 1030 particles. Every bacterial cell can potentially harbor 
many phages. These viruses use bacteria as a mean to replicate, almost always 
destroying their prokaryotic host in the process. Current knowledge states that 
phages ignore every cell but the strain of bacteria they have evolved to inhabit. This 
makes them ideal candidates to treat bacterial infections, while being harmless to 
mammalian cells and even non-target bacteria.  
Phages provide a valid alternative to antibiotics. Nevertheless, the effect of phages 
on the human immune response needs to be evaluated. Therefore we need to obtain 
highly purified phage preparations, free of endotoxins. The removal of these 
endotoxins is necessary as they are highly immunogenic (as highlighted in 
) and could influence the induced immune response. For this purpose, we evaluated 
the endotoxin removal efficacy of seven different endotoxin removal strategies, 
described in . These strategies consisted of Endotrap HD column 
purification and/or CsCl density centrifugation in combination with Endotrap 
purification, followed by organic solvent (1-octanol) treatment, detergent (Triton X-
100) treatment, enzymatic inactivation of the endotoxin using alkaline 
phosphatase, or removal of the endotoxin using CIM monolithic anion exchange 
chromatography, carried out for five different phages (i.e. four P. aeruginosa phages 
and one S. aureus phage).  
We showed that CsCl density purification of the P. aeruginosa phages, at an initial 
concentration of 1012 - 1013 pfu/ml, led to the strongest reduction of endotoxins, with 
an endotoxin removal efficacy of up to 99.6 %, whereas additional purification 
methods yielded an additional endotoxin removal efficacy of 23 to 99 % on top of the 
initial purification, although sometimes accompanied with strong losses in phage 
titer. 
Phage biology studies necessitate highly purified phage particles, when used in high 
concentration. Using the highly purified (CsCl density centrifugated, followed by 
Endotrap purification), endotoxin free, phage preparations, described in , 
we were able to study the immune response induced by these phages. 
 describes a transcriptome analysis of freshly isolated peripheral blood 
mononuclear cells (PBMCs), isolated from one healthy individual, stimulated for 20 
h with either a P. aeruginosa phage PNM lysate or its bacterial host P. aeruginosa 
strain 573.  The phage PNM lysate was shown to increase the production of IL10, 
IL6, SOCS1, SOCS3, CXCL2, CXCL3 and CXCL6 and decrease the production of 
LYZ, HLA-DMA, HLA-DMB, HLA-DRB1 and HLA-DRB4, CCL17, CCR1, CCR2 
and CCR5. These results showed that the P. aeruginosa phage PNM lysate possess 
the potential to induce an immune response. 
Further analysis on the potential of phages to induce an immune response was 
obtained by evaluating five different phages (S. aureus phage ISP and four P. 
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aeruginosa phages (i.e. PNM, LUZ19, 14-1 and GE-vB_Pae-Kakheti25)), discussed 
in . By means of specific RT-qPCR assays, we assessed the gene expression 
profile of PBMCs derived from six donors for twelve immunity-related genes (i.e. 
CD14, CXCL1, CXCL5, IL1A, IL1B, IL1RN, IL6, IL10, LYZ, SOCS3, TGFBI and 
TNFA). It was established that the phages were able to induce clear and 
reproducible immune responses.  
First, the five different phages induced a comparable immune response, although 
endotoxins could not be completely removed from the P. aeruginosa phage 
preparations. Second, the observed immune response was largely anti-
inflammatory, indicated by at least a fivefold up-regulation of IL1RN, IL10 and 
SOCS3. Third, the observed immune response was shown to be endotoxin-
independent. Addition of endotoxins to the highly purified phages did not cause an 
immune response comparable to the one induced by the (endotoxin containing) 
phage lysate, but remained similar to that of the initial highly purified phage. 
Using the observations made during these studies, we were able to construct a 
predictive hypothetical model on the outcome of phage therapy based on a previous 
model described by Hodyra-Stefaniak et al. (2015), described in . We 
expanded their initial model with the inclusion of an anti-inflammatory phage. This 
adaptation predicts important consequences on the theoretical outcome of a phage 
therapeutic intervention. Our model showed that when the phage has anti-
inflammatory properties, phage therapy succeeds whereas the initial model showed 










Bacteriofagen, bacteriële virussen, zijn de meest voorkomende biologische 
entiteiten op aarde, met een geschat aantal van 1030 partikels. Elke bacteriële cel 
heeft de mogelijkheid om fagen voort te brengen. Deze virussen gebruiken de 
bacteriën om zich te repliceren. Dit proces heeft als gevolg dat de prokaryote 
gastheer bijna altijd wordt vernietigd. Gebaseerd op de literatuur wordt er in het 
algemeen gezegd dat fagen elke cel negeert buiten de bacteriële stam waarvoor ze 
geëvolueerd zijn om te kunnen infecteren. Dit maakt van hen ideale kandidaten om 
bacteriële infecties te behandelen, terwijl ze onschadelijk zijn voor niet-target 
bacteriën en zelfs eukaryote cellen. 
Fagen vormen een belangrijk alternatief voor antibiotica. Desalniettemin is het 
belangrijk of de interactie van fagen met het humaan immuun systeem te 
evalueren. Daarvoor dienen we zeer zuivere, endotoxine vrije, faagbereidingen te 
bekomen. Het verwijderen van deze endotoxines is noodzakelijk omdat ze sterk 
immunogeen zijn (zoals aangehaald in ) en zouden de geïnduceerde 
immuun respons kunnen beïnvloeden. Voor deze reden hebben we de endotoxine 
verwijderingseffectiviteit van zeven verschillende endotoxine verwijdering 
strategieën geëvalueerd, beschreven in Deze strategieën omvatten een 
Endotrap HD kolom zuivering en/of CsCl densiteit centrifugatie in combinatie met 
Endotrap zuivering, gevolgd door een behandeling met organisch solvent (1-
octanol), detergent (Triton X-100) behandeling, enzymatisch inactiveren van het 
endotoxine door gebruik te maken van alkalisch fosfatase, of een verwijdering van 
endotoxines door gebruik te maken van CIM monolithische anion uitwisseling 
chromatografie, uitgevoerd voor vijf verschillende fagen (i.e. vier P. aeruginosa 
fagen en één S. aureus faag). 
We hebben kunnen aantonen dat CsCl densiteit centrifugatie van P. aeruginosa 
fagen, met een initiële concentratie van 1012 – 1013 pfu/ml, leidde tot de sterkste 
reductie in endotoxine concentratie, met een endotoxine verwijderingseffectiviteit 
van 99.6 %. Additionele zuiveringsmethodes leidde niet tot de volledige 
verwijdering van endotoxines uit de faag bereidingen, en leidde slechts tot een extra 
endotoxine verwijderingseffectiviteit van 23 tot 99 %, dit ging soms gepaard met 
een sterk verlies in faag concentratie. 
Faag biologische studies hebben nood aan hoog zuivere faag partikels in hoge 
concentraties. Gebruikmakend van de hoog zuivere (CsCl ultra gecentrifugeerde, 
Endotrap gezuiverde), endotoxine vrije, faag bereidingen, beschreven in 
, waren we instaat om de immuun respons te bestuderen geïnduceerd door deze 
fagen. 
 beschrijft een transcriptoom analyse van vers geïsoleerde perifere bloed 
mononucleaire cellen (PBMCs), geïsoleerd uit één gezonde individu, gestimuleerd 
voor 20 h met ofwel een P. aeruginosa faag PNM lysaat of zijn bacteriële gastheer 
P. aeruginosa stam 573. De faag PNM lysaat verhoogde de genexpressie van de 
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genen IL10, IL6, SOCS1, SOCS3, CXCL2, CXCL3 en CXCL6 en verlaagde de 
genexpressie van LYZ, HLA-DMA, HLA-DMB, HLA-DRB1, HLA-DRB4, CCL17, 
CCR1, CCR2 en CCR5. Deze resultaten toonde aan dat de P. aeruginosa faag PNM 
lysaat het potentieel bezit om een immuun respons te induceren. 
Verdere analyse in verband met de mogelijkheid van fagen om een immuun respons 
te induceren werd verkregen door vijf verschillende fagen (een S. aureus faag ISP 
en vier P. aeruginosa fagen (i.e. PNM, LUZ19, GE-vB_Pae-Kakheti25 en 14-1)) te 
evalueren, besproken in . Door middel van een specifieke RT-qPCR assay 
bestudeerden we het genexpressie profiel van perifere bloed mononucleaire cellen, 
geïsoleerd uit zes verschillende donoren, voor twaalf immuniteit gerelateerde genen 
(i.e. CD14, CXCL1, CXCL5, IL1A, IL1B, IL1RN, IL6, IL10, LYZ, SOCS3, TGFBI en 
TNFA). Het werd aangetoond dat fagen in staat zijn om een duidelijke en 
reproduceerbare immuun respons te induceren. 
Eerst en vooral, de vijf verschillende fagen induceren een vergelijkbare immuun 
respons, alhoewel alle endotoxines niet volledig verwijderd konden worden uit de P. 
aeruginosa faag bereidingen. Ten tweede, de geobserveerde immuun respons was 
hoofdzakelijk anti-inflammatoir, dit werd aangetoond door een vijfvoudige 
opregulatie van IL1RN, IL10 en SOCS3. Ten derde, er werd aangetoond dat de 
geobserveerde immuun respons endotoxine onafhankelijk was. Het toevoegen van 
endotoxines aan de sterk gezuiverde fagen zorgde er niet voor dat de geobserveerde 
immuun respons sterker lijkt op die van het (endotoxine bevattende) lysaat, maar 
bleef gelijkaardig aan dat van het initieel sterk gezuiverde faag preparaat. 
Gebruikmakende van de observaties gemaakt gedurende deze studies waren we in 
staat een hypothetisch model te generen die de uitkomst van een faag 
therapeutische behandeling kan voorspellen. Dit model is gebaseerd op een eerder 
beschreven model van Hodyra-Stefaniak et al. (2015), beschreven in , 
waarbij we hun model verder hebben uitgebreid om rekening te houden met een 
anti-inflammatoire faag. Deze aanpassing voorspelt belangrijke gevolgen op de 
theoretische uitkomst van een faag therapeutische interventie. Ons model toont aan 
dat, wanneer de fagen anti-inflammatoire eigenschappen hebben, faag therapie 
succesvol is. Het initiële model van Hodyra-Stefaniak daarentegen toonde een falen 










The original mathematical model described by Hodyra-Stefaniak et al. (2015), based 
on models of Levin and Bull (1996, 2004), and Payne and Jansen (2001, 2003) was 
expanded to include the anti-inflammatory properties of phages. The dynamics of 
bacteria, phage, innate and adaptive immunity and their interactions are described 
by differential equations. When the concentration of bacterial cells exceeds the 
threshold SC and resources are unlimited, the concentration of innate system 
particles grows exponentially with a constant rate of aI. When the phage 
concentration exceeds the threshold PC and resources are unlimited, the 
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Table A 2: Differentially expressed genes exclusively present in the phage PNM stimulated 
dataset. Peripheral blood mononuclear cells (PBMCs) derived from one healthy individual 
were stimulated for 20 h with a Pseudomonas aeruginosa phage PNM lysate or its 
corresponding host (P. aeruginosa strain 573). Gene expression was normalized against a 
non-stimulated control condition. Differential gene expression between the P. aeruginosa 
phage PNM and P. aeruginosa strain 573 was compared to identify the genes uniquely 
expressed in the P. aeruginosa phage PNM stimulated dataset. 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
RMRP -4.75 8.07E-06 1.07E-04 
CAMK1 -4.15 5.69E-58 9.10E-56 









MEIS3 -1.79 2.68E-04 2.61E-03 
SPRY2 -1.70 7.87E-10 1.72E-08 
F13A1 -1.64 1.22E-08 2.39E-07 
ADAMTSL4 -1.61 1.03E-08 2.04E-07 
ALCAM -1.57 1.95E-33 1.45E-31 
CABP4 -1.44 2.42E-10 5.49E-09 
ADAM28 -1.41 1.80E-22 8.34E-21 
PCSK6 -1.40 5.67E-04 5.09E-03 
HLA-DMA -1.37 1.68E-28 1.05E-26 
ADAMTS1 -1.30 1.04E-05 1.36E-04 
LOC729041 -1.30 9.65E-04 8.13E-03 
ITGA6 -1.30 1.96E-05 2.44E-04 
NME1 -1.28 7.28E-12 1.87E-10 
FLT3 -1.26 1.72E-04 1.74E-03 
NCR3 -1.25 5.76E-13 1.57E-11 
DENND1B -1.24 1.09E-14 3.35E-13 
NMUR1 -1.24 1.43E-06 2.13E-05 
DHCR24 -1.21 6.55E-19 2.54E-17 
LOC100505746 -1.21 3.36E-22 1.54E-20 
PLCB1 -1.20 1.20E-04 1.26E-03 
ZBED2 -1.16 2.10E-06 3.07E-05 
KCP -1.13 9.02E-04 7.66E-03 
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Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
DGKE -1.12 3.52E-11 8.56E-10 
CTNNBIP1 -1.12 6.95E-08 1.25E-06 
LY86 -1.11 7.98E-04 6.88E-03 
GATM -1.11 3.02E-05 3.64E-04 
RAB37 -1.09 1.17E-13 3.38E-12 
ITGAM -1.08 1.94E-13 5.50E-12 
HLA-DRB1 -1.07 9.18E-19 3.54E-17 
PRSS23 -1.06 4.60E-06 6.30E-05 
FCRL6 -1.05 1.62E-07 2.79E-06 
LPAR6 -1.03 4.11E-15 1.30E-13 
APOL4 -1.02 2.09E-05 2.58E-04 
HLA-DMB -1.02 1.29E-16 4.45E-15 
DLEU1 -1.02 6.86E-04 6.04E-03 
IER5 1.00 9.44E-20 3.82E-18 
FMN1 1.01 1.73E-05 2.17E-04 
LYN 1.01 4.19E-20 1.72E-18 
LONRF3 1.01 5.22E-04 4.72E-03 
STARD8 1.02 5.13E-10 1.14E-08 
RNF169 1.03 8.89E-07 1.37E-05 
LOC730227 1.03 2.54E-04 2.49E-03 
ARHGAP31 1.03 2.91E-17 1.06E-15 
NXPH4 1.03 7.45E-13 2.03E-11 
CXCR6 1.03 1.08E-15 3.51E-14 
MYO1G 1.03 4.43E-12 1.16E-10 
LOC100133445 1.03 4.02E-14 1.20E-12 
C5orf32 1.04 2.43E-15 7.74E-14 
LCP2 1.04 7.36E-21 3.12E-19 
NAB1 1.04 1.70E-11 4.26E-10 
FAM167A 1.05 2.75E-06 3.91E-05 
NFE2L2 1.05 1.10E-20 4.64E-19 
VAC14 1.06 5.43E-20 2.21E-18 
PRR16 1.06 5.55E-04 4.99E-03 
NKD1 1.06 2.74E-08 5.13E-07 
XVI 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
LRRC3 1.06 9.59E-05 1.03E-03 
LILRB1 1.06 3.32E-05 3.96E-04 
ACO1 1.06 8.37E-14 2.44E-12 
LRP12 1.07 1.16E-07 2.03E-06 
ERN1 1.07 4.01E-11 9.70E-10 
CSNK1E 1.07 1.80E-18 6.87E-17 
LYPD3 1.08 2.31E-11 5.70E-10 
KCNG1 1.08 6.59E-04 5.83E-03 
DLGAP3 1.08 3.29E-06 4.62E-05 
MAP7 1.08 9.32E-04 7.88E-03 
MTHFS 1.08 7.81E-07 1.22E-05 
ZSWIM4 1.08 2.26E-14 6.79E-13 
PMEPA1 1.09 2.76E-20 1.14E-18 
SPTBN5 1.10 1.33E-05 1.70E-04 
LRCH3 1.10 2.14E-06 3.12E-05 
NINJ1 1.11 7.40E-24 3.77E-22 
AQP9 1.11 1.26E-23 6.33E-22 
LOC100131532 1.11 1.19E-03 9.75E-03 
ELL 1.11 1.01E-22 4.81E-21 
PPAP2B 1.11 1.88E-11 4.70E-10 
SYN1 1.12 2.07E-11 5.15E-10 
PNKD 1.12 5.85E-21 2.50E-19 
RADIL 1.13 1.10E-03 9.13E-03 
MAP4K4 1.13 1.68E-23 8.43E-22 
HLX 1.13 1.57E-21 6.83E-20 
LOC100130357 1.13 2.40E-06 3.45E-05 
C6orf105 1.14 1.65E-11 4.15E-10 
PPP4R2 1.14 8.58E-11 2.01E-09 
CHST15 1.14 8.95E-23 4.27E-21 
SCG5 1.15 1.28E-04 1.33E-03 
TP53INP2 1.16 7.86E-23 3.77E-21 
MGLL 1.16 1.15E-22 5.45E-21 
PNPLA8 1.16 1.69E-08 3.23E-07 
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Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
DENND5A 1.17 2.38E-25 1.31E-23 
SPSB1 1.17 6.77E-15 2.11E-13 
S100B 1.17 1.56E-04 1.59E-03 
GPR157 1.17 5.31E-05 6.04E-04 
OAF 1.18 7.49E-22 3.36E-20 
CD48 1.18 1.07E-25 5.97E-24 
SLFN5 1.18 3.96E-05 4.63E-04 
C15orf48 1.19 6.66E-23 3.21E-21 
TRIM56 1.19 1.49E-08 2.88E-07 
RN7SL1 1.19 2.18E-04 2.16E-03 
FLJ45445 1.19 5.40E-19 2.11E-17 
PLK3 1.19 1.04E-25 5.81E-24 
RABGEF1 1.20 7.83E-14 2.29E-12 
FAM20A 1.20 4.73E-04 4.33E-03 
TBC1D30 1.20 4.42E-13 1.22E-11 
QPCT 1.21 3.79E-16 1.27E-14 
FAM70B 1.21 1.45E-08 2.80E-07 
AQP6 1.21 4.67E-05 5.40E-04 
ABCA1 1.21 7.91E-25 4.23E-23 
TNNT2 1.21 1.08E-05 1.40E-04 
PANX1 1.21 1.09E-11 2.78E-10 
LGALS3BP 1.21 1.03E-06 1.57E-05 
RASD1 1.22 1.30E-07 2.26E-06 
HELB 1.22 1.13E-04 1.19E-03 
LOC650623 1.22 6.00E-05 6.75E-04 
KIAA0247 1.22 5.80E-28 3.53E-26 
SLC22A15 1.23 7.25E-16 2.38E-14 
STX11 1.23 7.58E-26 4.27E-24 
TNIP1 1.23 2.80E-29 1.82E-27 
SESN2 1.24 1.17E-26 6.79E-25 
SLC16A10 1.24 2.62E-24 1.37E-22 
PTAFR 1.24 9.70E-09 1.93E-07 
WBP5 1.25 6.96E-04 6.11E-03 
XVIII 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
A4GALT 1.26 4.83E-04 4.42E-03 
XKR9 1.26 1.29E-04 1.35E-03 
BTG3 1.26 1.72E-15 5.51E-14 
DLC1 1.27 7.18E-04 6.27E-03 
ABL2 1.27 1.10E-17 4.09E-16 
ATP13A3 1.27 4.13E-30 2.74E-28 
S1PR3 1.27 2.75E-04 2.67E-03 
CDC42EP3 1.28 1.88E-22 8.70E-21 
ELK1 1.28 1.37E-22 6.43E-21 
CEP135 1.28 3.45E-23 1.70E-21 
IRS2 1.28 3.35E-24 1.75E-22 
NEFH 1.28 9.09E-04 7.70E-03 
MAP3K4 1.29 8.50E-28 5.12E-26 
ZP3 1.29 1.31E-08 2.56E-07 
CSDA 1.30 6.64E-29 4.23E-27 
NCRNA00241 1.30 3.28E-04 3.12E-03 
SLC30A4 1.30 1.09E-08 2.14E-07 
CFP 1.30 6.70E-06 8.98E-05 
WLS 1.31 5.63E-06 7.64E-05 
SPRED3 1.31 3.55E-06 4.95E-05 
TJP2 1.32 6.96E-22 3.12E-20 
FMNL2 1.33 2.08E-07 3.53E-06 
MSC 1.33 7.11E-05 7.86E-04 
TBC1D7 1.34 2.48E-17 9.04E-16 
TMEM38B 1.35 4.93E-17 1.76E-15 
DCUN1D3 1.35 6.20E-23 3.01E-21 
PLAGL2 1.36 2.36E-12 6.27E-11 
MN1 1.36 3.12E-22 1.43E-20 
MB21D2 1.36 1.94E-18 7.37E-17 
ANKRD57 1.37 1.84E-23 9.18E-22 
SRC 1.37 3.32E-35 2.61E-33 
TMEM44 1.38 2.79E-19 1.10E-17 
L1CAM 1.38 1.60E-17 5.91E-16 
XIX 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
ITIH1 1.39 5.18E-05 5.92E-04 
RAB31 1.39 1.87E-34 1.44E-32 
IRAK3 1.39 9.11E-30 6.03E-28 
CREG1 1.39 1.72E-14 5.25E-13 
MTF1 1.40 1.25E-33 9.38E-32 
OSGIN2 1.41 2.13E-04 2.12E-03 
ETS2 1.42 2.97E-18 1.13E-16 
KNDC1 1.43 2.88E-05 3.49E-04 
MEFV 1.43 6.06E-05 6.80E-04 
C9orf46 1.43 1.17E-13 3.38E-12 
SMPDL3A 1.43 2.51E-09 5.26E-08 
LILRA1 1.44 2.87E-05 3.47E-04 
GPR137B 1.44 3.01E-33 2.22E-31 
ARL4A 1.45 4.80E-04 4.39E-03 
TSPY26P 1.45 1.19E-04 1.25E-03 
HYDIN2 1.46 5.33E-12 1.38E-10 
MT1H 1.46 1.18E-03 9.70E-03 
LAD1 1.47 8.86E-29 5.62E-27 
ERGIC1 1.48 7.67E-38 6.77E-36 
FLJ34208 1.48 8.45E-10 1.84E-08 
ST6GALNAC2 1.49 7.13E-05 7.87E-04 
FMO5 1.49 8.08E-07 1.26E-05 
CLEC4D 1.50 1.84E-07 3.15E-06 
FNDC3B 1.50 6.84E-32 4.81E-30 
BASP1 1.50 1.78E-41 1.76E-39 
ARHGEF10L 1.50 3.42E-35 2.68E-33 
NANOS3 1.50 5.06E-04 4.60E-03 





C12orf61 1.51 5.60E-07 8.97E-06 
ALPK2 1.52 2.03E-12 5.40E-11 
CPM 1.52 1.20E-15 3.87E-14 
XX 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
SPARC 1.52 4.84E-08 8.80E-07 
CTSH 1.52 1.90E-42 1.99E-40 
PLSCR1 1.53 5.16E-07 8.30E-06 
LPP-AS2 1.53 1.35E-05 1.73E-04 
HCK 1.54 4.62E-44 5.21E-42 
CD82 1.56 1.63E-44 1.87E-42 
UPB1 1.56 4.19E-09 8.66E-08 
KCNH4 1.56 9.08E-07 1.40E-05 
ENTPD7 1.58 1.01E-08 2.00E-07 
MAFA 1.58 7.30E-04 6.36E-03 
DFNA5 1.58 5.83E-16 1.93E-14 
EBLN2 1.59 5.28E-04 4.77E-03 
HTRA3 1.59 1.71E-04 1.73E-03 
C9orf30 1.59 1.54E-33 1.15E-31 
DLEU7 1.60 6.68E-05 7.42E-04 
BAI1 1.60 1.67E-24 8.86E-23 
DNER 1.60 2.37E-35 1.87E-33 
CHI3L1 1.61 7.02E-04 6.16E-03 
CH25H 1.61 1.01E-04 1.08E-03 
PAPSS2 1.62 1.16E-16 3.99E-15 
ARHGEF17 1.62 2.65E-11 6.52E-10 
LY6E 1.63 1.66E-04 1.69E-03 
SEMA3C 1.63 4.90E-15 1.54E-13 
AMPD3 1.63 1.33E-45 1.58E-43 
WNK2 1.64 1.09E-07 1.92E-06 
TRAF3IP2 1.64 8.42E-43 9.06E-41 
VNN3 1.66 5.91E-21 2.51E-19 
LOC200261 1.66 2.52E-08 4.73E-07 
MT1F 1.67 1.18E-16 4.08E-15 
HRH1 1.67 1.82E-17 6.68E-16 
IRF7 1.67 3.59E-07 5.92E-06 
AGRN 1.69 2.88E-31 2.00E-29 
CCRL2 1.69 5.83E-46 7.09E-44 
XXI 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
SLCO4A1 1.71 8.32E-04 7.15E-03 
SMTN 1.72 1.69E-10 3.85E-09 
NAMPT 1.73 2.29E-54 3.35E-52 
KANK1 1.74 6.00E-24 3.06E-22 
SLC2A6 1.75 7.59E-54 1.10E-51 
TGFA 1.76 1.05E-12 2.83E-11 
HMGN2P46 1.77 1.25E-12 3.37E-11 
ZC3H12A 1.77 3.24E-29 2.10E-27 
NLRP3 1.78 4.04E-24 2.08E-22 
ADA 1.78 5.21E-55 7.68E-53 
EHD1 1.79 1.08E-57 1.69E-55 
MYLK 1.80 5.33E-05 6.07E-04 
LDLRAD3 1.83 4.35E-11 1.05E-09 
CDC42EP2 1.86 4.06E-58 6.56E-56 
MCTP1 1.86 1.68E-07 2.89E-06 
TBC1D9 1.87 4.96E-49 6.50E-47 
ZFP92 1.88 5.92E-04 5.28E-03 
P2RY2 1.89 3.97E-07 6.50E-06 
TMEM54 1.90 1.31E-05 1.68E-04 
ZBED3 1.92 3.79E-04 3.54E-03 
NTSR1 1.93 1.37E-12 3.65E-11 
ACSL5 1.94 3.16E-16 1.06E-14 
TM4SF19 1.94 1.11E-15 3.60E-14 
SLC24A4 1.94 4.12E-16 1.38E-14 
MPZL1 1.96 5.48E-23 2.67E-21 
NKX3-1 1.96 5.82E-16 1.92E-14 
C13orf29 1.98 2.41E-06 3.47E-05 
C22orf45 2.00 2.96E-09 6.16E-08 
NR6A1 2.00 2.81E-04 2.72E-03 
SCARF1 2.02 9.46E-22 4.20E-20 
SOCS3 2.02 2.57E-44 2.93E-42 
SPATC1 2.03 2.16E-09 4.56E-08 
PHACTR1 2.06 2.24E-23 1.12E-21 
XXII 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
TBC1D16 2.06 9.10E-07 1.40E-05 
LIF 2.10 3.79E-46 4.67E-44 
PTGIR 2.12 3.67E-52 5.09E-50 
HRH2 2.13 2.37E-05 2.90E-04 
LOC100127888 2.15 5.14E-04 4.66E-03 
EIF2AK2 2.16 3.69E-05 4.36E-04 
FNIP2 2.16 2.79E-57 4.31E-55 
RFX8 2.19 1.21E-10 2.80E-09 
SOD2 2.21 6.80E-22 3.06E-20 
DTX4 2.21 1.52E-05 1.92E-04 
STON2 2.21 1.27E-04 1.33E-03 
MT1G 2.21 3.15E-08 5.85E-07 
STEAP1 2.22 7.91E-06 1.05E-04 
LIMK2 2.23 1.14E-83 3.04E-81 
DUSP1 2.25 4.59E-29 2.94E-27 
LILRA3 2.29 2.23E-05 2.74E-04 
C1orf61 2.29 9.93E-05 1.06E-03 
FFAR2 2.31 1.23E-06 1.87E-05 
BCAT1 2.31 9.30E-80 2.20E-77 
MARCKS 2.34 2.39E-92 7.84E-90 
SIGLEC14 2.34 1.51E-18 5.80E-17 
CASP5 2.35 2.17E-20 8.99E-19 
MT2A 2.35 1.46E-84 3.96E-82 
STC2 2.35 8.13E-13 2.20E-11 
ARNT2 2.37 2.06E-65 3.81E-63 
CXCL3 2.37 1.07E-27 6.41E-26 
TRIM36 2.37 1.43E-15 4.61E-14 
HS3ST3B1 2.37 7.38E-58 1.17E-55 
C19orf59 2.38 2.32E-90 7.24E-88 
DCBLD1 2.41 7.16E-21 3.04E-19 
HBEGF 2.41 1.24E-91 4.00E-89 
MT1E 2.41 1.79E-20 7.43E-19 
CLGN 2.42 1.05E-04 1.12E-03 
XXIII 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
SERPINB2 2.43 3.42E-08 6.32E-07 





ACSL1 2.47 2.14E-98 8.00E-96 
FAM110B 2.54 1.06E-15 3.46E-14 
ADAMTS14 2.55 1.03E-47 1.31E-45 
CDK1 2.55 4.75E-14 1.41E-12 
GPR84 2.56 1.47E-82 3.76E-80 
PLAUR 2.56 4.00E-78 9.02E-76 
WNT5A 2.58 2.84E-23 1.40E-21 
CACNA2D3 2.58 6.61E-06 8.87E-05 
SIAH3 2.59 2.93E-06 4.15E-05 
OSMR 2.59 9.60E-07 1.47E-05 
FAM108C1 2.60 8.78E-36 7.06E-34 





CLEC4E 2.68 6.06E-89 1.77E-86 
CCNE2 2.70 1.21E-05 1.55E-04 
GLIS3 2.73 7.83E-36 6.34E-34 
GUCY1B2 2.74 9.81E-09 1.95E-07 
LRRC38 2.78 5.26E-08 9.54E-07 
BMP6 2.85 3.30E-18 1.25E-16 
PAPLN 2.89 2.40E-47 3.02E-45 
SIGLEC5 2.90 3.25E-37 2.83E-35 
SLC9A7P1 2.93 1.42E-19 5.70E-18 
MT1M 2.95 7.66E-15 2.37E-13 
KL 2.96 1.50E-06 2.24E-05 
CXCL1 2.99 1.98E-11 4.94E-10 
SLC7A7 3.01 3.92E-58 6.39E-56 







Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 
CXCL6 3.09 1.16E-05 1.50E-04 
LOC100652730 3.10 4.19E-08 7.69E-07 
SGIP1 3.19 3.45E-05 4.10E-04 
TRPV4 3.21 3.28E-04 3.12E-03 
FJX1 3.22 1.44E-13 4.12E-12 
GJA1 3.26 1.36E-04 1.40E-03 
CES1 3.31 1.70E-24 8.98E-23 
GPR124 3.35 3.22E-11 7.83E-10 
PNPLA1 3.36 2.14E-39 1.99E-37 
FGF2 3.37 1.68E-08 3.22E-07 
LARP6 3.39 4.11E-29 2.65E-27 





TDRD9 3.43 1.10E-27 6.55E-26 
ZDHHC19 3.51 3.48E-06 4.86E-05 
FAM124A 3.54 1.21E-38 1.10E-36 
SERPIND1 3.58 1.46E-10 3.37E-09 





C3 3.69 3.89E-37 3.37E-35 
DYSF 3.72 1.82E-34 1.40E-32 
SBSN 3.90 1.73E-07 2.96E-06 
SLC24A3 3.92 2.11E-14 6.37E-13 
HAS1 4.00 6.37E-10 1.40E-08 





TNFRSF6B 4.41 4.39E-43 4.78E-41 
DDAH1 4.43 1.40E-04 1.45E-03 
C9orf70 4.58 3.88E-05 4.56E-04 
RETN 4.72 6.23E-23 3.01E-21 
ATOH8 4.78 2.41E-07 4.08E-06 
XXV 
 
Gene symbol log2Ratio 
(P. aeruginosa phage PNM/Control) 
P-value FDR 





IL36B 6.02 6.68E-14 1.96E-12 
CA12 6.34 2.19E-06 3.17E-05 
FLJ36644 12.99 1.10E-03 9.10E-03 
CDC42EP5 13.41 7.10E-04 6.22E-03 

















Abedon, S., and Thomas-Abedon, C. (2010). Phage therapy pharmacology. Curr. Pharm. 
Biotechnol. (11), 28–47. 
Abedon, S.T., Kuhl, S.S.J., Blasdel, B.G.B., and Kutter, E.E.M. (2011). Phage treatment of 
human infections. Bacteriophage (1), 66–85. 
Ackermann, H.-W. (1998). Tailed Bacteriophages: The Order Caudovirales. In Advances in 
Virus Research, pp. 135–201. 
Ackermann, H.W. (2011). Bacteriophage taxonomy. Microbiol. Aust. (32), 90–94. 
Ackermann, H.-W., and DuBow, M.S. (1987). Viruses of Prokaryotes. 
Adams, T.E., Hansen, J.A., Starr, R., Nicola, N.A., Hilton, D.J., and Billestrup, N. (1998). 
Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel 
inhibitor of cytokine receptor signaling. J. Biol. Chem. (273), 1285–1287. 
Aderem, A., and Ulevitch, R.J. (2000). Toll-like receptors in the induction of the innate 
immune response. Nature (406), 782–787. 
Adhya, S., Merril, C.R., and Biswas, B. (2014). Therapeutic and prophylactic applications of 
bacteriophage components in modern medicine. Cold Spring Harb. Perspect. Med. (4), 
a012518. 
Adriaenssens, E.M., Lehman, S.M., Vandersteegen, K., Vandenheuvel, D., Philippe, D.L., 
Cornelissen, A., Clokie, M.R.J., García, A.J., De Proft, M., Maes, M., et al. (2012). CIM(®) 
monolithic anion-exchange chromatography as a useful alternative to CsCl gradient 
purification of bacteriophage particles. Virology (434), 265–270. 
Ahearn, J.M., and Fearon, D.T. (1989). Structure and function of the complement receptors, 
CR1 (CD35) and CR2 (CD21). In Advances in Immunology, pp. 183–219. 
Ahn, V.E., Lo, E.I., Engel, C.K., Chen, L., Hwang, P.M., Kay, L.E., Bishop, R.E., and Privé, 
G.G. (2004). A hydrocarbon ruler measures palmitate in the enzymatic acylation of endotoxin. 
EMBO J. (23), 2931–2941. 
Aida, Y., and Pabst, M.J. (1990). Removal of endotoxin from protein solutions by phase 
separation using triton X-114. J. Immunol. Methods (132), 191–195. 
Akira, S., and Kishimoto, T. (1997). NF-IL6 and NF-kappa B in cytokine gene regulation. 
Adv. Immunol. (65), 1–46. 
Akira, S., and Takeda, K. (2004). Toll-like receptor signalling. Nat. Rev. Immunol. (4), 499–
511. 
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. 
Cell (124), 783–801. 
Aktories, K., and Barbieri, J.T. (2005). Bacterial cytotoxins: targeting eukaryotic switches. 
Nat. Rev. Microbiol. (3), 397–410. 
Alanis, A.J. (2005). Resistance to antibiotics: Are we in the post-antibiotic era?. Arch. Med. 
Res. (36), 697–705. 
XXIX 
 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002). Molecular 
Biology of the Cell, Fourth Edition. 
Alexander, W.S. (2002). Suppressors of cytokine signalling (SOCS) in the immune system. 
Nat. Rev. Immunol. (2), 410–416. 
Alexander, C., and Rietschel, E.T. (2001). Invited review: Bacterial lipopolysaccharides and 
innate immunity. J. Endotoxin Res. (7), 167–202. 
Alexander, W.S., and Hilton, D.J. (2004). The role of suppressors of cytokine signaling (SOCS) 
proteins in regulation of the immune response. Annu. Rev. Immunol. (22), 503–529. 
Alexander, W.S., Starr, R., Fenner, J.E., Scott, C.L., Handman, E., Sprigg, N.S., Corbin, J.E., 
Cornish, A.L., Darwiche, R., Owczarek, C.M., et al. (1999). SOCS1 is a critical inhibitor of 
interferon gamma signaling and prevents the potentially fatal neonatal actions of this 
cytokine. Cell (98), 597–608. 
Alexopoulou, L., Thomas, V., Schnare, M., Lobet, Y., Anguita, J., Schoen, R.T., Medzhitov, 
R., Fikrig, E., and Flavell, R. a (2002). Hyporesponsiveness to vaccination with Borrelia 
burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. (8), 878–
884. 
Aliprantis, A.O. (1999). Cell activation and apoptosis by bacterial lipoproteins through Toll-
like receptor-2. Science (285), 736–739. 
Alisky, J., Iczkowski, K., Rapoport, A., and Troitsky, N. (1998). Bacteriophages show promise 
as antimicrobial agents. J. Infect. (36), 5–15. 
Allen, C.D.C., Okada, T., and Cyster, J.G. (2007). Germinal-center organization and cellular 
dynamics. Immunity (27), 190–202. 
Allen, L., Dockrell, D.H., Pattery, T., Lee, D.G., Cornelis, P., Hellewell, P.G., and Whyte, 
M.K.B. (2005). Pyocyanin production by Pseudomonas aeruginosa induces neutrophil 
apoptosis and impairs neutrophil-mediated host defenses in vivo. J. Immunol. (174), 3643–
3649. 
Aman, M.J., Migone, T.-S., Sasaki, A., Ascherman, D.P., Zhu, M., Soldaini, E., Imada, K., 
Miyajima, A., Yoshimura, A., and Leonard, W.J. (1999). CIS associates with the Interleukin-
2 receptor β chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. (274), 
30266–30272. 
Amitai, G., and Sorek, R. (2016). CRISPR–Cas adaptation: insights into the mechanism of 
action. Nat. Rev. Microbiol. (advance on), 1–10. 
An, T.-W., Kim, S.-J., Lee, Y.-D., Park, J.-H., and Chang, H.-I. (2014). The immune-enhancing 
effect of the Cronobacter sakazakii ES2 phage results in the activation of nuclear factor-κB 
and dendritic cell maturation via the activation of IL-12p40 in the mouse bone marrow. 
Immunol. Lett. (157), 1–8. 
Anspach, F.B. (2001). Endotoxin removal by affinity sorbents. J. Biochem. Biophys. 
Methods (49), 665–681. 
XXX 
 
Arend, W.P. (2001). Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role 
of interleukin-1 receptor antagonist. Semin. Arthritis Rheum. (30), 1–6. 
Armstrong, P.B., and Rickles, F.R. (1982). Endotoxin-induced degranulation of the Limulus 
amebocyte. Exp. Cell Res. (140), 15–24. 
Arnold, C.E., Whyte, C.S., Gordon, P., Barker, R.N., Rees, A.J., and Wilson, H.M. (2014). A 
critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation 
and function in vitro and in vivo. Immunology (141), 96–110. 
Arthur, M., and Courvalin, P. (1993). Genetics and mechanisms of glycopeptide resistance in 
enterococci. Antimicrob. Agents Chemother. (37), 1563–1571. 
Audic, S., and Claverie, J.M. (1997). The significance of digital gene expression profiles. 
Genome Res. (7), 986–995. 
Auernhammer, C.J., and Melmed, S. (1999). Interleukin-11 stimulates proopiomelanocortin 
gene expression and adrenocorticotropin secretion in corticotroph cells: Evidence for a 
redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology 
(140), 1559–1566. 
Auernhammer, C.J., Chesnokova, V., Bousquet, C., and Melmed, S. (1998). Pituitary 
corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated 
proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol. Endocrinol. 
(12), 954–961. 
Auernhammer, C.J., Bousquet, C., and Melmed, S. (1999). Autoregulation of pituitary 
corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. 
Natl. Acad. Sci. (96), 6964–6969. 
Babinski, K.J., Kanjilal, S.J., and Raetz, C.R.H. (2002a). Accumulation of the lipid A 
precursor UDP-2,3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene. 
J. Biol. Chem. (277), 25947–25956. 
Babinski, K.J., Ribeiro, A.A., and Raetz, C.R.H. (2002b). The Escherichia coli gene encoding 
the UDP-2,3-diacylglucosamine pyrophosphatase of lipid A biosynthesis. J. Biol. Chem. 
(277), 25937–25946. 
Bacon, E.J., Richmond, S.J., Wood, D.J., Stirling, P., Bevan, B.J., and Chalmers, W.S. (1986). 
Serological detection of phage infection in Chlamydia psittaci recovered from ducks. Vet. Rec. 
(119), 618–620. 
Baggiolini, M., Dewald, B., and Moser, B. (1997). Human chemokines - an update. Annu. 
Rev. Immunol. (15), 675–705. 
Barb, A.W., Jiang, L., Raetz, C.R.H., and Zhou, P. (2007). Structure of the deacetylase LpxC 
bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand 
binding. Proc. Natl. Acad. Sci. (104), 18433–18438. 
Bardwell, P.D., Martin, A., Wong, E., Li, Z., Edelmann, W., and Scharff, M.D. (2003). Cutting 
edge: the G-U mismatch glycosylase methyl-CpG binding domain 4 is dispensable for somatic 
hypermutation and class switch recombination. J. Immunol. (170), 1620–1624. 
XXXI 
 
Barfoot, R., Denham, S., Gyure, L.A., Hall, J.G., Hobbs, S.M., Jackson, L.E., and Robertson, 
D. (1989). Some properties of dendritic macrophages from peripheral lymph. Immunology 
(68), 233–239. 
Barksdale, L., and Arden, S.B. (1974). Persisting bacteriophage infections, lysogeny, and 
phage conversions. Annu. Rev. Microbiol. (28), 265–299. 
Barnes, D.E., and Lindahl, T. (2004). Repair and genetic consequences of endogenous DNA 
base damage in mammalian cells. Annu. Rev. Genet. (38), 445–476. 
Barnich, N., Aguirre, J.E., Reinecker, H.-C., Xavier, R., and Podolsky, D.K. (2005). Membrane 
recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor–κB activation 
in muramyl dipeptide recognition. J. Cell Biol. (170), 21–26. 
Barr, J.J., Auro, R., Furlan, M., Whiteson, K.L., Erb, M.L., Pogliano, J., Stotland, A., 
Wolkowicz, R., Cutting, A.S., Doran, K.S., et al. (2013). Bacteriophage adhering to mucus 
provide a non-host-derived immunity. Proc. Natl. Acad. Sci. (110), 10771–10776. 
Barr, J.J., Auro, R., Sam-Soon, N., Kassegne, S., Peters, G., Bonilla, N., Hatay, M., Mourtada, 
S., Bailey, B., Youle, M., et al. (2015). Subdiffusive motion of bacteriophage in mucosal 
surfaces increases the frequency of bacterial encounters. Proc. Natl. Acad. Sci. (112), 13675–
13680. 
Barton, B.E. (1997). IL-6: insights into novel biological activities. Clin. Immunol. 
Immunopathol. (85), 16–20. 
Barton, G.M., and Medzhitov, R. (2002). Control of adaptive immune responses by Toll-like 
receptors. Curr. Opin. Immunol. (14), 380–383. 
Barton, B.E., Shortall, J., and Jackson, J. V (1996). Interleukins 6 and 11 protect mice from 
mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect. Immun. (64), 
714–718. 
Batista, F.D., and Harwood, N.E. (2009). The who, how and where of antigen presentation to 
B cells. Nat. Rev. Immunol. (9), 15–27. 
Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.R., Zlotnik, 
A., and Schall, T.J. (1997). A new class of membrane-bound chemokine with a CX3C motif. 
Nature (385), 640–644. 
Beard, W.A., and Wilson, S.H. (2006). Structure and mechanism of DNA polymerase β. Chem. 
Rev. (106), 361–382. 
Bébéar, C.M., and Pereyre, S. (2005). Mechanisms of drug resistance in Mycoplasma 
pneumoniae. Curr. Drug Targets. Infect. Disord. (5), 263–271. 
Belvin, M.P., and Anderson, K. V. (1996). A conserved signaling pathway: the Drosophila toll-
dorsal pathway. Annu. Rev. Cell Dev. Biol. (12), 393–416. 
Ben-Baruch, A. (2008). Organ selectivity in metastasis: Regulation by chemokines and their 
receptors. Clin. Exp. Metastasis (25), 345–356. 
XXXII 
 
Bendelac, A., Lantz, O., Quimby, M.E., Yewdell, J.W., Bennink, J.R., and Brutkiewicz, R.R. 
(1995). CD1 recognition by mouse NK1+ T lymphocytes. Science (268), 863–865. 
Bentala, H., Verweij, W.R., Huizinga-Van der Vlag, A., van Loenen-Weemaes, A.M., Meijer, 
D.K.F., and Poelstra, K. (2002). Removal of phosphate from lipid A as a strategy to detoxify 
lipopolysaccharide. Shock (18), 561–566. 
Bérard, S., Chateau, A., Pompidor, N., Guertin, P., Bergeron, A., and Swenson, K.M. (2016). 
Aligning the unalignable: bacteriophage whole genome alignments. BMC Bioinformatics 
(17), 30. 
Berger-Bächi, B. (1994). Expression of resistance to methicillin. Trends Microbiol. (2), 389–
393. 
Berlato, C., Cassatella, M. a., Kinjyo, I., Gatto, L., Yoshimura, A., and Bazzoni, F. (2002). 
Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-
10 on lipopolysaccharide-induced macrophage activation. J. Immunol. (168), 6404–6411. 
Bernad, A., Kopf, M., Kulbacki, R., Weich, N., Koehler, G., and Gutierrez-Ramos, J.C. (1994). 
Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of 
the hematopoietic system. Immunity (1), 725–731. 
Berthold, W., and Walter, J. (1994). Protein purification: aspects of processes for 
pharmaceutical products. Biologicals (22), 135–150. 
Bertin, A., de Frutos, M., and Letellier, L. (2011). Bacteriophage–host interactions leading to 
genome internalization. Curr. Opin. Microbiol. (14), 492–496. 
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and 
Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of pathogenic 
effector TH17 and regulatory T cells. Nature (441), 235–238. 
Beutler, B. (2004). Inferences, questions and possibilities in Toll-like receptor signalling. 
Nature (430), 257–263. 
Bieback, K., Lien, E., Klagge, I.M., Avota, E., Schneider-Schaulies, J., Duprex, W.P., Wagner, 
H., Kirschning, C.J., ter Meulen, V., and Schneider-Schaulies, S. (2002). Hemagglutinin 
protein of wild-type measles virus activates Toll-like receptor 2 signaling. J. Virol. (76), 8729–
8736. 
Bishop, R.E. (2008). Structural biology of membrane-intrinsic β-barrel enzymes: Sentinels of 
the bacterial outer membrane. Biochim. Biophys. Acta - Biomembr. (1778), 1881–1896. 
Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., Carlton, R., and Merril, 
C.R. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of 
vancomycin-resistant Enterococcus faecium. Infect. Immun. (70), 204–210. 
Bjørbaek, C., Elmquist, J.K., Frantz, J.D., Shoelson, S.E., and Flier, J.S. (1998). 
Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell (1), 
619–625. 
Bjørbæk, C., Elmquist, J.K., El-Haschimi, K., Kelly, J., Ahima, R.S., Hileman, S., and Flier, 
XXXIII 
 
J.S. (1999). Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary 
neurotrophic factor. Endocrinology (140), 2035–2043. 
Bjorkman, P.J. (1997). MHC restriction in three dimensions: A view of T cell receptor/ligand 
interactions. Cell (89), 167–170. 
Blasius, A.L., and Beutler, B. (2010). Intracellular Toll-like receptors. Immunity (32), 305–
315. 
Bloch, H. (1940). Experimental investigation of the relationship between bacteriophage and 
malignant tumors. Arch. Gesamte. Virusforsch. (1), 481–496. 
von Boehmer, H., Kisielow, P., Kishi, H., Scott, B., Borgulya, P., and Teh, H.S. (1989). The 
expression of CD4 and CD8 accessory molecules on mature T cells is not random but correlates 
with the specificity of the alpha beta receptor for antigen. Immunol. Rev. (109), 143–151. 
Bohach, G.A., Fast, D.J., Nelson, R.D., and Schlievert, P.M. (1990). Staphylococcal and 
streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. 
Rev. Microbiol. (17), 251–272. 
Boisclair, Y.R., Wang, J., Shi, J., Hurst, K.R., and Ooi, G.T. (2000). Role of the suppressor of 
cytokine signaling-3 in mediating the inhibitory effects of Interleukin-1β on the growth 
hormone-dependent transcription of the acid-labile subunit gene in liver cells. J. Biol. Chem. 
(275), 3841–3847. 
Bonilla, F.A., and Oettgen, H.C. (2010). Adaptive immunity. J. Allergy Clin. Immunol. 
(125), S33–S40. 
Bonilla, N., Rojas, M.I., Netto Flores Cruz, G., Hung, S., Rohwer, F., and Barr, J.J. (2016). 
Phage on tap–a quick and efficient protocol for the preparation of bacteriophage laboratory 
stocks. PeerJ (4), e2261. 
Bonten, M.J.M., Bergmans, D.C.J.J., Speijer, H., and Stobberingh, E.E. (1999). 
Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive 
care units: Implications for infection control. Am. J. Respir. Crit. Care Med. (160), 1212–
1219. 
Boratynski, J., Danuta, S., Weber-Dąbrowska, B., Lusiak-Szelachowska, M., Pozniak, G., and 
Gorski, A. (2004). Preperations of endotoxin-free bacteriophages. Cell. Mol. Biol. Lett. (9), 
253–259. 
Bordier, C. (1981). Phase separation of integral membrane proteins in Triton X-114 solution. 
J. Biol. Chem. (256), 1604–1607. 
Børsheim, K. (1993). Native marine bacteriophages. FEMS Microbiol. Lett. (102), 141–159. 
Bourette, R.P., De Sepulveda, P., Arnaud, S., Dubreuil, P., Rottapel, R., and Mouchiroud, G. 
(2001). Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating 
factor receptor and negatively regulates its proliferation signal. J. Biol. Chem. (276), 22133–
22139. 
Bowie, A., and O’Neill, L.A. (2000). The interleukin-1 receptor/Toll-like receptor superfamily: 
XXXIV 
 
signal generators for pro-inflammatory interleukins and microbial products. J. Leukoc. 
Biol. (67), 508–514. 
Bowie, A.G., and Haga, I.R. (2005). The role of Toll-like receptors in the host response to 
viruses. Mol. Immunol. (42), 859–867. 
Bradley, D.E. (1967). Ultrastructure of bacteriophage and bacteriocins. Bacteriol. Rev. (31), 
230–314. 
Brandenburg, K., and Wiese, A. (2004). Endotoxins: relationships between structure, function, 
and activity. 1127–1146. 
Brandtzaeg, P., Osnes, L., Ovstebo, R., Joo, G.B., Westvik, A.B., and Kierulf, P. (1996). Net 
inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target 
cell assay: identification of interleukin-10 as a major functional deactivator of human 
monocytes. J. Exp. Med. (184), 51–60. 
Breidenstein, E.B.M., de la Fuente-Núñez, C., and Hancock, R.E.W. (2011). Pseudomonas 
aeruginosa: All roads lead to resistance. Trends Microbiol. (19), 419–426. 
Breitbart, M., Haynes, M., Kelley, S., Angly, F., Edwards, R.A., Felts, B., Mahaffy, J.M., 
Mueller, J., Nulton, J., Rayhawk, S., et al. (2008). Viral diversity and dynamics in an infant 
gut. Res. Microbiol. (159), 367–373. 
Brightbill, H.D. (1999). Host defense mechanisms triggered by microbial lipoproteins through 
Toll-like receptors. Science (285), 732–736. 
Brigl, M., and Brenner, M.B. (2004). CD1: antigen presentation and T cell function. Annu 
Rev Immunol (22), 817–890. 
Brisson-Noël, A., Trieu-Cuot, P., and Courvalin, P. (1988). Mechanism of action of spiramycin 
and other macrolides. J. Antimicrob. Chemother. (22 Suppl B), 13–23. 
Brown, M.A., and Hural, J. (1997). Functions of IL-4 and control of its expression. Crit. Rev. 
Immunol. (17), 1–32. 
Brozek, K.A., and Raetz, C.R.H. (1990). Biosynthesis of lipid A in Escherichia coli: Acyl carrier 
protein-dependent incorporation of laurate and myristate. J. Biol. Chem. (265), 15410–
15417. 
Brozek, K.A., Hosaka, K., Robertson, A.D., and Raetz, C.R.H. (1989). Biosynthesis of 
lipopolysaccharide in Escherichia coli. Cytoplasmic enzymes that attach 3-deoxy-D-manno-
octulosonic acid to lipid A. J. Biol. Chem. (264), 6956–6966. 
Brühl, H., Cihak, J., Schneider, M.A., Plachý, J., Rupp, T., Wenzel, I., Shakarami, M., Milz, 
S., Ellwart, J.W., Stangassinger, M., et al. (2004). Dual role of CCR2 during initiation and 
progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. 
Immunol. (172), 890–898. 
Bruttin, A., and Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 
orally: a safety test of phage therapy. Antimicrob. Agents Chemother. (49), 2874–2878. 
XXXV 
 
Buetow, L., Smith, T.K., Dawson, A., Fyffe, S., and Hunter, W.N. (2007). Structure and 
reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis. Proc. Natl. Acad. Sci. (104), 
4321–4326. 
Buttimer, C., Hendrix, H., Oliveira, H.A.M., Casey, A., Neve, H., McAuliffe, O., Ross, R.P., 
Hill, C., Noben, J.-P., and O’Mahony, J. (2017). Things are getting hairy: Enterobacteria 
bacteriophage vB_PcaM_CBB. Front. Microbiol. (8), 44. 
Cacalano, N.A., Sanden, D., and Johnston, J.A. (2001). Tyrosine-phosphorylated SOCS-3 
inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat. Cell Biol. (3), 
460–465. 
Cadwell, K. (2015). The virome in host health and disease. Immunity (42), 805–813. 
Cairns, B.J., Timms, A.R., Jansen, V. a a, Connerton, I.F., and Payne, R.J.H. (2009). 
Quantitative Models of In Vitro Bacteriophage–Host Dynamics and Their Application to 
Phage Therapy. PLoS Pathog. (5), e1000253. 
Calis, J.J.A., and Rosenberg, B.R. (2014). Characterizing immune repertoires by high 
throughput sequencing: Strategies and applications. Trends Immunol. (35), 581–590. 
Calzascia, T., Masson, F., Di Berardino-Besson, W., Contassot, E., Wilmotte, R., Aurrand-
Lions, M., Rüegg, C., Dietrich, P.Y., and Walker, P.R. (2005). Homing phenotypes of tumor-
specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 
(22), 175–184. 
Campos, M.A.S., Almeida, I.C., Takeuchi, O., Akira, S., Valente, E.P., Procopio, D.O., 
Travassos, L.R., Smith, J.A., Golenbock, D.T., and Gazzinelli, R.T. (2001). Activation of Toll-
like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. 
Immunol. (167), 416–423. 
Cannon, J.G. (2000). Inflammatory cytokines in nonpathological states. News Physiol. Sci. 
(15), 298–303. 
Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. V (1996). TRAF6 is a signal 
transducer for interleukin-1. Nature (383), 443–446. 
Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., and Iannelli, D. (2007). Experimental 
phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 
(51), 2765–2773. 
Carlton, R.M. (1999). Phage therapy: past history and future prospects. Arch. Immunol. 
Ther. Exp. (Warsz). (47), 267–274. 
Carroll, M.C. (2000). A protective role for innate immunity in autoimmune disease. Clin. 
Immunol. (95), S30–S38. 
Cassatella, M.A., Gasperini, S., Bovolenta, C., Calzetti, F., Vollebregt, M., Scapini, P., 
Marchi, M., Suzuki, R., Suzuki, A., and Yoshimura, A. (1999). Interleukin-10 (IL-10) 
selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an 




Ceyssens, P.-J., Miroshnikov, K., Mattheus, W., Krylov, V., Robben, J., Noben, J.-P., 
Vanderschraeghe, S., Sykilinda, N., Kropinski, A.M., Volckaert, G., et al. (2009). Comparative 
analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. 
Environ. Microbiol. (11), 2874–2883. 
Chamaillard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L., Ogura, Y., 
Kawasaki, A., Fukase, K., Kusumoto, S., et al. (2003). An essential role for NOD1 in host 
recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. (4), 
702–707. 
Chambers, H.F. (1997). Methicillin resistance in staphylococci: molecular and biochemical 
basis and clinical implications. Clin. Microbiol. Rev. (10), 781–791. 
Chambers, H.F., and Deleo, F.R. (2009). Waves of resistance: Staphylococcus aureus in the 
antibiotic era. Nat. Rev. Microbiol. (7), 629–641. 
Chan, B.K., and Abedon, S.T. (2012). Phage therapy pharmacology. Phage cocktails. Adv. 
Appl. Microbiol. (78), 1–23. 
Chaplin, D.D. (2010). Overview of the immune response. J. Allergy Clin. Immunol. (125), 
S3–S23. 
Charo, I. (2004). CCR2: from cloning to the creation of knockout mice. Chem. Immunol. (72), 
30–41. 
Charo, I.F., and Peters, W. (2003). Chemokine receptor 2 (CCR2) in atherosclerosis, infectious 
diseases, and regulation of T-cell polarization. Microcirculation (10), 259–264. 
Charo, I.F., and Ransohoff, R.M. (2006). The many roles of chemokines and chemokine 
receptors in inflammation. N. Engl. J. Med. (354), 610–621. 
Chaudhuri, J., Tian, M., Khuong, C., Chua, K., Pinaud, E., and Alt, F.W. (2003). 
Transcription-targeted DNA deamination by the AID antibody diversification enzyme. 
Nature (422), 726–730. 
Chen, C.-M., Huang, M., Chen, H.-F., Ke, S.-C., Li, C.-R., Wang, J.-H., and Wu, L.-T. (2011). 
Fusidic acid resistance among clinical isolates of methicillin-resistant Staphylococcus aureus 
in a Taiwanese hospital. BMC Microbiol. (11), 98. 
Cherukuri, A., Shoham, T., Sohn, H.W., Levy, S., Brooks, S., Carter, R., and Pierce, S.K. 
(2004). The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell 
antigen receptor complexes into signaling-active lipid rafts. J. Immunol. (172), 370–380. 
Chicz, R.M., Urban, R.G., Gorga, J.C., Vignali, D.A., Lane, W.S., and Strominger, J.L. (1993). 
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. 
Exp. Med. (178), 27–47. 
Chopra, I., and Roberts, M. (2001). Tetracycline antibiotics: Mode of action, applications, 
molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. (65), 
232–260. 
Christmann, M., Tomicic, M.T., Roos, W.P., and Kaina, B. (2003). Mechanisms of human DNA 
XXXVII 
 
repair: an update. Toxicology (193), 3–34. 
Clarke, C.J.P., Hales, A., Hunt, A., and Foxwell, B.M.J. (1998). IL-10-mediated suppression 
of TNF-α production is independent of its ability to inhibit NFκB activity. Eur. J. Immunol. 
(28), 1719–1726. 
Cohney, S.J., Sanden, D., Cacalano, N.A., Yoshimura, A., Mui, A., Migone, T.S., and 
Johnston, J.A. (1999). SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and 
suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell. Biol. (19), 
4980–4988. 
Compton, T., Kurt-Jones, E. a., Boehme, K.W., Belko, J., Latz, E., Golenbock, D.T., and 
Finberg, R.W. (2003). Human cytomegalovirus activates inflammatory cytokine responses via 
CD14 and Toll-like receptor 2. J. Virol. (77), 4588–4596. 
Cone, R.A. (2009). Barrier properties of mucus. Adv. Drug Deliv. Rev. (61), 75–85. 
Cook, D.N., Prosser, D.M., Forster, R., Zhang, J., Kuklin, N.A., Abbondanzo, S.J., Niu, X.D., 
Chen, S.C., Manfra, D.J., Wiekowski, M.T., et al. (2000). CCR6 mediates dendritic cell 
localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 
(12), 495–503. 
Cooper, C.J., Denyer, S.P., and Maillard, J.-Y. (2014). Stability and purity of a bacteriophage 
cocktail preparation for nebulizer delivery. Lett. Appl. Microbiol. (58), 118–122. 
Cooper, C.J., Khan Mirzaei, M., and Nilsson, A.S. (2016). Adapting drug approval pathways 
for bacteriophage-based therapeutics. Front. Microbiol. (7), 1–15. 
Cornett, J.B., and Wentland, M.P. (1986). Quinolone antibacterial agents. In 
Comprehensive Medicinal Chemistry II, (Chichester, UK: John Wiley & Sons, Ltd), 
pp. 139–148. 
Council of Europe. (1997). European pharmacopoeia. (Strasbourg: Council of Europe). 
Cox, G., and Wright, G.D. (2013). Intrinsic antibiotic resistance: Mechanisms, origins, 
challenges and solutions. Int. J. Med. Microbiol. (303), 287–292. 
Craig, L., Pique, M.E., and Tainer, J.A. (2004). Type IV pilus structure and bacterial 
pathogenicity. Nat. Rev. Microbiol. (2), 363–378. 
Cresswell, P., Bangia, N., Dick, T., and Diedrich, G. (1999). The nature of the MHC class I 
peptide loading complex. Immunol. Rev. (172), 21–28. 
Croker, B. a, Krebs, D.L., Zhang, J.-G., Wormald, S., Willson, T. a, Stanley, E.G., Robb, L., 
Greenhalgh, C.J., Förster, I., Clausen, B.E., et al. (2003). SOCS3 negatively regulates IL-6 
signaling in vivo. Nat. Immunol. (4), 540–545. 
Crowell, D.N., Anderson, M.S., and Raetz, C.R.H. (1986). Molecular cloning of the genes for 
lipid A disaccharide synthase and UDP-N-acetylglucosamine acyltransferase in Escherichia 
coli. J. Bacteriol. (168), 152–159. 
Crowell, D.N., Reznikoff, W.S., and Raetz, C.R.H. (1987). Nucleotide sequence of the 
XXXVIII 
 
Escherichia coli gene for lipid A disaccharide synthase. J. Bacteriol. (169), 5727–5734. 
Cyster, J.G. (1999). Chemokines and cell migration in secondary lymphoid organs. Science 
(286), 2098–2102. 
Cyster, J.G. (2003). Lymphoid organ development and cell migration. Immunol. Rev. (195), 
5–14. 
Cyster, J., Ngo, V., Ekland, E., Gunn, M., Sedgwick, J., and Ansel, K. (1999). Chemokines 
and B-cell homing to follicles. Curr. Top. Microbiol. Immunol. (246), 87–92. 
da Silva Correia, J., Soldau, K., Christen, U., Tobias, P.S., and Ulevitch, R.J. (2001). 
Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor 
complex. J. Biol. Chem. (276), 21129–21135. 
Dąbrowska, K., Opolski, A., Wietrzyk, J., Switala-Jelen, K., Boratynski, J., Nasulewicz, A., 
Lipinska, L., Chybicka, A., Kujawa, M., Zabel, M., et al. (2004). Antitumor activity of 
bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 
integrin signaling pathway. Acta Virol. (48), 241–248. 
Dąbrowska, K., Switala-Jelen, K., Opolski, A., Weber-Dąbrowska, B., and Gorski, A. (2005). 
Bacteriophage penetration in vertebrates. J. Appl. Microbiol. (98), 7–13. 
Dąbrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., Ka 
mierczak, Z., Letarov, A., and Gorski, A. (2014a). Immunogenicity studies of Proteins Forming 
the T4 Phage Head Surface. J. Virol. (88), 12551–12557. 
Dąbrowska, K., Miedzybrodzki, R., Miernikiewicz, P., Figura, G., and Gorski, A. (2014b). 
Phage Therapy: Current Research and Applications. 
Dahl, M.R., Thiel, S., Matsushita, M., Fujita, T., Willis, A.C., Christensen, T., Vorup-Jensen, 
T., and Jensenius, J.C. (2001). MASP-3 and its association with distinct complexes of the 
mannan-binding lectin complement activation pathway. Immunity (15), 127–135. 
Daly, C., and Rollins, B.J. (2003). Monocyte chemoattractant protein-1 (CCL2) in 
inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. 
Microcirculation (10), 247–257. 
Daneshian, M., Guenther, A., Wendel, A., Hartung, T., and von Aulock, S. (2006). In vitro 
pyrogen test for toxic or immunomodulatory drugs. J. Immunol. Methods (313), 169–175. 
Davies, J. (1994). Inactivation of antibiotics and the dissemination of resistance genes. 
Science (264), 375–382. 
Davies, J.E. (2007). Origins, acquisition and dissemination of antibiotic resistance 
determinants. In Ciba Foundation Symposium 207 - Antibiotic Resistance: Origins, 
Evolution, Selection and Spread, pp. 15–35. 
Davis, M.M., and Bjorkman, P.J. (1988). T-cell antigen receptor genes and T-cell recognition. 
Nature (334), 395–402. 
de Oliveira Magalhães, P., Lopes, A.M., Mazzola, P.G., Rangel-Yagui, C., Penna, T.C. V, and 
XXXIX 
 
Pessoa, A. (2007). Methods of endotoxin removal from biological preparations: A review. J. 
Pharm. Pharm. Sci. (10), 388–404. 
De Sepulveda, P., Okkenhaug, K., La Rose, J., Hawley, R.G., Dubreuil, P., and Rottapel, R. 
(1999). Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent 
proliferation. EMBO J. (18), 904–915. 
Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Balloy, V., and 
Touqui, L. (2010). Bacteriophages can treat and prevent Pseudomonas aeruginosa lung 
infections. J. Infect. Dis. (201), 1096–1104. 
Debarbieux, L., Pirnay, J.P., Verbeken, G., De Vos, D., Merabishvili, M., Huys, I., Patey, O., 
Schoonjans, D., Vaneechoutte, M., Zizi, M., et al. (2016). A bacteriophage journey at the 
European Medicines Agency. FEMS Microbiol. Lett. (363), fnv225. 
Deenick, E.K., Hasbold, J., and Hodgkin, P.D. (1999). Switching to IgG3, IgG2b, and IgA is 
division linked and independent, revealing a stochastic framework for describing 
differentiation. J. Immunol. (163), 4707–4714. 
Demuth, J., Neve, H., and Witzel, K.P. (1993). Direct electron microscopy study on the 
morphological diversity of bacteriophage populations in Lake Plusssee. Appl. Env. 
Microbiol. (59), 3378–3384. 
Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C., and 
Chen, Z.J. (2000). Activation of the IκB kinase complex by TRAF6 requires a dimeric 
ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (103), 351–
361. 
Dengjel, J., Schoor, O., Fischer, R., Reich, M., Kraus, M., Müller, M., Kreymborg, K., 
Altenberend, F., Brandenburg, J., Kalbacher, H., et al. (2005). Autophagy promotes MHC 
class II presentation of peptides from intracellular source proteins. Proc. Natl. Acad. Sci. 
(102), 7922–7927. 
Denning, G.M., Wollenweber, L.A., Railsback, M.A., Cox, C.D., Stoll, L.L., and Britigan, B.E. 
(1998). Pseudomonas pyocyanin increases interleukin-8 expression by human airway 
epithelial cells. Infect. Immun. (66), 5777–5784. 
Deplano, A., Denis, O., Poirel, L., Hocquet, D., Nonhoff, C., Byl, B., Nordmann, P., Vincent, 
J.L., and Struelens, M.J. (2005). Molecular characterization of an epidemic clone of 
panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. (43), 1198–1204. 
Destoumieux-Garzón, D., Duquesne, S., Peduzzi, J., Goulard, C., Desmadril, M., Letellier, L., 
Rebuffat, S., and Boulanger, P. (2005). The iron–siderophore transporter FhuA is the receptor 
for the antimicrobial peptide microcin J25: role of the microcin Val 11 –Pro 16 β-hairpin 
region in the recognition mechanism. Biochem. J. (389), 869–876. 
Di Giovine, M., Salone, B., Martina, Y., Amati, V., Zambruno, G., Cundari, E., Failla, C.M., 
and Saggio, I. (2001). Binding properties, cell delivery, and gene transfer of adenoviral penton 
base displaying bacteriophage. Virology (282), 102–112. 
Dickerson, S.K., Market, E., Besmer, E., and Papavasiliou, F.N. (2003). AID mediates 
hypermutation by deaminating single stranded DNA. J. Exp. Med. (197), 1291–1296. 
XL 
 
Diebold, S.S. (2004). Innate antiviral responses by means of TLR7-mediated recognition of 
single-stranded RNA. Science (303), 1529–1531. 
Diehl, S., and Rincón, M. (2002). The two faces of IL-6 on Th1/Th2 differentiation. Mol. 
Immunol. (39), 531–536. 
Diekema, D.J., Pfaller, M.A., Schmitz, F.J., Smayevsky, J., Bell, J., Jones, R.N., and Beach, 
M. (2001). Survey of infections due to Staphylococcus species: Frequency of occurrence and 
antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, 
Europe, and the Western Pacific region for the SENTRY antimicrobial surveillanc. Clin. 
Infect. Dis. (32), S114–S132. 
Dieu, M.C., Vanbervliet, B., Vicari, A., Bridon, J.M., Oldham, E., Aït-Yahia, S., Brière, F., 
Zlotnik, A., Lebecque, S., and Caux, C. (1998). Selective recruitment of immature and mature 
dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 
(188), 373–386. 
Dinarello, C.A. (1994). Interleukin-1 in disease. Keio J. Med. (43), 131–136. 
Dinarello, C.A. (1997a). Interleukin-1. Cytokine Growth Factor Rev. (8), 253–265. 
Dinarello, C.A. (1997b). Induction of interleukin-1 and interleukin-1 receptor antagonist. 
Semin. Oncol. (24), S9-81-S9-93. 
Dinarello, C.A. (1998). Interleukin-1, interleukin-1 receptors and interleukin-1 receptor 
antagonist. Int. Rev. Immunol. (16), 457–499. 
Dinarello, C.A. (1999). IL-18: A T(H1)-inducing, proinflammatory cytokine and new member 
of the IL-1 family. J. Allergy Clin. Immunol. (103), 11–24. 
Dinarello, C.A. (2000). Proinflammatory cytokines. CHEST J. (118), 503–508. 
Dinarello, C. a, and Thompson, R.C. (1991). Blocking IL-1: interleukin 1 receptor antagonist 
in vivo and in vitro. Immunol. Today (12), 404–410. 
Ding, J.L., and Ho, B. (1999). Assays for endotoxin. 
Ding, J.L., and Ho, B. (2001). A new era in pyrogen testing. Trends Biotechnol. (19), 277–
281. 
Ding, J.L., and Ho, B. (2010). Endotoxin detection – from Limulus Amebocyte Lysate to 
recombinant Factor C. In Subcellular Biochemistry, pp. 187–208. 
Dinges, M.M., Orwin, P.M., and Schlievert, P.M. (2000). Exotoxins of Staphylococcus aureus. 
Clin. Microbiol. Rev. (13), 16–34. 
Doerrler, W.T. (2006). Lipid trafficking to the outer membrane of Gram-negative bacteria. 
Mol. Microbiol. (60), 542–552. 
Dong, Q., Fan, R., Zhao, S., and Wang, Y. (2009). Over-expression of SOCS-3 gene promotes 
IL-10 production by JEG-3 trophoblast cells. Placenta (30), 11–14. 
Dongre, A.R., Kovats, S., DeRoos, P., McCormack, A.L., Nakagawa, T., Paharkova-
XLI 
 
Vatchkova, V., Eng, J., Caldwell, H., Yates, J.R., and Rudensky, A.Y. (2001). In vivo MHC 
class II presentation of cytosolic proteins revealed by rapid automated tandem mass 
spectrometry and functional analyses. Eur. J. Immunol. (31), 1485–1494. 
Donlan, R.M., and Costerton, J.W. (2002). Biofilms: Survival mechanisms of clinically 
relevant microorganisms. Clin. Microbiol. Rev. (15), 167–193. 
Driscoll, J.A., Brody, S.L., and Kollef, M.H. (2007). The epidemiology, pathogenesis and 
treatment of Pseudomonas aeruginosa infections. Drugs (67), 351–368. 
Dubois, V., Arpin, C., Melon, M., Melon, B., Andre, C., Frigo, C., and Quentin, C. (2001). 
Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy 
of cefepime-amikacin therapy and analysis of beta-lactam resistance. J. Clin. Microbiol. 
(39), 2072–2078. 
Duckworth, D. (1987). History and basic properties of bacterial viruses. In Phage Ecology, 
pp. 1–44. 
Duckworth, D.H. (1976). “Who discovered bacteriophage?”. Bacteriol. Rev. (40), 793–802. 
Duerkop, B.A., and Hooper, L. V (2013). Resident viruses and their interactions with the 
immune system. Nat. Immunol. (14), 654–659. 
Duerr, D.M., White, S.J., and Schluesener, H.J. (2004). Identification of peptide sequences 
that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. 
Methods (116), 177–180. 
Dufour, N., Henry, M., Ricard, J.-D., and Debarbieux, L. (2016). Commentary: 
Morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to 
stimulate cytokine release In vitro. Front. Microbiol. (7), 10–12. 
Dunnick, W., Hertz, G.Z., Scappino, L., and Gritzmacher, C. (1993). Corrigenda: Dna 
sequences at immunoglobulin switch region recombination sites. Nucleic Acids Res. (21), 
2285. 
Dustin, M.L. (2009). The cellular context of T cell signaling. Immunity (30), 482–492. 
Edgar, R., Domrachev, M., and Lash, A.E. (2002). Gene Expression Omnibus: NCBI gene 
expression and hybridization array data repository. Nucleic Acids Res. (30), 207–210. 
Egwuagu, C.E., Yu, C.-R., Zhang, M., Mahdi, R.M., Kim, S.J., and Gery, I. (2002). Suppressors 
of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications 
for Th cell lineage commitment and maintenance. J. Immunol. (168), 3181–3187. 
Elson, C.O. (1996). The basis of current and future therapy for inflammatory bowel disease. 
Am. J. Med. (100), 656–662. 
Emanuelli, B., Peraldi, P., Filloux, C., Sawka-Verhelle, D., Hilton, D., and Van Obberghen, 
E. (2000). SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. 
Chem. (275), 15985–15991. 
Emilsson, V., Arch, J.R.S., De Groot, R.P., Lister, C.A., and Cawthorne, M.A. (1999). Leptin 
XLII 
 
treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS 
Lett. (455), 170–174. 
Endo, T.A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, 
A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997). A new protein containing an SH2 
domain that inhibits JAK kinases. Nature (387), 921–924. 
Epelman, S., Stack, D., Bell, C., Wong, E., Neely, G.G., Krutzik, S., Miyake, K., Kubes, P., 
Zbytnuik, L.D., Ma, L.L., et al. (2004). Different domains of Pseudomonas aeruginosa 
exoenzyme S activate distinct TLRs. J. Immunol. (173), 2031–2040. 
Epstein, F.H., and Parrillo, J.E. (1993). Pathogenetic mechanisms of septic shock. N. Engl. J. 
Med. (328), 1471–1477. 
Eriksson, F., Culp, W.D., Massey, R., Egevad, L., Garland, D., Persson, M.A.A., and Pisa, P. 
(2007). Tumor specific phage particles promote tumor regression in a mouse melanoma model. 
Cancer Immunol. Immunother. (56), 677–687. 
Eriksson, F., Tsagozis, P., Lundberg, K., Parsa, R., Mangsbo, S.M., Persson, M.A.A., Harris, 
R.A., and Pisa, P. (2009). Tumor-specific bacteriophages induce tumor destruction through 
activation of tumor-associated macrophages. J. Immunol. (182), 3105–3111. 
Erridge, C., Bennett-Guerrero, E., and Poxton, I.R. (2002). Structure and function of 
lipopolysaccharides. Microbes Infect. (4), 837–851. 
Fearon, D.T. (2000). Innate immunity--beginning to fulfill its promise?. Nat. Immunol. (1), 
102–103. 
Feezor, R.J., Oberholzer, C., Baker, H. V., Novick, D., Rubinstein, M., Moldawer, L.L., 
Pribble, J., Souza, S., Dinarello, C.A., Ertel, W., et al. (2003). Molecular characterization of 
the acute inflammatory response to infections with gram-negative versus gram-positive 
bacteria. Infect. Immun. (71), 5803–5813. 
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock, D.T., Coyle, 
A.J., Liao, S.-M., and Maniatis, T. (2003). IKKepsilon and TBK1 are essential components of 
the IRF3 signaling pathway. Nat. Immunol. (4), 491–496. 
Fleischer, B.Y.B., and Schrezenmeier, H. (1988). T cell stimulation by Staphylococcal 
enterotoxins. J. Exp. Med. (167), 1697–1707. 
Fleming, A. (1945). Nobel Lecture: Penicillin. 
Flier, J., Boorsma, D.M., van Beek, P.J., Nieboer, C., Stoof, T.J., Willemze, R., and Tensen, 
C.P. (2001). Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and 
CXCL11 in different types of skin inflammation. J. Pathol. (194), 398–405. 
Focà, A., Liberto, M.C., Quirino, A., Marascio, N., Zicca, E., and Pavia, G. (2015). Gut 
inflammation and immunity: What is the role of the human gut virome?. Mediators 
Inflamm. (2015), 1–7. 
Fogelman, I., Davey, V., Ochs, H.D., Elashoff, M., Feinberg, M.B., Mican, J., Siegel, J.P., 
Sneller, M., and Lane, H.C. (2000). Evaluation of CD4+ T cell function In vivo in HIV-infected 
XLIII 
 
patients as measured by bacteriophage phiX174 immunization. J. Infect. Dis. (182), 435–
441. 
Fokine, A., and Rossmann, M. (2014). Molecular architecture of tailed double-stranded DNA 
phages. Bacteriophage (4), e28281. 
Fokine, A., Leiman, P.G., Shneider, M.M., Ahvazi, B., Boeshans, K.M., Steven, A.C., Black, 
L.W., Mesyanzhinov, V. V, and Rossmann, M.G. (2005). Structural and functional 
similarities between the capsid proteins of bacteriophages T4 and HK97 point to a common 
ancestry. Proc. Natl. Acad. Sci. (102), 7163–7168. 
Forde, A., and Fitzgerald, G.F. (1999). Bacteriophage defence systems in lactic acid bacteria. 
Antonie van Leeuwenhoek, Int. J. Gen. Mol. Microbiol. (76), 89–113. 
Foster, T.J. (2005). Immune evasion by staphylococci. Nat. Rev. Microbiol. (3), 948–958. 
Foster, T.J., and Höök, M. (1998). Surface protein adhesins of Staphylococcus aureus. Trends 
Microbiol. (6), 484–488. 
Fourmy, D., Recht, M.I., Blanchard, S.C., and Puglisi, J.D. (1996). Structure of the A site of 
Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 
(274), 1367–1371. 
Franchi, L., Warner, N., Viani, K., and Nuñez, G. (2009). Function of Nod-like receptors in 
microbial recognition and host defense. Immunol. Rev. (227), 106–128. 
Frank, H., and Moebus, K. (1987). An electron microscopic study of bacteriophages from 
marine waters. Helgoländer Meeresuntersuchungen (41), 385–414. 
Fraser, I.P., Koziel, H., and Ezekowitz, R.A.A. (1998). The serum mannose-binding protein 
and the macrophage mannose receptor are pattern recognition molecules that link innate and 
adaptive immunity. Semin. Immunol. (10), 363–372. 
Fraser, J.S., Yu, Z., Maxwell, K.L., and Davidson, A.R. (2006). Ig-like domains on 
bacteriophages: A tale of promiscuity and deceit. J. Mol. Biol. (359), 496–507. 
Fraser, J.S., Maxwell, K.L., and Davidson, A.R. (2007). Immunoglobulin-like domains on 
bacteriophage: weapons of modest damage?. Curr. Opin. Microbiol. (10), 382–387. 
Fu, H., Coburn, J., and Collier, R.J. (1993). The eukaryotic host factor that activates 
exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc. Natl. 
Acad. Sci. (90), 2320–2324. 
Fugmann, S.D., Lee, A.I., Shockett, P.E., Villey, I.J., and Schatz, D.G. (2000). The RAG 
proteins and V(D)J recombination: complexes, ends, and transposition. Annu. Rev. 
Immunol. (18), 495–527. 
Fujita, T. (2002). Evolution of the lectin–complement pathway and its role in innate immunity. 
Nat. Rev. Immunol. (2), 346–353. 
Fujita, T., Endo, Y., and Nonaka, M. (2004). Primitive complement system - Recognition and 
activation. In Molecular Immunology, pp. 103–111. 
XLIV 
 
Gadola, S.D., Zaccai, N.R., Harlos, K., Shepherd, D., Castro-Palomino, J.C., Ritter, G., 
Schmidt, R.R., Jones, E.Y., and Cerundolo, V. (2002). Structure of human CD1b with bound 
ligands at 2.3 A, a maze for alkyl chains. Nat. Immunol. (3), 721–726. 
Gao, Y., Flori, L., Lecardonnel, J., Esquerré, D., Hu, Z.-L., Teillaud, A., Lemonnier, G., 
Lefèvre, F., Oswald, I.P., and Rogel-Gaillard, C. (2010). Transcriptome analysis of porcine 
PBMCs after in vitro stimulation by LPS or PMA/ionomycin using an expression array 
targeting the pig immune response. BMC Genomics (11), 292. 
Garbi, N., Tanaka, S., Momburg, F., and Hämmerling, G.J. (2006). Impaired assembly of the 
major histocompatibility complex class I peptide-loading complex in mice deficient in the 
oxidoreductase ERp57. Nat. Immunol. (7), 93–102. 
Garrett, T.A., Kadrmas, J.L., and Raetz, C.R.H. (1997). Identification of the gene encoding 
the Escherichia coli lipid A 4’- kinase: Facile phosphorylation of endotoxin analogs with 
recombinant LpxK. J. Biol. Chem. (272), 21855–21864. 
Garrett, T.A., Que, N.L.S., and Raetz, C.R.H. (1998). Accumulation of a lipid A precursor 
lacking the 4’-phosphate following inactivation of the Escherichia coli lpxK gene. J. Biol. 
Chem. (273), 12457–12465. 
Gaynes, R., Edwards, J.R., and National Nosocomial Infections Surveillance System (2005). 
Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. (41), 
848–854. 
Gellatly, S.L., and Hancock, R.E.W. (2013). Pseudomonas aeruginosa: New insights into 
pathogenesis and host defenses. Pathog. Dis. (67), 159–173. 
Gellert, M. (1997). Recent advances in understanding V(D)J recombination. Adv. Immunol. 
(64), 39–64. 
Gellert, M. (2002). V(D)J recombination: RAG proteins, repair factors, and regulation. Annu 
Rev Biochem (71), 101–132. 
Gerard, C., and Rollins, B.J. (2001). Chemokines and disease. Nat. Immunol. (2), 108–115. 
Gerba, C.P., and Hou, K. (1985). Endotoxin removal by charge-modified filters. Appl. Env. 
Microbiol. (50), 1375–1377. 
Gerszten, R.E., Garcia-Zepeda, E.A., Lim, Y.-C., Yoshida, M., Ding, H.A., Jr, M.A.G., Luster, 
A.D., and Rosenzweig, F.W.L.A. (1999). MCP-1 and IL-8 trigger firm adhesion of monocytes 
to vascular endothelium under flow conditions. Nature (398), 718–723. 
Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-κB AND REL proteins: Evolutionarily 
conserved mediators of immune responses. Annu. Rev. Immunol. (16), 225–260. 
Ghuysen, J.M. (1994). Molecular structures of penicillin-binding proteins and beta-
lactamases. Trends Microbiol. (2), 372–380. 
Gibbons, H.S., Lin, S., Cotter, R.J., and Raetz, C.R.H. (2000). Oxygen requirement for the 
biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A. J. Biol. 
Chem. (275), 32940–32949. 
XLV 
 
Gibbons, H.S., Reynolds, C.M., Guan, Z., and Raetz, C.R.H. (2008). An inner membrane 
dioxygenase that generates the 2-hydroxymyristate moiety of Salmonella lipid A. 
Biochemistry (47), 2814–2825. 
Giedraitienė, A., Vitkauskienė, A., Naginienė, R., and Pavilonis, A. (2011). Antibiotic 
resistance mechanisms of clinically important bacteria. Medicina  (47), 137–146. 
Gilfillan, S., Dierich, A., Lemeur, M., Benoist, C., and Mathis, D. (1993). Mice lacking TdT: 
mature animals with an immature lymphocyte repertoire. Science (261), 1175–1178. 
Gill, D.J., Tham, K.M., Chia, J., Wang, S.C., Steentoft, C., Clausen, H., Bard-Chapeau, E.A., 
and Bard, F.A. (2013). Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum 
promotes cancer cell invasiveness. Proc. Natl. Acad. Sci. (110), E3152–E3161. 
Gilleron, M., Quesniaux, V.F.J., and Puzo, G. (2003). Acylation state of the 
phosphatidylinositol hexamannosides from Mycobacterium bovis, Bacillus calmette guérin 
and Mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response. J. 
Biol. Chem. (278), 29880–29889. 
Gioannini, T.L., and Weiss, J.P. (2007). Regulation of interactions of Gram-negative bacterial 
endotoxins with mammalian cells. Immunol. Res. (39), 249–260. 
Giordanetto, F., and Kroemer, R.T. (2003). A three-dimensional model of Suppressor Of 
Cytokine Signalling 1 (SOCS-1). Protein Eng. (16), 115–124. 
Girardin, S.E., Boneca, I.G., Carneiro, L.A.M., Antignac, A., Jéhanno, M., Viala, J., Tedin, 
K., Taha, M.-K., Labigne, A., Zähringer, U., et al. (2003). Nod1 detects a unique muropeptide 
from gram-negative bacterial peptidoglycan. Science (300), 1584–1587. 
Girlich, D., Naas, T., and Nordmann, P. (2004). Biochemical characterization of the naturally 
occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents 
Chemother. (48), 2043–2048. 
Girn, H.R., Orsi, N.M., and Homer-Vanniasinkam, S. (2007). An overview of cytokine 
interactions in atherosclerosis and implications for peripheral arterial disease. Vasc. Med. 
(12), 299–309. 
Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R., and Mathieu, C. (2001). 
An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. 
Methods (25), 386–401. 
Gohda, J., Matsumura, T., and Inoue, J. (2004). Cutting edge: TNFR-associated factor (TRAF) 
6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing 
adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J. Immunol. (173), 
2913–2917. 
Goldmann, O., Rohde, M., Chhatwal, G.S., and Medina, E. (2004). Role of macrophages in 
host resistance to group A Streptococci. Infect. Immun. (72), 2956–2963. 




Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. (3), 23–35. 
Gordon, R.J., and Lowy, F.D. (2008). Pathogenesis of methicillin‐resistant Staphylococcus 
aureus infection. Clin. Infect. Dis. (46), S350–S359. 
Gorski, A., Dąbrowska, K., Switala-Jele, K., Nowaczyk, M., Weber-Dąbrowska, B., 
Boratynski, J., Wietrzyk, J., and Opolski, A. (2003). New insights into the possible role of 
bacteriophages in host defense and disease. Med. Immunol. (5), 1–5. 
Górski, A., and Weber-Dąbrowska, B. (2005). The potential role of endogenous bacteriophages 
in controlling invading pathogens. Cell. Mol. Life Sci. (62), 511–519. 
Górski, A., Ważna, E., Weber-Dąbrowska, B., Dąbrowska, K., Switała-Jelen, K., and 
Miedzybrodzki, R. (2006a). Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 
(46), 313–319. 
Górski, A., Kniotek, M., Perkowska-Ptasińska, A., Mróz, A., Przerwa, A., Gorczyca, W., 
Da ̧browska, K., Weber-Da ̧browska, B., and Nowaczyk, M. (2006b). Bacteriophages and 
transplantation tolerance. In Transplantation Proceedings, pp. 331–333. 
Górski, A., Międzybrodzki, R., Borysowski, J., Dąbrowska, K., Wierzbicki, P., Ohams, M., 
Korczak-Kowalska, G., Olszowska-Zaremba, N., Łusiak-Szelachowska, M., Kłak, M., et al. 
(2012). Phage as a modulator of immune responses: practical implications for phage therapy. 
Adv. Virus Res. (83), 41–71. 
Grallert, H., Leopoldseder, S., Schuett, M., Kurze, P., and Buchberger, B. (2011). EndoLISA 
® : a novel and reliable method for endotoxin detection. Nat. Publ. Gr. (8). 
Greenfeder, S.A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R.A., and Ju, G. (1995). 
Molecular cloning and characterization of a second subunit of the interleukin 1 receptor 
complex. J. Biol. Chem. (270), 13757–13765. 
Greenhalgh, C.J., Miller, M.E., Hilton, D.J., Lund, P.K., Davis, S., Flier, J., Myers, M., 
Suzuki, R., Suzuki, A., Yoshimura, A., et al. (2002). Suppressors of cytokine signaling: 
Relevance to gastrointestinal function and disease. Gastroenterology (123), 2064–2081. 
Gu, L., Tseng, S., Horner, R.M., Tam, C., Loda, M., and Rollins, B.J. (2000). Control of TH2 
polarization by the chemokine monocyte chemoattractant protein-1. Nature (404), 407–411. 
Guarner, F., and Malagelada, J.R. (2003). Gut flora in health and disease. Lancet (361), 512–
519. 
Guay, D.R.P. (2008). Contemporary management of uncomplicated urinary tract infections. 
Drugs (68), 1169–1205. 
Guo, B., and Cheng, G. (2007). Modulation of the interferon antiviral response by the 
TBK1/IKKi adaptor protein TANK. J. Biol. Chem. (282), 11817–11826. 
Haag, A.F., Wehmeier, S., Beck, S., Marlow, V.L., Fletcher, V., James, E.K., and Ferguson, 
G.P. (2009). The Sinorhizobium meliloti LpxXL and AcpXL proteins play important roles in 
bacteroid development within alfalfa. J. Bacteriol. (191), 4681–4686. 
XLVII 
 
Haan, S., Ferguson, P., Sommer, U., Hiremath, M., McVicar, D.W., Heinrich, P.C., Johnston, 
J.A., and Cacalano, N.A. (2003). Tyrosine phosphorylation disrupts elongin interaction and 
accelerates SOCS3 degradation. J. Biol. Chem. (278), 31972–31979. 
Häcker, H., Mischak, H., Miethke, T., and Liptay, S. (1998). CpG-DNA-specific activation of 
antigen-presenting cells requires stress kinase activity and is preceded by non-specific 
endocytosis and endosomal maturation. EMBO J. (17), 6230–6240. 
Hagenbaugh, A., Sharma, S., Dubinett, S.M., Wei, S.H., Aranda, R., Cheroutre, H., Fowell, 
D.J., Binder, S., Tsao, B., Locksley, R.M., et al. (1997). Altered immune responses in 
interleukin 10 transgenic mice. J. Exp. Med. (185), 2101–2110. 
Hajjar, A.M., O’Mahony, D.S., Ozinsky, A., Underhill, D.M., Aderem, A., Klebanoff, S.J., and 
Wilson, C.B. (2001). Cutting Edge: Functional interactions between Toll-like receptor (TLR) 2 
and TLR1 or TLR6 in response to phenol-soluble modulin. J. Immunol. (166), 15–19. 
Halaby, D.M., and Mornon, J.P.E. (1998). The immunoglobulin superfamily: An insight on 
its tissular, species, and functional diversity. J. Mol. Evol. (46), 389–400. 
Hamad, A.R., Marrack, P., and Kappler, J.W. (1997). Transcytosis of Staphylococcal 
superantigen toxins. J. Exp. Med. (185), 1447–1454. 
Hamanaka, I., Saito, Y., Yasukawa, H., Kishimoto, I., Kuwahara, K., Miyamoto, Y., Harada, 
M., Ogawa, E., Kajiyama, N., Takahashi, N., et al. (2001). Induction of JAB/SOCS-1/SSI-1 
and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat 
treated with cardiotrophin-1 in vivo. Circ. Res. (88), 727–732. 
Hamill, R.J., Vann, J.M., and Proctor, R.A. (1986). Phagocytosis of Staphylococcus aureus by 
cultured bovine aortic endothelial cells: Model for postadherence events in endovascular 
infections. Infect. Immun. (54), 833–836. 
Hamzeh-Mivehroud, M., Mahmoudpour, A., Rezazadeh, H., and Dastmalchi, S. (2008). Non-
specific translocation of peptide-displaying bacteriophage particles across the gastrointestinal 
barrier. Eur. J. Pharm. Biopharm. (70), 577–581. 
Hanaki, H., Kuwahara-Arai, K., Boyle-Vavra, S., Daum, R.S., Labischinski, H., and 
Hiramatsu, K. (1998a). Activated cell-wall synthesis is associated with vancomycin resistance 
in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. 
Antimicrob. Chemother. (42), 199–209. 
Hanaki, H., Labischinski, H., Inaba, Y., Kondo, N., Murakami, H., and Hiramatsu, K. 
(1998b). Increase in glutamine-non-amidated muropeptides in the peptidoglycan of 
vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 
(42), 315–320. 
Handley, S.A., Thackray, L.B., Zhao, G., Presti, R., Miller, A.D., Droit, L., Abbink, P., 
Maxfield, L.F., Kambal, A., Duan, E., et al. (2012). Pathogenic simian immunodeficiency virus 
infection is associated with expansion of the enteric virome. Cell (151), 253–266. 
Hansen, J.A., Lindberg, K., Hilton, D.J., Nielsen, J.H., and Billestrup, N. (1999). Mechanism 
of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling 
proteins. Mol. Endocrinol. (13), 1832–1843. 
XLVIII 
 
Harbarth, S., Ferrière, K., Hugonnet, S., Ricou, B., Suter, P., and Pittet, D. (2002). 
Epidemiology and prognostic determinants of bloodstream infections in surgical intensive 
care. Arch. Surg. (137), 1353–9; discussion 1359. 
Hart, P.H., Vitti, G.F., Burgess, D.R., Whitty, G.A., Piccoli, D.S., and Hamilton, J.A. (1989). 
Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor 
necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. (86), 
3803–3807. 
Hartman, B.J., and Tomasz, A. (1984). Low-affinity penicillin-binding protein associated with 
beta-lactam resistance in Staphylococcus aureus. J. Bacteriol. (158), 513–516. 
Hartmann, G., and Krieg,  a M. (1999). CpG DNA and LPS induce distinct patterns of 
activation in human monocytes. Gene Ther. (6), 893–903. 
Hasbold, J., Lyons, A.B., Kehry, M.R., and Hodgkin, P.D. (1998). Cell division number 
regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4. 
Eur. J. Immunol. (28), 1040–1051. 
Hashimoto, C., Hudson, K.L., and Anderson, K. V. (1988). The Toll gene of drosophila, 
required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. 
Cell (52), 269–279. 
Hauser, A.R. (2009). The type III secretion system of Pseudomonas aeruginosa: infection by 
injection. Nat. Rev. Microbiol. (7), 654–665. 
Hawkey, P.M. (1998). The origins and molecular basis of antibiotic resistance. BMJ (317), 
657–660. 
Hawkins, C., Harper, D., Burch, D., Änggård, E., and Soothill, J. (2010). Topical treatment of 
Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical 
trial. Vet. Microbiol. (146), 309–313. 
Hawlisch, H., and Köhl, J. (2006). Complement and Toll-like receptors: Key regulators of 
adaptive immune responses. Mol. Immunol. (43), 13–21. 
Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., Eng, J.K., Akira, 
S., Underhill, D.M., and Aderem, A. (2001). The innate immune response to bacterial flagellin 
is mediated by Toll- like receptor 5. Nature (410), 1099–103. 
Haziot, A., Chen, S., Ferrero, E., Low, M.G., Silber, R., and Goyert, S.M. (1988). The monocyte 
differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol 
linkage. J. Immunol. (141), 547–552. 
Haziot, A., Ferrero, E., Köntgen, F., Hijiya, N., Yamamoto, S., Silver, J., Stewart, C.L., and 
Goyert, S.M. (1996). Resistance to Endotoxin Shock and Reduced Dissemination of Gram-
Negative Bacteria in CD14-Deficient Mice. Immunity (4), 407–414. 
Hedrick, S.M. (2008). Thymus lineage commitment: A single switch. Immunity (28), 297–
299. 
Heeg, K., and Zimmermann, S. (2000). CpG DNA as a Th1 trigger. Int. Arch. Allergy 
XLIX 
 
Immunol. (121), 87–97. 
Heil, F. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 
and 8. Science (303), 1526–1529. 
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, 
H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds activate immune cells via 
the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (3), 196–200. 
Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H., Kawai, T., Hoshino, 
K., Takeda, K., and Akira, S. (2004). The roles of two IkappaB kinase-related kinases in 
lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 
(199), 1641–1650. 
Henriksson, M.L., Sundin, C., Jansson, A.L., Forsberg, Å., Palmer, R.H., and Hallberg, B. 
(2002). Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) 
activities towards small GTPases in vivo. Biochem. J. (367), 617–628. 
Hinckley, M.B., Reynolds, C.M., Ribeiro, A.A., McGrath, S.C., Cotter, R.J., Lauw, F.N., 
Golenbock, D.T., and Raetz, C.R.H. (2005). A Leptospira interrogans enzyme with similarity 
to yeast Ste14p that methylates the 1-phosphate group of lipid A. J. Biol. Chem. (280), 
30214–30224. 
Hiramatsu, K. (2001). Vancomycin-resistant Staphylococcus aureus: A new model of 
antibiotic resistance. Lancet Infect. Dis. (1), 147–155. 
Hirschfeld, M., Weis, J.J., Toshchakov, V., Salkowski, C.A., Cody, M.J., Ward, D.C., Qureshi, 
N., Michalek, S.M., and Vogel, S.N. (2001). Signaling by Toll-Like Receptor 2 and 4 Agonists 
Results in Differential Gene Expression in Murine Macrophages. Infect. Immun. (69), 1477–
1482. 
Hochrein, H., Schlatter, B., O’keeffe, M., Wagner, C., Schmitz, F., Schiemann, M., Bauer, S., 
Suter, M., and Wagner, H. (2004). Herpes simplex virus type-1 induces IFN-alpha production 
via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. (101), 
11416–11421. 
Hodgkin, P.D., Lee, J.H., and Lyons, A.B. (1996). B cell differentiation and isotype switching 
is related to division cycle number. J. Exp. Med. (184), 277–281. 
Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., 
Lecion, D., Kaźmierczak, Z., Beta, W., Majewska, J., Harhala, M., et al. (2015). Mammalian 
host-versus-phage immune response determines phage fate in vivo. Sci. Rep. (5), 14802. 
Hoebe, K., Janssen, E., and Beutler, B. (2004). The interface between innate and adaptive 
immunity. Nat. Immunol. (5), 971–974. 
Hofer, U. (2013). Viral evolution: Variation in the gut virome. Nat. Rev. Microbiol. (11), 
596. 
Hoffmann, J.A. (2003). The immune response of Drosophila. Nature (426), 33–38. 
Hoffmann, J.A., Kafatos, F.C., Janeway, C.A., and Ezekowitz, R.A. (1999). Phylogenetic 
L 
 
perspectives in innate immunity. Science (284), 1313–1318. 
Hoffmann, M.L., Jablonski, L.M., Crum, K.K., Hackett, S.P., Chi, Y.I., Stauffacher, C. V, 
Stevens, D.L., and Bohach, G.A. (1994). Predictions of T-cell receptor- and major 
histocompatibility complex-binding sites on staphylococcal enterotoxin C1. Infect. Immun. 
(62), 3396–3407. 
Homey, B., Alenius, H., Müller, A., Soto, H., Bowman, E.P., Yuan, W., McEvoy, L., Lauerma, 
A.I., Assmann, T., Bünemann, E., et al. (2002). CCL27-CCR10 interactions regulate T cell-
mediated skin inflammation. Nat. Med. (8), 157–165. 
Honda, K., and Taniguchi, T. (2006). IRFs: master regulators of signalling by Toll-like 
receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. (6), 644–658. 
Hong, F., Nguyen, V.A., and Gao, B. (2001). Tumor necrosis factor alpha attenuates interferon 
alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance 
to interferon therapy. FASEB J. (15), 1595–1597. 
Hooper, D.C. (2002). Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. 
Dis. (2), 530–538. 
Hooper, L. V, Xu, J., Falk, P.G., Midtvedt, T., and Gordon, J.I. (1999). A molecular sensor 
that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. 
Proc. Natl. Acad. Sci. (96), 9833–9838. 
Hooper, L. V., Littman, D.R., and Macpherson,  a. J. (2012). Interactions between the 
microbiota and the immune system. Science (336), 1268–1273. 
Horikawa, K., Martin, S.W., Pogue, S.L., Silver, K., Peng, K., Takatsu, K., and Goodnow, C.C. 
(2007). Enhancement and suppression of signaling by the conserved tail of IgG memory-type 
B cell antigen receptors. J. Exp. Med. (204), 759–769. 
Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., and 
Akira, S. (1999). Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive 
to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. (162), 3749–
3752. 
Hou, K.C., and Zaniewski, R. (1990a). Endotoxin removal by anion-exchange polymeric 
matrix. Biotechnol. Appl. Biochem. (12), 315–324. 
Hou, K.C., and Zaniewski, R. (1990b). Depyrogenation by endotoxin removal with positively 
charged depth filter cartridge. J. Parenter. Sci. Technol. (44), 204–209. 
Housby, J.N., and Mann, N.H. (2009). Phage therapy. Drug Discov. Today (14), 536–540. 
Howard, M., and O’Garra, A. (1992). Biological properties of interleukin 10. Immunol. 
Today (13), 198–200. 
Huff, W.E., Huff, G.R., Rath, N.C., and Donoghue, A.M. (2010). Immune interference of 
bacteriophage efficacy when treating colibacillosis in poultry. Poult. Sci. (89), 895–900. 
Hurley, J.C. (1995). Endotoxemia: methods of detection and clinical correlates. Clin. 
LI 
 
Microbiol. Rev. (8), 268–292. 
Huston, D.P. (1997). The biology of the immune system.  J. Am. Med. Assoc. (278), 1804–
1814. 
Hwang, P.M., Bishop, R.E., and Kay, L.E. (2004). The integral membrane enzyme PagP 
alternates between two dynamically distinct states. Proc. Natl. Acad. Sci. (101), 9618–9623. 
Illson, T.R.A.W., Prigg, N.A.S.S., Tarr, R.O.S., Icholson, S.A.E.N., Etcalf, D.O.M., Hilton, 
D.J., Richardson, R.T., Alexander, W.S., Viney, E.M., Willson, T.A., et al. (1998). Twenty 
proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. 
Sci. (95), 114–119. 
Inchley, C.J., and Howard, J.G. (1969). The immunogenicity of phagocytosed T4 
bacteriophage: cell replacement studies with splenectomized and irradiated mice. Clin. Exp. 
Immunol. (5), 189–198. 
Inohara, N., Chamaillard, M., McDonald, C., and Nuñez, G. (2005). NOD-LRR PROTEINS: 
Role in Host-Microbial Interactions and Inflammatory Disease. Annu. Rev. Biochem. (74), 
355–383. 
Isaksen, D.E., Baumann, H., Trobridge, P.A., Farr, A.G., Levin, S.D., and Ziegler, S.F. (1999). 
Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction. J. 
Immunol. (163), 5971–5977. 
Ishikawa, H., Naito, T., Iwanaga, T., Takahashi-Iwanaga, H., Suematsu, M., Hibi, T., and 
Nanno, M. (2007). Curriculum vitae of intestinal intraepithelial T cells: Their developmental 
and behavioral characteristics. Immunol. Rev. (215), 154–165. 
Israelachvili, J.N. (2011). Intermolecular and Surface Forces (Academic Press). 
Ivanov, I.I., Frutos, R. de L., Manel, N., Yoshinaga, K., Rifkin, D.B., Sartor, R.B., Finlay, 
B.B., and Littman, D.R. (2008). Specific microbiota direct the differentiation of IL-17-
producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe (4), 337–
349. 
Iwanaga, S., and Lee, B.L. (2005). Recent advances in the innate immunity of invertebrate 
animals. J. Biochem. Mol. Biol. (38), 128–150. 
Jain, J., Loh, C., and Rao, A. (1995). Transcriptional regulation of the IL-2 gene. Curr. Opin. 
Immunol. (7), 333–342. 
Janeway, C.A. (1989). Approaching the asymptote? Evolution and revolution in immunology. 
In Cold Spring Harbor Symposia on Quantitative Biology, pp. 1–13. 
Janeway, C. a, and Medzhitov, R. (2002). Innate immune recognition. Annu. Rev. Immunol. 
(20), 197–216. 
Jeggo, P.A. (1998). DNA breakage and repair. Adv. Genet. (38), 185–218. 
Jenkinson, E.J., Jenkinson, W.E., Rossi, S.W., and Anderson, G. (2006). The thymus and T-
cell commitment: the right niche for Notch?. Nat. Rev. Immunol. (6), 551–555. 
LII 
 
Jentoft, N. (1990). Why are proteins O-glycosylated?. Trends Biochem. Sci. (15), 291–294. 
Jerne, N.K. (1952). Bacteriophage inactivation by antiphage serum diluted in distilled water. 
Nature (169), 117–118. 
Jerne, N.K. (1956). The presence in normal serum of specific antibody against bacteriophage 
T4 and its increase during the earliest stages of immunization. J. Immunol. (76), 209–216. 
Johansen, F.E., and Brandtzaeg, P. (2004). Transcriptional regulation of the mucosal IgA 
system. Trends Immunol. (25), 150–157. 
Johansson, M.E. V., Phillipson, M., Petersson, J., Velcich, A., Holm, L., Hansson, G.C., 
Petersson, J., Velcich, A., Holm, L., Hansson, G.C., et al. (2008). The inner of the two Muc2 
mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl. Acad. Sci. (105), 
15064–15069. 
Jończyk-Matysiak, E., Łusiak-Szelachowska, M., Kłak, M., Bubak, B., Międzybrodzki, R., 
Weber-Dąbrowska, B., Zaczek, M., Fortuna, W., Rogóz, P., Letkiewicz, S., et al. (2015). The 
effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. 
Immunol. Res. (2015). 
Joshi, N.S., and Kaech, S.M. (2008). Effector CD8 T cell development: A balancing act between 
memory cell potential and terminal differentiation. J. Immunol. (180), 1309–1315. 
Joyce, S., and Van Kaer, L. (2003). CD1-restricted antigen presentation: An oily matter. Curr. 
Opin. Immunol. (15), 95–104. 
Kamme, C. (2009). Antibioties against Staphylococcal bacteriophages in human sera. Acta 
Pathol. Microbiol. Scand. Sect. B Microbiol. Immunol. (81B), 741–748. 
Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W.G., Conaway, R.C., and Conaway, J.W. 
(1998). The Elongin BC complex interacts with the conserved SOCS-box motif present in 
members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. (12), 
3872–3881. 
Kanjilal-Kolar, S., Basu, S.S., Kanipes, M.I., Guan, Z., Garrett, T.A., and Raetz, C.R.H. 
(2006). Expression cloning of three Rhizobium leguminosarum lipopolysaccharide core 
galacturonosyltransferases. J. Biol. Chem. (281), 12865–12878. 
Kantoch, M., and Mordarski, M. (1958). Binding of bacterial viruses by cancer cells in vitro. 
Postepy Hig. Med. Dosw. (12), 191–192. 
Kaplan, M.H., Schindler, U., Smiley, S.T., and Grusby, M.J. (1996a). Stat6 is required for 
mediating responses to IL-4 and for the development of Th2 cells. Immunity (4), 313–319. 
Kaplan, M.H., Sun, Y.L., Hoey, T., and Grusby, M.J. (1996b). Impaired IL-12 responses and 
enhanced development of Th2 cells in Stat4-deficient mice. Nature (382), 174–177. 
Kapp, A., Freudenberg, M., and Galanos, C. (1987). Induction of human granulocyte 
chemiluminescence by bacterial lipopolysaccharides. Infect. Immun. (55), 758–761. 
Karlsen, A.E., Rønn, S.G., Lindberg, K., Johannesen, J., Galsgaard, E.D., Pociot, F., Nielsen, 
LIII 
 
J.H., Mandrup-poulsen, T., Nerup, J., and Billestrup, N. (2001). Suppressor of cytokine 
signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -
mediated toxicity. Proc. Natl. Acad. Sci. (98), 12191–12196. 
Karnitz, L.M., and Abraham, R.T. (1996). Interleukin-2 receptor signaling mechanisms. Adv. 
Immunol. (61), 147–199. 
Karplus, T.E., Ulevitch, R.J., and Wilson, C.B. (1987). A new method for reduction of 
endotoxin contamination from protein solutions. J. Immunol. Methods (105), 211–220. 
Karumidze, N., Thomas, J. a., Kvatadze, N., Goderdzishvili, M., Hakala, K.W., Weintraub, 
S.T., Alavidze, Z., and Hardies, S.C. (2012). Characterization of lytic Pseudomonas 
aeruginosa bacteriophages via biological properties and genomic sequences. Appl. Microbiol. 
Biotechnol. (94), 1609–1617. 
Kasai, T., Inada, K., Takakuwa, T., Yamada, Y., Inoue, Y., Shimamura, T., Taniguchi, S., 
Sato, S., Wakabayashi, G., and Endo, S. (1997). Anti-inflammatory cytokine levels in patients 
with septic shock. Res. Commun. Mo.l Pathol. Pharmacol. (98), 34–42. 
Kasman, L.M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M.G., and Norris, J.S. (2002). 
Overcoming the phage replication threshold: a mathematical model with implications for 
phage therapy. J. Virol. (76), 5557–5564. 
Katayama, Y., Ito, T., and Hiramatsu, K. (2000). A new class of genetic element, 
staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus 
aureus. Antimicrob. Agents Chemother. (44), 1549–1555. 
Katschke, K.J., Rottman, J.B., Ruth, J.H., Qin, S., Wu, L., LaRosa, G., Ponath, P., Park, C.C., 
Pope, R.M., and Koch, A.E. (2001). Differential expression of chemokine receptors on 
peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid 
arthritis. Arthritis Rheum. (44), 1022–1032. 
Kaur, S., Harjai, K., and Chhibber, S. (2014). Bacteriophage-aided intracellular killing of 
engulfed methicillin-resistant Staphylococcus aureus (MRSA) by murine macrophages. Appl. 
Microbiol. Biotechnol. (98), 4653–4661. 
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: 
update on Toll-like receptors. Nat. Immunol. (11), 373–384. 
Kawai, T., and Akira, S. (2011). Toll-like receptors and their crosstalk with other innate 
receptors in infection and immunity. Immunity (34), 637–650. 
Kawasaki, K., Ernst, R.K., and Miller, S.I. (2004). 3- O-Deacylation of lipid A by PagL, a 
PhoP/PhoQ-regulated deacylase of Salmonella typhimurium , modulates signaling through 
Toll-like receptor 4. J. Biol. Chem. (279), 20044–20048. 
Kawazoe, Y., Naka, T., Fujimoto, M., Kohzaki, H., Morita, Y., Narazaki, M., Okumura, K., 
Saitoh, H., Nakagawa, R., Uchiyama, Y., et al. (2001). Signal transducer and activator of 
transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 
(SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor 
substrate 1 (IRS-1) phosphorylation. J. Exp. Med. (193), 263–269. 
LIV 
 
Kazakova, S. V., Hageman, J.C., Matava, M., Srinivasan, A., Phelan, L., Garfinkel, B., Boo, 
T., McAllister, S., Anderson, J., Jensen, B., et al. (2005). A clone of methicillin-resistant 
Staphylococcus aureus among professional football players. N. Engl. J. Med. (352), 468–475. 
Keller, R., and Engley, F.B. (1958). Fate of Bacteriophage Particles Introduced into Mice by 
Various Routes. Exp. Biol. Med. (98), 577–580. 
Kelner, G.S., Kennedy, J., Bacon, K.B., Kleyensteuber, S., Largaespada, D.A., Jenkins, N.A., 
Copeland, N.G., Bazan, J.F., Moore, K.W., Schall, T.J., et al. (1994). Lymphotactin: a cytokine 
that represents a new class of chemokine. Science (266), 1395–1399. 
Kelso, A. (1995). Th1 and Th2 subsets: paradigms lost?. Immunol. Today (16), 374–379. 
Kelso, A. (1998). Cytokines: Principles and prospects. Immunol. Cell Biol. (76), 300–317. 
Ki, T., Hade, T.S., Mamai, U.W.E., Nter, G., Brade, H., Loepno, H., and Pava, F.O.D.I. (1994). 
Bacterial endotoxin: molecular relationschip of structure to activity and function. FASEB J. 
(8), 217–225. 
Kim, T.W., Staschke, K., Bulek, K., Yao, J., Peters, K., Oh, K.-H., Vandenburg, Y., Xiao, H., 
Qian, W., Hamilton, T., et al. (2007). A critical role for IRAK4 kinase activity in Toll-like 
receptor-mediated innate immunity. J. Exp. Med. (204), 1025–1036. 
King, J.D., Kocíncová, D., Westman, E.L., and Lam, J.S. (2009). Review: Lipopolysaccharide 
biosynthesis in Pseudomonas aeruginosa. Innate Immun. (15), 261–312. 
Kingsley, D.M. (1994). The TGF-beta superfamily: new members, new receptors, and new 
genetic tests of function in different organisms. Genes Dev. (8), 133–146. 
Kipnis, E., Sawa, T., and Wiener-Kronish, J. (2006). Targeting mechanisms of Pseudomonas 
aeruginosa pathogenesis. Med. Mal. Infect. (36), 78–91. 
Kitchens, R.L. (2000). Role of CD14 in cellular recognition of bacterial lipopolysaccharides. 
Chem. Immunol. (74), 61–82. 
Kloss, P., Xiong, L., Shinabarger, D.L., and Mankin, A.S. (1999). Resistance Mutations in 23 
S rRNA Identify the Site of Action of Protein Synthesis Inhibitor Linezolid in the Ribosomal 
Peptidyl Transferase Center. J. Mol. Biol. (294), 93–101. 
Kluytmans, J., Van Belkum, A., and Verbrugh, H. (1997). Nasal carriage of Staphylococcus 
aureus: Epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 
(10), 505–520. 
Koch, A.E. (2005). Chemokines and their receptors in rheumatoid arthritis: future targets?. 
Arthritis Rheum. (52), 710–721. 
Kodelja, V., Müller, C., Politz, O., Hakij, N., Orfanos, C.E., and Goerdt, S. (1998). Alternative 
macrophage activation-associated CC-chemokine-1, a novel structural homologue of 
macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J. 
Immunol. (160), 1411–1418. 
Kollef, M.H., Shorr, A., Tabak, Y.P., Gupta, V., Liu, L.Z., and Johannes, R.S. (2005). 
LV 
 
Epidemiology and outcomes of health-care–associated pneumonia. CHEST J. (128), 3854–
3862. 
Komori, T., Okada, A., Stewart, V., and Alt, F.W. (1993). Lack of N regions in antigen receptor 
variable region genes of TdT-deficient lymphocytes. Science (261), 1171–1175. 
Kong, K.-F., Jayawardena, S.R., Del Puerto, A., Wiehlmann, L., Laabs, U., Tümmler, B., and 
Mathee, K. (2005). Characterization of poxB, a chromosomal-encoded Pseudomonas 
aeruginosa oxacillinase. Gene (358), 82–92. 
König, B., Vasil, M.L., and König, W. (1997). Role of hemolytic and nonhemolytic 
phospholipase C from Pseudomonas aeruginosa for inflammatory mediator release from 
human granulocytes. Int. Arch. Allergy Immunol. (112), 115–124. 
König, R., Fleury, S., and Germain, R.N. (1996). The structural basis of CD4-MHC class II 
interactions: coreceptor contributions to T cell receptor antigen recognition and 
oligomerization-dependent signal transduction. Curr. Top. Microbiol. Immunol. (205), 
19–46. 
Kopf, M., Gros, G. Le, Bachmann, M., Lamers, M.C., Bluethmann, H., Köhler, G., Le Gros, 
G., Bachmann, M., Lamers, M.C., Bluethmann, H., et al. (1993). Disruption of the murine IL-
4 gene blocks Th2 cytokine responses. Nature (362), 245–248. 
Kopp, E.B., and Medzhitov, R. (1999). The Toll-receptor family and control of innate 
immunity. Curr. Opin. Immunol. (11), 13–18. 
Kotenko, S. V, Izotova, L.S., Mirochnitchenko, O. V, Esterova, E., Dickensheets, H., Donnelly, 
R.P., and Pestka, S. (2001). Identification, cloning, and characterization of a novel soluble 
receptor that binds IL-22 and neutralizes its activity. J. Immunol. (166), 7096–7103. 
Kranzer, K., Eckhardt, A., Aigner, M., Knoll, G., Deml, L., Speth, C., Lehn, N., Rehli, M., and 
Schneider-Brachert, W. (2004). Induction of maturation and cytokine release of human 
dendritic cells by Helicobacter pylori. Infect. Immun. (72), 4416–4423. 
Krieg, A.M. (2000). The role of CpG motifs in innate immunity. Curr. Opin. Immunol. (12), 
35–43. 
Krieg, A.M., Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, 
G.A., and Klinman, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. 
Nature (374), 546–549. 
Kropinski,  a M. (2000). Sequence of the genome of the temperate, serotype-converting, 
Pseudomonas aeruginosa bacteriophage D3. J. Bacteriol. (182), 6066–6074. 
Krug, A., French, A.R., Barchet, W., Fischer, J.A.A., Dzionek, A., Pingel, J.T., Orihuela, 
M.M., Akira, S., Yokoyama, W.M., and Colonna, M. (2004a). TLR9-dependent recognition of 
MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK 
cell function. Immunity (21), 107–119. 
Krug, A., Luker, G.D., Barchet, W., Leib, D.A., Akira, S., and Colonna, M. (2004b). Herpes 
simplex virus type 1 activates murine natural interferon-producing cells through toll-like 
receptor 9. Blood (103), 1433–1437. 
LVI 
 
Krüger, D.H., and Bickle, T.A. (1983). Bacteriophage survival: multiple mechanisms for 
avoiding the deoxyribonucleic acid restriction systems of their hosts. Microbiol. Rev. (47), 
345–360. 
Krych-Goldberg, M., and Atkinson, J.P. (2001). Structure-function relationships of 
complement receptor type 1. Immunol. Rev. (180), 112–122. 
Kubo, M., Hanada, T., and Yoshimura, A. (2003). Suppressors of cytokine signaling and 
immunity. Nat. Immunol. (4), 1169–1176. 
Kufer, T.A., Kremmer, E., Adam, A.C., Philpott, D.J., and Sansonetti, P.J. (2008). The 
pattern-recognition molecule Nod1 is localized at the plasma membrane at sites of bacterial 
interaction. Cell. Microbiol. (10), 477–486. 
Kuhn, R., Rajewsky, K., and Muller, W. (1991). Generation and analysis of interleukin-4 
deficient mice. Science (254), 707–710. 
Kumar, H., Kawai, T., and Akira, S. (2009a). Pathogen recognition in the innate immune 
response. Biochem. J. (420), 1–16. 
Kumar, H., Kawai, T., and Akira, S. (2009b). Toll-like receptors and innate immunity. 
Biochem. Biophys. Res. Commun. (388), 621–625. 
Kumar, H., Kawai, T., and Akira, S. (2011). Pathogen recognition by the innate immune 
system. Int. Rev. Immunol. (30), 16–34. 
Kunkel, T.A., and Erie, D.A. (2005). DNA mismatch repair. Annu. Rev. Biochem. (74), 681–
710. 
Kurt-Jones, E.A., Popova, L., Kwinn, L., Haynes, L.M., Jones, L.P., Tripp, R.A., Walsh, E.E., 
Freeman, M.W., Golenbock, D.T., Anderson, L.J., et al. (2000). Pattern recognition receptors 
TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. (1), 398–
401. 
Kurt-Jones, E. a, Chan, M., Zhou, S., Wang, J., Reed, G., Bronson, R., Arnold, M.M., Knipe, 
D.M., and Finberg, R.W. (2004). Herpes simplex virus 1 interaction with Toll-like receptor 2 
contributes to lethal encephalitis. Proc. Natl. Acad. Sci. (101), 1315–1320. 
Kurzȩpa, A., Da̧browska, K., Skaradziński, G., and Górski, A. (2009). Bacteriophage 
interactions with phagocytes and their potential significance in experimental therapy. Clin. 
Exp. Med. (9), 93–100. 
Kutateladze, M., and Adamia, R. (2010). Bacteriophages as potential new therapeutics to 
replace or supplement antibiotics. Trends Biotechnol. (28), 591–595. 
Kutter, E., and Sulakvelidze, A. (2004). Bacteriophages: biology and applications. 
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., and Abedon, S.T. 
(2010). Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. 
Biotechnol. (11), 69–86. 
L, F.-C., and K, F.-C. (2006). Staphylococcus aureus infections. 
LVII 
 
Laarman, A., Milder, F., Van Strijp, J., and Rooijakkers, S. (2010). Complement inhibition by 
Gram-positive pathogens: Molecular mechanisms and therapeutic implications. J. Mol. Med. 
(88), 115–120. 
Labrie, S.J., Samson, J.E., and Moineau, S. (2010). Bacteriophage resistance mechanisms. 
Nat. Rev. Microbiol. (8), 317–327. 
Lafaille, J.J., DeCloux, A., Bonneville, M., Takagaki, Y., and Tonegawa, S. (1989). Junctional 
sequences of T cell receptor γδ genes: Implications for γδ T cell lineages and for a novel 
intermediate of V-(D)-J joining. Cell (59), 859–870. 
Lalani, I., Bhol, K., and Ahmed, A.R. (1997). Interleukin-10: biology, role in inflammation 
and autoimmunity. Ann. Allergy. Asthma Immunol. (79), 469–483. 
Lammens, E., Ceyssens, P.-J., Voet, M., Hertveldt, K., Lavigne, R., and Volckaert, G. (2009). 
Representational Difference Analysis (RDA) of bacteriophage genomes. J. Microbiol. 
Methods (77), 207–213. 
Lang, R., Pauleau, A.-L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J.N., Rutschman, R., 
and Murray, P.J. (2003). SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 
(4), 546–550. 
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol. (10), R25. 
Lari, A.R., and Alaghehbandan, R. (2000). Nosocomial infections in an Iranian burn care 
center. Burns (26), 737–740. 
Lau, G.W., Hassett, D.J., and Britigan, B.E. (2005). Modulation of lung epithelial functions 
by Pseudomonas aeruginosa. Trends Microbiol. (13), 389–397. 
Lavigne, R., and Robben, J. (2012). Professor Dr. Richard Bruynoghe: A 1951 overview of his 
bacteriophage research spanning three decades. Bacteriophage (2), 1–4. 
Lavigne, R., Ceyssens, P.-J., and Robben, J. (2009). Phage proteomics: applications of mass 
spectrometry. Methods Mol. Biol. (502), 239–251. 
Lee, H., Hsu, F.F., Turk, J., and Groisman, E.A. (2004). The PmrA-regulated pmrC gene 
mediates phosphoethanolamine modification of lipid A and polymyxin resistance in 
Salmonella enterica. J. Bacteriol. (186), 4124–4133. 
Leidal, K.G., Munson, K.L., and Denning, G.M. (2001). Small molecular weight secretory 
factors from Pseudomonas aeruginosa have opposite effects on IL-8 and RANTES expression 
by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. (25), 186–195. 
Lejeune, D., Demoulin, J.-B., and Renauld, J.-C. (2001). Interleukin 9 induces expression of 
three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of 
cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses 
interleukin 9 signalling. Biochem. J. (353), 109–116. 
Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., and Hoffmann, J.A. (1996). The 
dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal 
LVIII 
 
response in Drosophila adults. Cell (86), 973–983. 
Letarov, A., and Kulikov, E. (2009). The bacteriophages in human- and animal body-
associated microbial communities. J. Appl. Microbiol. (107), 1–13. 
Letterio, J.J., and Roberts, A.B. (1997). TGF-beta: a critical modulator of immune cell 
function. Clin. Immunol. Immunopathol. (84), 244–250. 
Leung, C.Y. (Joey), and Weitz, J.S. (2017). Modeling the synergistic elimination of bacteria by 
phage and the innate immune system. J. Theor. Biol. (429), 241–252. 
Levin, J. (1988). The horseshoe crab: a model for Gram-negative sepsis in marine organisms 
and humans. Prog. Clin. Biol. Res. (272), 3–15. 
Levin, B.R., and Bull, J.J. (1996). Phage therapy revisited: The population biology of a 
bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat. (147), 881. 
Levin, B.R., and Bull, J.J. (2004). Population and evolutionary dynamics of phage therapy. 
Nat. Rev. Microbiol. (2), 166–173. 
Levin, J., and Bang, F.B. (1964). The role of endotoxin in the extracellular coagulation of 
limulus blood. Bull. Johns Hopkins Hosp. (115), 265–274. 
Levine, D.P. (2006). Vancomycin: a history. Clin. Infect. Dis. (42 Suppl 1), S5-12. 
Levy, S.B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes, challenges 
and responses. Nat. Med. (10), S122-9. 
Lew, W., Pai, M., Oxlade, O., Martin, D., and Menzies, D. (2008). Initial drug resistance and 
tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med. 
(149), 123–134. 
Lewis, S.M. (1994a). The mechanism of V(D)J joining: lessons from molecular, 
immunological, and comparative analyses. Adv. Immunol. (56), 27–150. 
Lewis, S.M. (1994b). P nucleotide insertions and the resolution of hairpin DNA structures in 
mammalian cells. Proc. Natl. Acad. Sci. (91), 1332–1336. 
Li, R., Yu, C., Li, Y., Lam, T.W., Yiu, S.M., Kristiansen, K., and Wang, J. (2009). SOAP2: An 
improved ultrafast tool for short read alignment. Bioinformatics (25), 1966–1967. 
Libert, C., Takahashi, N., Cauwels, A., Brouckaert, P., Bluethmann, H., and Fiers, W. (1994). 
Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes 
and lethality. Eur. J. Immunol. (24), 2237–2242. 
Liehn, E.A., Radu, E., and Schuh, A. (2013). Chemokine contribution in stem cell engraftment 
into the infarcted myocardium. Curr. Stem Cell Res. Ther. (8), 278–283. 
Lien, E., Means, T.K., Heine, H., Yoshimura, A., Kusumoto, S., Fukase, K., Fenton, M.J., 
Oikawa, M., Qureshi, N., Monks, B., et al. (2000). Toll-like receptor 4 imparts ligand-specific 
recognition of bacterial lipopolysaccharide. J. Clin. Invest. (105), 497–504. 
Lim, D., and Strynadka, N.C.J. (2002). Structural basis for the beta lactam resistance of 
LIX 
 
PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. (9), 870–876. 
Linden, S.K., Sutton, P., Karlsson, N.G., Korolik, V., and McGuckin, M.A. (2008). Mucins in 
the mucosal barrier to infection. Mucosal Immunol. (1), 183–197. 
Ling, W.L.W., Longley, R.L., Brassard, D.L., Armstrong, L., and Schaefer, E.J. (2002). Role 
of integrin αVβ3 in the production of recombinant adenoviruses in HEK-293 cells. Gene Ther. 
(9), 907–914. 
Liu, T., Sae-ueng, U., Li, D., Lander, G.C., Zuo, X., Jönsson, B., and Rau, D. (2014). Solid-to-
fluid – like DNA transition in viruses facilitates infection. Proc. Natl. Acad. Sci. (111), 
14675–14680. 
Livermore, D.M. (2007). Introduction: the challenge of multiresistance. Int. J. Antimicrob. 
Agents (29 Suppl 3), S1-7. 
Loc-Carrillo, C., and Abedon, S.T. (2011). Pros and cons of phage therapy. Bacteriophage 
(1), 111–114. 
Lodge, J.M., Minchin, S.D., Piddock, L.J., and Busby, S.J. (1990). Cloning, sequencing and 
analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa 
chromosomal ampC beta-lactamase. Biochem. J. (272), 627–631. 
Lomaga, M.A., Yeh, W.C., Sarosi, I., Duncan, G.S., Furlonger, C., Ho, A., Morony, S., 
Capparelli, C., Van, G., Kaufman, S., et al. (1999). TRAF6 deficiency results in osteopetrosis 
and defective interleukin-1, CD40, and LPS signaling. Genes Dev. (13), 1015–1024. 
Łoś, M., and Węgrzyn, G. (2012). Pseudolysogeny. In Advances in Virus Research, pp. 
339–349. 
Losman, J.A., Chen, X.P., Hilton, D., and Rothman, P. (1999). Cutting edge: SOCS-1 is a 
potent inhibitor of IL-4 signal transduction. J. Immunol. (162), 3770–3774. 
Lowy, F. (2003). Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. 
Invest. (111), 1265–1273. 
Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., and Knight, R. (2012). Diversity, 
stability and resilience of the human gut microbiota. Nature (489), 220–230. 
Lu, M.J., and Henning, U. (1994). Superinfection exclusion by T-even-type coliphages. Trends 
Microbiol. (2), 137–139. 
Lu, M.J., Stierhof, Y.D., and Henning, U. (1993). Location and unusual membrane topology 
of the immunity protein of the Escherichia coli phage T4. J. Virol. (67), 4905–4913. 
Lu, Y.C., Yeh, W.C., and Ohashi, P.S. (2008). LPS/TLR4 signal transduction pathway. 
Cytokine (42), 145–151. 
Lund, J., Sato, A., Akira, S., Medzhitov, R., and Iwasaki, A. (2003). Toll-like receptor 9-
mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 
(198), 513–520. 
Łusiak-Szelachowska, M., Żaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., 
LX 
 
Fortuna, W., Letkiewicz, S., Rogóż, P., Szufnarowski, K., Jończyk-Matysiak, E., et al. (2014). 
Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. (27), 295–
304. 
Luster, A.D. (1998). Chemokines--chemotactic cytokines that mediate inflammation. N. Engl. 
J. Med. (338), 436–445. 
Luster, A.D. (2002). The role of chemokines in linking innate and adaptive immunity. Curr. 
Opin. Immunol. (14), 129–135. 
Ly-Chatain, M.H. (2014). The factors affecting effectiveness of treatment in phages therapy. 
Front. Microbiol. (5), 1–7. 
Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T., 
and Springer, T.A. (1998). Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar 
neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. (95), 9448–
9453. 
Mackay, C. (2001). Chemokines: immunology’s high impact factors. Nat. Immunol. (2), 95–
101. 
Mackay, I.R., Rosen, F.S., Medzhitov, R., and Janeway, C. (2000). Innate Immunity. N. Engl. 
J. Med. (343), 338–344. 
Magrangeas, F., Boisteau, O., Denis, S., Jacques, Y., and Minvielle, S. (2001a). Negative 
regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3). Eur. 
Cytokine Netw. (12), 309–315. 
Magrangeas, F., Boisteau, O., Denis, S., Jacques, Y., and Minvielle, S. (2001b). Negative 
cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine 
signalling-3 (SOCS-3). Biochem. J. (353), 223–230. 
Mahad, D.J., Trebst, C., Kivisäkk, P., Staugaitis, S.M., Tucky, B., Wei, T., Lucchinetti, C.F., 
Lassmann, H., and Ransohoff, R.M. (2004). Expression of chemokine receptors CCR1 and 
CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III 
multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. (63), 262–273. 
Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Kłopot, A., Kaźmierczak, Z., 
Miernikiewicz, P., Piotrowicz, A., Ciekot, J., Owczarek, B., et al. (2015). Oral application of 
T4 phage induces weak antibody production in the gut and in the blood. Viruses (7), 4783–
4799. 
Manis, J.P., Tian, M., and Alt, F.W. (2002). Mechanism and control of class-switch 
recombination. Trends Immunol. (23), 31–39. 
Mann, N.H. (2008). The potential of phages to prevent MRSA infections. Res. Microbiol. 
(159), 400–405. 
Mantovani, A. (1999). The chemokine system: Redundancy for robust outputs. Immunol. 
Today (20), 254–257. 
Marcus, L., and Prusky, D. (1987). Effect of particle size of activated charcoal on seperation 
LXI 
 
of triton X-100 from protein, liver cytosol, and lipoxygenase extracts. Anal. Biochem. (163), 
112–116. 
Maresso, A.W., Baldwin, M.R., and Barbieri, J.T. (2004). Ezrin/Radixin/Moesin proteins are 
high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS. J. Biol. Chem. 
(279), 38402–38408. 
Marine, J.C., Topham, D.J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, 
A., and Ihle, J.N. (1999). SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. 
Cell (98), 609–616. 
Marrack, P., and Kappler, J. (1990). The staphylococcal enterotoxins and their relatives. 
Science (248), 705–711. 
Martens, E.C., Chiang, H.C., and Gordon, J.I. (2008). Mucosal glycan foraging enhances 
fitness and transmission of a saccharolytic human gut bacterial symbiont. Cell Host 
Microbe (4), 447–457. 
Martin, S.W., and Goodnow, C.C. (2002). Burst-enhancing role of the IgG membrane tail as a 
molecular determinant of memory. Nat. Immunol. (3), 182–188. 
Martinez, J.L., and Baquero, F. (2000). Mutation frequencies and antibiotic resistance. 
Antimicrob. Agents Chemother. (44), 1771–1777. 
Martinon, F., and Tschopp, J. (2005). NLRs join TLRs as innate sensors of pathogens. Trends 
Immunol. (26), 447–454. 
Mathis, D., and Benoist, C. (2009). AIRE. Annu. Rev. Immunol. (27), 287–312. 
Matloubian, M., David, A., Engel, S., Ryan, J.E., and Cyster, J.G. (2000). A transmembrane 
CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. (1), 298–304. 
Matsui, T., Akahoshi, T., Namai, R., Hashimoto, A., Kurihara, Y., Rana, M., Nishimura, A., 
Endo, H., Kitasato, H., Kawai, S., et al. (2001). Selective recruitment of CCR6-expressing cells 
by increased production of MIP-3 alpha in rheumatoid arthritis. Clin. Exp. Immunol. (125), 
155–161. 
Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, 
Z., Fujimoto, S., Nasimuzzaman, M.D., et al. (2003). Experimental protection of mice against 
lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J. Infect. Dis. 
(187), 613–624. 
Matsuzaki, S., Rashel, M., Uchiyama, J., Sakurai, S., Ujihara, T., Kuroda, M., Ikeuchi, M., 
Tani, T., Fujieda, M., Wakiguchi, H., et al. (2005). Bacteriophage therapy: A revitalized 
therapy against bacterial infectious diseases. J. Infect. Chemother. (11), 211–219. 
Matsuzaki, S., Uchiyama, J., Takemura-Uchiyama, I., and Daibata, M. (2014). Perspective: 
The age of the phage. Nature (509), S9–S9. 
Mazmanian, S.K., Cui, H.L., Tzianabos, A.O., and Kasper, D.L. (2005). An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune 
system. Cell (122), 107–118. 
LXII 
 
McGeough, M.D., Pena, C.A., Mueller, J.L., Pociask, D.A., Broderick, L., Hoffman, H.M., and 
Brydges, S.D. (2012). Cutting edge: IL-6 is a marker of inflammation with no direct role in 
inflammasome-mediated mouse models. J. Immunol. (189), 2707–2711. 
McMahon, S.A., Miller, J.L., Lawton, J.A., Kerkow, D.E., Hodes, A., Marti-Renom, M.A., 
Doulatov, S., Narayanan, E., Sali, A., Miller, J.F., et al. (2005). The C-type lectin fold as an 
evolutionary solution for massive sequence variation. Nat. Struct. Mol. Biol. (12), 886–892. 
McVay, C.S., Velásquez, M., and Fralick, J.A. (2007). Phage therapy of Pseudomonas 
aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. (51), 
1934–1938. 
Medhekar, B., and Miller, J.F. (2007). Diversity-generating retroelements. Curr. Opin. 
Microbiol. (10), 388–395. 
Medzhitov, R. (2007). Recognition of microorganisms and activation of the immune response. 
Nature (449), 819–826. 
Medzhitov, R., and Janeway, C.A.J. (1997). Innate immunity: impact on the adaptive immune 
response. Curr. Opin. Immunol. (9), 4–9. 
Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., and Janeway, 
C.A. (1998). MyD88 Is an Adaptor Protein in the hToll/IL-1 Receptor Family Signaling 
Pathways. Mol. Cell (2), 253–258. 
Medzhitov R, Preston-Hurlburt P, and Janeway CA Jr (1997). A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature (388), 394–397. 
Melief, C.J.M. (2003). Mini-review: Regulation of cytotoxic T lymphocyte responses by 
dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur. J. Immunol. 
(33), 2645–2654. 
Menéndez-Benito, V., and Neefjes, J. (2007). Autophagy in MHC class II presentation: 
sampling from within. Immunity (26), 1–3. 
Menzies, B.E. (2003). The role of fibronectin binding proteins in the pathogenesis of 
Staphylococcus aureus infections. Curr. Opin. Infect. Dis. (16), 225–229. 
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., 
Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009). Quality-Controlled Small-Scale 
Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS 
One (4), e4944. 
Merril, C.R. (2008). Bacteriophage Ecology (Cambridge: Cambridge University Press). 
Merril, C.R., Trigg, M.E., and Geier, M.R. (1973). Fate of Bacteriophage Lamba in non-
immune germ-free mice. Nature (246), 221–223. 
Merril, C.R., Biswas, B., Carlton, R., Jensen, N.C., Creed, G.J., Zullo, S., and Adhya, S. 




Metcalf, D., Greenhalgh, C.J., Viney, E., Willson, T.A., Starr, R., Nicola, N.A., Hilton, D.J., 
and Alexander, W.S. (2000). Gigantism in mice lacking suppressor of cytokine signalling-2. 
Nature (405), 1069–1073. 
Metzger IV, L.E., and Raetz, C.R.H. (2009). Purification and characterization of the lipid A 
disaccharide synthase (LpxB) from Escherichia coli, a peripheral membrane protein. 
Biochemistry (48), 11559–11571. 
Meyer, J.M., Neely, A., Stintzi, A., Georges, C., and Holder, I.A. (1996). Pyoverdin is essential 
for virulence of Pseudomonas aeruginosa. Infect. Immun. (64), 518–523. 
Meylan, E., Burns, K., Hofmann, K., Blancheteau, V., Martinon, F., Kelliher, M., and 
Tschopp, J. (2004). RIP1 is an essential mediator of Toll-like receptor 3–induced NF-κB 
activation TL - 5. Nat. Immunol. (5 VN-re), 503–507. 
Miao, E.A., Andersen-Nissen, E., Warren, S.E., and Aderem, A. (2007). TLR5 and Ipaf: dual 
sensors of bacterial flagellin in the innate immune system. Semin. Immunopathol. (29), 
275–288. 
Miedzybrodzki, R., Switala-Jelen, K., Fortuna, W., Weber-Dąbrowska, B., Przerwa, A., 
Lusiak-Szelachowska, M., Dąbrowska, K., Kurzepa, A., Boratynski, J., Syper, D., et al. 
(2008). Bacteriophage preparation inhibition of reactive oxygen species generation by 
endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. (131), 233–242. 
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., 
Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., et al. (2012). Clinical 
aspects of phage therapy. In Advances in Virus Research, pp. 73–121. 
Miernikiewicz, P., Dąbrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielińska, 
J., Rossowska, J., Pajtasz-Piasecka, E., Hodyra, K., Macegoniuk, K., et al. (2013). T4 phage 
and its head surface proteins do not stimulate inflammatory mediator production. PLoS One 
(8), e71036. 
Miernikiewicz, P., Kłopot, A., Soluch, R., Szkuta, P., Kęska, W., Hodyra-Stefaniak, K., 
Konopka, A., Nowak, M., Lecion, D., Kaźmierczak, Z., et al. (2016). T4 phage tail adhesin 
Gp12 counteracts LPS-induced inflammation in vivo. Front. Microbiol. (7). 
Miller, J.F.A.P. (2002). The discovery of thymus function and of thymus-derived lymphocytes. 
Immunol. Rev. (185), 7–14. 
Miller, L.G., and Diep, B.A. (2008). Colonization, fomites, and virulence: rethinking the 
pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. 
Clin. Infect. Dis. (46), 752–760. 
Mills, S., Shanahan, F., Stanton, C., Hill, C., Coffey, A., and Ross, R.P. (2013). Influence of 
bacteriophages in shaping the mammalian gut microbiota. Gut Microbes (4), 4–16. 
Min, I.M., Rothlein, L.R., Schrader, C.E., Stavnezer, J., and Selsing, E. (2005). Shifts in 
targeting of class switch recombination sites in mice that lack mu switch region tandem 
repeats or Msh2. J. Exp. Med. (201), 1885–1890. 
Minamoto, S., Ikegame, K., Ueno, K., Narazaki, M., Naka, T., Yamamoto, H., Matsumoto, T., 
LXIV 
 
Saito, H., Hosoe, S., and Kishimoto, T. (1997). Cloning and functional analysis of new 
members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. 
Biophys. Res. Commun. (237), 79–83. 
Minot, S., Sinha, R., Chen, J., Li, H., Keilbaugh, S. a, Wu, G.D., Lewis, J.D., and Bushman, 
F.D. (2011). The human gut virome: Inter-individual variation and dynamic response to diet. 
Genome Res. (21), 1616–1625. 
Minot, S., Grunberg, S., Wu, G.D., Lewis, J.D., and Bushman, F.D. (2012). Hypervariable loci 
in the human gut virome. Proc. Natl. Acad. Sci. (109), 3962–3966. 
Miyake, K. (2007). Innate immune sensing of pathogens and danger signals by cell surface 
Toll-like receptors. Semin. Immunol. (19), 3–10. 
Moak, M., and Molineux, I.J. (2000). Role of the Gp16 lytic transglycosylase motif in 
bacteriophage T7 virions at the initiation of infection. Mol. Microbiol. (37), 345–355. 
Moldovan, R., Chapman-McQuiston, E., and Wu, X.L. (2007). On kinetics of phage adsorption. 
Biophys. J. (93), 303–315. 
Momburg, F., and Tan, P. (2002). Tapasin—the keystone of the loading complex optimizing 
peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol. Immunol. (39), 
217–233. 
Monaco, J.J. (1992). A molecular model of MHC class-I-restricted antigen processing. 
Immunol. Today (13), 173–179. 
Moon, C., and Stappenbeck, T.S. (2012). Viral interactions with the host and microbiota in 
the intestine. Curr. Opin. Immunol. (24), 405–410. 
Moore, N.M., and Flaws, M.L. (2011). Antimicrobial resistance mechanisms in Pseudomonas 
aeruginosa. Clin. Lab. Sci. (24), 47–51. 
Moore, G.E., Gerner, R.E., and Franklin, H.A. (1967). Culture of normal human leukocytes.  
J. Am. Med. Assoc. (199), 519–524. 
Moore, K.J., Andersson, L.P., Ingalls, R.R., Monks, B.G., Li, R., Arnaout, M.A., Golenbock, 
D.T., and Freeman, M.W. (2000). Divergent response to LPS and bacteria in CD14-deficient 
murine macrophages. J. Immunol. (165), 4272–4280. 
Moreillon, P., Que, Y.A., and Bayer, A.S. (2002). Pathogenesis of streptococcal and 
staphylococcal endocarditis. Infect. Dis. Clin. North Am. (16), 297–318. 
Morgan, B.P., Marchbank, K.J., Longhi, M.P., Harris, C.L., and Gallimore, A.M. (2005). 
Complement: Central to innate immunity and bridging to adaptive responses. Immunol. 
Lett. (97), 171–179. 
Morita, Y., Naka, T., Kawazoe, Y., Fujimoto, M., Narazaki, M., Nakagawa, R., Fukuyama, 
H., Nagata, S., and Kishimoto, T. (2000). Signals transducers and activators of transcription 
(STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) 
suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc. Natl. Acad. 
Sci. (97), 5405–5410. 
LXV 
 
Morrison, D.C., and Leive, L. (1975). Fractions of lipopolysaccharide from Escherichia coli 
O111:B4 prepared by two extraction procedures. J. Biol. Chem. (250), 2911–2919. 
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008). Mapping and 
quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods (5), 621–628. 
Moser, B., Wolf, M., Walz, A., and Loetscher, P. (2004). Chemokines: Multiple levels of 
leukocyte migration control. Trends Immunol. (25), 75–84. 
Moskowitz, S.M., and Ernst, R.K. (2010). Endotoxins: structure, function and 
recognition (Springer Netherlands). 
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., and Coffman, R.L. (1986). Two 
types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities 
and secreted proteins. J. Immunol. (136), 2348–2357. 
Mosser, D.M. (2003). The many faces of macrophage activation. J. Leukoc. Biol. (73), 209–
212. 
Moynagh, P.N. (2005). TLR signalling and activation of IRFs: revisiting old friends from the 
NF-κB pathway. Trends Immunol. (26), 469–476. 
Müller, G., Höpken, U.E., and Lipp, M. (2003). The impact of CCR7 and CXCR5 on lymphoid 
organ development and systemic immunity. Immunol. Rev. (196), 265. 
Müller-Eberhard, H.J. (1988). Molecular organization and function of the complement system. 
Annu. Rev. Biochem. (57), 321–347. 
Munoz, C., Carlet, J., Fitting, C., Misset, B., Blériot, J.P., and Cavaillon, J.M. (1991). 
Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 
(88), 1747–1754. 
Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and Honjo, T. (2000). 
Class switch recombination and hypermutation require activation-induced cytidine 
deaminase (AID), a potential RNA editing enzyme. Cell (102), 553–563. 
Murphy, P.M. (2002). International Union of Pharmacology. XXX. Update on chemokine 
receptor nomenclature. Pharmacol. Rev. (54), 227–229. 
Murphy, K., Travers, P., and Walport, M. (2008). Janeway’s Immunobiology. 
Muta, T., and Iwanaga, S. (1996). Clotting and immune defense in Limulidae. Prog. Mol. 
Subcell. Biol. (15), 154–189. 
Muto, C.A., Jernigan, J.A., Ostrowsky, B.E., Richet, H.M., Jarvis, W.R., Boyce, J.M., Farr, 
B.M., and SHEA (2003). SHEA guideline for preventing nosocomial transmission of 
multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect. Control 
Hosp. Epidemiol. (24), 362–386. 
Muzio, M., Natoli, G., Saccani, S., Levrero, M., and Mantovani, A. (1998). The human toll 
signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream 
of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. (187), 2097–2101. 
LXVI 
 
Muzio, M., Polentarutti, N., Bosisio, D., Prahladan, M.K., and Mantovani, A. (2000). Toll-like 
receptors: a growing family of immune receptors that are differentially expressed and 
regulated by different leukocytes. J. Leukoc. Biol. (67), 450–456. 
Nagai, Y., Akashi, S., Nagafuku, M., Ogata, M., Iwakura, Y., Akira, S., Kitamura, T., Kosugi, 
A., Kimoto, M., and Miyake, K. (2002). Essential role of MD-2 in LPS responsiveness and 
TLR4 distribution. Nat. Immunol. (3), 667–672. 
Nagaki, M., Hughes, R.D., Lau, J.Y.N., and Williams, R. (1991). Removal of endotoxin and 
cytokines by adsorbents and the effect of plasma protein binding. Int. J. Artif. Organs (14), 
43–50. 
Nagaoka, H., Yu, W., and Nussenzweig, M.C. (2000). Regulation of RAG expression in 
developing lymphocytes. Curr. Opin. Immunol. (12), 187–190. 
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., 
Kajita, T., Taga, T., Yoshizaki, K., et al. (1997). Structure and function of a new STAT-
induced STAT inhibitor. Nature (387), 924–929. 
Navarro, F., and Muniesa, M. (2017). Phages in the human body. Front. Microbiol. (8), 566. 
Neefjes, J., M Jongsma, M.L., and Paul, P. (2011). Towards a systems understanding of MHC 
class I and MHC class II antigen presentation. Nat. Rev. Immunol. (11), 823–836. 
Neidhardt, E.A., Luther, M.A., and Recny, M.A. (1992). Rapid, two-step purification process 
for the preparation of pyrogen-free murine immunoglobulin G1 monoclonal antibodies. J. 
Chromatogr. A (590), 255–261. 
Ng, E., Trucksis, M., and Hooper, D. (1996). Quinolone resistance mutations in topoisomerase 
IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary 
target and DNA gyrase is. Antimicrob. Agents Chemother. (40), 1881–1888. 
Ng, E.Y.W., Trucksis, M., and Hooper, D.C. (1994). Quinolone resistance mediated by norA: 
Physiologic characterization and relationship to flqB, a quinolone resistance locus on the 
Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. (38), 1345–1355. 
Nguyen, H.H., Zemlin, M., Ivanov, I.I., Andrasi, J., Zemlin, C., Vu, H.L., Schelonka, R., 
Schroeder, H.W., and Mestecky, J. (2007). Heterosubtypic immunity to influenza A virus 
infection requires a properly diversified antibody repertoire. J. Virol. (81), 9331–9338. 
Nguyen, S., Baker, K., Padman, B.S., Weston, T.A., Schlosser, K., Lazarou, M., Luque, A., 
Rohwer, F., Blumberg, R., and Barr, J.J. (2017). Bacteriophage penetrate the body via 
epithelial transcytosis. MBio 1–22. 
Nicas, T.I., and Hancock, R.E. (1983). Pseudomonas aeruginosa outer membrane 
permeability: isolation of a porin protein F-deficient mutant. J. Bacteriol. (153), 281–285. 
Nicholson, S.E., Willson, T.A., Farley, A., Starr, R., Zhang, J.G., Baca, M., Alexander, W.S., 
Metcalf, D., Hilton, D.J., and Nicola, N.A. (1999). Mutational analyses of the SOCS proteins 
suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 
signal transduction. EMBO J. (18), 375–385. 
LXVII 
 
Nicholson, S.E., De Souza, D., Fabri, L.J., Corbin, J., Willson, T.A., Zhang, J.G., Silva, A., 
Asimakis, M., Farley, A., Nash, A.D., et al. (2000). Suppressor of cytokine signaling-3 
preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. 
Proc. Natl. Acad. Sci. (97), 6493–6498. 
Nicola, N.A., and Metcalf, D. (1988). Binding, internalization, and degradation of 125I-
multipotential colony-stimulating factor (interleukin-3) by FDCP-1 cells. Growth Factors 
(1), 29–39. 
Niedermann, G. (2002). Immunological functions of the proteasome. In Current Topics in 
Microbiology and Immunology, (Springer Berlin Heidelberg), pp. 91–136. 
Nitta, T., Murata, S., Ueno, T., Tanaka, K., and Takahama, Y. (2008). Thymic 
microenvironments for T-cell repertoire formation. Adv. Immunol. (99), 59–94. 
Nomiyama, H., Osada, N., and Yoshie, O. (2010). The evolution of mammalian chemokine 
genes. Cytokine Growth Factor Rev. (21), 253–262. 
Nordström, K., and Forsgren, A. (1974). Effect of protein A on adsorption of bacteriophages to 
Staphylococcus aureus. J. Virol. (14), 198–202. 
Nørgaard, P., Hougaard, S., Poulsen, H.S., and Spang-Thomsen, M. (1995). Transforming 
growth factor beta and cancer. Cancer Treat. Rev. (21), 367–403. 
Northrop, J.H. (1958). Studies on the origin of bacterial viruses. I-IV. J. Gen. Physiol. (42), 
109–136. 
Nurieva, R.I., Liu, X., and Dong, C. (2009). Yin-Yang of costimulation: Crucial controls of 
immune tolerance and function. Immunol. Rev. (229), 88–100. 
O’Garra, A., McEvoy, L.M., and Zlotnik, A. (1998). T-cell subsets: chemokine receptors guide 
the way. Curr. Biol. (8), R646–R649. 
O’Neill, L.A.J., and Bowie, A.G. (2007). The family of five: TIR-domain-containing adaptors 
in Toll-like receptor signalling. Nat. Rev. Immunol. (7), 353–364. 
O’Toole, G.A., and Kolter, R. (1998). Flagellar and twitching motility are necessary for 
Pseudomonas aeruginosa biofilm development. Mol. Microbiol. (30), 295–304. 
Ochs, H.D., Davis, S.D., and Wedgwood, R.J. (1971). Immunologic responses to bacteriophage 
phi-X 174 in immunodeficiency diseases. J. Clin. Invest. (50), 2559–2568. 
Oettgen, H.C. (2000). Regulation of the IgE isotype switch: new insights on cytokine signals 
and the functions of ε germline transcripts. Curr. Opin. Immunol. (12), 618–623. 
Oganesyan, G., Saha, S.K., Guo, B., He, J.Q., Shahangian, A., Zarnegar, B., Perry, A., and 
Cheng, G. (2006). Critical role of TRAF3 in the Toll-like receptor-dependent and -independent 
antiviral response. Nature (439), 208–211. 
Ogawa, S.K., Yurberg, E.R., Hatcher, V.B., Levitt, M.A., and Lowy, F.D. (1985). Bacterial 
adherence to human endothelial cells in vitro. Infect. Immun. (50), 218–224. 
Ogikubo, Y., Norimatsu, M., Noda, K., Takahashi, J., Inotsume, M., Tsuchiya, M., and 
LXVIII 
 
Tamura, Y. (2004). Evaluation of the bacterial endotoxin test for quantification of endotoxin 
contamination of porcine vaccines. Biologicals (32), 88–93. 
Okabe, S., Tauchi, T., Morita, H., Ohashi, H., Yoshimura, A., and Ohyashiki, K. (1999). 
Thrombopoietin induces an SH2-containing protein, CIS1, which binds to MP1: Involvement 
of the ubiquitin proteosome pathway. Exp. Hematol. (27), 1542–1547. 
van der Oost, J., Westra, E.R., Jackson, R.N., and Wiedenheft, B. (2014). Unravelling the 
structural and mechanistic basis of CRISPR-Cas systems. Nat. Rev. Microbiol. (12), 479–
492. 
Opal, S.M., Wherry, J.C., and Grint, P. (1998). Interleukin-10: potential benefits and possible 
risks in clinical infectious diseases. Clin. Infect. Dis. (27), 1497–1507. 
Opals, S.M., and DePalo, V.A. (2000). Anti-inflammatory cytokines. Impact Basic Res. 
Tomorrow’s Med. (117), 1162–1172. 
Orlofsky, A., Lin, E.Y., and Prystowsky, M.B. (1994). Selective induction of the beta 
chemokine C10 by IL-4 in mouse macrophages. J. Immunol. (152), 5084–5091. 
Orsini, E., Guarini, A., Chiaretti, S., Mauro, F.R., and Foa, R. (2003). The circulating 
dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective 
and unable to stimulate an effective T-cell response. Cancer Res. (63), 4497–4506. 
Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003). TICAM-1, an 
adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. 
Nat. Immunol. (4), 161–167. 
Osmon, S., Ward, S., Fraser, V.J., and Kollef, M.H. (2004). Hospital mortality for patients 
with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. CHEST J. (125), 
607–616. 
Ouyang, W., Rutz, S., Crellin, N., Valdez, P.A., and Hymowitz, S.G. (2011). Regulation and 
functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. 
Immunol. (29), 71–109. 
Ozinsky, A., Underhill, D.M., Fontenot, J.D., Hajjar, A.M., Smith, K.D., Wilson, C.B., 
Schroeder, L., and Aderem, A. (2000). The repertoire for pattern recognition of pathogens by 
the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. 
Acad. Sci. (97), 13766–13771. 
Pan, Y., Lloyd, C., Zhou, H., Dolich, S., Deeds, J., Gonzalo, J.A., Vath, J., Gosselin, M., Ma, 
J., Dussault, B., et al. (1997). Neurotactin, a membrane-anchored chemokine upregulated in 
brain inflammation. Nature (387), 611–617. 
Pankhaniya, R.R., Tamura, M., Allmond, L.R., Moriyama, K., Ajayi, T., Wiener-Kronish, J.P., 
and Sawa, T. (2004). Pseudomonas aeruginosa causes acute lung injury via the catalytic 
activity of the patatin-like phospholipase domain of ExoU. Crit. Care Med. (32), 2293–2299. 
Papadakis, K.A., and Targan, S.R. (2000). Role of cytokines in the pathogenesis of 
inflammatory bowel disease. Annu. Rev. Med. (51), 289–298. 
LXIX 
 
Papageorgiou, A.C., Collins, C.M., Gutman, D.M., Kline, J.B., O’Brien, S.M., Tranter, H.S., 
and Acharya, K.R. (1999). Structural basis for the recognition of superantigen streptococcal 
pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. EMBO J. (18), 
9–21. 
Park, E.S., Kim, H., Suh, J.M., Park, S.J., Kwon, O.-Y., Kim, Y.K., Ro, H.K., Cho, B.Y., 
Chung, J., and Shong, M. (2000). Thyrotropin induces SOCS-1 (Suppressor of Cytokine 
Signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol. Endocrinol. (14), 440–448. 
Park, K., Cha, K.E., and Myung, H. (2014). Observation of inflammatory responses in mice 
orally fed with bacteriophage T7. J. Appl. Microbiol. (117), 627–633. 
Parker, D. (1993). T Cell-dependent B cell activation. Annu. Rev. Immunol. (11), 331–360. 
Parracho, H.M., Burrowes, B.H., Enright, M.C., McConville, M.L., and Harper, D.R. (2012). 
The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. 
Genet. Med. (6), 279–286. 
Patti, J.M., Allen, B.L., McGavin, M.J., and Höök, M. (1994). MSCRAMM-mediated 
adherence of microorganisms to host tissues. Annu. Rev. Microbiol. (48), 585–617. 
Paul, W.E. (1991). Interleukin-4: a prototypic immunoregulatory lymphokine. Blood (77), 
1859–1870. 
Paul, J.H., and Jiang, S.C. (2001). Lysogeny and transduction. Methods Microbiol. (30), 
105–125. 
Pavlovskis, O.R., Iglewski, B.H., and Pollack, M. (1978). Mechanism of action of Pseudomonas 
aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation 
of elongation factor 2. Infect. Immun. (19), 29–33. 
Payne, R.J., and Jansen, V. a (2001). Understanding bacteriophage therapy as a density-
dependent kinetic process. J. Theor. Biol. (208), 37–48. 
Payne, R.J.H., and Jansen, V.A.A. (2003). Pharmacokinetic principles of bacteriophage 
therapy. Clin. Pharmacokinet. (42), 315–325. 
Payne, R.J.H., and Jansen, V. a a (2000). Phage therapy: The peculiar kinetics of self-
replicating pharmaceuticals. Clin. Pharmacol. Ther. (68), 225–230. 
Peled, J.U., Kuang, F.L., Iglesias-ussel, M.D., Roa, S., Kalis, S.L., Goodman, M.F., and 
Scharff, M.D. (2008). The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 
(26), 481–511. 
Perrier, S., Darakhshan, F., and Hajduch, E. (2006). IL-1 receptor antagonist in metabolic 
diseases: Dr Jekyll or Mr Hyde?. FEBS Lett. (580), 6289–6294. 
Perry, A.K., Chen, G., Zheng, D., Tang, H., and Cheng, G. (2005). The host type I interferon 
response to viral and bacterial infections. Cell Res. (15), 407–422. 
Petersen, S.V., Thiel, S., Jensen, L., Vorup-Jensen, T., Koch, C., and Jensenius, J.C. (2000). 




Petersen-Mahrt, S.K., Harris, R.S., and Neuberger, M.S. (2002). AID mutates E. coli 
suggesting a DNA deamination mechanism for antibody diversification. Nature (418), 99–
103. 
Petsch, D., and Anspach, F.B. (2000). Endotoxin removal from protein solutions. J. 
Biotechnol. (76), 97–119. 
Pezet, A., Lè, H., Favre, N., Kelly, P.A., and Edery, M. (1999). Inhibition and restoration of 
prolactin signal transduction by suppressors of cytokine signaling. J. Biol. Chem. (274), 
24497–24502. 
Pham, P., Bransteitter, R., Petruska, J., and Goodman, M.F. (2003). Processive AID-catalysed 
cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 
(424), 103–107. 
Pincus, N.B., Reckhow, J.D., Saleem, D., Jammeh, M.L., Datta, S.K., and Myles, I.A. (2015). 
Strain specific phage treatment for Staphylococcus aureus infection is influenced by host 
immunity and site of infection. PLoS One (10), 1–16. 
Pingoud, A., Fuxreiter, M., Pingoud, V., and Wende, W. (2005). Type II restriction 
endonucleases: Structure and mechanism. Cell. Mol. Life Sci. (62), 685–707. 
Pires, D.P., Vilas Boas, D., Sillankorva, S., and Azeredo, J. (2015). Phage therapy: a step 
forward in the treatment of Pseudomonas aeruginosa infections. J. Virol. (89), JVI.00385-15. 
Pirnay, J.P., De Vos, D., Cochez, C., Bilocq, F., Pirson, J., Struelens, M., Duinslaeger, L., 
Cornelis, P., Zizi, M., and Vanderkelen, A. (2003). Molecular epidemiology of Pseudomonas 
aeruginosa colonization in a burn unit: Persistence of a multidrug-resistant clone and a silver 
sulfadiazine-resistant clone. J. Clin. Microbiol. (41), 1192–1202. 
Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., 
Silva, M., Galanos, C., et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr 
mice: mutations in Tlr4 gene. Science (282), 2085–2088. 
Poltorak, A., Ricciardi-Castagnoli, P., Citterio, S., and Beutler, B. (2000). Physical contact 
between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. 
Proc. Natl. Acad. Sci. (97), 2163–2167. 
Poole, K. (2007). Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. (39), 162–
176. 
Poulsen, L.K., Lan, F., Kristensen, C.S., Hobolth, P., Molin, S., and Krogfelt, K.A. (1994). 
Spatial distribution of Escherichia coli in the mouse large intestine inferred from rRNA in 
situ hybridization. Infect. Immun. (62), 5191–5194. 
Prasad, G.S., Radhakrishnan, R., Mitchell, D.T., Earhart, C.A., Dinges, M.M., Cook, W.J., 
Schlievert, P.M., and Ohlendorf, D.H. (1997). Refined structures of three crystal forms of toxic 




Pride, D.T., Salzman, J., Haynes, M., Rohwer, F., Davis-Long, C., White, R.A., Loomer, P., 
Armitage, G.C., and Relman, D.A. (2012). Evidence of a robust resident bacteriophage 
population revealed through analysis of the human salivary virome. ISME J. (6), 915–926. 
Proctor, L.M. (1997). Advances in the study of marine viruses. Microsc. Res. Tech. (37), 
136–161. 
Proudfoot, A.E., Handel, T.M., Johnson, Z., Lau, E.K., LiWang, P., Clark-Lewis, I., Borlat, 
F., Wells, T.N., and Kosco-Vilbois, M.H. (2003). Glycosaminoglycan binding and 
oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. 
Sci. (100), 1885–1890. 
Przerwa, A., Zimecki, M., Świtała-Jeleń, K., Dąbrowska, K., Krawczyk, E., Łuczak, M., 
Weber-Dąbrowska, B., Syper, D., Miȩdzybrodzki, R., and Górski, A. (2006). Effects of 
bacteriophages on free radical production and phagocytic functions. Med. Microbiol. 
Immunol. (195), 143–150. 
Puig, A., Jofre, J., Araujo, R., Frias-Lopez, J., Jofre, J., and Frias-Lopez, J. (2001). 
Identification of cell wall proteins of Bacteroides fragilis to which bacteriophage B40-8 binds 
specifically. Microbiol. (147), 281–288. 
Pulendran, B., Palucka, K., and Banchereau, J. (2001). Sensing pathogens and tuning 
immune responses. Science (293), 253–256. 
Qasimi, P., Ming-Lum, A., Ghanipour, A., Ong, C.J., Cox, M.E., Ihle, J., Cacalano, N., 
Yoshimura, A., and Mui, A.L.-F. (2006). Divergent mechanisms utilized by SOCS3 to mediate 
interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by 
macrophages. J. Biol. Chem. (281), 6316–6324. 
Qin, H., Holdbrooks, A.T., Liu, Y., Reynolds, S.L., Yanagisawa, L.L., and Benveniste, E.N. 
(2012). SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J. 
Immunol. (189), 3439–3448. 
Qu, C., Edwards, E.W., Tacke, F., Angeli, V., Llodrá, J., Sanchez-Schmitz, G., Garin, A., 
Haque, N.S., Peters, W., van Rooijen, N., et al. (2004). Role of CCR8 and other chemokine 
pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J. Exp. Med. 
(200), 1231–1241. 
Que-Gewirth, N.L.S., Karbarz, M.J., Kalb, S.R., Cotter, R.J., and Raetz, C.R.H. (2003). Origin 
of the 2-amino-2-deoxy-gluconate unit in Rhizobium leguminosarum lipid A: Expression 
cloning of the outer membrane oxidase LpxQ. J. Biol. Chem. (278), 12120–12129. 
Qureshi, S.T., Larivière, L., Leveque, G., Clermont, S., Moore, K.J., Gros, P., and Malo, D. 
(1999). Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 
(189), 615–625. 
Rada, C., Williams, G.T., Nilsen, H., Barnes, D.E., Lindahl, T., and Neuberger, M.S. (2002). 
Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in 
UNG-deficient mice. Curr. Biol. (12), 1748–1755. 
Raetz, C. (1990). Biochemistry of endotoxins. Annu. Rev. Biochem. (59), 129–170. 
LXXII 
 
Raetz, C.R., and Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 
(71), 635–700. 
Raetz, C.R.H., Reynolds, C.M., Trent, M.S., and Bishop, R.E. (2007). Lipid A modification 
systems in gram-negative bacteria. Annu. Rev. Biochem. (76), 295–329. 
Ram, P.A., and Waxman, D.J. (1999). SOCS/CIS protein inhibition of growth hormone-
stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. (274), 35553–35561. 
Ramesh, V., Fralick, J.A., and Rolfe, R.D. (1999). Prevention of Clostridium difficile-induced 
ileocecitis with bacteriophage. Anaerobe (5), 69–78. 
Rammensee, H.G., Falk, K., and Rötzschke, O. (1993). Peptides naturally presented by MHC 
class I molecules. Annu. Rev. Immunol. (11), 213–244. 
Ramsay, A.J., Husband, A.J., Ramshaw, I.A., Bao, S., Matthaei, K.I., Koehler, G., and Kopf, 
M. (1994). The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science (264), 
561–563. 
Ramsey, D.M., and Wozniak, D.J. (2005). Understanding the control of Pseudomonas 
aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic 
fibrosis. Mol. Microbiol. (56), 309–322. 
Rao, A., Luo, C., and Hogan, P.G. (1997). Transcription factors of the NFAT family: regulation 
and function. Annu Rev Immunol (15), 707–747. 
Reddy, K.J., Kuwabara, T., and Sherman, L.A. (1988). A simple and efficient procedure for 
the isolation of high-quality phage λ DNA using a DEAE-cellulose column. Anal. Biochem. 
(168), 324–331. 
Reindel, R., and Fiore, C.R. (2017). Phage therapy: Considerations and challenges for 
development. Clin. Infect. Dis. (64), 1589–1590. 
Rello, J., Ollendorf, D.A., Oster, G., Vera-Llonch, M., Bellm, L., Redman, R., and Kollef, M.H. 
(2002). Epidemiology and outcomes of ventilator-associated pneumonia in a large US 
database. CHEST J. (122), 2115–2121. 
Ren, S., Peng, Z., Mao, J.-H., Yu, Y., Yin, C., Gao, X., Cui, Z., Zhang, J., Yi, K., Xu, W., et al. 
(2012). RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene 
fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 
(22), 806–821. 
Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R., Granucci, F., 
Kraehenbuhl, J.P., and Ricciardi-Castagnoli, P. (2001). Dendritic cells express tight junction 
proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. (2), 361–
367. 
Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O., Catalan, N., Forveille, M., 
Dufourcq-Lagelouse, R., Gennery, A., et al. (2000). Activation-induced cytidine deaminase 
(AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). 
Cell (102), 565–575. 
LXXIII 
 
Reyes, A., Haynes, M., Hanson, N., Angly, F.E., Heath, A.C., Rohwer, F., and Gordon, J.I. 
(2010). Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature (466), 
334–338. 
Reynolds, C.M. (2006). An outer membrane enzyme encoded by Salmonella typhimurium lpxR 
that removes the 3’-acyloxyacyl moiety of lipid A. J. Biol. Chem. (281), 21974–21987. 
Reynolds, C.M., Kalb, S.R., Cotter, R.J., and Raetz, C.R.H. (2005). A phosphoethanolamine 
transferase specific for the outer 3-deoxy-D-manno-octulosonic acid residue of Escherichia coli 
lipopolysaccharide: Identification of the eptB gene and Ca2+ hypersensitivity of an eptB 
deletion mutant. J. Biol. Chem. (280), 21202–21211. 
Rhoads, D.D., Wolcott, R.D., Kuskowski, M. a, Wolcott, B.M., Ward, L.S., and Sulakvelidze, 
A. (2009). Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety 
trial. J. Wound Care (18), 237–238, 240–243. 
Richardella, A., Roushan, P., Mack, S., Zhou, B., Huse, D.A., Awschalom, D.D., and Yazdani, 
A. (2010). Visualizing critical correlations near the metal-insulator transition in Ga1-
xMnxAs. Science (327), 665–669. 
Roach, D.R., Leung, C.Y., Henry, M., Morello, E., Singh, D., Santo, P.D., Weitz, J.S., 
Debarbieux, L., Unit, I.I., Di Santo, J.P., et al. (2017). Synergy between the host immune 
system and bacteriophage is essential for successful phage therapy against an acute 
respiratory pathogen. Cell Host Microbe (22), 38–47.e4. 
Robinson, D., Walsh, P.R., and Bonventre, J.A. (2001). Restriction Endonucleases 
(Springer Berlin Heidelberg). 
Rödström, K.E.J., Elbing, K., and Lindkvist-Petersson, K. (2014). Structure of the 
superantigen Staphylococcal enterotoxin B in complex with TCR and peptide–MHC 
demonstrates absence of TCR–peptide contacts. J. Immunol. (193), 1998–2004. 
Rollins, B.J. (1997). Chemokines. Blood (90), 909–928. 
Rose, T., Verbeken, G., Vos, D.D., Merabishvili, M., Vaneechoutte, M., Jennes, S., Zizi, M., 
and Pirnay, J.-P. (2014). Experimental phage therapy of burn wound infection : difficult first 
steps. Int. J. Burn Trauma (4), 66–73. 
Rossi, D., and Zlotnik, A. (2000). The biology of chemokines and their receptors. Annu. Rev. 
Immunol. (18), 217–242. 
Rotundicauda, C. (1998). Cloned factor C cDNA of the singapore horshoe crab, 
Carcinoscorpius rottundicauda and purification of factor C proenzyme. Patent 81–84. 
Rubinstein, A., Mizrachi, Y., Bernstein, L., Shliozberg, J., Golodner, M., Liu, G.Q., and Ochs, 
H.D. (2000). Progressive specific immune attrition after primary, secondary and tertiary 
immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS 
(14), F55–F62. 
Ruiz, N., Gronenberg, L.S., Kahne, D., and Silhavy, T.J. (2008). Identification of two inner-
membrane proteins required for the transport of lipopolysaccharide to the outer membrane of 
Escherichia coli. Proc. Natl. Acad. Sci. (105), 5537–5542. 
LXXIV 
 
Rus, H., Cudrici, C., and Niculescu, F. (2005). The role of the complement system in innate 
immunity. Immunol. Res. (33), 103–112. 
Rush, J.S., Liu, M., Odegard, V.H., Unniraman, S., and Schatz, D.G. (2005). Expression of 
activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic 
basis for division-linked class switch recombination. Proc. Natl. Acad. Sci. (102), 13242–
13247. 
Rutten, L., Geurtsen, J., Lambert, W., Smolenaers, J.J.M., Bonvin, A.M., de Haan, A., van 
der Ley, P., Egmond, M.R., Gros, P., and Tommassen, J. (2006). Crystal structure and 
catalytic mechanism of the LPS 3-O-deacylase PagL from Pseudomonas aeruginosa. Proc. 
Natl. Acad. Sci. (103), 7071–7076. 
Ruzek, M.C., Miller, A.H., Opal, S.M., Pearce, B.D., and Biron, C.A. (1997). Characterization 
of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous 
glucocorticoid induction during murine cytomegalovirus infection. J. Exp. Med. (185), 1185–
1192. 
Sadegh-Nasseri, S., Chen, M., Narayan, K., and Bouvier, M. (2008). The convergent roles of 
tapasin and HLA-DM in antigen presentation. Trends Immunol. (29), 141–147. 
Sadikot, R.T., Blackwell, T.S., Christman, J.W., and Prince, A.S. (2005). Pathogen-host 
interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. (171), 
1209–1223. 
Sadowski, C.L., Choi, T.S., Le, M., Wheeler, T.T., Wang, L.H., and Sadowski, H.B. (2001). 
Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is 
mediated by Stat5. J. Biol. Chem. (276), 20703–20710. 
Saldanha, A.J. (2004). Java Treeview--extensible visualization of microarray data. 
Bioinformatics (20), 3246–3248. 
Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C.R., Qin, S., and 
Lanzavecchia, A. (1998). Rapid and coordinated switch in chemokine receptor expression 
during dendritic cell maturation. Eur. J. Immunol. (28), 2760–2769. 
Salmond, R.J., Filby, A., Qureshi, I., Caserta, S., and Zamoyska, R. (2009). T-cell receptor 
proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, 
differentiation, and tolerance. Immunol. Rev. (228), 9–22. 
Samarasinghe, R., Tailor, P., Tamura, T., Kaisho, T., Akira, S., and Ozato, K. (2006). 
Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor 
signaling. J. Interf. Cytokine Res. (26), 893–900. 
Sampson, T.R., Saroj, S.D., Llewellyn, A.C., Tzeng, Y.-L., and Weiss, D.S. (2013). A 
CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature (497), 
254–257. 
Samson, J.E., Magadán, A.H., Sabri, M., and Moineau, S. (2013). Revenge of the phages: 
defeating bacterial defences. Nat. Rev. Microbiol. (11), 675–687. 
Sartor, R.B. (1994). Cytokines in intestinal inflammation: pathophysiological and clinical 
LXXV 
 
considerations. Gastroenterology (106), 533–539. 
Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I., and Yoshimura, A. (2000). 
CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and 
JAK2. J. Biol. Chem. (275), 29338–29347. 
Sato, H., Frank, D.W., Hillard, C.J., Feix, J.B., Pankhaniya, R.R., Moriyama, K., Finck-
Barbançon, V., Buchaklian, A., Lei, M., Long, R.M., et al. (2003). The mechanism of action of 
the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J. (22), 2959–2969. 
Sato, S., Sanjo, H., Takeda, K., Ninomiya-Tsuji, J., Yamamoto, M., Kawai, T., Matsumoto, 
K., Takeuchi, O., and Akira, S. (2005). Essential function for the kinase TAK1 in innate and 
adaptive immune responses. Nat. Immunol. (6), 1087–1095. 
Sayner, S.L., Frank, D.W., King, J., Chen, H., VandeWaa, J., and Stevens, T. (2004). 
Paradoxical cAMP-induced lung endothelial hyperpermeability revealed by Pseudomonas 
aeruginosa ExoY. Circ. Res. (95), 196–203. 
Scarpellini, E., Ianiro, G., Attili, F., Bassanelli, C., De Santis, A., and Gasbarrini, A. (2015). 
The human gut microbiota and virome: Potential therapeutic implications. Dig. Liver Dis. 
(47), 1007–1012. 
Schad, E.M., Zaitseva, I., Zaitsev, V.N., Dohlsten, M., Kalland, T., Schlievert, P.M., 
Ohlendorf, D.H., and Svensson, L.A. (1995). Crystal structure of the superantigen 
staphylococcal enterotoxin type A. EMBO J. (14), 3292–3301. 
Schluter, J., and Foster, K.R. (2012). The evolution of mutualism in gut microbiota via host 
epithelial selection. PLoS Biol. (10), e1001424. 
Schmid, D., Pypaert, M., and Münz, C. (2007). Antigen-loading compartments for major 
histocompatibility complex class II molecules continuously receive input from 
autophagosomes. Immunity (26), 79–92. 
Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P.C., and Schaper, F. (2000). SOCS3 exerts 
its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site 
of gp130. J. Biol. Chem. (275), 12848–12856. 
Schrader, C.E., Vardo, J., Linehan, E., Twarog, M.Z., Niedernhofer, L.J., Hoeijmakers, J.H.J., 
and Stavnezer, J. (2004). Deletion of the nucleotide excision repair gene Ercc1 reduces 
immunoglobulin class switching and alters mutations near switch recombination junctions. 
J. Exp. Med. (200), 321–330. 
Schrader, C.E., Linehan, E.K., Mochegova, S.N., Woodland, R.T., and Stavnezer, J. (2005). 
Inducible DNA breaks in Ig S regions are dependent on AID and UNG. J. Exp. Med. (202), 
561–568. 
Schreuder, H., Tardif, C., Trump-Kallmeyer, S., Soffientini, A., Sarubbi, E., Akeson, A., 
Bowlin, T., Yanofsky, S., and Barrett, R.W. (1997). A new cytokine-receptor binding mode 
revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature (386), 194–
200. 
Schroeder, H.W., and Cavacini, L. (2010). Structure and function of immunoglobulins. J. 
LXXVI 
 
Allergy Clin. Immunol. (125), S41–S52. 
Schulz, B.L., Sloane, A.J., Robinson, L.J., Prasad, S.S., Lindner, R.A., Robinson, M., Bye, 
P.T., Nielson, D.W., Harry, J.L., Packer, N.H., et al. (2007). Glycosylation of sputum mucins 
is altered in cystic fibrosis patients. Glycobiology (17), 698–712. 
Schutyser, E., Struyf, S., and Van Damme, J. (2003). The CC chemokine CCL20 and its 
receptor CCR6. Cytokine Growth Factor Rev. (14), 409–426. 
Schwab, J.H., Brown, R.R., Anderle, S.K., and Schlievert, P.M. (1993). Superantigen can 
reactivate bacterial cell wall-induced arthritis. J. Immunol. (150), 4151–4159. 
Schwalbe, R.S., Stapleton, J.T., and Gilligan, P.H. (1987). Emergence of Vancomycin 
resistance in coagulase-negative Staphylococci. N. Engl. J. Med. (316), 927–931. 
Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C.J. (1999). 
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 
2. J. Biol. Chem. (274), 17406–17409. 
Servick, K. (2016). Beleaguered phage therapy trial presses on. Science (352), 1506–1506. 
Sewunet, T., Demissie, Y., Mihret, A., and Abebe, T. (2013). Bacterial profile and 
antimicrobial susceptibility pattern of isolates among burn patients at yekatit 12 hospital 
burn center, Addis Ababa, Ethiopia. Ethiop. J. Health Sci. (23), 490–491. 
Shaver, C.M., and Hauser, A.R. (2004). Relative contributions of Pseudomonas aeruginosa 
ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. (72), 6969–6977. 
Shaw, M.H., Reimer, T., Kim, Y.-G., and Nuñez, G. (2008). NOD-like receptors (NLRs): bona 
fide intracellular microbial sensors. Curr. Opin. Immunol. (20), 377–382. 
Shearer, W.T., Lugg, D.J., Rosenblatt, H.M., Nickolls, P.M., Sharp, R.M., Reuben, J.M., and 
Ochs, H.D. (2001). Antibody responses to bacteriophage φX-174 in human subjects exposed to 
the Antarctic winter-over model of spaceflight. J. Allergy Clin. Immunol. (107), 160–164. 
Shen, X., Hong, F., Nguyen, V.-A., and Gao, B. (2000). IL-10 attenuates IFN-α-activated 
STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. (480), 132–136. 
Shimaoka, T., Kume, N., Minami, M., Hayashida, K., Kataoka, H., Kita, T., and Yonehara, 
S. (2000). Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, 
SR-PSOX, on macrophages. J. Biol. Chem. (275), 40663–40666. 
Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., and Kimoto, M. 
(1999). MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 
4. J. Exp. Med. (189), 1777–1782. 
Showsh, S. a, Boever, E.H.D., and Don, B. (2001). Vancomycin resistance plasmid in 
Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by 
Staphylococcus aureus. Antimicrob. Agents Chemother. (45), 2177–2179. 
Sigal, L.J., Crotty, S., Andino, R., and Rock, K.L. (1999). Cytotoxic T-cell immunity to virus-




Silipo, A., and Molinaro, A. (2010). Endotoxins: Structure, function and recognition. 
Sims, J.E., Gayle, M.A., Slack, J.L., Alderson, M.R., Bird, T.A., Giri, J.G., Colotta, F., Re, F., 
Mantovani, A., and Shanebeck, K. (1993). Interleukin 1 signaling occurs exclusively via the 
type I receptor. Proc. Natl. Acad. Sci. (90), 6155–6159. 
Skurnik, M., and Strauch, E. (2006). Phage therapy: Facts and fiction. Int. J. Med. 
Microbiol. (296), 5–14. 
Sleckman, B., Gorman, J., and Alt, F. (1996). Accessibility control of antigen-receptor 
variable-region gene assembly: role of cis-acting elements. Annu. Rev. Immunol. (14), 459–
481. 
Smale, S.T. (2014). Transcriptional regulation in the immune system: A status report. Trends 
Immunol. (35), 190–194. 
Smith, H.W., Huggins, M.B., and Shaw, K.M. (1987). Factors influencing the survival and 
multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. 
(133), 1127–1135. 
Snapper, C.M., Marcu, K.B., and Zelazowski, P. (1997). The immunoglobulin class switch: 
beyond “accessibility.” Immunity (6), 217–223. 
Solomon, S., Horan, T., Andrus, M., Edwards, J., Emori, G., Fridkin, S., Peavy, G., Tolson, 
J., Upadhyayula, S., and Yi, B. (2002). National Nosocomial Infections Surveillance (NNIS) 
System report, data summary from January 1992 to June 2002, issued August 2002. Am. J. 
Infect. Control (30), 458–475. 
Song, M.M., and Shuai, K. (1998). The suppressor of cytokine signaling (SOCS) 1 and SOCS3 
but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. 
J. Biol. Chem. (273), 35056–35062. 
Song, W., Lee, K.M., Kang, H.J., Shin, D.H., and Kim, D.K. (2001). Microbiologic aspects of 
predominant bacteria isolated from the burn patients in Korea. Burns (27), 136–139. 
Sonnenburg, J.L. (2005). Glycan foraging in vivo by an intestine-adapted bacterial symbiont. 
Science (307), 1955–1959. 
Soothill, J.S. (1994). Bacteriophage prevents destruction of skin grafts by Pseudomonas 
aeruginosa. Burns (20), 209–211. 
Sørensen, T.L., Tani, M., Jensen, J., Pierce, V., Lucchinetti, C., Folcik, V.A., Qin, S., Rottman, 
J., Sellebjerg, F., Strieter, R.M., et al. (1999). Expression of specific chemokines and 
chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. 
Invest. (103), 807–815. 
Sozzani, S., Allavena, P., D’Amico, G., Luini, W., Bianchi, G., Kataura, M., Imai, T., Yoshie, 
O., Bonecchi, R., and Mantovani, A. (1998). Differential regulation of chemokine receptors 




Sozzani, S., Allavena, P., Vecchi, A., and Mantovani, A. (2000). Chemokines and dendritic cell 
traffic. J. Clin. Immunol. (20), 151–160. 
Sperandeo, P., Cescutti, R., Villa, R., Di Benedetto, C., Candia, D., Dehò, G., and Polissi, A. 
(2007). Characterization of lptA and lptB, two essential genes implicated in 
lipopolysaccharide transport to the outer membrane of Escherichia coli. J. Bacteriol. (189), 
244–253. 
Sperandeo, P., Lau, F.K., Carpentieri, A., De Castro, C., Molinaro, A., Dehò, G., Silhavy, T.J., 
and Polissi, A. (2008). Functional analysis of the protein machinery required for transport of 
lipopolysaccharide to the outer membrane of Escherichia coli. J. Bacteriol. (190), 4460–4469. 
Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., and Gerlo, 
S. (2011). Interleukin-6, a mental cytokine. Brain Res. Rev. (67), 157–183. 
Sporri, B., Kovanen, P.E., Sasaki, A., Yoshimura, A., and Leonard, W.J. (2001). 
JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood (97), 221–
226. 
Spratt, B.G., and Cromie, K.D. (1988). Penicillin-binding proteins of gram-negative bacteria. 
Rev. Infect. Dis. (10), 699–711. 
Sriramulu, D.D., Lünsdorf, H., Lam, J.S., and Römling, U. (2005). Microcolony formation: a 
novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. 
Microbiol. (54), 667–676. 
Starr, R., Willson, T.A., Viney, E.M., Murray, L.J., Rayner, J.R., Jenkins, B.J., Gonda, T.J., 
Alexander, W.S., Metcalf, D., Nicola, N.A., et al. (1997). A family of cytokine-inducible 
inhibitors of signalling. Nature (387), 917–921. 
Stavnezer, J. (1996a). Antibody class switching. Adv. Immunol. (61), 79–146. 
Stavnezer, J. (1996b). Immunoglobulin class switching. Curr. Opin. Immunol. (8), 199–
205. 
Stavnezer, J., and Schrader, C.E. (2006). Mismatch repair converts AID-instigated nicks to 
double-strand breaks for antibody class-switch recombination. Trends Genet. (22), 23–28. 
Stavnezer, J., Guikema, J.E.J., and Schrader, C.E. (2008). Mechanism and regulation of class 
switch recombination. Annu. Rev. Immunol. (26), 261–292. 
Steele, E.J. (2009). Mechanism of somatic hypermutation: Critical analysis of strand biased 
mutation signatures at A:T and G:C base pairs. Mol. Immunol. (46), 305–320. 
Steen, S.B., Zhu, C., and Roth, D.B. (1996). Double-strand breaks, DNA hairpins, and the 
mechanism of V(D)J recombination. Curr. Top. Microbiol. Immunol. (217), 61–77. 
Strateva, T., and Yordanov, D. (2009). Pseudomonas aeruginosa - a phenomenon of bacterial 
resistance. J. Med. Microbiol. (58), 1133–1148. 
Stummeyer, K., Schwarzer, D., Claus, H., Vogel, U., Gerardy-Schahn, R., and Mühlenhoff, 
M. (2006). Evolution of bacteriophages infecting encapsulated bacteria: Lessons from 
LXXIX 
 
Escherichia coli K1-specific phages. Mol. Microbiol. (60), 1123–1135. 
Sugamura, K., Asao, H., Kondo, M., Tanaka, N., Ishii, N., Ohbo, K., Nakamura, M., and 
Takeshita, T. (1996). The interleukin-2 receptor gamma chain: its role in the multiple cytokine 
receptor complexes and T cell development in XSCID. Annu. Rev. Immunol. (14), 179–205. 
Sulakvelidze, A. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. (45), 
649–659. 
Sulakvelidze, A., Alavidze, Z., and Morris, J.G.J. (2001). Bacteriophage therapy. 
Antimicrob. Agents Chemother. (45), 649–659. 
Summers, W.C. (2001). Bacteriophage therapy. Annu. Rev. Micriobiology (55), 437–451. 
Summers, W.C. (2011). In the beginning…. Bacteriophage (1), 50–51. 
Summers, W.C. (2016). Félix Hubert d’Herelle (1873–1949): History of a scientific mind. 
Bacteriophage (6), e1270090. 
Sutherland, I.W. (1995). Polysaccharide lyases. FEMS Microbiol. Rev. (16), 323–347. 
Sutherland, I.W. (1999). Polysaccharases for microbial exopolysaccharides. Carbohydr. 
Polym. (38), 319–328. 
Sutherland, I.W., Hughes, K.A., Skillman, L.C., and Tait, K. (2004). The interaction of phage 
and biofilms. FEMS Microbiol. Lett. (232), 1–6. 
Suttle, C.A. (2005). Viruses in the sea. Nature (437), 356–361. 
Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., Ueda, O., 
Sakaguchi, H., Higashi, T., Suzuki, T., et al. (1997). A role for macrophage scavenger receptors 
in atherosclerosis and susceptibility to infection. Nature (386), 292–296. 
Suzuki, N., Suzuki, S., Duncan, G.S., Millar, D.G., Wada, T., Mirtsos, C., Takada, H., 
Wakeham, A., Itie, A., Li, S., et al. (2002). Severe impairment of interleukin-1 and Toll-like 
receptor signalling in mice lacking IRAK-4. Nature (416), 750–756. 
Swaminathan, S., Furey, W., Pletcher, J., and Sax, M. (1992). Crystal structure of 
staphylococcal enterotoxin B, a superantigen. Nature (359), 801–806. 
Szekanecz, Z., Kim, J., and Koch, A.E. (2003). Chemokines and chemokine receptors in 
rheumatoid arthritis. Semin. Immunol. (15), 15–21. 
Szermer-Olearnik, B., and Boratyński, J. (2015). Removal of endotoxins from bacteriophage 
preparations by extraction with organic solvents. PLoS One (10), e0122672. 
Tabeta, K., Georgel, P., Janssen, E., Du, X., Hoebe, K., Crozat, K., Mudd, S., Shamel, L., 
Sovath, S., Goode, J., et al. (2004). Toll-like receptors 9 and 3 as essential components of innate 
immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. (101), 
3516–3521. 
Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y., 
Matsushima, K., Yoshida, N., Nishikawa, S., et al. (1998). The chemokine receptor CXCR4 is 
LXXX 
 
essential for vascularization of the gastrointestinal tract. Nature (393), 591–594. 
Takahama, Y. (2006). Journey through the thymus: stromal guides for T-cell development and 
selection. Nat. Rev. Immunol. (6), 127–135. 
Takase, H., Nitanai, H., Hoshino, K., and Otani, T. (2000). Impact of siderophore production 
on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect. Immun. (68), 
1834–1839. 
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation. Cell 
(140), 805–820. 
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, O., Takeda, K., and 
Akira, S. (1999). Differential roles of TLR2 and TLR4 in recognition of gram-negative and 
gram-positive cell wall components. Immunity (11), 443–451. 
Takeuchi, O., Hoshino, K., and Akira, S. (2000a). Cutting Edge: TLR2-deficient and MyD88-
deficient mice are highly susceptible to staphylococcus aureus infection. J. Immunol. (165), 
5392–5396. 
Takeuchi, O., Kaufmann, A., Grote, K., Kawai, T., Hoshino, K., Morr, M., Mühlradt, P.F., and 
Akira, S. (2000b). Cutting edge: preferentially the R-stereoisomer of the mycoplasmal 
lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like 
receptor 2- and MyD88-dependent signaling pathway. J. Immunol. (164), 554–557. 
Takeuchi, O., Kawai, T., Mühlradt, P.F., Morr, M., Radolf, J.D., Zychlinsky, A., Takeda, K., 
and Akira, S. (2001). Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. 
Immunol. (13), 933–940. 
Tamura, M., Ajayi, T., Allmond, L.R., Moriyama, K., Wiener-Kronish, J.P., and Sawa, T. 
(2004). Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin 
ExoU. Biochem. Biophys. Res. Commun. (316), 323–331. 
te Velde, A.A., Huijbens, R.J., Heije, K., de Vries, J.E., and Figdor, C.G. (1990). Interleukin-
4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human 
monocytes. Blood (76), 1392–1397. 
Tegla, C.A., Cudrici, C., Patel, S., Trippe, R., Rus, V., Niculescu, F., and Rus, H. (2011). 
Membrane attack by complement: The assembly and biology of terminal complement 
complexes. Immunol. Res. (51), 45–60. 
Terstegent, L., Gatsios, P., Bode, J.G., Schaper, F., Heinrich, P.C., and Graeve, L. (2000). The 
inhibition of interleukin-6-dependent STAT activation by mitogen- activated protein kinases 
depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J. Biol. Chem. (275), 
18810–18817. 
Thannickal, V.J., and Fanburg, B.L. (2000). Reactive oxygen species in cell signaling. Am. J. 
Physiol. Lung Cell Mol. Physiol. (279), L1005-1028. 




Thoma-Uszynski, S. (2001). Induction of direct antimicrobial activity through mammalian 
Toll-like receptors. Science (291), 1544–1547. 
Thomas, C.A., Li, Y., Kodama, T., Suzuki, H., Silverstein, S.C., and El Khoury, J. (2000). 
Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent 
phagocytosis. J. Exp. Med. (191), 147–156. 
Thomson, A.W., and Lotze, M.T. (2003). The Cytokine Handbook, Two-Volume Set 
(Elsevier). 
Tilg, H., Trehu, E., Atkins, M.B., Dinarello, C.A., and Mier, J.W. (1994). Interleukin-6 (IL-6) 
as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and 
soluble tumor necrosis factor receptor p55. Blood (83), 113–118. 
Tiwari, B.R., Kim, S., Rahman, M., and Kim, J. (2011). Antibacterial efficacy of lytic 
Pseudomonas bacteriophage in normal and neutropenic mice models. J. Microbiol. (49), 
994–999. 
Tobias, P.S., Soldau, K., and Ulevitch, R.J. (1986). Isolation of a lipopolysaccharide-binding 
acute phase reactant from rabbit serum. J. Exp. Med. (164), 777–793. 
Tonegawa, S. (1983). Somatic generation of antibody diversity. Nature (302), 575–581. 
Touzé, T., Tran, A.X., Hankins, J. V, Mengin-Lecreulx, D., and Trent, M.S. (2008). 
Periplasmic phosphorylation of lipid A is linked to the synthesis of undecaprenyl phosphate. 
Mol. Microbiol. (67), 264–277. 
Trebst, C., Lykke Sørensen, T., Kivisäkk, P., Cathcart, M.K., Hesselgesser, J., Horuk, R., 
Sellebjerg, F., Lassmann, H., and Ransohoff, R.M. (2001). CCR1+/CCR5+ mononuclear 
phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. 
J. Pathol. (159), 1701–1710. 
Trent, M.S., Ribeiro, A.A., Lin, S., Cotter, R.J., and Raetz, C.R.H. (2001). An inner membrane 
enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to 
lipid A: Induction in polymyxin-resistant mutants and role of a novel lipid-linked donor. J. 
Biol. Chem. (276), 43122–43131. 
Trop, S. (2001). Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell 
receptor-induced proliferation but not differentiation of immature thymocytes. Blood (97), 
2269–2277. 
Tung, H. s, Guss, B., Hellman, U., Persson, L., Rubin, K., Rydén, C., and Ryden, C. (2000). A 
bone sialoprotein-binding protein from Staphylococcus aureus: a member of the staphylococcal 
Sdr family. Biochel. J. (345 Pt 3), 611–619. 
Turley, S.J. (2000). Transport of peptide-MHC class II complexes in developing dendritic cells. 
Science (288), 522–527. 
Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, 
M.L., Jones, W.J., Roe, B.A., Affourtit, J.P., et al. (2009). A core gut microbiome in obese and 
lean twins. Nature (457), 480–484. 
LXXXII 
 
Ulevitch, R.J., and Tobias, P.S. (1995). Receptor-dependent mechanisms of cell stimulation by 
bacterial endotoxin. Annu Rev Immunol (13), 437–457. 
Ulich, T.R., Yin, S., Guo, K., Yi, E.S., Remick, D., and del Castillo, J. (1991). Intratracheal 
injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta 
inhibit acute inflammation. Am. J. Pathol. (138), 1097–1101. 
Underhill, D.M., Ozinsky, A., Hajjar, A.M., Stevens, A., Wilson, C.B., Bassetti, M., and 
Aderem, A. (1999). The Toll-like receptor 2 is recruited to macrophage phagosomes and 
discriminates between pathogens. Nature (401), 811–815. 
Van Belleghem, J.D., Merabishvili, M., Vergauwen, B., Lavigne, R., and Vaneechoutte, M. 
(2017a). A comparative study of different strategies for removal of endotoxins from 
bacteriophage preparations. J. Microbiol. Methods (132), 153–159. 
Van Belleghem, J.D., Merabishvili, M., Clement, F., Lavigne, R., and Vaneechoutte, M. 
(2017b). Pro- and anti- inflammatory responses of peripheral blood mononuclear cells induced 
by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci. Rep. (7), 8004. 
van Hal, S.J., Jensen, S.O., Vaska, V.L., Espedido, B.A., Paterson, D.L., and Gosbell, I.B. 
(2012). Predictors of Mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev. 
(25), 362–386. 
Van Kaer, L. (2001). Accessory proteins that control the assembly of MHC molecules with 
peptides. Immunol. Res. (23), 205–214. 
Van Lith, M., McEwen-Smith, R.M., and Benham, A.M. (2010). HLA-DP, HLA-DQ, and HLA-
DR have different requirements for invariant chain and HLA-DM. J. Biol. Chem. (285), 
40800–40808. 
van Regenmortel, M.H. V. (1992). Concept of virus species. Biodivers. Conserv. (1), 263–
266. 
Vandenheuvel, D., Lavigne, R., and Brüssow, H. (2015). Bacteriophage therapy: Advances in 
formulation strategies and human clinical trials. Annu. Rev. Virol. (2), 599–618. 
Vandersteegen, K., Mattheus, W., Ceyssens, P.-J., Bilocq, F., De Vos, D., Pirnay, J.-P., Noben, 
J.-P., Merabishvili, M., Lipinska, U., Hermans, K., et al. (2011). Microbiological and 
molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS 
One (6), e24418. 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and 
Speleman, F. (2002). Accurate normalization of real-time quantitative RT -PCR data by 
geometric averaging of multiple internal control genes. Genome Biol. (3), 1–12. 
Vannier, E., Miller, L.C., and Dinarello, C.A. (1992). Coordinated antiinflammatory effects of 
interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene 
expression and synthesis of interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. (89), 
4076–4080. 
Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stockinger, B. (2006). TGF-
beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-
LXXXIII 
 
17-producing T cells. Immunity (24), 179–189. 
Verbeken, G., and Pirnay, J.. (2015). Viruses that can cure, when antibiotics fail... J. Microb. 
Biochem. Technol. (8), 21–24. 
Verbeken, G., Pirnay, J.-P., Lavigne, R., Jennes, S., De Vos, D., Casteels, M., and Huys, I. 
(2014a). Call for a dedicated european legal framework for bacteriophage therapy. Arch. 
Immunol. Ther. Exp. (Warsz). 
Verbeken, G., Huys, I., Pirnay, J.-P., Jennes, S., Chanishvili, N., Scheres, J., Górski, A., De 
Vos, D., and Ceulemans, C. (2014b). Taking bacteriophage therapy seriously: a moral 
argument. Biomed. Res. Int. (2014), 621316. 
Verbeken, G., Huys, I., Ceulemans, C., Jennes, S., De Vos, D., and Pirnay, J.P. (2016). 
Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy 
regulation. Burns (42), 11–12. 
Waisman, A., Kraus, M., Seagal, J., Ghosh, S., Melamed, D., Song, J., Sasaki, Y., Classen, S., 
Lutz, C., Brombacher, F., et al. (2007). IgG1 B cell receptor signaling is inhibited by CD22 
and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. 
J. Exp. Med. (204), 747–758. 
Walsh, C. (2000). Molecular mechanisms that confer antibacterial drug resistance. Nature 
(406), 775–781. 
Walsh, T.R., and Howe, R.A. (2002). The prevalence and mechanisms of vancomycin 
resistance in Staphylococcus aureus. Annu. Rev. Microbiol. (56), 657–675. 
Walsh, C.T., Fisher, S.L., Park, I.-S., Prahalad, M., and Wu, Z. (1996). Bacterial resistance to 
vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. (3), 21–28. 
Wang, C.R., and Liu, M.F. (2003). Regulation of CCR5 expression and MIP-1alpha production 
in CD4+ T cells from patients with rheumatoid arthritis. Clin. Exp. Immunol. (132), 371–
378. 
Wang, X., and Quinn, P.J. (2010). Endotoxins: structure, function and recognition 
(Dordrecht: Springer Netherlands). 
Wang, P., Wu, P., Siegel, M.I., Egan, R.W., and Billah, M.M. (1995). Interleukin (IL)-10 
inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-
4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. (270), 9558–9563. 
Wang, Q., Miyakawa, Y., Fox, N., and Kaushansky, K. (2000a). Interferon-alpha directly 
represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through 
induction of SOCS-1. Blood (96), 2093–2099. 
Wang, W., Soto, H., Oldham, E.R., Buchanan, M.E., Homey, B., Catron, D., Jenkins, N., 
Copeland, N.G., Gilbert, D.J., Nguyen, N., et al. (2000b). Identification of a novel chemokine 
(CCL28), which binds CCR10 (GPR2). J. Biol. Chem. (275), 22313–22323. 
Wang, X., Karbarz, M.J., McGrath, S.C., Cotter, R.J., and Raetz, C.R.H. (2004). MsbA 
transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner 
LXXXIV 
 
membrane: Topography of Francisella novicida LpxE expressed in Escherichia coli. J. Biol. 
Chem. (279), 49470–49478. 
Wang, X., McGrath, S.C., Cotter, R.J., and Raetz, C.R.H. (2006). Expression Cloning and 
Periplasmic Orientation of the Francisella novicida Lipid A 4’-Phosphatase LpxF. J. Biol. 
Chem. (281), 9321–9330. 
Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J., 
Sakurai, S., Matsuzaki, S., Imai, S., et al. (2007). Efficacy of bacteriophage therapy against 
gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents 
Chemother. (51), 446–452. 
Watts, C. (2004). The exogenous pathway for antigen presentation on major histocompatibility 
complex class II and CD1 molecules. Nat. Immunol. (5), 685–692. 
Weber-Dąbrowska, B., Dabrowski, M., and Slopek, S. (1987). Studies on bacteriophage 
penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. (Warsz). 
(35), 563–568. 
Weber-Dąbrowska, B., Zimecki, M., and Mulczyk, M. (2000). Effective phage therapy is 
associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. 
Ther. Exp. (Warsz). (48), 31–37. 
Weinbauer, M.G. (2004). Ecology of prokaryotic viruses. FEMS Microbiol. Rev. (28), 127–
181. 
Wenger, S.L., Turner, J.H., and Petricciani, J.C. (1978). The cytogenetic, proliferative and 
viability effects of four bacteriophages on human lymphocytes. In Vitro (14), 543–549. 
Wertheim, H.F., Melles, D.C., Vos, M.C., van Leeuwen, W., van Belkum, A., Verbrugh, H.A., 
and Nouwen, J.L. (2005). The role of nasal carriage in Staphylococcus aureus infections. 
Lancet Infect. Dis. (5), 751–762. 
Werts, C., Tapping, R.I., Mathison, J.C., Chuang, T.H., Kravchenko, V., Saint Girons, I., 
Haake, D.A., Godowski, P.J., Hayashi, F., Ozinsky, A., et al. (2001). Leptospiral 
lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 
(2), 346–352. 
Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S., and Cao, Z. (1997). MyD88: an adapter that 
recruits IRAK to the IL-1 receptor complex. Immunity (7), 837–847. 
White, D.W., Suzanne Beard, R., and Barton, E.S. (2012). Immune modulation during latent 
herpesvirus infection. Immunol. Rev. (245), 189–208. 
White, J., Herman, A., Pullen, A.M., Kubo, R., Kappler, J.W., and Marrack, P. (1989). The 
Vβ-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and 
clonal deletion in neonatal mice. Cell (56), 27–35. 
Whyte, C.S., Bishop, E.T., Rückerl, D., Gaspar-Pereira, S., Barker, R.N., Allen, J.E., Rees, 
A.J., and Wilson, H.M. (2011). Suppressor of cytokine signaling (SOCS)1 is a key determinant 
of differential macrophage activation and function. J. Leukoc. Biol. (90), 845–854. 
LXXXV 
 
Wick, M.J., Hamood, A.N., and Iglewski, B.H. (1990). Analysis of the structure-function 
relationship of Pseudomonas aeruginosa exotoxin A. Mol. Microbiol. (4), 527–535. 
Wickham, T.J., Mathias, P., Cheresh, D.A., and Nemerow, G.R. (1993). Integrins αvβ3 and 
αvβ5 promote adenovirus internalization but not virus attachment. Cell (73), 309–319. 
Wickham, T.J., Filardo, E.J., Cheresh, D.A., Nemerow, G.R., and Jolla, L. (1994). Integrin 
alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. 
Cell Biol. (127), 257–264. 
Wiener-Kronish, J.P., Sakuma, T., Kudoh, I., Pittet, J.F., Frank, D., Dobbs, L., Vasil, M.L., 
and Matthay, M.A. (1993). Alveolar epithelial injury and pleural empyema in acute P. 
aeruginosa pneumonia in anesthetized rabbits. J. Appl. Physiol. (75), 1661–1669. 
Wiest, R., and Garcia-Tsao, G. (2005). Bacterial translocation (BT) in cirrhosis. Hepatology 
(41), 422–433. 
Wilke, M.S., Lovering, A.L., and Strynadka, N.C. (2005). Β-Lactam antibiotic resistance: a 
current structural perspective. Curr. Opin. Microbiol. (8), 525–533. 
Wilkins, C., and Gale, M. (2010). Recognition of viruses by cytoplasmic sensors. Curr. Opin. 
Immunol. (22), 41–47. 
Williams, D.H. (1996). The glycopeptide story – how to kill the deadly “superbugs.” Nat. Prod. 
Rep. (13), 469–477. 
Williams, A.H., and Raetz, C.R.H. (2007). Structural basis for the acyl chain selectivity and 
mechanism of UDP-N-acetylglucosamine acyltransferase. Proc. Natl. Acad. Sci. (104), 
13543–13550. 
Williams, R.E.O., Jevons, M.P., Shooter, R.A., Hunter, C.J.W., Girling, J.A., Griffiths, J.D., 
and Taylor, G.W. (1959). Nasal Staphylococci and sepsis in hospital patients. BMJ (2), 658–
662. 
Wills, Q., Kerrigan, C., and Soothill, J. (2005). Experimental bacteriophage protection against 
Staphylococcus aureus abscesses in a rabbit model. Antimicrob. Agents Chemother. (49), 
1220–1222. 
Wilson, H.M. (2014). SOCS proteins in macrophage polarization and function. Front. 
Immunol. (5), 357. 
Woodford, N., and Livermore, D.M. (2009). Infections caused by Gram-positive bacteria: a 
review of the global challenge. J. Infect. (59), S4–S16. 
Wright, G.D. (2005). Bacterial resistance to antibiotics: Enzymatic degradation and 
modification. Adv. Drug Deliv. Rev. (57), 1451–1470. 
Wright,  a, Hawkins, C.H., Anggård, E.E., and Harper, D.R. (2009). A controlled clinical trial 
of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant 
Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. (34), 349–357. 
Wright, S.D., Tobias, P.S., Ulevitch, R.J., and Ramos, R.A. (1989). Lipopolysaccharide (LPS) 
LXXXVI 
 
binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on 
macrophages. J. Exp. Med. (170), 1231–1241. 
Wright, S.D., Ramos, R. a, Tobias, P.S., Ulevitch, R.J., and Mathison, J.C. (1990). CD14, a 
receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (249), 
1431–1433. 
Xu, Y., Narayana, S.V.L., and Volanakis, J.E. (2001). Structural biology of the alternative 
pathway convertase. Immunol. Rev. (180), 123–135. 
Yahr, T.L., Vallis, A.J., Hancock, M.K., Barbieri, J.T., and Frank, D.W. (1998). ExoY, an 
adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc. Natl. Acad. 
Sci. (95), 13899–13904. 
Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and Akira, S. (2002). 
Cutting Edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially 
activates the IFN-promoter in the Toll-like receptor signaling. J. Immunol. (169), 6668–6672. 
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V.E.T., Silvennoinen, O., and O’Shea, J.J. (2004). 
The Janus kinases (Jaks). Genome Biol. (5), 253. 
Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, 
S., Imaizumi, T., Matsuda, T., Ihle, J.N., et al. (1999). The JAK-binding protein JAB inhibits 
Janus tyrosine kinase activity through binding in the activation loop. EMBO J. (18), 1309–
1320. 
Yasukawa, H., Sasaki, A., and Yoshimura, A. (2000). Negative regulation of cytokine 
signaling pathways. Annu. Rev. Immunol. (18), 143–164. 
Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, 
K., Akira, S., Hoshijima, M., et al. (2003). IL-6 induces an anti-inflammatory response in the 
absence of SOCS3 in macrophages. Nat. Immunol. (4), 551–556. 
Yokoo, H., and Oshima, T. (1979). Is bacteriophage φX174 DNA a message from an 
extraterrestrial intelligence?. Icarus (38), 148–153. 
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N.A., Gilbert, D.J., Copeland, N.G., Hara, 
T., and Miyajima, A. (1995). A novel cytokine-inducible gene CIS encodes an SH2-containing 
protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. 
EMBO J. (14), 2816–2826. 
Yoshimura, A., Naka, T., and Kubo, M. (2007). SOCS proteins, cytokine signalling and 
immune regulation. Nat. Rev. Immunol. (7), 454–465. 
Youd, M.E., Ferguson, A.R., and Corley, R.B. (2002). Synergistic roles of IgM and complement 
in antigen trapping and follicular localization. Eur. J. Immunol. (32), 2328. 
Zaczek, M., Łusiak-Szelachowska, M., Jończyk-Matysiak, E., Weber-Dąbrowska, B., 
Miedzybrodzki, R., Owczarek, B., Kopciuch, A., Fortuna, W., Rogóz, P., Górski, A., et al. 
(2016). Antibody production in response to Staphylococcal MS-1 phage cocktail in patients 
undergoing phage therapy. Front. Microbiol. (7), 1–14. 
LXXXVII 
 
Zajonc, D.M., Elsliger, M.A., Teyton, L., and Wilson, I.A. (2003). Crystal structure of CD1a in 
complex with a sulfatide self antigen at a resolution of 2.15 A. Nat. Immunol. (4), 808–815. 
Zelante, T., and Ricciardi-Castagnoli, P. (2012). The yin-yang nature of CSF1R-binding 
cytokines. Nat. Immunol. (13), 717–719. 
Zhang, F.X., Kirschning, C.J., Mancinelli, R., Xu, X.-P., Jin, Y., Faure, E., Mantovani, A., 
Rothe, M., Muzio, M., and Arditi, M. (1999a). Bacterial Lipopolysaccharide Activates Nuclear 
Factor-κB through Interleukin-1 Signaling Mediators in Cultured Human Dermal 
Endothelial Cells and Mononuclear Phagocytes. J. Biol. Chem. (274), 7611–7614. 
Zhang, J.G., Farley, A., Nicholson, S.E., Willson, T.A., Zugaro, L.M., Simpson, R.J., Moritz, 
R.L., Cary, D., Richardson, R., Hausmann, G., et al. (1999b). The conserved SOCS box motif 
in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins 
to proteasomal degradation. Proc. Natl. Acad. Sci. (96), 2071–2076. 
Zhao, W.-H., and Hu, Z.-Q. (2010). Beta-lactamases identified in clinical isolates of 
Pseudomonas aeruginosa. Crit. Rev. Microbiol. (36), 245–258. 
Zinkernagel, R.M., and Doherty, P.C. (1997). The discovery of MHC restriction. Immunol. 
Today (18), 14–17. 
Zlotnik, A., and Yoshie, O. (2000). Chemokines: a new classification system and their role in 
immunity. Immunity (12), 121–127. 
Zlotnik, A., and Yoshie, O. (2012). The chemokine superfamily revisited. Immunity (36), 705–
716. 
Zong, C.S., Chan, J., Levy, D.E., Horvath, C., Sadowski, H.B., and Wang, L.H. (2000). 
Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 
(275), 15099–15105. 
Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R. (1998). Function of 














Bosstraat 39A | 9111 Puivelde | Belgium 
Van.Belleghem.Jonas@gmail.com | 07 May 1990 
 
PhD student 
Immunomodulation by Bacteriophages. 
Laboratory Bacteriology Research  
Department Clinical Chemistry, Microbiology and 
Immunology  
Faculty of Medicine and Health Sciences, Ghent University 
Promoter: Prof. Dr. Mario Vaneechoutte 
Co-promoter: Prof. Dr. Rob Lavigne (KULeuven) 
Master Biochemistry-Biotechnology, Ghent University 
Master thesis: Study of Staphylococcus aureus phage ISP 
and derived proteins. Potential use as antibacterial 
therapeutics and anti-inflammatory properties 
Promoter: Prof. Dr. Mario Vaneechoutte 
Great distinction 




4. Van Belleghem, J.D., Merabishvili, M., Clement, F., Lavigne, R. & Vaneechoutte, 
M. 
. Sci. Rep. 8: 8004 – 8016 (2017) 
Featured in Science:  DOI: 
10.1126/science.aar5441 
 
3. Merabishvili, M., Monserez, R., Van Belleghem, J.D., Rose, T., Jennes, S., De Vos, 
D., Verbeken, G., Vaneechoutte, M. & Pirnay, J.P. 
 Plos One 12(7):e0182121 (2017) 
 
2. Van Belleghem, J.D., Merabishvili, M., Vergauwen, B., Lavigne, R. & 
Vaneechoutte, M. 
. J. Microbiol. Methods 132, 153 – 159 (2017) 
 
1. Van Hoecke, H., De Paepe, A., Lambert, E., Van Belleghem, J.D., Cools, P., Van 
Simaey, L., Deschaght, P., Vaneechoutte, M. & Dhooge, I. 





Effects of bacteriophages on the human immune 
response 




     Presentation:  
Immunomodulation by bacteriophages 
Tbilisi, Georgia 
 
     Attendant 
     Online 
 
     Poster presentation: 
Immunomodulation by bacteriophages - 
Differential expression of immune cells stimulated 
with different phages 
Liverpool, United Kingdom 
 
     Attendant 
     Ghent, Belgium 
 
     Presentation + Poster presentation: 
Immunomodulation by bacteriophages - 
Differential expression of immune cells stimulated 
with different phages 
     Leuven (Heverlee), Belgium 
 
Poster presentation:  
Immunomodulation by bacteriophages - 
Differential expression of immune cells stimulated 
with a Pseudomonas aeruginosa phage 
     The Evergreen State College, Olympia, Washington 
XCII 
 
     Attendant 
     Braga, Portugal 
 
Invited speaker (Phages and the Immune System) 
Scientific Symposium of the Leibniz-Institute 




     Attendant 
     Ghent, Belgium 
 
Attendant  
     Zurich, Switzerland. 
 
01/01/2014 – 01/01/2018: IWT/FWO: PhD Scholarship Strategic Basic 
Research 
 
 
 
 
 
 
 
